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Macrophages (M<j)s) play a critical role in regulating and effecting both innate and acquired immune
responses. Their presence in increased numbers and as epithelioid granulomas in the liver of patients
with the chronic cholestatic liver disease primary biliary cirrhosis (PBC) suggests they may be
important in the pathogenesis of this idiopathic disease. Biliary epithelial cells (BECs) of the small bile
ducts are specifically targeted in this disease and their death is thought to occur via apoptosis, mediated
by autoimmune mechanisms. A mycobacterial aetiology in association with specific genetic and
environmental factors has been suggested in the initiation of PBC. The murine natural resistance-
associated macrophage (nrampl) gene was identified as the gene responsible for susceptibility to a
number of intracellular pathogens, including Mycobacterium tuberculosis, Leishmania dorwvani and
Salmonella typhimurium, and has profound and pleiotropic effects on M(|> activation and function. The
gene is expressed specifically in M(j)s and granulocytes. Overexpression of the human homologue,
NRAMP1, has been hypothesised to result in hyperstimulation of M(|)s, contributing to the pathogenesis
of autoimmune and chronic diseases, while underexpression may contribute to susceptibility to
infectious diseases. Rheumatoid arthritis (RA), like PBC, is an autoimmune disease in which M(j>s are
propounded to play a destructive role and susceptibility has been associated with a specific
microsatellite repeat polymorphic site in the 5' promoter region of NRAMP1. Alleles at this site affect
levels of NRANfP I expression, the allele driving highest expression being associated with RA.
Conversely, alleles at this site which fail to respond appropriately to immune stimuli, resulting in
insufficient NRAMPl expression and incomplete M<j) activation, have been associated with tuberculosis
and leprosy. These findings support the theory that the balance of NRANIP1 expression influences an
individual's susceptibility to autoimmune or infectious disease.
This thesis reports the use of immunohistochemistry to identify increased expression of the pro-
apoptotic proteins, bax and bcl-x, in BECs of PBC patients which suggests these cells are inherently
susceptible to this form of programmed cell death supporting the belief that the cells die by apoptosis.
An increased frequency of Ki-67 expression was also observed in BECs in PBC liver sections, showing
these cells are capable of proliferation, but p53, bcI-2 and Fas/CD95 expression was similar to BECs of
normal liver. Expression ofNRAMPl was detected by reverse transcription-polymerase chain reaction
(RT-PCR) in PBC and normal liver tissue. A genotyping strategy, based on restriction fragment length
polymorphism (RFLP) analysis, was developed to genotype PBC and control groups for the 5'
microsatellite repeat polymorphism to investigate if a similar association existed in PBC patients as RA
patients. Two novel alleles were identified at this site, one ofwhich was found at significantly increased
frequency in the PBC population, though it was still uncommon. The allele driving the highest levels of
expression, found at increased frequency in RA, was found at a similar frequency in the PBC
population and control populations studied. To investigate the effect of overexpression of NRANIP1,
MM6 and U937 cell lines were transfected with a plasmid constructed to drive high levels ofNRANfPl
expression. The presence and expression of plasmid sequence in transfectants was confirmed by PCR
and RT-PCR, respectively. Analysis of the transfectants' divalent cation cellular content by inductively
coupled plasma mass spectrometry (ICPMS) after culture in increased concentrations of manganese
provide further evidence that the NRAMP1 protein is a divalent cation transporter protein, though the
specificity of its substrate(s) requires further analysis.
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MS multiple sclerosis
neo neomycin phosphotransferase gene
neoFl PCR described in 2.8.5
neoFexp PCR described in 2.8.6
nm nanometre
nrampl mouse natural resistance-associated macrophage
protein 1 gene
nramp2 mouse natural resistance-associated macrophage
protein 2 gene
nrampl mouse natural resistance-associated macrophage
protein 1 protein
nramp2 mouse natural resistance-associated macrophage
protein 2 protein
N nolar or amino for protein/peptide description
NADPH reduced form of nicotinamide adenine dinucleotide
phosphate
NBT nitro blue tetrazolium






NOS nitric oxide synthase
NOSI see cNOS
NOSII see iNOS
NRAMP1 human natural resistance-associated macrophage
protein 1 gene
NRAMP2 human natural resistance-associated macrophage
protein 2 gene
NRAMP1 human natural resistance-associated macrophage
protein 1 protein
NRAMP2 human natural resistance-associated macrophage
protein 2 protein
NRAMPalu PCR described in 2.8.3
NRAMPpol PCR described in 2.8.1
NRpCI PCR described in 2.8.4
NRS normal rabbit serum
NSS normal swine serum






orf open reading frame
OsNramp OsNramp gene
OsNramp OsNramp protein
pCIneo plasmid pCI-neo Mammalian Expression Vector
pmol picomole
PAK2 p21-activated kinase
PBC primary biliary cirrhosis
PBL peripheral blood lymphocyte
PBMC peripheral blood mononuclear cell
PBS phosphate buffered saline
PBST PBS/0.05% Tween 20
PCD programmed cell death
PCR polymerase chain reaction
PDC pyruvate dehydrogenase complex
PDC-E2 dihydrolipoamide acetyltransferase component of PDC
PDGF platelet derived growth factor
PEP processing enhancing protein
pge2 prostaglandin E2
PHA phytohaemagglutinin
PKC protein kinase C
PLL poly-L-lysine
PMA phorbol-myristate-acetate
PMSF phenyl methyl sulphonyl fluoride
PNS peripheral nervous system
PPD purified protein derivative
PSC primary sclerosing cholangitis
PSS progressive systemic sclerosis
rbc red blood cell
rpm revolutions per minute
RA rheumatoid arthritis
RAIDD RIP-associated Ich-1/CED3 homologous protein with a
death domain
RAM-BIO biotinylated rabbit anti-mouse Ig antibody
RAM-HRP HRP conjugated rabbit anti-mouse Ig antibody
RE reticuloendothelial system
RFLP restriction fragment length polymorphism
RIP receptor interacting protein
RNA ribonucleic acid
RNase deoxyribonuclease





S. spp. Schistosoma species except
S. aureus Staphylococcus aureus
S. cerevisiae Sacharomyces cerevisiae
S. dublin Salmonella dublin
S. gordonii Streptococcus gordonii
S. parasanguis Streptococcus parasanguis
S. pneumoniae Streptococcus pneumoniae
S. typhimurium Salmonella typhimurium
SAR-BIO biotinylated swine anti-rabbit Ig antibody
SAP shrimp alkaline phosphatase
SAR-HRP HRP conjugated swine anti-rabbit Ig antibody
SCID severe combined immunodeficienct
SDS sodium dodecyl sulphate
SDS-PAGE SDS-polyacrylamide gel electrophoresis
SH3 src homology 3
SITS 4-acetamido-4'-isothyocyanatostibene-2,2'-disulphonic
acid




T. spp. Toxoplasma species
TAP transporters associated with antigen processing protein
TBE tris-borate EDTA
TB tuberculosis
TBS Tris buffered saline
TBST TBS Tween





TGF transforming growth factor




TNF tumour necrosis factor
TNTR TNF receptor
TRADD TNFR-associated death domain
TRAF2 TNFR-associated factor-2





VCAM-1 vascular cell adhesion molecule-1
WAS Wiskott-Aldrich syndrome




It is ninety one years since Elie Metchnikoff and Paul Ehrlich were awarded the
Nobel Prize for Physiology and Medicine (Metchnikoff 1989) "in recognition of their
work on immunity". Metchnikoff s observation, some twenty five years earlier in
1882, when he introduced small tangerine thorns into the larvae of Bipinnaria
(starfish), of "a mass of moving cells surrounding the foreign bodies" was a turning
point, not only in his own personal life, but for the discipline, and our understanding,
of immunology. The eminent scientist, primarily an embryologist, has been
associated with the terms "phagocytosis" to describe the engulfment of cellular or
particulate matter, and "phagocyte" (cell eater) as the cell which undertakes the
phagocytosis.
The great scientists working at the turn of the century laid the seeds which have
flourished into modern day immunology. Though they could not reconcile all their
observations, and a battle as vehement and ferocious as that between pathogen and
immune system appeared to rage between the advocates of cellular and humoral
immunity, it is fascinating to see how many of their theories of "amboceptor",
"complement", "endolysis", "leukins" and "endotoxins", for example, have been
elaborated and elucidated over the years. Perhaps one of the most important lessons
we can learn since their polemics is the holistic nature of the immune system which
we know to act as a concerted whole with cellular, humoral, innate and acquired
components orchestrating an effective defence system. It will be important to
remember through the course of this thesis, though the focus will be on the role of
the macrophage (M<j>) (synonymous with Metchnikoff s white corpuscle phagocyte),
that the action of this cell, though of major importance, constitutes only one
component of the complex system of interacting cells, chemicals and proteins we
know as the immune system.
1.1 PRIMARY BILIARY CIRRHOSIS
Twenty eight percent of the first 227 orthotopic liver transplantations carried out by
the Scottish Liver Transplantation Unit between 1992 and 1997 were for end stage
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primary biliary cirrhosis (PBC), the greatest single reason for transplantation.
(Appendix A). This statistic reflects, in part, amongst ethical considerations,
favourable prognosis post transplantation, organ-patient compatibility etc., the
paucity of effective treatment regimes for this disease making liver transplantation a
necessity for the survival of sufferers with advanced disease.
PBC is an idiopathic, progressive, cholestatic liver disease and somewhat of a
misnomer in so far as a presymptomatic and precirrhotic stage of the disease may
last for many years before true cirrhosis is established as the disease progresses
(Portmann and MacSween 1987). The term chronic non suppurative destructive
cholangitis (CNSDC) may be a more accurate description of the initial lesions where
destruction of biliary epithelial cells (BEC) of ducts between 30pm and 100pm
diameter can be observed histologically.
PBC remains poorly understood, despite documentation of its symptoms as early as
the 1800s (reviewed in Jorge and Leuschner 1996), but the bile duct damage is
believed to be mediated by autoimmune mechanisms. Indeed PBC has been cited as
the paradigm of organ-specific autoimmune diseases (Gershwin and Mackay 1997)
where there is a breakdown of immunological self tolerance. In an organ specific
disease of this sort the body's immune responses target self tissue and the reactions
are limited to a particular organ, which in the case of PBC is the BECs of small to
medium sized bile ducts in the liver.
1.1.1 Clinical Features
Patients with PBC usually present with intense pruritis, increasing skin pigmentation
and eventually cholestatic jaundice, though icterus may not develop for months or
years after the initial symptoms. 30% of patients exhibit xanthomas/xanthelasma.
Weight loss and fatigue are other common symptoms and portal hypertension may
manifest itself before cirrhosis is established. Asymptomatic patients may be
identified due to hepatomegaly, raised serum alkaline phosphatase or anti-
mitochondrial antibody (AMA) levels in the serum and it is possible for these
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patients to experience a normal life expectancy. Symptomatic patients may survive
for 5-15 years but the onset of jaundice heralds a worsening prognosis and clinical
deterioration. Patients with advanced PBC may suffer pathologic fractures due to
osteomalacia and osteoporosis. PBC is ultimately fatal, usually due to hepatocellular
failure with approximately a third of cases suffering from bleeding from oesophageal
varices (Portmann and MacSween 1987; Borum 1998).
1.1.2 Histology
Histologically PBC is divided into four stages (Scheuer 1988) though an individual
biopsy section or biopsies taken from different areas of the same liver may show
characteristics of more than one of these stages due to the chronic, segmental and
progressive nature of the disease.
Stage I is characterised by florid bile duct lesions and necrotic bile ducts with BECs
appearing shrunken and vacuolated. Granulomatous inflammation consisting of
lymphocytes, plasma cells, histiocytes, eosinophils and giant cells surround the
lesions and it is the presence of granulomas in PBC biopsy sections which is
characteristic of the disease. Inflammation spreads out from the portal triads in stage
II and biliary piecemeal necrosis characterised by vacuolated periportal hepatocytes,
surrounded by foamy M(j)s is observed. The fibrosis progresses to scarring in stage III
and fibrous septa link adjacent portal tracts. Cholestasis may be apparent due to the
deposition of copper-associated protein. Stage IV is characterised by the presence of
established cirrhosis.
1.1.3 Incidence of PBC
As with many autoimmune diseases there is a preponderance of female sufferers,
with an incidence of approximately nine female sufferers per male sufferer (Borum
1998), though the disease is similar in both sexes. It has generally been postulated
that hormonal differences are key to the different incidence of many autoimmune
diseases between sexes, but an interesting theory has been proposed for the 90%
female bias of systemic lupus erythematosus (SLE) sufferers which may also be
applicable to PBC (Stewart 1998). X-chromosome inactivation in females leads to
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two classes of cells differing in a subset of transcribed genes and hence, self proteins
expressed and presented by these cells will also differ. A skew in X-inactivation of
one of the X chromosomes in key antigen presenting cells (APC) such as dendritic
cells (DC) could result in the evasion of tolerance induction of T lymphocytes in the
thymus towards the silenced genes' products of the inactivated X chromosome.
PBC typically affects middle aged females with a peak incidence among 40-60 year
olds, though onset in childhood has been reported which may or may not be a special
paediatric form of PBC (Melegh et al. 1998). Estimates of disease prevalence vary
between 20 and 240 cases per million population with an annual incidence between
4 and 30 per million (Hislop 1980; Triger 1980; Watson et al. 1995; reviewed in
Kaplan 1996; reviewed in Metcalf and James 1997; reviewed in Neuberger 1997).
The reported incidence of PBC is increasing but it is not known if this represents a
true increase in disease prevalence or a greater awareness of the disease (reviewed in
Neuberger 1997).
1.1.4 Aetiology
The aetiology of PBC remains a mystery. A geographical variation in incidence has
been reported, with a low incidence in the Indian and African subcontinents
(Portmann and MacSween 1987; Neuberger 1997) and a familial history of PBC is
widely accepted as a predisposing factor to development of disease (Bach and
Schnaffer 1994; Jorge and Leuschner 1996; reviewed in Neuberger 1997). This
familial association suggests genetic factors may make certain individuals more
susceptible to the effects of additional environmental and/or infectious agents, which
together initiate the disease. To date studies to identify predisposing genotypes or
mutations have failed to identify genes playing a major role and the search is still on
to identify susceptibility loci.
A variety of infectious agents have been suggested which may trigger PBC initiation
via a molecular mimicry mechanism (Burroughs et al. 1992; reviewed in Galperin
and Gershwin 1996; reviewed in Jones 1996). PBC patients have been reported to
have a higher incidence of urinary tract infections with Escherichia coli (E. coli)
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which has been suggested to contribute to the onset of disease (Burroughs et al.
1984), though there is doubt whether this is prevalent across the whole PBC
population (reviewed in O'Donohue and Williams 1996a). The sera from PBC
patients has been shown to contain antibodies (Ab) reactive against Mycobacterium,
gordonae (M. spp.) which cross react with the major mitochondrial autoantigens, to
be discussed in 1.1.5.1 (Vilagut et al. 1994a). M. gordonae deoxyribonucleic acid
(DNA) has also been detected in PBC liver sections (Vilagut et al. 1994b) though
this has not been conclusively established (O'Donohue et al. 1998). Antigens cross-
reactive with PBC specific autoantigens have also been found to be expressed in
gram negative bacteria (Enterobacteriacae and Salmonella) and gram positive
bacteria have been suggested as potential factors initiating disease (Hiramatsu et al.
1998) supporting the hypothesis of a bacterial aetiology (Stemerowicz et al. 1988).
Using confocal laser scanning microscopy lipopolysaccharide (LPS) has been
identified, by immunofluorescence, in BECs and to a lesser level in infiltrating cells
around the bile ducts and hepatocytes (Sakisaka et al. 1997) and has been proposed
to facilitate the expression of adhesion molecules by BECs, accelerating infiltration
of inflammatory cells which may then target and attack the BECs. The endotoxin
may also be released from BECs into the portal areas leading to infiltration of
inflammatory cells around the bile ducts.
The association of viral infections with the onset of PBC has also been proposed and
challenged (Podda et al. 1990; Le Cann et al. 1997; Malamud et al. 1997; reviewed
in Neuberger 1997; Wang and Tschen 1997) and remains an area for continued
study.
The familial association of PBC (Bach and Schaffner 1994) has led to many studies
analysing particular genetic loci for an association with the disease. In the majority
of cases these have failed to identify any strong association or where a positive
association has been alleged to exist subsequent analysis has often proven
controversial.
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The most obvious candidate locus for association with an autoimmune mediated
disease is the major histocompatibility complex (MHC) containing region of the
genome. However, the existing data remains far from clear with possible
associations with human leukocyte antigen (HLA)-DR3, HLA-DR8, HLA-DR2,
HLA-DPB1, HLA-DRB4, HLA-DR8-DQB1 *04, HLA-DRB1 *0301-DQA1*0501-
DQB1*0201 amongst others being reported (Ercilla et al. 1979; Clemente et al.
1998; reviewed in Leung et al. 1996; Lindgren et al. 1998). These and other studies
(Santrach et al. 1990; Fugger et al. 1991; Morling et al. 1992; Underhill et al. 1992
and 1995; Gregory et al. 1993; Seki et al. 1993; Onishi et al. 1994; Zhang et al.
1994a; Mella et al. 1995) leave the possible HLA association unresolved. Based on
circumstantial evidence a "three-way mimicry" hypothesis has been proposed to
account for the role of MHC haplotypes in a number of autoimmune diseases,
including PBC, and may be a possible explanation for the lack of strong HLA linkage
to PBC (Baum and Staines 1997).
Studies to investigate polymorphisms at the tumour necrosis factor (TNF)-a (Fugger
et al. 1989; Spengler et al. 1990; Messer et al. 1991; Gordon et al. 1996; Watt et al.
1997; Tanaka et al. 1998 and 1999; Jones et al. 1999), transporters associated with
antigen processing protein (TAP)l and TAP2 (Gregory et al. 1994), GSTM1 (Davies
et al. 1993), interleukin (IL)-10 (Zappala et al. 1998), CTLA-4 (Agarwal et al. 1998)
and C4B2 (Briggs et al. 1987) loci have been carried out but to date only weak or
unconfirmed associations for TNFa and C4B2 have been reported.
1.1.5 Immunological Aspects
The autoimmune basis for PBC is supported by:
1. The frequent association of PBC with other immunological abnormalities or
autoimmune disease including "sicca complex", CREST syndrome (calcinosis,
Reynaud's phenomenon, oesophageal dysfunction, sclerodactyl and
telangiectasis), rheumatoid arthritis (RA), polyarthritis, autoimmune thyroiditis,
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renal tubular acidosis, coeliac disease, SLE and intestinal pulmonary fibrosis
(reviewed in Kaplan 1996).
2. The increased frequency of certain MHC antigens i.e. HLA-DRW8, though these
findings are inconsistent in different populations.
3. The presence of infiltrates containing T lymphocytes within the portal tract which
show histological evidence of bile duct damage.
4. A number of immunological abnormalities including MHC Class II antigen
expression and in vitro T cell proliferative responses.
5. The frequent association of numerous serum autoantibodies (AAb).
1.1.5.1 Autoantibodies
The first evidence suggesting PBC may have an autoimmune component arose in
1958 when complement fixing anti-tissue Abs were identified in patients' sera, with
subsequent detection of Abs to cell mitochondria (reviewed in Mackay 1994).
However, it took until the late 1980s to identify the dihydrolipoamide
acetyltransferase component of the pyruvate dehydrogenase complex (PDC-E2) as
the major autoantigen reacting with PBC sera and show that the AAbs were reacting
against the non-catalytic, inner lipoyl domain of the E2 component (Fussey et al.
1990; reviewed in Neuberger 1997). Though the inner lipoyl domain of PDC-E2 may
contain important B cell epitopes it appears that only a minority of PBC patients' T
cells, which are responsive to PDC, respond to lipoylated recombinant PDC-E2 inner
lipoyl domain or a lipoylated peptide of this domain (Palmer et al. 1999). In addition
to antibodies reacting with PDC-E2 PBC patients frequently possess AAbs reactive
against other components of the pyruvate dehydrogenase complex and the two other
2-oxoacid dehydrogenase enzyme complexes (2-oxoglutarate dehydrogenase and
branched-chain 2-oxoacid dehydrogenase). Anti-nuclear (gp210, SplOO), anti-alpha-
enolase, anti-platelet, anti-thyroid, anti-centromere and anti-DNA Abs amongst other
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AAbs have also been identified in PBC sera (Akisawa et al. 1997; Feistauer et al.
1997; reviewed in Neuberger 1997; Tsuji et al. 1997; Luettig et al. 1998).
One of the presently accepted criteria for the diagnosis of PBC is the presence of
anti-mitochondrial antibodies (AMA). Some advocate the presence of an AMA titre
>1/40 is strongly suggestive of PBC, even in the absence of symptoms and the
presence of normal alkaline phosphatase levels (Mitchison et al. 1986). However,
there is a subset of patients presenting with "PBC symptoms" clinically and
histologically, bar the presence of AMAs, who would previously have been
diagnosed as suffering from PBC, but are now diagnosed with autoimmune
cholangitis (AIC). The lack of AMAs in these patients initially appeared to be the
only factor distinguishing them from PBC sufferers, questioning a genuine need for
such a distinction and challenging the notion that the AMAs are truly pathogenic, at
least in initiation of PBC, or even disease specific, as AMA are also found in the
general population (though these may be of a different specificity). However, there is
some evidence that there is a greater frequency of anti-nuclear antibodies, lower
serum immunoglobulin (Ig) M levels, a lower frequency of the DR8 genotype and
serum aspartate aminotransferase levels may differ in AIC patients compared to PBC
patients (Czaja et al. 1998). Despite these observations it is still unclear whether AIC
is a distinct disease. In fact it is probable that AIC is a cholestatic liver disease with a
natural history similar to AMA positive PBC despite some differences in serology
(reviewed in Heathcote 1997).
1.1.5.2 T lymphocytes
It has been postulated that clusters of differentiation (CD) 8+ cytotoxic T
lymphocytes (CTL) mediate BEC damage in PBC. Indeed, a decrease in the number
of CD8+ and CD28+ cells in peripheral blood of patients has been reported which
may reflect infiltration of these cells into the liver (Moreno-Otero et al. 1994;
Kurokohchi et al. 1998) and the lymphocytes observed in close contact with BECs
have been reported to show similar morphology to that of cytotoxic lymphocytes
observed in in vitro lymphocytotoxic systems (Bernuau et al. 1981). CD8+
lymphocytes have been observed infiltrating the damaged bile ducts over the
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basement membrane (Deguchi et al. 1998). As well as CD8+ T lymphocytes CD4+
cells are present in the lymphoid infiltrates within the liver, particularly around the
portal tracts. The CD4+ T lymphocytes may partake in the destructive process via
cytokine secretion, augmentation of CD8+ lymphocyte cytotoxicity mediated against
BECs and/or enhancing B lymphocyte/plasma cell activity. There is evidence that T
cell expansion in PBC patients is antigen driven and multiple T cell clones
accumulate in the liver (Ohmoto et al. 1997; Okamoto et al. 1998). An increase in
the memory (CD4+CD45RA"ROhlgh) to naive (CD4+CD45RAhlghRO") T lymphocyte
ratio in peripheral blood lymphocytes and liver infiltrating lymphocytes has been
reported implying cells of the former subset are functionally potent, requiring less
stimulation to become activated (Bjorkland et al. 1991; Leon et al. 1995a). The
literature regarding the T cell phenotype of the lymphocytes in PBC remains
inconclusive and controversial (reviewed in Van de Water et al. 1997) exemplifying
that the situation is complex and remains a conundrum for future study.
In the light of the infectious agent initiator hypothesis (1.1.4) it is interesting to note
that expression of the CD Id antigen has been identified in periductal granulomas and
early stage bile ducts in PBC liver (Tsuneyama et al. 1998). CDld is one of a family
of CD1 MHC Class I-like molecules which are believed to be important in non-Class
I or -Class II antigen presentation pathways. The CD1 molecules can present
microbial non-peptide lipid antigens to CD4-/CD8- T lymphocytes and it is possible
that the CDld molecules expressed in PBC granulomas and small bile ducts may be
serving this purpose. Though CDld expression was also observed in granulomas in
the liver of patients with sarcoidosis the ductal epithelial staining was virtually
unique to early stage PBC liver, the exception being one primary sclerosing
cholangitis (PSC) case. The positive ducts in the PBC cases were all less than
100pm, i.e. those destined for destruction, and no late stage cases were positive. It is
interesting to speculate whether this aberrant CDld expression is involved in antigen
presentation to surrounding T lymphocytes and what the nature of the antigen might
be. Mycobacterial or bacterial components are prime candidates though modified
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endogenous lipidic compounds related to bile ducts or biliary substance are other
possibilities.
1.1.5.3 Cytokines
On the basis that PBC is an immunologically based disease analysis of the patients'
cytokine expression profile and pattern may help elucidate the nature of the disease.
However, this task is not an easy one because the majority of the patient liver
material available for study represents late stage disease, by which point it may be
argued that the immunological responses present are likely to have little bearing on
those initiating the disease. Many early studies examined the cytokine expression
profiles of peripheral blood mononuclear cells (PBMC), which may be
unrepresentative of the situation in the liver, and the majority of studies have looked
at mRNA levels which do not necessarily correspond to protein levels or give any
indication of the origin of expression.
Individual T lymphocytes may express a variety of cytokines but chronic immune
responses are often dominated by a T lymphocyte helper (Th) 1 (i.e. interferon (IFN)
y, IL-12, TNFa) or Th2 (IL-4, IL-5, IL-10) type cytokine profile (reviewed in
Janeway and Travers 1994). Thl and Th2 T lymphocytes develop from the same
CD4+ T helper lymphocytes and the differentiation pathway is determined by the
type of stimulation the precursor receives, in particular the cytokine environment
present at the time of antigen recognition. The principal effector function of Thl
cells is in phagocyte and cell mediated immune (CMI) responses against infections.
Th2 type responses are effective against extracellular pathogens such as helminths
and arthropods and Th2 cytokines stimulate B lymphocytes to enhance antibody
mediated responses. Though a Thl mediated response is highly desirable in resolving
a variety of infectious agents, under certain circumstances an inappropriate or
exaggerated response may occur which proves detrimental to the host, resulting in
self tissue damage and pathology. These undesirable responses are known as delayed
type hypersensitivity (DTH) responses and are believed to be the pathological cause
ofmany autoimmune diseases.
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The differentiation of naive CD4+ lymphocytes into Thl or Th2 cells is influenced
by cytokines produced early in response to the initiating agent such that the
orchestrators of the innate response have a profound effect on the evolution and
development of the acquired response. M<j>s infected with Listeria, Mycobacterium or
Leishmania produce IL-12 which initiates development of a Thl response and
natural killer (NK) cells can be stimulated by viruses, for instance, to produce IFNy
which acts on M<|>s to induce IL-12 secretion. This scenario illustrates an important
link between an innate immunity mediator, IL-12, and a specific immune response
and the central role of the M<j) in development of the latter. IL-12 also enhances CTL
and NK cell activity and IFNy release, which inhibits development and enhancement
of a Th2 response. When a response is initiated in the presence of IL-4 development
of a Th2 response follows. As for the Thl response there is a reciprocal inhibitory
effect of the Th2 cytokine IL-10 on development of a Thl response.
It would be helpful to determine whether the immune response mediating PBC is
mainly a Thl or Th2 response because there is the potential to manipulate these
responses and hence, hopefully, alleviate the cellular destruction. When late stage
liver biopsies and extracts have been analysed by RT-PCR there appears to be
variations in patients' expression profiles between and within studies but IL-1 and
TNFa levels have been reported to be negative or reduced compared with controls
(Tovey et al. 1991; Shindo et al. 1996). In contrast, Yasoshima and colleagues
identified increased expression of TNFa and IL-6, by immunohistochemistry and in
situ hybridisation, in BECs of stage I and stage II PBC biopsies. Other hepatobiliary
disease BECs showed mild or moderate expression while expression in normal liver
samples was mild or absent. TNF receptor and IL-6 receptor a-chain were also
detected on damaged bile ducts (Yasoshima et al. 1998). Analysis of IL-ip, IL-2, IL-
6, IFNy and transforming growth factor (TGF) p expression levels showed little
difference between PBC patients and autoimmune chronic active hepatitis patients in
one study, except for more frequent IFNy expressing PBC patients. However, IL-5
mRNA expression was confined to PBC patients (Martinez et al. 1995). The elevated
IL-5 levels may contribute to the high eosinophilia reported in PBC livers,
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particularly in those showing stage I and II histology (Nakamura et al. 1996;
Yamazaki et al. 1996). Some report that PBC patients exhibit elevated serum IFNy
levels (Galatola et al. 1998) while others report increased IL-ip and IFNy expression
in CAH compared with PBC (Napoli et al. 1994). Increased levels of IL-2, IL-6 and
IL-8 have been detected by RT-PCR in PBC liver tissue of patients undergoing
transplantation. However, as expected, this finding was common to other forms of
cirrhosis and was not PBC-specific (Napoli et al. 1994). Shindo et al. failed to detect
mRNA for IL-1, IL-2, IL-4, IL-5, IL-6 or TNFa from PBC liver biopsies, which
contrasts with many of the above findings, but found IFNy expression more
frequently as disease progressed (Shindo et al 1996). Harada et al. have detected
mRNA for both IFNy and IL-4 in PBC livers with CD4+ cells being the predominant
source of IFNy. They observed a greater number of IFNy positive cells than IL-4
positive cells and suggest a Thl response predominates (Harada et al. 1997a).
Analysis of individual liver-derived autoantigen-specific T cell clones suggest that
both Thl- and Th2-like clones are present. This suggests both cell mediated and Ab
mediated immune responses may co-exist (Van de Water et al. 1995; reviewed in
Leung et al. 1996) though there are signs of defects in both Thl and Th2 responses
(Jones et al. 1997). It has been hypothesised that the destructive response in PBC is a
Thl mediated DTH type response and the Th2 like cells detected may be playing a
regulatory role (reviewed in Berg et al. 1997), though much work remains to be done
in this area before confirming or disproving this theory.
1.1.5.4 Macrophages and Kupffer Cells
The frequent incidence of epithelioid granulomas or epithelioid cell aggregation
around damaged bile ducts, especially in the early histological stages of disease, is of
particular interest and suggests Kupffer cells (KC), M(j)s and/or M(|) derived cells
(discussed in 1.3), may be important players in the early lesions (Nakanuma and
Ohta 1983; reviewed in Nakanuma et al. 1995). These granulomas are not restricted
to the vicinity of the bile ducts and may also be observed in hepatic lobules
(reviewed in Nakanuma et al. 1995). Mathew et al. have quantitatively analysed the
M([) and KC distribution and morphology in PBC liver sections
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immunohistochemically using the KP1 and EBM 11 anti-CD68 clones (Mathew et
al 1994). They observed larger cells showing increased cytoplasmic KP1 and EBM
11 staining in the PBC sections, with histological stage 3 sections showing the
greatest numbers of positive cells. The authors believe that the expanded KC
population mediates the stimulation of perisinusoidal cells, via release of factors
such as TNFa, TGFa and TGF-(31, resulting in increased extracellular matrix protein
synthesis and fibrosis. A histological study of twenty one stage I or stage II liver
sections showed granulomas in the portal tract area of every section, frequently near
damaged ducts, but additional interlobular granulomas were more frequent in AMA
negative cases (Yunoye et al. 1984). Takezawa and Yamada report that the
granulomas in PBC were closely related to interlobular bile duct lesions and suggest
something derived from the ducts plays an important role in granuloma formation
(Takezawa and Yamada 1984). The PBC patients analysed with granulomas were
histologically of early stage, some being asymptomatic.
1.1.6 Therapy
UDCA (ursodeoxycholic acid) is gaining favour in managing the symptoms of PBC,
improving patients' biochemical parameters, though whether it is effective in
increasing life expectancy is unclear. It is one of the curiosities of PBC that, given its
potentially autoimmune and immunological basis, the disease appears refractory to
immunosuppressive therapies. The inevitable progression to cirrhosis and liver
failure means that liver transplantation is presently the only therapeutic option for
end stage cases (reviewed in Heathcote 1996) though graft rejection or recurrence of
PBC following transplantation are serious problems (Van de Water et al. 1996).
1.1.7 Mechanisms of Cell Death
The exact mechanism by which the BECs are destroyed in PBC has not been fully
elucidated. Before current knowledge of this subject is considered "cell death" in a
more general fonn will be discussed.
Death is fundamentally as critical to living biological systems as life itself. A fine
balance of cell proliferation and cell death exists continuously throughout life from
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conception to death of the whole organism. Disruption of this homeostasis has major
implications for health and may be the cause of conditions including cancer,
psoriasis, autoimmune disease, neurodegeneration, Alzheimer's disease and
congenital malformations to name a few. For maintenance of health, when faced
with a plethora of pathogenic infectious agents, the body must adopt mechanisms to
kill these exogenous pathogens while limiting damage to self tissue. Within the
immune system death of self reactive thymocytes, during their development in the
thymus, is the first level of regulation and control to prevent the emergence of
autoreactive T lymphocytes.
The complexities of the mechanisms culminating in the demise of host and foreign
cells are great, but are generally categorised to result in apoptosis or necrosis.
Apoptosis is a morphological description of a form of programmed cell death (PCD).
The effector mechanisms appear to be similar in all cell types and are remarkably
conserved between species. The characteristics of an apoptotic cell include
chromatin condensation and cell shrinkage, cytoplasmic vacuolisation, blebbing of
the plasma membrane and elaboration of apoptotic bodies (membrane-wrapped
packets containing the cell's contents). Phagocytes subsequently take up the
apoptotic bodies. Apoptosis epitomises a "tidy" removal of undesired material
leaving no trace and, importantly, not initiating an inflammatory response. In
contrast, a necrotic cell "leaves its mark". By spilling its contents, after lysis of the
plasma membrane due to cell and organelle swelling, an inflammatory response
follows shortly. Such a scenario is obviously undesirable as a mechanism of removal
of effete body tissue or extensive infections.
1.1.7.1 Caspases
Initiation of the apoptotic process results in activation of cysteine aspartic acid-
specific proteases known as caspases which disable key homeostatic and repair
enzymes and bring about systematic destruction of the cell. Within the nucleus
chromosomal DNA becomes degraded into nucleosomal sized fragments.
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Caspases are a family of proteases whose members have distinct roles in
inflammation and apoptosis (reviewed in Thornberry and Lazebnik 1998). The
regulation of proteases is limited to control of their activity and substrate availability
because proteolysis is irreversible. By synthesising caspases as inactive precursors
large amounts of protein can accumulate which can be activated on demand by
another protease or by regulated autocatalysis. Proteolytic processing of the caspases
results in formation of heterodimers which themselves dimerise to form complexes
with two active sites. Caspases are among the most specific proteases known and
they cleave a select set of proteins in a co-ordinated manner during apoptosis. They
can regulate their own activation by positive and negative feedback loops and can be
inhibited by protease inhibitors e.g. the crmA, p35 and IAP (inhibitor of apoptosis)
proteins.
The contribution of caspases to the events of apoptosis is not fully understood but
some of their substrates have been identified. They inactivate proteins such as
Icad/DFF45, which inhibits CAD (caspase activated deoxyribonuclease) releasing
CAD's nuclease activity, and bcl-2 proteins (1.1.7.5), producing pro-apoptotic
fragments. They cleave lamins causing collapse of nuclear lamina contributing to
chromatin condensation and cleave proteins involved in cytoskeletal regulation e.g.
gelosin, focal adhesion kinase (FAK) and p21-activated kinase (PAK2). Other
caspase substrates include polyadenosine diphosphate (ADP) ribose polymerase,
actin, rho-GDI and SREBP (reviewed in Nagata 1997). Caspases appear to cut off
contact with surrounding cells, reorganise the cytoskeleton, shut down DNA
replication and repair, interrupt splicing, destroy DNA, disrupt the nuclear structure,
induce signals marking the cell for phagocytosis and disintegrate the cell into
apoptotic bodies.
Activation of initiator caspases e.g. caspase-8 and caspase-9 leads to activation of
effector caspases. By activating common effector caspases different signals leading




Nitric oxide (NO) has been implicated as an inducer of apoptosis and may be an
important factor initiating apotosis triggered by immune cells. High levels of NO
produced by M(j)s generated by inducible NO synthase (iNOS) induce apoptotic death
in a variety of cells (reviewed in Williams et al. 1998) and NO released from KCs
has been shown to modulate the biological viability of cocultured hepatocytes and
hepatoma cells, inducing apoptosis. Stimulation of the T cell receptor (TCR), under
conditions which trigger PCD induces NO formation and inhibition of nitric oxide
synthase (NOS) protects T lymphocytes from activation induced cell death (Williams
et al. 1998). It has been suggested that NO and its metabolites react with amino acids
in the target cells which may play a part in the induction of apoptosis (Higuchi et al.
1995; Kurose et al. 1995) and Fas ligand mRNA expression is known to be increased
by reactive oxygen intermediates (ROI) (reviewed in Watson 1999). NO can induce
necrosis as well as apoptosis and in some studies it has been shown to have a
protective affect on apoptosis.
1.1.7.3 Reactive Oxygen Intermediates
Mitochondria are a major source of reactive oxygen intermediates (ROI) and
excessive production of ROIs, i.e. oxidative stress, results in massive cellular
damage associated with lipid peroxidation and protein and nucleic acid alterations
leading to necrotic cell death. The hydroxyl ("OH) radical is believed to be
responsible for most of the oxidative damage resulting in necrosis. ROIs can also act
as signalling molecules and are believed to be central in the transduction pathways
culminating in PCD. They have been implicated in activating PCD triggered by
TNFa, ionising irradiation, anthracyclines, ceramides, glucocorticoids or survival
factor withdrawal and may also be required for the execution of the death program
itself. It is likely that the level of ROIs determines whether apoptosis, necrosis, or
apoptosis converting to necrosis at the late stage of PCD occurs (reviewed in
Mignotte and Vayssiere 1998).
1.1.7.4 Perforin and Granzymes
CTLs are known to induce apoptosis in their cellular targets which may be mediated
through Fas/Fas ligand interaction (1.1.7.5) or perforin and granzymes. The CTLs'
granules contain the pore-forming protein perforin and a family of serine proteinases
termed granzymes. Perforin polymerises in the target cell membrane producing
lesions analogous to those of the complement membrane attack complex (MAC),
though perforin alone is incapable of producing the DNA fragmentation observed in
CTL-mediated target cell death. Perforin is required for the primary lytic mechanism
of antiviral, alloreactive peritoneal exudates and of NK effector cells. CTLs utilise
the pore-forming capacity of perforin in conjunction with granzyme proteinases
which are capable of fragmentation of target cell DNA (reviewed in Smyth and
Trapani 1995).
1.1.7.5 Death Receptors
Death receptors are cell surface receptors which transmit apoptotic signals initiated
by specific "death ligands" (reviewed in Ashkenazi and Dixit 1998). Within seconds
of ligand binding, the receptors can activate death caspases resulting in death by
apoptosis within hours. The receptors belong to the TNF receptor (TNFR) family and
share a homologous cytoplasmic "death domain" sequence which enables the
receptors to engage the cell's apoptotic machinery.
Fas
One of these receptor/ligand pairs is Fas (Apol/CD95) and Fas ligand. The Fas/Fas
ligand system is particularly important in peripheral deletion of activated mature T
lymphocytes at the end of an immune response, killing of target cells such as virus
infected or cancer cells by CTLs or NK cells and killing inflammatory cells at
"immune privileged" sites such as the eye. Defects in Fas or Fas ligand in mice or
humans can lead to the accumulation of peripheral lymphoid cells, enlargement of
lymph nodes and a fatal autoimmune syndrome (reviewed in Nagata 1997).
When homotrimeric Fas ligand complexes bind trimeric Fas molecules an interaction
of the Fas death domain with the death domain of the adapter protein FADD (Fas-
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associated death domain, also called Mortl) follows. FADD also contains a "death
domain" which binds an analogous tandem repeated domain within the zymogen
form of caspase-8 (FLICE/MACH). The FADD mediated oligomerisation of caspase-
8 initiates the latter's self cleavage and activation which results in activation of
downstream effector caspases such as caspase-9, the functional homologue of
Caenorhabditis elegans' (C. elegans) CED 3, and execution of the apoptotic
pathway (reviewed in Nagata 1997; reviewed in Ashkenazi and Dixit 1998; reviewed
in Faubion and Gores 1999). Other cytoplasmic proteins besides FADD may
recognise the Fas death domain e.g. Daxx and FLIP and regulate apoptotic signals
through Fas. Fas/Fas ligand interaction may also activate caspase-2 using receptor
interacting protein (RIP) and RAIDD (RIP-associated Ich-1/CED3 homologous
protein with a death domain), as the adapter molecules, via pathways distinct from
those involving cytochrome c release from mitochondria (discussed in 1.1.7.6) and
are not inhibited by bcl-2 (discussed in 1.1.7.8) (reviewed in Watson 1999). FADD
not only transduces a death signal on Fas ligation but is also essential for mitogen or
antigen induced proliferation of T lymphocytes and B lymphocyte production
(reviewed in Strasser and Newton 1999).
Tumour Necrosis Factor
M(j)s and T lymphocytes are the major source of TNF and its ligation with TNFRI
(p55) activates the NF-kB and AP-1 transcription factors and induction of pro¬
inflammatory and immunomodulatory genes. TNF may also induce apoptosis
through TNFRI, though this is usually dependent on a block in protein synthesis,
suggestive of synthesis of suppressive factors thought to be mediated through NF-kB
and JNK (jun kinase)/AP-l. As for Fas, trimeric complexes of TNF interact with
TNFRI and the adapter protein TRADD (TNFR-associated death domain) binds
TNFRI recruiting a number of signalling molecules to the complex (reviewed in
Nagata 1997; reviewed in Ashkenazi and Dixit 1998; reviewed in Faubion and Gores
1999). Recruitment of TRAF2 (TNFR-associated factor-2) and RIP activates NF-kB-
inducing kinase (NIK) which activates the inhibitor of kB (I-kB) kinase complex
(IKK). IKK phosphorylates I-kB resulting in its degradation which allows NF-kB to
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enter the nucleus and activate transcription. The TRAF2 and RIP recruitment also
activates JNK/AP-1 through a signalling cascade involving the mitogen-activated
protein (map) kinases MEKK1 (map/Erk kinase kinase-1), JNKK (JNK kinase) and
JNK. TNFRI-TRADD-FADD interaction results in caspase-8 interaction and
apoptosis induction while apoptosis can also be induced through a TNFRI-TRADD-
RIP-RAIDD interaction, initiated through the binding ofRAIDD to caspase-2.
The TNF and TNFR families are extensive and also include Apo2L (TRAIT.), Apo3L,
DR3 (Apo3), DR4 and DR5, as well as several decoy receptors which inhibit Apo2L-
DR4 or DR5 mediated signalling. Thus, multiple physiological apoptosis initiators
exist which may endow specificity or redundancy to the critical regulatory system.
1.1.7.6 Mitochondria and Apoptosis
Apoptosis is independent of oxidative phosphorylation and does not require
mitochondrial DNA, though mitochondria play a central role in apoptosis in many
systems. There is evidence for a caspase-independent commitment to death and
some pro-apoptotic proteins such as bax (discussed in 1.1.7.8), which target
mitochondrial membranes, can induce mitochondrial damage and cell death when
caspases are inactivated (reviewed in Green and Reed 1998). At least three general
mechanisms, whose effects may be interrelated, are known of how mitochondria
control life and death. These include:
1) Disruption of electron transport (probably at the cytochrome b-c^cytochrome c
step), oxidation, phosphorylation and adenosine triphosphate (ATP) production.
2) Release of proteins which trigger caspase activation (i.e. cytochrome c,
procaspase-3, apoptosis inducing factor (AIF)).
3) Alteration of the cell's redox potential.
Cytosolic cytochrome c fonns part of the vertebrate "apoptosome" which is
composed of cytochrome c, apoptosis protease-activating factor 1 (Apaf-1) and
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procaspase-9, resulting in caspase-9 activation and subsequent apoptosis. This is a
rapid process but release of cytochrome c may also result in necrosis due to collapse
of electron transport, generation of oxygen free radicals and decreased ATP
production. Release of cytochrome c from the mitochondria is likely to be mediated
through opening of a large conductance channel, the mitochondrial permeability
transition pore, which results in dissipation of the membrane potential, matrix
swelling and disruption of the outer membrane. However, it has also been suggested
that the outer membrane disruption may involve hyperpolarization.
Many bcl-2 family members (discussed in 1.1.7.8) are situated in the outer
mitochondrial membrane, orientated towards the cytosol. Bcl-2, bcl-x and bax can
form ion channels in synthetic membranes and they may communicate functionally
or physically with inner membrane proteins governing ion transport or they may
regulate the intermembrane space pH. The anti-apoptotic bcl-2 family members' role
is much more complex than merely suppressers of caspase-activated proteins, which
is considered in 1.1.7.8,
1.1.7.7 p53
p53 is a tumour suppressor transcription factor (reviewed in Evan and Littlewood
1998) which is normally maintained in abeyance at low levels through its interaction
with Mdm-2, which signals its degradation. Phosphorylation of p53 or Mdm-2,
induced by DNA damage, prevents their interaction, resulting in stabilisation and
activation of p53. p53 activation may lead to growth arrest in the G1 and G2 stage of
the cell cycle, mediated through the cyclin-dependent kinase (cdk) inhibitor p21, or
to apoptosis. Genes implicated as p53 targets involved in apoptosis include those
coding for bax, insulin-like growth factor (IGF) 1 receptor, IGF binding protein 3
(IGF-BP3), proteins regulating angiogenesis and components of the renin-
angiotensin system. p53 may also trans-repress anti-apoptotic genes and p53 has
been shown to upregulate Fas and Fas ligand (reviewed in Watson 1999). Responses
to other stimuli such as physical damage, metabolic deprivation, heat shock, hypoxia
and expression of certain oncogenes (e.g. myc and E1A) may involve p53.
1.1.7.8 The bcl-2 Family Members
Bcl-2 was the first mammalian regulator of apoptosis identified, due to a
chromosomal translocation in a human follicular lymphoma which resulted in bcl-2
gene activation and cytokine independent survival of cytokine dependent
haematopoietic cells. Bcl-2 is a functional homologue of C elegans' Ced-9 and
inhibits apoptosis induced by many physiological and experimental stimuli. The
protein acts as a dominant repressor of apoptosis at a point where several
independent signal transduction pathways converge. However, some apoptotic
inducers, including antigen-receptor activation induced cell death and cytotoxic T
lymphocyte and TNF-mediated cytolysis are not inhibited by bcl-2 (Strasser 1995).
Proliferation promotes apoptosis and suppression of apoptosis appears to suppress
proliferation in certain circumstances. Elevated bcl-2 expression suppresses
apoptosis but the cells have difficulty entering the cell cycle (Evan and Littlewood
1998).
Apoptosis is regulated by a fine balance between pro- and anti-apoptotic members of
the bcl-2 family (reviewed in Adams and Cory 1998). At least fifteen members have
been identified in mammalian cells. Bcl-2 is structurally and functionally
homologous to Caenorhabditis elegans' (C. elegans) Ced-9 and their survival
function is opposed by proteins such as bax, mammalian bik (or Nbk) and nematode
EGL-1. Structurally the proteins most similar to bcl-2 which contain all four or the
first two of the conserved motifs known as bcl-2 homology domains (BH1-BH4), are
anti-apoptotic. The pro-apoptotic members fall into two subfamilies possessing BH1,
2 and 3 (i.e. bax, bak, bok) or only BH3 (i.e. bik, blk, bad, bid). The BH1, 2 and 3
domains are involved in homo- and hetero-dimerisation of the family members,
which regulates their function. Post translational phosphorylation events also affect
their activity. The effector mechanisms of these proteins is still being elucidated but
bcl-X[ (the larger product of two splice variants of bcl-x mRNA) may prevent
caspase-9 activation by inhibiting Apaf-l/caspase-9 interaction and bcl-2 may act in
part by preventing cytochrome c release from mitochondria (discussed in 1.1.7.6).
These proteins may also protect cells from apoptosis by shifting the cellular redox
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potential to a more reduced state and inhibiting the availability of cytochrome c in
the cytosol (reviewed in Mignotte and Vayssiere 1998). The ability of the BH1 and
BH2 containing proteins to insert into membranes and their resemblance to bacterial
toxins suggests the proteins may form channels in organelles but their substrates or
role in killing remains to be established. In particular the ability of bax to initiate
caspase-independent death has been hypothesised to be mediated via channel
forming activity promoting mitochondrial permeability or puncturing the
mitochondrial outer membrane.
The anti-apoptotic effect of bcl-2 is active in response against a diverse range of
cytotoxic insults (y radiation, ultraviolet (UV) radiation, cytokine withdrawal,
dexamethasone, staurosporin, cytotoxic drugs), but provides little protection against
Fas mediated apoptosis of lymphocytes or death of autoreactive T lymphocytes in the
thymus.
1.1.7.9 Macrophages and Apoptosis
M<j)s have been implicated in playing the role of passive scavenger of apoptotic cells
in regression of a variety of tissues, but they seem to play a more active role in
certain situations as M<() ablation studies show their apparent requirement for cell
death during regression of ocular capillaries (Aliprantis et al. 1996). M<j) derived
TNFa may be central in induction of apoptosis, particularly the membrane-bound
form of TNFa which activates TNFRII (p75), consistent with the observation that
cell-to-cell contact appears essential in M(])-mediated apoptosis.
1.1.7.10 Cell Death in the Context of PBC
Electron microscopy studies have shown BECs in PBC patients to display various
abnormalities including irregular shaped nuclei, dilated endoplasmic reticulum (ER),
swollen mitochondria and numerous cytoplasmic cytolysosomes. This form of
necrosis has been described as cytoplasmic focal necrosis and has also been observed
in many other cholestatic liver diseases (Bernuau et al. 1981). Of particular interest
in the above study was the report of "..particular type ofnecrosis....fragmentation of
the nuclear chromatin and condensation of the cytoplasm in which closely packed
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organelles were still recognizable. " This is a classic description of a cell undergoing
apoptosis and apoptotic bodies were also identified within cytoplasmic vacuoles of
BECs. Though only some BECs in a few of the cases studied exhibited this
phenotype it provides good evidence for apoptosis contributing to the loss of BECs
in PBC. Nakanuma et al. reported four types of biliary epithelial injury suggesting
cell death in the ducts; coagulative necrosis; lytic necrosis without detachment of
affected cells from the biliary epithelial layer; apoptosis; and detachment of several
adjoining biliary cells from the basement membrane and neighbouring biliary cells
(Nakanuma et al. 1983). Apoptotic cells were rare and affected cells were most
frequently those of bile ductules (structures containing not more than five nuclei).
These studies and others (Kuroki et al. 1996; Elarada et al. 1997b; Koga et al. 1997)
suggest that death of the BECs may be mediated by multiple mechanisms, including
apoptosis, and further investigation is warranted to elucidate the extent and potential
for manipulation of the pathways involved.
Kuroki et al. report that cell death and cell proliferation were simultaneous in the
same affected bile duct and their findings indicate that the cell death was faster than
the proliferation (Kuroki et al. 1996). The balance between cell death and
proliferation during the course of this chronic disease is clearly an important
determinant of the net number of viable BECs as a small imbalance, biased towards
death, will lead to a cumulative large deficit of cells. It is widely accepted that within
the liver of PBC patients there is proliferation of hepatocytes and cells which take on
the form of BECs, but the progenitor of the latter is uncertain. The so called
"ductular metaplasia" observed may originate from pre-existing BECs, from
hepatocytes or from a stem cell proposed to reside within the duct of Hering
(Aterman 1992; Marucci et al. 1993; Nakanuma and Harada 1993; Rubin et al. 1995;
Rudi et al. 1995). Bcl-2 expression in small interlobular bile ducts of normal liver
and in cirrhotic livers was found to be more prominent in ductules at the borders of
cirrhotic nodules (Koukoulis et al. 1995) and may influence the extent of viability
loss of these cells.
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Extensive hepatocyte injury does not appear to be prominent in the early evolution of
PBC (Klion and Schaffneer 1966) and the liver cell damage observed as disease
progresses is thus likely to be the result of secondary damage in the organ.
Using in situ nick-end labelling an increased frequency of BECs positive for DNA
fragmentation was seen in PBC sections compared with chronic viral hepatitis C and
normal controls, and in PBC and hepatitis C hepatocytes compared with normal
controls (Sakisaka et al. 1997). Though not specific for apoptosis this method for
detecting DNA fragmentation suggests that cellular injury of BECs and hepatocytes
in PBC may be the result of apoptosis. In contrast Ballardini et al. found apoptosis,
measured by a DNA fragmentation assay, to be a rare event in early stage PBC liver
sections (Ballardini et al. 1998). They found only four positive BECs in three
biopsies, but this low incidence is not surprising due to the short duration of
apoptotic events (2-4 hours) which extrapolated to an 5% apoptosis rate implies a
daily death rate as high as 40%. Koga et al. report increased DNA fragmentation and
bcl-2 expression in BECs and hepatocytes which may reflect apoptotic stress in the
PBC cases they analysed (Koga et al. 1997).
Immunohistochemistry studies have shown increased expression of Fas in BECs and
more frequent Fas ligand expressing CD4+ and CD8+ T lymphocytes around bile
ducts in PBC liver sections compared with those from hepatitis C patients (Koga et
al. 1998) which may suggest Fas mediated apoptosis contributes to BEC loss.
1.1.8 Pathogenesis
The pathogenesis of PBC remains an enigma, with various ideas and possible
mechanisms having been proposed without substantial evidence to support them. A
major problem in the understanding of PBC is the lack of a suitable animal model
for the disease. Though attempts have been made to induce PBC in animals by
administrating AMAs; attempting to induce these antibodies in a variety of ways
such as immunisation with the antigen; or immunising severe combined
immunodeficient (SCID) mice with peripheral blood lymphocytes (PBL) from PBC
patients, the results are a poor attempt at replicating the human disease (Krams et al.
1989a and 1989b; Kobashi et al. 1994; Abedi et al. 1996). PBC and grafit-versus-host
disease (GVHD) share a number of features which has led people to suggest
understanding one of these phenomena may further our understanding of the other
(Bernuau et al. 1981; Shulman et al. 1988; reviewed in Czaja 1994). However, these
hopes have yet to be realised and stark differences are apparent between GVHD and
PBC including the lack of AMA in the sera of GVHD sufferers (Quaranta et al.
1998) and lack of response of PBC to immunosuppressive therapy. Murine GVHD
systems, which are sometimes used as a model for PBC, are far from ideal and may
actually be misleading regarding the pathogenesis of PBC.
The following observations may give some insight into potential defects or
abnormalities suffered by PBC patients which may have some bearing on the
manifestation of disease.
1.1.8.1 Immunological Abnormalities
Numerous reports of intrinsic abnormalities or differential behaviour/responses of
components of PBC patients' immune systems have been published. These
observations reinforce the immunological basis for this disease but fail to provide
definitive proof of the precise abnormality which patients suffer. However, some of
the findings may reflect secondary effects of the disease process, or results of in vitro
studies may be due to the differential activation status of the cells in question at the
time of collection from the patients. A by no means exhaustive collection of reported
observations on this topic shall be mentioned to emphasise the breadth of studies in
this area.
DCs from PBC patients are reported to have a lower stimulatory capacity but higher
NO levels compared to controls in allogeneic mixed lymphocyte reactions (MLR)
(Yamamoto et al. 1998a and 1998b) yet the NO level measurements of whole blood
venous specimens from PBC patients showed an inverse correlation with disease
progression (Battista et al. 1997). SI00 positive cells with DC morphology have
been identified inside the basement membrane between BECs of septal bile ducts in
early, but not late, stage PBC liver sections and may partake in initiation and/or
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progression of the disease. It is interesting to note that these SI 00 positive cells were
found less frequently in other chronic inflammatory liver diseases studied (Demetris
etal. 1989).
T lymphocytes from PBC patients appear deficient in their responsiveness to IL-2
(Menendez et al. 1992) and their mitogen-induced production of TNFa, TNF(3 and
LFNy (Spengler et al. 1992).
Monocytes derived from PBC patients have been reported to exhibit markedly
reduced production of IL-1 (Saibara et al. 1984) yet increased levels of superoxide
(02~) production, both when unstimulated or stimulated with phorbol-myristate-
acetate (PMA) (Sipos et al. 1995). They have also been reported to produce
approximately threefold more prostaglandin E2 (PGE2) than monocytes from normal
or alcoholic cirrhosis controls when stimulated with phytohaemagglutinin (PHA)
which may account for the reduced proliferation of PBC cultures observed by others
(Chiricolo et al. 1989). Ultrastructural examination ofPBC liver biopsies by electron
microscopy has shown M([)s surrounding bile ducts, especially in the later stages of
disease, though their role in destruction of the BECs is uncertain (Chedid et al.
1974).
In vitro spontaneous and LPS-stimulated TNF production by cultured mononuclear
cells from PBC patients is significantly lower than that of cells from PSC patients
(Broome et al. 1992). PBLs from PBC patients show reduced NK activity (James and
Jones 1985) and a defect in the spontaneous cytotoxic function of surface Ig
negative, Ig fragment crystallisable (Fc) receptor (FcR) positive lymphocytes against
Chang cells (Vierling et al. 1977).
Though elevated levels of y8 T lymphocytes have been associated with autoimmune
disease it appears that in end stage PBC cases there is a significant reduction in the
proportion of hepatic lymphocytes expressing the y8 TCR (Curry et al. 1998). The
altered balance between y5 and ap TCR+ T lymphocytes is likely to reflect the
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infiltration of circulating ap TCR+ T lymphocytes and may affect the immune
homeostasis provided by the former T cell subset.
The eosinophilia observed in portal tracts in the vicinity of damaged bile ducts,
particularly during the histologically early stages of PBC, the deposition of major
basic protein and increased IL-5 mRNA levels discussed previously (1.1.5.3)
suggest eosinophils may be involved in the pathogenesis of bile duct damage
(reviewed in Nakanuma et al. 1995; Nakamura et al. 1996; Yamazaki et al. 1996). In
vitro studies of the effect of bile acids (taurochenodeoxycholic acid (TCDCA) and
tauroursodeoxycholic acid (TUDCA)) on these cells have shown a dose dependent
activation or cytotoxic effect which may contribute to the cholangiocyte injury
(Yamazaki et al. 1998).
Both MHC Class I and II molecules have been found to be expressed by BECs and
hepatocytes in PBC liver sections which has led to suggestions that these cells could
partake in antigen presentation (Ballardini et al. 1984; Tsuneyama et al. 1995a and
1995b; reviewed in O'Donohue and Williams 1996a). However, for effective antigen
presentation to CD4+ T lymphocytes additional costimulatory molecules must be
expressed on the APC in addition to the MHC molecules (reviewed in Harlan et al.
1995). It has been shown that B7-1 (CD80) and B7-2 (CD86) expression on BECs
can only be detected in sections showing histological late stage disease (Tsuneyama
et al. 1995a; Spengler et al. 1997) and in vitro studies suggest it is unlikely that
human intrahepatic BECs play a direct role in activation of antigen specific CD4+ T
lymphocytes (Leon et al. 1996) and their ability to express B7 is questionable (Leon
et al. 1995b). Thus, a role of the BECs acting as "professional APCs" for the
infiltrating T lymphocytes is unlikely to be an initiator of disease. However, they
may contribute to the pathology as disease progresses, in combination with the
observed intercellular adhesion molecule-1 (ICAM-1) and vascular cell adhesion
molecule-1 (VCAM-1) expression of these cells in PBC which are not detected on
ducts in normal livers (reviewed in Leung et al. 1996; Nakanuma et al. 1997).
Though elevated or aberrant expression of surface molecules, such as ICAM-1, MHC
Class I and MHC Class II, on interlobular bile ducts has been observed in PBC liver
sections it is not disease specific as this expression pattern is also seen in other
immune-mediated liver disease states and the data regarding ICAM-1 expression is
inconsistent (Spengler et al. 1988; Hashimoto et al. 1993; Tsuneyama et al. 1995a
and 1995b; reviewed in Broome et al. 1996; Kamegaya et al. 1997; reviewed in
Nakanuma et al. 1997).
The presence of secretory IgA anti-PDC antibodies in the saliva of PBC patients has
led to suggestions that these antibodies may be present in the liver and partake in the
BEC damage. By trafficking through the BECs the antibodies could bind PDC
intracellularly, depleting the cells of PDC causing metabolic cell damage. The
complex would then be secreted into the lumen of the ducts (Palmer et al. 1998). In
support of this theory PBC liver sections show high levels of IgA staining in the
luminal region of bile duct epithelium which is not seen in controls (Van de Water et
al. 1993), though other cholestatic diseases also show the presence of IgA in bile
ducts (reviewed in Krams et al. 1990). There is evidence for abnormal expression of
either PDC-E2, a PDC-E2 peptide or a possible cross-reactive molecule by BECs (as
well as salivary epithelium) in PBC and AIC patients which may contribute to
disease initiation or progression should this molecule be the focus of immunological
attack (Tsuneyama et al. 1995a, 1995b and 1997; Cha et al. 1996; reviewed in Leung
et al. 1996; reviewed in O'Donohue and Williams 1996b). However, it is also
possible that these or other antigens may be absorbed from bile or periductal tissue
into the BECs. Odin and colleagues suggested that apoptosis might modify PDC-E2
and propose high levels of reduced PDC-E2 after large scale BEC apoptosis may
prompt the autoantibody response (Odin et al. 1999). The PDC-E2 (or cross-reactive
molecule) expression observed in PBC BECs precedes Class II expression, the latter
seldom being found in liver sections of early stage disease (Tsuneyama et al. 1995a
and 1995b) suggesting antigen presentation by BECs of PDC or a cross reactive
antigen is unlikely to occur at the onset of disease. An observation of significant
interest regards the expression of PDC-E2 mRNA in liver determined by in situ
hybridisation (Harada et al. 1997c). This revealed that the aberrant apical staining
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pattern on interlobular bile ducts seen in PBC but not control liver, using an antibody
against PDC-E2, is not reflected by the expression levels of the mRNA. The control
cases included a variety of hepatic diseases and tissue showing no significant change
histologically. The majority of cases (over 88%) showed PDC-E2 mRNA expression
in periportal hepatocytes whereas less than 24% and less than 38% of cases showed
expression in interlobular and septal bile ducts, respectively. Proliferating bile
ductules, in contrast, showed expression of the mRNA in over 80% of cases. These
findings appear to support the view that the molecule which the anti-PDC-E2
antibody reacts with showing the aberrant apical staining pattern in PBC interlobular
bile ducts is not actually PDC-E2 but a cross reactive molecule.
BECs in PBC biopsy sections appear to have an impairment in high junctions with
increased paracellular permeability, which may allow toxic bile acids or various
antigens to leak into the periductal area from the bile duct lumen (Sakisaka et al.
1997). Whether this is a primary or secondary event in the pathogenesis of PBC is
not clear. Lymphoid and liver cells of PBC patients show altered mRNA and protein
expression of anion exchange genes which has been suggested to play a role in the
cholestasis, exocrine failure and immunodysfunction associated with the disease
(Prieto et al. 1993; Medina et al. 1997). The basement membrane of bile ducts in
PBC liver sections is disrupted, sometimes with multilayering and loss of continuity
(Chedid et al. 1974).
1.1.8.2 The Role of the Macrophage in PBC
As has been alluded to previously the presence of epithelioid cells and granulomas in
PBC liver sections is one of the few distinguishing histological observations when
various chronic biliary diseases are compared. In some patients epithelioid
granulomas are also found in lymph nodes, spleen and lungs. Within the liver the
number of epithelioid granulomas correlates with the presence of bile ducts such that
granulomas are less predominant in cases with extensive bile duct loss, suggesting
their subsequent disappearance after BEC destruction. Granulomas are not confined
to the bile duct lesions and epithelioid cells and granulomatous necrosis may be
predominant within the hepatic parenchyma. The inciting agent(s) inducing the
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granuloma formation is unknown but a number of suggestions have been made
including bacterial/mycobacterial infection, the absorption by M(j>s of biliary fats or
bile pigments which have leaked from the hyperpermeable biliary epithelial layer, a
hypersensitivity reaction against altered bile proteins or tissue proteins due to tissue-
damaging biliary substances, the effect of cytokines released by infiltrating
mononuclear cells or the presence of undigested immune complexes (Nakanuma and
Ohta 1983; reviewed in Nakanuma et al. 1995). Whatever its origin the epithelioid
granuloma formation is a fundamental lesion of PBC. Bearing this in mind the M(j)
and its role in health and disease will be discussed in more detail (1.2 and 1.3)
before considering the influence and effect of the natural resistance-associated
macrophage protein (NRAMP1) gene on this cell type and PBC (1.8).
1.2 THE MACROPHAGE AND THE IMMUNE SYSTEM
The human immune system has evolved and adapted effective and efficient
mechanisms to protect the body from infectious and harmful agents. The innate
immune system offers a first line of defence, employing non-antigen-specific attack
mechanisms which hold the pathogen in check while an antigen specific response is
mounted. M<j)s and neutrophils/granulocytes are central effector cells of the early
non-specific response, and M(j) participation during this stage equips them for the
role of APCs. Antigen presentation to antigen specific T lymphocytes is a pre¬
requisite for the highly specific acquired immune response involving T and B
lymphocytes. Their activation and products should effectively result in elimination of
infectious agents which have survived the innate immune response. Again the M(j)
comes into play during a cell mediated response and it plays additional roles during a
humoral response, emphasising the cell's multifunctional role from the earliest
stages of infection to the final demise of the offending agent.
1.3 THE MACROPHAGE
The mononuclear phagocyte system (MPS) (reviewed in Auger and Ross 1992)
comprises bone marrow monoblasts and promonocytes, peripheral blood monocytes,
tissue M(j)s and DCs. It constitutes the second major cell population of the immune
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system. Metchnikoff coined the term Mcj) or "big eater" in 1892, though we are still
faced with many questions concerning the origin and function of these cells.
Throughout the body M<|)S are widely distributed and display great functional and
structural heterogeneity. They are found in lymphoid organs, the liver, lungs,
gastrointestinal tract, central nervous system (CNS), serous cavities, bone synovium
and skin.
M<()s were originally assigned to the reticuloendothelial (RE) system in 1924 by
Aschoff. However, this did not constitute a true system as it included cells of non-
M(j) lineage which were capable of taking up "vital dyes", hence the introduction of
the MPS in 1969 to encompass cells of the M(j) lineage sharing functional
characteristics in vivo, including high phagocytic capacity, and being of monocyte
origin (van Furth et al. 1972).
1.3.1 Origin of the Macrophage
The M(J> originates initially, ontogenetically in the yolk sac (Moore and Metcalf
1970), then the fetal liver and subsequently in the bone marrow (reviewed in Auger
and Ross 1992) from a common progenitor of the monocyte and
neutrophil/granulocyte known as the colony-forming unit, granulocyte-macrophage
(CFU-GM) (Metcalf 1971). The decision of commitment to the monocytic or
granulocytic pathway is likely to take place at a stage preceding the promonocyte
and promyelocyte stage. However, the HL-60 human promyelocytic leukaemia cell
line can be differentiated in vitro down either path in the presence of certain phorbol
esters (to monocyte/M(j)) or dimethyl sulphoxide (DMSO) (to neutrophil) (reviewed
in Auger and Ross 1992). This suggests the switch may be at a later stage, but as
with all observations of cell lines the transposition of findings in vitro of a
malignant/mutant cell to a physiological, in vivo situation must be considered with
caution.
Monoblasts are the least mature cell of the MPS. They contain relatively small
quantities of lysozyme and non-specific esterase and possess limited phagocytic
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capacity. Monoblasts divide to form two promonocytes which contain lysozyme,
non-specific esterase and granules of peroxidase. Promonocytes phagocytose to a
large extent and are capable of phagocytosing opsonised bacteria, which the
monoblast can not, as well as IgG coated red blood cells (rbc), but relatively few
C3b-coated rbcs. The promonocytes give rise to monocytes, which remain in the
bone marrow for less than 24 hours, in the mouse, before entering the circulation,
where they remain for between 36 and 104 hours. The monocytes subsequently
migrate into extravascular tissue to become M<j)s. Migration involves adherence to
endothelium, migration between endothelial cells and through endothelial structures,
utilising high molecular weight glycoproteins on the monocyte, lymphocyte function
associated antigen 1 (LFA-1 or CD 11 a/CD 18), which interacts with ICAM-1 on
vascular endothelial cells. IFNy and IL-1 can augment ICAM-1 expression,
facilitating monocyte migration to inflammatory sites. Once monocytes have left the
peripheral blood they do not return.
The epithelioid cell is believed to be a terminal stage of development of the M(j)
system. These cells develop abundant cytoplasm and a morphological resemblance
to skin epithelial cells. Epithelioid cells can fuse to form multinucleated giant cells
and these cell types are common in granulomatous lesions, which will be discussed
later (1.4). They have lower levels of cell surface Ig and complement receptors (CR)
and are poorly phagocytic but exhibit increased lysosomal and respiratory enzyme
activity.
Monocytes and older resident tissue M())s generally have limited functional potential.
M(j)s from sites of inflammation (inflammatory M())s) have greatly increased
properties for endocytosis, digestion and secretion of neutral proteases, acid
hydrolases and regulatory proteins. Fully activated M(|)S which have been exposed to
microorganisms and/or products of sensitised T lymphocytes have in addition to the
properties of inflammatory M(j)s the ability to act as professional APCs, secrete large
amounts of ROIs and kill microbes and tumour cells efficiently.
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More than 95% of tissue M(j>s originate from blood monocytes while the remaining
5% appear to derive from the local division of mononuclear phagocytes which have
arrived in the tissues and body cavities from the bone marrow within the previous 24
hours, before completion of cell division. The fate of the tissue M<|> is unclear. They
may die in situ in the tissue or in local draining lymph nodes. Wherever or however
they die, the number of dying cells must be considerable, based on statistics from the
mouse, where approximately 1.5 x 106 monocytes are produced every 24 hours
which will eventually leave the bone marrow to become tissue M<j>s.
Our knowledge of the factors regulating monocytopoiesis in vivo is relatively sparse.
Macrophage colony-stimulating factor (M-CSF) and granulocyte macrophage
colony-stimulating factor (GM-CSF) are haematopoietic growth factors produced by
M(j)s themselves and their production is stimulated by exposure to external stimuli
including phagocytosable particles and endotoxin. M<|) derived IL-1 and TNF can
induce non-haematopoietic cells, such as fibroblasts and endothelial cells, to produce
M-CSF and GM-CSF, and hence mononuclear phagocyte development. T
lymphocyte derived GM-CSF and IL-3 are likely to contribute to M<|) activity in DTH
reactions, and serum derived factor increasing monocytopoiesis (FIM) stimulates
monocytopoiesis in mice and rabbit bone marrow. M-CSF is likely to regulate steady
state monocytopoiesis while GM-CSF and IL-3 may play a greater role in the
regulation during an inflammatory response.
1.3.2 Functions of the Macrophage
Mononuclear phagocytes encompass the clearest example of a cell population which
is critical for natural immunity but has additionally adapted to play a central role in
specific acquired immunity. Their principal functions in natural immunity include
the following (reviewed in Abbas et al. 1994):
1) M(j)s function as the principal scavenger cells of the body, phagocytosing foreign
and potentially harmful particles including microbes, macromolecules, antigens
and injured or dead self tissue. Recognition of these substances involves cell
34
surface receptors, possibly for phospholipids and sugars. Once internalised,
lysosomal enzymes degrade the substances. M(|)s also secrete enzymes, reactive
oxygen species, NO and lipid derived mediators, e.g. prostaglandins, which kill
microbes and control the spread of infections but they are also capable of injuring
normal tissue in the immediate vicinity.
2) M(j>s secrete a wide range of cytokines, enzymes and biologically active
substances: over 100 have been reported ranging from superoxide anions to
fibronectin, growth factors to mediators of cell death. They release cytokines
which attract neutrophils and other inflammatory cells to a site of inflammation
and are responsible for many of the systemic effects of inflammation e.g. fever.
Functioning as accessory cells in immune responses, M(j>s play an important role in
the cognitive, activation and effector phase of specific immunity including:
1) M(j)s function as accessory cells in lymphocyte activation by presenting antigen to
T lymphocytes and expressing proteins promoting T lymphocyte activation.
2) During CMI responses antigen stimulated T lymphocytes secrete cytokines which
activate Mijis, enhancing the latter's phagocytic, degradative and cytocidal
functions. In an activated state Mtjis play a principal part in cell mediated
immunity.
3) M(j)s also partake in the elimination of foreign antigens by humoral responses by
taking up antibody or complement opsonized particles much more efficiently than
uncoated particles. Mtjis themselves are an important source of complement
components.
1.3.3 Activation and Signal Transduction
At least three distinct signal transduction pathways have been identified during the
induction of M(j> activation which are related and interact. Within seconds to minutes
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after a given activating molecule ligates its receptor, a series of rapid events occur.
Intermediate events occur within minutes to 4 hours and slow events occur within
hours to days. IFNy initiates intermediate events, termed cascade I, including
generation of slow Ca2+ fluxes and changes in protein kinase C (PKC) potential. LPS
is an endotoxin derived from gram negative bacteria which is a potent activator of
M(j)s. It fonns a complex with the LPS-biding protein (LBP), an acute phase reactant
present in serum, and the LPS-LBP complex is the ligand for CD 14 (Wright et al.
1990). CD 14 is a well known marker for monocytes and M(j)s and its ligation can
stimulate production of TNFa, IL-1, IL-6 and IL-8. LPS initiates events collectively
termed cascade II which comprise the breakdown of polyphosphoinositides,
diacylglycerol generation, PKC stimulation and protein phosphorylation, as well as
the generation of inositol triphosphate (IP3) isomers and subsequent Ca2+ fluxes. A
distinct cascade of events, cascade III, also initiated by LPS, results in synthesis of a
distinct set of polypeptides, which are likely to have a regulatory role, and
transcription of the competence KC gene.
1.3.4 Macrophage Heterogeneity
There is no evidence that the tissue destination ofmonocytes is pre-programmed and
seeding to different tissues is thought to be random. In the absence of inflammatory
signals resident M(|)s are widely distributed and display regional heterogeneity with
regards to functional, morphological and phenotypic characteristics, which are likely
to result from the local environment of the M(j>. These heterogeneous populations
include alveolar M<j>s of the lung, KCs of the liver, red pulp M(|)s of the spleen,
histiocytes of connective tissue, microglia of the CNS and M(j)s of the intestine to
name a few. It is the role of the KC, in particular, which is of most interest with
respect to pathology of the liver and will be considered in more detail.
Named after the pathologist C. von Kupffer, Kupffer cells (KC) are the resident M(j)s
of the liver and comprise the largest component of tissue M(()s in the body,
constituting 80-90% of the total fixed M(j)s (reviewed in te Velde 1994). They are
located in the liver sinusoid in close contact with the fenestrated sinusoidal
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endothelium. Non-parenchymal sinusoidal cells constitute 10% of the liver mass, of
which 30% are KCs, 60% endothelial cells and 10% Ito cells. KCs of the periportal
area are usually larger, have a higher endocytic and lysosomal enzyme activity and
are at a higher density than those of the venous area. Their location in the hepatic
sinusoid makes KCs the first M(j)s to contact products reaching the circulation via the
portal vein. KCs remove potentially harmful materials such as viruses, bacteria,
microorganisms, tumour cells, immune complexes and portal antigens and hence
form a protective barrier for the systemic circulation. To assign KCs to the role as
mere scavengers of these agents understates their true potential. Once activated, after
exposure to endotoxins or circulating cytokines from the portal circulation, KCs
function as inflammatory M(j>s. They release cytokines, lysosmal enzymes and ROIs,
and display enhanced chemotaxis and phagocytosis. Upregulation of MHC Class II
antigens on their surface and IL-1 production makes them capable of presenting
antigens to T lymphocytes. Though the liver plays a predominant role in clearing
systemic bacterial infections it is rarely infected itself. The clearance of infections
from the portal vein is highly dependent on KCs but it has been suggested that the
demise of these infections may be a concerted effort of the KC binding the bacteria
extracellularly and recruited neutrophils killing the extracellular bacteria, rather than
the KCs acting alone (Gregory and Wing 1998).
1.4 GRANULOMATOUS INFLAMMATION
Granulomas (reviewed in Adams and Hamilton 1989) are a characteristic feature of
many human diseases including tuberculosis, sarcoidosis and leprosy. They represent
focal, organised, chronic inflammation in which the M(j) is the predominant
constituent but other cells, including T and B lymphocytes, eosinophils, mast cells
and fibroblasts may be present and play important roles. Within the granuloma the
mononuclear phagocytes (small mononuclear cells, M(j)s, epithelioid cells and giant
cells) have either migrated into the tissue or divided within the lesion.
There are two distinct kinetic types of granuloma, high turnover granulomas which
tend to be induced by toxic substances such as mycobacteria, and low turnover
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granulomas which are usually induced by inert substances such as foreign materials.
High turnover granulomas contain many epithelioid cells and the irritant is usually
contained within a small number of M(])s in the granuloma, whereas in low turnover
granulomas the irritant is distributed within most of the M(j)s throughout the
granuloma. As the irritant is digested and degraded in high turnover granulomas
these generally evolve into low turnover granulomas. The "turnover" refers to the
rate of death and replacement of M<J)s in the granulomas.
Granulomas are generally evoked by relatively high concentrations of indigestible or
poorly degradable, persistent, inanimate or living substances, which are frequently
particulate. Microorganisms which evoke granulomas often induce a strong DTH
response and the accompanying T lymphocytes' secretion of factors, including
migration inhibitory factor (MIF), chemotactic agents, IFNy, and TNF, promotes the
accumulation and activation of M<j>s within the granulomas and expansion of the
lymphocyte population. The extent and duration of the granulomatous inflammation
can be dampened by Th2 lymphocytes suppressing the Thl population and a fine
balance between host inflammatory responses and the nature of the inciting agent
determines the progression of the granuloma. The granuloma is further regulated by
monokines and other factors released by cellular components other than T
lymphocytes. These can include pro-inflammatory factors, anti-inflammatory agents,
factors stimulating fibroblast activity and fibrosis, inducers of acute phase reactants
and factors promoting leukocyte production in the bone marrow. The development of
mononuclear phagocytes in granulomas mirrors that of monocytes through to
activated M(|>s described earlier (1.3.1).
1.5 DEFENCE MECHANISMS MEDIATED BY MACROPHAGES
1.5.1 Phagocytosis
As mentioned previously, M<j)s and neutrophils are highly phagocytic (1.3) and this
defence mechanism can be very effective in limiting and curtailing infections.
Opsonized particles which have been coated with complement or Ab are taken up
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most efficiently but the phagocytes also express receptors which recognise microbe
surface components, ligation of which enhances phagocytosis. M(J) phagocytic
receptors include FcyRI, FcyRII FcyRIII, Fca, CR1, CR3, ClqR, CD14 and
mannosyl/fucosyl receptors (reviewed in Speert 1992). The receptors for opsonized
material provides a way of recognising and phagocytosing a wide array of species
with broad heterogeneity in surface characteristics, using a limited number of
receptors. The surface expresssion of these receptors is influenced by local
conditions, cytokines and the differentiation state of the phagocytes. Formation of
the phogososme initiates a complex biochemical signalling pathway activating a
unique reduced form of nicotinamide adenine dinucleotide phosphate (NADPH)-
dependent oxidase complex which reduces oxygen (02) to superoxide (02"). The Of
is secreted into the phagosome and dismutased to hydrogen peroxide (H202). The
phagocyte's primary (or azurophilic) cytoplasmic granules fuse with the phogosome.
These contain myeloperoxidase (MPO), hydrolases (acid hydrolases, lysozyme,
neutral proteases, deoxyribonucleases (RNase)), elastase, cathepsin G and defensins.
Secondary (or specific) cytoplasmic granules, which contain lactoferrin, lysozyme,
vitamin B12-binding protein and the membrane proteins CDllb/CD18 (Mac-1),
cytochrome b558 and formyl-methionyl-leucyl-phenylalanine, fuse with the plasma
membrane releasing their contents (Calafat et al. 1993). Lysozyme is present in
relatively high concentrations in M<f>s, however its bactericidal function has been
questioned and it has been suggested that its principal role may be digestive. Other
lysosomal enzymes produced by M<j)s (including plasminogen activator, elastase,
collagenase, lipoprotein lipase, phospholipase, lysosomal acid hydrolases, arginase,
RNase, deoxynucleases (DNase), acid phosphatase and cathepsin) are able to lyse
bacteria and digest bacterial cell walls, but their direct role in antibacterial defence
has not been established clearly.
1.5.2 Reactive Oxygen Intermediates
Reactive oxygen intermediates (ROI) exhibit a broad spectrum of biotoxicity and the
optimal microbicidal activity of phagocytic cells, such as M(j)s, depends on these
substances i.e. 02", H202, 'OH, hypochlorous acids (HOX; X=halide ion).
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Microorganisms have evolved mechanisms to avoid contact with, and protect
themselves from, phagocyte derived oxidants. Likewise, host cells have developed
similar mechanisms to protect themselves from exposure to oxidants. The 02" ion is
moderately reactive and can act as an oxidant or reductant in biological systems. Due
to its relative inactivity it can diffuse for considerable distances before exerting its
toxic effects and extracellularly generated 02" (or a substance with similar
properties) can access intracellular targets via cellular ion channels (Roos et al.
1984). At low pH (e.g. inflammatory sites and inside phagolysosomes) 02" is
protonated to form 'H02 which is more membrane permeable and likely to react
with itself to form H202. H202 is more reactive than 02" and readily diffuses across
cell membranes. In the presence of catalytically active iron the Haber Weiss reaction
can occur resulting in 'OH and OH" species. The 'OH is a more potent oxidant than
the 02" ion and H202 and may in fact be mediating injury in cases where the latter
species have been implicated, however, its high reactivity limits diffusion and it is
unlikely to travel far before oxidising a substrate. It must, therefore, be generated in
close proximity to its target, and targets at a distant site may be injured by initiation
of a free radical cascade (Weiss 1986; Buettner 1993). These ROIs cause damage to
cellular membranes, enzymes and DNA, inhibit membrane transport processes and
are effective antimicrobial agents. Stimulated monocytes and neutrophils release
MPO which interacts with H202 to form HOC1, and chloramines, tyrosyl radical and
'OH are also produced by activated monocytes and neutrophils via an MPO-
dependent pathway adding to the defensive arsenal of these cells. The developmental
stage of the cells of the MPS determines their respiratory burst capacity and in vitro
cultured human monocytes show decreased MPO content and cytocidal activity
compared to freshly isolated monocytes (Locksley et al. 1987).
1.5.3 Reactive Nitrogen Intermediates
Nitric oxide (NO) is a gaseous free radical (i.e. an uncharged molecule with an
unpaired electron) generated by the five-electron oxidation of one of the terminal
guanidine nitrogen atoms of L-arginine to L-citrulline by NOSs (Vladutui 1995). At
least three NOS isoenzymes have been cloned. cNOS (NOSI) is constitutively
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expressed in neurones and certain epithelial cells. iNOS (NOSH) is transcriptionally
regulated and expressed in many cell types including M<j>s, hepatocytes and
respiratory epithelium. The activity of iNOS is dependent on fluctuations in
intracellular Ca2+ and microorganisms, microbial products and cytokines modulate
iNOS levels. NOSIII is also constitutively expressed, mostly in endothelial cells, but
its expression can be upregulated (e.g. by stress). NO can act as an oxidising agent or
interact with 02" to generate peroxynitrite (ONOO") and ultimately 'OH via ONOO"
formation and decomposition. NO's cytostatic and cytotoxic effects involve its
interaction with iron containing key enzymes of the respiratory cycle (e.g.
glyceraldehyde-3-phosphate dehydrogenase (GAPDH)) and DNA synthesis,
formation of nitrosothiol groups on proteins and formation of toxic alkylating agents.
ONOO" may be more important in mediating cytotoxicity by oxidising sulfhydryl
groups and DNA bases, catalysing iron dependent membrane lipid peroxidation and
reacting with metals or metaloproteins e.g. superoxide dismutase (SOD) to form the
toxic nitronium ion N02". NO may mediate cell death by apoptosis or necrosis,
depending on the cell type investigated, and convincing demonstrations of a
protective role for NO in oxidative stress have been reported (reviewed in Kroncke et
al. 1997).
1.5.4 Factors Augmenting Macrophage Function
Complement enhances M<j>s' antimicrobial activity, which may be mediated by its
chemotactic properties for mononuclear phagocytes and neutrophils and its roles as
an opsonin enhancing phagocytosis (reviewed in Speert 1992). It may also facilitate
the lysis of gram negative bacteria. Fibronectin is a widely distributed glycoprotein
which enhances the capacity of human monocyte derived M(j)s to ingest complement
coated particles and kill ingested bacteria. In the lung surfactant protein A may act as
an opsonin. It has similarities to the Clq complement factor and mannose binding
protein (MBP) which enables it to bind ClqR, enhancing phagocytosis by
mononuclear phagocytes. MBP can act in a similar fashion. 1,25 (OH)-vitamin D
enhances the anti-tuberculosis activity of human monocyte derived M(|)s, particularly
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in the presence of autologous serum, and may explain the enhanced natural
resistance to infection with M. tuberculosis offered by sunlight.
1.6 MONONUCLEAR PHAGOCYTES IN HEALTH AND DISEASE
Monocytes and M(j)s play an extensive role in health and disease. Their role in innate
immunity is crucial to hold infections at bay until an antigen specific acquired
immune response is mounted and initiation of this response may be M(|) mediated
through antigen presentation to T lymphocytes. During a cell mediated response they
again take on the role of effector cells. Defects in any of their immune functions are
likely to be to the detriment of the host. Their activity, however, may not always be
beneficial to the host when damage to host tissue, hyperactivation of M(j>s and
inappropriate immune responses occur.
Impairment of M<j> function can be primary, where it is the cause of the pathology, or
secondary, where it is a consequence of other immune cells' dysfunction, but may
facilitate the development and progression of disease. M(()s may exert their effect on
an immune response either directly or indirectly, by providing induction signals for
other immune cells. Due to the common lineage of M(j>s and granulocytes/neutrophils
defects observed in the function ofM(j>s may also manifest themselves in the function
of granulocytes/neutrophils, and visa versa. Hence, many syndromes and disease
with a M(|) component may also be the result of granulocyte/neutrophil dysfunction.
1.6.1 Immune Functions and Role in Disease of Macrophages
In response to injurious stimuli or immunological disorders, there is a rapid
adjustment of plasma protein composition known as the acute phase response
(reviewed in Auger and Ross 1992). The liver is the major organ synthesising acute
phase proteins however, it is the monocyte/M(j) which plays a central role in
regulating the response by secreting the cytokines IL-1, TNFa and in particular IL-6.
IL-la and IL-1 p (reviewed in Rees and Parry 1992) act as endogenous pyrogens,
lymphocyte activation factors and inducers of acute phase proteins. IL-1 P is the
predominant form found in activated monocytes and up to 5% of the total mRNA in
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these cells codes for it. IL-1J3 is the major secreted form with IL-la predominantly
functioning as a membrane bound cytokine. IL-1 increases the ability ofNK cells to
bind to their target tumour cells and synergises with IL-2 to induce lymphokine
activated killer (LAX) activity. IL-1 induces IL-2 secretion and expression of high
affinity IL-2 receptors on activated T lymphocytes and is chemotactic for CD3+ T
lymphocytes. TNFa (reviewed in Rees and Parry 1992) occurs naturally as a dimer,
secreted or membrane bound. It is linked to septic shock and its synthesis is induced
by PMA, LPS, IL-1, IL-2, IFNy and TNFa itself. TNFa can exhibit growth inhibitory
and promoting activity and is important in the activation and differentiation of cells
of the immune system. It induces MHC Class I expression and Class I and Class II
expression when it synergises with FFNy. As discussed previously it can be a potent
inducer of apoptosis (1.1.7.5). IL-6 (reviewed in Auger and Ross 1992) acts as a B
cell differentiation and growth factor and as a co-signal for IL-2 production and
proliferation ofT lymphocytes.
The M(|) employs both oxygen dependent and oxygen independent mechanisms to
destroy infectious agents, including viruses, bacteria, protozoa and parasites. M(j)s are
attracted to sites of infection and phagocytose the infectious agent. The mechanisms
employed to destroy different agents vary and the battle between 'prey and predator'
is continually evolving as microorganisms evolve mechanisms to avoid the
mononuclear phagocytes' potent microbicidal activity (discussed in 1.7). The
oxygen dependent defence mechanism is often referred to as the respiratory burst
and includes the production and intracellular release of reactive oxygen species such
as 02", H202, 'OH as discussed previously (1.5.2). Oxidized halogens can kill
bacteria and destroy many of their components, including redox enzymes and
nucleotides. The oxygen independent acidification of the phagolysosome to a pH of
4.5-5 provides optimal conditions for the activity of lysosomal acid hydrolases,
which kill a number of species.
Rheumatoid arthritis (RA) (reviewed in Pollack and Etzioni 1992) is an
inflammatory joint disease affecting the wrists and small joints of the hands and feet,
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but may also present as a systemic disease. Rheumatic nodules consist of necrotic
material which is surrounded predominantly by M<|)s which often have epithelioid
characteristics. RA sufferers have high levels of activated monocytes in their
peripheral blood which produce elevated prostaglandin E2 (PGE2) levels. Two main
hypotheses have been proposed to explain the pathogenesis of RA: M<j)-fibroblast
interactions and M(j)-T cell interactions (reviewed in Kingsley. and Panayi 1997),
both of which involve M<|)s as central players in joint destruction. The role of the
M(j)/granulocyte-specific gene NRAMP1 and pathogenesis ofRA will be discussed in
more detail later.
M(j)s have been cited as playing a contributory role in the immune responses resulting
in a number of diseases including systemic lupus erythematosus (SLE) (reviewed in
Pollack and Etzioni 1992), scleroderma (reviewed in Pollack and Etzioni 1992),
Guillain-Barre Syndrome (GBS) (Hartung et al. 1995), multiple sclerosis (MS)
(Bauer et al. 1996) and sarcoidosis (Chilosi et al. 1988). They also play a role in
wound healing, haemostasis (reviewed in Auger and Ross 1992) and atherosclerosis
(reviewed in Parums 1992).
1.6.2 Macrophages and Mycobacterial Infection
The re-emergence of tuberculosis (TB) as a serious threat to human health
throughout the world, after a period of relative "Western World freedom" from this
scourge, has been widely publicised throughout the medical profession and media.
However, the true scale of the problem may not be fully appreciated. At the 1993
symposium on "Immunology of Tuberculosis" in Berlin it was predicted that by the
year 2000, ten million people will freshly acquire active disease annually, of which a
third will die (Ehlers et al. 1994).
The course of TB can be divided into four stages. In stage 1 there is no bacillary
growth, and the organism is usually destroyed or inhibited by mature resident
alveolar M(j)s which ingest it. If it is not destroyed the tubercle bacillus grows in non
activated M<j>s and destroys them. In stage 2 the bacilli grow logarithmically within
44
immature M(j)s from the blood stream and early lesions form. During stage 3 the
number of viable bacilli becomes stationary due to the cell mediated and DTH
responses which are mounted and inhibit bacilli growth. The tubercle forms with a
solid caseous centre, and extracellular bacilli within it can not multiply due to the
anoxic conditions, low pH and inhibitory fatty acids. By killing the non-activated
M(j)s, in which the bacilli are growing, by the CMI and DTH responses, the host
eliminates the intracellular environment favourable for bacilli growth. Bacilli present
in immature M(j)s around the caseous centre are able to multiply, but in hosts which
have mounted a good DTH response, multiplication is inhibited and bacilli are
destroyed in highly activated M(j)s and epithelioid cells. These ingest and destroy
bacilli escaping from the caseum and can arrest the disease. However, in severely
infected and highly immunocompromised hosts, and in some cases even if the CMI
response is well developed, the bacillus evades the host defences and in stage 4 the
caseous centres may liquify resulting in unrestricted growth of the bacilli in the
liquified mestruum. In the lung DTH responses against the extensive bacilli growth
cause necrosis of the surrounding tissues and erosion of the walls of small bronchi,
resulting in cavity formation and spread of the bacilli to adjacent tissues and the
environment.
At the stage 3 point in the disease progression the difference in M<j> activation
determines the subsequent course of the disease. In resistant rabbits and most
immunocompetent adult humans the lesion becomes surrounded by numerous
microbicidal M([)S, activated by T lymphocyte derived lymphokines. Bacilli escaping
the caseous centre are ingested and destroyed, the tubercle becomes walled off and
disease arrests. In susceptible rabbits, infants and immunocompromised adults many
poorly activated M(|)s, which permit intracellular bacilli growth, surround the lesion.
The DTH response kills these M([>s, enlarging the caseous centre. Bacilli lodging in
the draining tracheobronchial lymph nodes are not destroyed and multiple
uncontrolled tubercles with extensive caseation form throughout the body ultimately
leading to death.
1.6.3 Macrophages and Parasite Infections
The outcome of many parasitic infections is dependent on mounting an appropriate
Thl or Th2 response to eradicate or contain the pathogen. The Mtj) appears to be
instrumental in the outcome of a number of parasite infections and is likely to
influence the type of response mounted. In many cases resulting pathology is due to
an inappropriate host response. Extracellular parasites of the helminth family
Schistosoma (S. spp.): S. japonicum, S. mekongi, S. mansoni and S. haematobium)
cause disease world wide (reviewed in Sadick 1992). Leishmania (L. spp.) is an
obligate intra-macrophage parasite in the mammalian host and L. major, L.
donovani, L. donovani chagasi, L. mexicana and L. braziliensis are responsible for
Leishmaniasis in humans (reviewed in Sadick 1992). In schistosomiasis a
granulomatous response to the schistosome eggs is common. In this infection a Thl
response is protective and a Th2 response results in disease. In leishmaniasis the
reverse is true and the genetic effect of the gene nra?npl on innate immunity to
Leishmania infection in mice will be considered in more detail later (1.8).
1.6.4 Macrophages and Viral Infections
Blood monocytes, tissue M<j>s and DCs are the major cellular elements in the
clearance and inactivation of many viral pathogens (reviewed in Gendelman and
Morahan 1992). However, they are also the major target cell and infectious reservoir
for many viruses, particularly lentiviruses. The phagocytic capacity of mononuclear
phagocytes enables them to eliminate blood borne virus from the circulation. M<j)s
can also restrict virus infection or replication in other cells by M(j) mediated antibody
dependent cell cytotoxicity (ADCC) when virus induced antibodies are present
which can neutralise and bind to infected cells. M(j>s may initiate immune reactions,
increasing the host's antiviral defence activity through release of cytokines (e.g.
IFNa, IFNP, TNFa, colony stimulating factors (CSF) and platelet derived growth
factor (PDGF)) and may themselves be activated to an antiviral state by the action of
cytokines released by virus specific T lymphocytes. M<j>s may also release factors
with antiviral potential e.g. complement factors, arachidonic acid metabolites and
neutral proteases. By acting as APCs and inducing specific antiviral T lymphocyte
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mediated responses they initiate the second specific phase of the immune response.
If a primary infection has not been successfully prevented they may act as a
permissive target cell for viral latency and persistence.
The classic example of the effect of the hosts' genotype influencing infectivity of a
virus is resistance to HIV infection in individuals who do not express the chemokine
receptor CCR5, which acts as a co-receptor with CD4 for the virus. HIV not only
infects CD4+T lymphocytes but M<|)s and DCs as well and the effect of the virus
within these cells is likely to have major implications on the course of infection and
transition to AIDS.
1.6.5 Macrophages and Primary Immunodeficiencies
The broad range of functions which M(j)s partake (i.e. inflammatory responses,
antigen presentation, immunomodulatory networks) results in their dysfunction being
involved in a wide variety of cellular and humoral immunodeficiency conditions.
However, the fact that no condition has been reported to date where there is
complete lack of the M<j) cell population supports the indispensable role of this cell
lineage. Mononuclear phagocytes are not only central to the immune system but
during embryogenesis they clear the developing body of apoptotic cells which have
died by PCD as the body form and organs of the foetus develop.
M(jis or monocytes have been shown to be defective in a variety of ways in patients
suffering from a number of diseases including chronic granulomatous disease (CGD)
(Donowitz and Mandell 1982), chronic mucocutaneous candidiasis (CMC)
(reviewed in Pollack and Etzioni 1992), common variable immunodeficiency
(CVID) (Arala-Chaves et al. 1982; Eibl et al. 1982a, 1982b and 1983; Pollack et al.
1985), Wiskott-Aldrich syndrome (WAS) (reviewed in Pollack and Etzioni 1992),
leucocyte adhesion deficiency (LAD) (reviewed in Pollack and Etzioni 1992) and
Chadiak-Higashi syndrome (CHS) (Gallin et al. 1975; Komiyama et al. 1986;
reviewed in Griffiths 1995). Such conditions render sufferers to succumb to frequent
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infections including Staphylococcus aureus (S. aureus), enteric gram negative rods,
Aspergillus spp. and Candida spp. and pyrogenic bacteria.
A number of primary familial monocyte disorders have been documented where
patients' monocytes exhibit reduced phagocytic activity and accessory cell function
(Prieto et al. 1990) and abnormal mobility and phagocytosis-killing ability against C.
albicans (Yamazaki et al. 1984).
Protective immunity to intracellular bacteria such as Mycobacterium and Salmonella
is dependent on CMI, a major effector mechanism of which is believed to be
activation of infected M(j)s by type 1 cytokines including IFNy. IFNy is produced by
Thl lymphocytes and NK cells, and regulated by IL-12, which is released by M<j)s
and DCs. Severe and selective susceptibilty to infection with Mycobacteria of low
grade virulence, and sometimes Salmonella, occurs in individuals with complete
IFNy receptor (IFNyR) 1 deficiencies (Ottenhoff et al. 1998). Poorly differentiated
mycobacterial granulomata develop with many scattered M(j>s, but a lack of
epithelioid cells, giant cells and surrounding lymphocytes. The immunodeficiency is
often fatal. The IFNyR 1 gene has been identified as harbouring a mutation hot spot
for deletions which result in dominant negative mutations inferring susceptibility to
the same pathogens as the complete IFNyR 1 mutations (reviewed in Foote 1999;
Jouanguy et al. 1999). Partial IFNyR 1 deficiency has also been reported which
impairs, but does not abrogate, IFNyR affinity for its ligand (Ottenhoff et al. 1998).
The deficiency appears to predispose individuals to curable "tuberculoid-like"
mycobacterial infections. A single case of complete IFNyR2 deficiency has been
identified which clinically, immunologically and histopathologically closely
resembles the cases of complete IFNyR 1 deficiency (Ottenhoff et al. 1998).
Individuals with IL-12 p40 and IL-12R(31 deficiencies have also been described who
show similar clinical syndromes to partial IFNyR 1 deficiency (Ottenhoff et al. 1998).
The selectivity of the infections with poorly pathogenic mycobacteria, and in some
cases Salmonella, in the absence of other severe microbial infections suggests the
type 1 cytokine pathway and its effect on M<j> function is essential in controlling
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these infections and there is no redundant protective immune response in these
individuals.
This collection of examples of human disease syndromes associated with M(j)
dysfunction serve to highlight their importance in the maintenance of health and
resistance to infection. It is apparent that their function and activity may be regulated
and affected, either subtly or significantly, by genetic factors and determining these
loci may help extend our understanding of how M(j)s perform effectively.
1.7 INTRACELLULAR EVASION MECHANISMS AGAINST
MACROPHAGE DEFENCE
The M(j) is the target cell for a large and diverse range of microorganisms
demonstrating an obligate requirement for an intracellular environment in which to
survive and replicate. In order to survive they need to overcome the defence
mechanisms of the M<() which include the oxygen dependent production of ROIs and
reactive nitrogen intermediates (RNI) and the oxygen independent acidification of
the phagolysosmal vacuole and action of hydrolytic lysosomal enzymes, nutrient
deprivation, defensins and other antimicrobial proteins. The complexity and multi-
layered make up of the host defence means there are many levels where parasites
may interfere with development of the response. Intracellular pathogens can actively
alter cell signalling leading to M<() deactivation and deactivation can also result from
the induction of auto-inhibitory cytokines such as IL-10 and TGFp. A number of
infectious agents including Leishmania, Mycobacterium, Plasmodium, Yersinia and
HIV can result in M<j> dysfunction. Many microbes secrete toxins to kill the
phagocyte which include streptolysin of Streptococcus spp. and leukocidin of S.
aureus. Neisseria meningitidis and pnemococci cover their surface with a
hydrophobic capsule to resist phagocytosis. Organisms including Chlamydia,
Legionella pneumophila (L. pneumophila), Leishmania, Mycobacterium,
Toxoplasma gondii (T. gondii) and Trypanosome cruzi have adopted strategies to
survive the hostile phagolysosome e.g. inhibition of its acidification or phagosome-
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lysosome fusion or escape from the vacuole (reviewed in Hall and Joiner 1991;
reviewed in Sadick 1992; reviewed in Speert 1992; reviewed in Reiner 1994 ).
Having discussed the M<j), its actions and importance in the maintenance of well
being our present knowledge about a gene of particular importance in the function of
this cell lineage will now be considered in detail and the possible role the gene may
play in human disease.
1.8 NATURAL RESISTANCE-ASSOCIATED MACROPHAGE
PROTEIN
1.8.1 History and Isolation of the Nramp Gene
As mentioned previously, intracellular bacterial parasite infections represent a
serious problem and genetic analysis of mice showing distinct phenotypic
differences in their response to such infections is one approach to understanding the
natural response against these pathogens. Gros et al. reported that, in mice, natural
resistance to the intracellular BCG (Bacillus Calmette-Gurein) parasite is controlled
by a single, dominant, autosomal gene, which is not linked to the H-2 locus (Gros et
al. 1981). Phenotypic expression of the gene, defined as Beg, could be detected as
early as 24 hours after infection and susceptible strains of mice showed active
multiplication of BCG up to 3 weeks, after which bacterial counts started to decline.
Beg exerts its effect during the early innate immune response and appears to control
early in vivo multiplication of the bacilli, rather than their elimination. Independently
a similar observation was made with respect to susceptibility and resistance to L.
donovani with susceptible mice unable to contain growth of the parasite during the
early stage of infection and the locus responsible was named Lsh (Bradley 1974).
The same pattern of resistance and susceptibility was observed with Salmonella
typhimurium (S. typhimurium) infection, the phenotype being inherited in a single,
autosomal, recessive Mendelian fashion (Plant and Glynn 1976). The locus
responsible was termed Ity. However, unlike with the Bcg/Lsh genotype, and
mycobacterial/leishmanial infections, S. typhimurium infection in susceptible
animals is fatal by day 10-16 post infection. The difference is due to the highly
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virulent nature of this mouse pathogen, which replicates very rapidly in RE organs
producing an overwhelming, lethal infection before a specific immune response has
been established.
Significant evidence existed which suggested the Beg, Lsh and Ity loci were one and
the same (Plant et al. 1982; Skamene et al. 1982). This was confirmed when a
candidate gene, which had been mapped to mouse chromosome 1 (Schurr et al.
1989) was cloned (Vidal et al. 1993) and named natural resistance-associated
macrophage protein (nramp).
Evidence from a variety of sources, including silica treatment, radio-resistance,
explantation ofMtjis from resistant to susceptible mice and the cellular tropism of the
infectious agents, indicated that the M<j) was the cell type expressing the genetic
differences between the resistant and susceptible strains of mice. In addition, in vitro
stimulated M(J)s from resistant and susceptible mice show temporal, qualitative and
quantitative differences in mRNA expression of early response genes including c-fos,
c-myc, JE and KC. The microbistatic effect against L. donovani is most pronounced
in KCs: however, it and the antimycobacterial activity of activated M(j>s is
independent of the respiratory burst. Though differences in the latter are observed in
resistant and susceptible strains this appears to be a marker of the activation state of
the M(j>s, rather than mediating the antimicrobial effect of the cells. Killing of
Leishmania in resistant strains does appear, however, to be dependent on NO
production mediated through a TNFa autocrine fashion (Blackwell et al. 1991). It is
important to note that the early resistance/susceptibility controlled by the Bcg/Lsh'lty
locus is independent of a functional T cell population. However, the genotypic status
may have "knock on" effects on the course of infection due to upregulation of MHC
Class II antigens in resistant M(f>s and more efficient antigen presentation to CD4+ T
lymphocytes. For instance CD4+ splenic T lymphocytes from resistant mice infected
with L. donovani retain an enhanced and increased ability to generate IFNy in
response to in vitro re-stimulation with leishmanial antigen which is not seen in
susceptible mice. Similar findings have been observed following M. bovis BCG
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infection (reviewed in Lang et al. 1997). Thymic, euthymic and athymic nude mice
of the //y-resistant phenotype showed no difference in S. typhimurium growth during
the early innate stage of infection (O'Brien and Metcalf 1982). There have also been
reports showing that BALB/c (susceptible) mice are actually more resistant to the
virulent H37Rv strain of M. tuberculosis than DBA/2 (resistant) mice, emphasising
that the ultimate outcome of such infections is regulated by additional genetic loci to
nramp (Medina and North 1996 and 1998; Medina et al. 1996). Studies using NOSH
knockout mice have identified iNOS to be of paramount importance in controlling
M. tuberculosis infection in mice (MacMicking et al. 1997). The NOSH7" mice did
not appear affected with respect to many cellular components of the immune
response considered important i.e. CD4+ and CD8+ T lymphocyte populations, Thl
proliferative responses to other intracellular pathogens, IFNy induced MHC Class II
upregulation, respiratory burst and IFNy and TNFa elaboration, yet the mice
succumbed to infection and died. The susceptibility was independent of nramp
genotype. However, it is important to point out that the end points and responses
measured in this study were taken at times beyond those where nramp dependent
responses are measurable. iNOS and NO production are obviously critically
important in influencing the end outcome and chronicity of M tuberculosis
infection, and may well be a point of convergence of IFNy and TNFa signals.
Nramp, though pivotal in orchestrating the early innate response, may not be able to
override the regulation and effect of determinants of the specific immune response,
which is the final death knell of such infections.
Penninger et al. have shown that ligand recognition of yS transgenic T cell
hybridomas, which was dependent on the y5 TCR, but independent of TAP-2 and
MHC Class I or II, was influenced by the nramp gene. The hybridomas did not
respond against M(f>s from susceptible mice but the role of nramp in the recognition
by the y5 T lymphocytes is not clear nor the implication of this finding in
physiological situations and infections (Penninger et al. 1995).
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Vidal et al. isolated nramp as a candidate for the Bcg/Ls/z/Ity gene by a positional
cloning approach (Vidal et al. 1993). The gene was later renamed nramp1 when
further homologous genes were isolated. Its expression was found to be restricted to
RE organs, populations enriched in M(j)s and a M(j) cell line. This expression profile
has subsequently been confirmed and the gene is expressed specifically in M(j)s and
granulocytes (Vidal et al. 1993; Govoni et al. 1997).
1.8.2 Nrampl Protein
Computer assisted analysis of the predicted amino acid sequence translation of the
nrampl gene identified ten or twelve hydrophobic potential transmembrane (TM)
domains (now believed to be twelve), two potential N-linked glycosylation sites, five
potential PKC phosphorylation sites and a putative src homology 3 (SH3) binding
domain (Vidal et al. 1993; Barton et al. 1994). The latter two are not conserved in all
the other family members of this protein, which will be discussed later (1.8.3),
suggesting a lack of functional importance or differences in regulation of the
different proteins across species. A twenty amino acid transport motif, initially
identified in a group of bacterial proteins (including the histidine, maltose and
oligopeptide transporters of E. coli), known as the "binding protein-dependent
transport system inner membrane component signature" (which will be referred to as
the conserved transport motif) was also present in nrampl. This motif has the
sequence (E,Q) (S,T,)2 3X G 6X (L,I,V,M,Y,F,A) N4X (F,L,I,V) (P,K) where
residues in brackets are alternative residues and X represents any residue (Gruenheid
et al. 1995). Bacterial permeases containing this motif are multi-subunit transporters
composed of a periplasmic substrate-binding protein, one or two homologous highly
hydrophobic inner membrane proteins believed to participate in substrate
translocation and one or two peripheral ATP-binding energy coupling subunits. They
are members of the ATP-binding cassette (abc) superfamily of membrane
transporters and the motif is postulated to mediate the interaction of peripheral ATP
binding subunits with the membrane components to energise transport (reviewed in
Belouchi et al. 1997). Eukaryotic abc transporters have not retained the conserved
transport motif, having integrated ATP binding subunits and membrane anchors in
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the same polypeptide. However, certain eukaryotic transport proteins i.e. (Na+, K+)
ATPase of Drosophila melanogaster (D. melanogaster), uracil permease of
Sacharomyces cerevisiae (S. cerevisiae), Aspergillus nidulans' (A. nidulans) nitrate
uptake protein, murine and human nramp2 proteins, Oryza sativa (0. sativa) nramp
proteins and sequences from C. elegans and M. leprae show high sequence identity
and similarity which is most marked in the motif and hydrophobic core of the
proteins (33-75% identity). This degree of conservation is remarkable for membrane
proteins separated by up to a billion years (reviewed in Cellier et al. 1995). The most
conserved region of the nramp family member proteins shares several invariant
residues (T M T (X)4 G (D,Q) (X)4 G F notation as for the conserved transport motif
described above) with a highly conserved region of animal voltage-gated K+
channels and a pattern of conserved residues with the proteolipid subunit of the
vacuolar H+/ATPase family (vATPase) (reviewed in Skamene et al. 1998). Human
NRAMP1 (discussed in 1.8.8) and mouse nrampl proteins are 89% homologous and
share the same characteristic features including potentially charged residues in six of
the TM domains, which are also highly conserved in the other family members
analysed. This may suggest that the proteins function as water-filled pores or
hydrophilic conducting channels. The TM segments are believed to form helical
structures which form a bundle with the more conserved face of the helices,
containing the invariant polar/charged residues, positioned towards the interior of the
channel and the hydrophobic exterior towards the lipid membrane.
Substantial evidence that nrampl was responsible for the Bcg/Lsh/lty phenotype
came from the identification of a single g>a transition present in the nrampl gene of
seven susceptible strains, but none of the twenty resistant strains, of mice analysed
(Vidal et al. 1995a). Based on the predicted multispanning transporter model this
would result in substitution of glycine (G), a small flexible residue, with aspartic
acid (D), a negatively charged residue, at position 169 on a strongly hydrophobic
face of the proposed helix within TM 4. Such a change would be expected to have
profound effects on the physical properties of the domain. Vidal et al. have failed to
identify mature nramp protein in susceptible mice by Western blotting, suggesting
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this single amino acid change prevents proper folding and/or causes aberrant
targeting to the Golgi and subsequent degradation of the mutant protein (Vidal et al.
1996). In fact the G>D mutation is a null allele in mice. These mutants have the
same phenotype as that of nrampl" mice (Vidal 1995a and 1995b), showing the
profound impact a single base change can have.
Definitive proof that nrampl was the Bcg/Lsh/lty gene was provided by targeted
gene disruption of nrampl and transfer of the wild type allele onto a susceptible
background (Vidal et al. 1995a and 1995b; Govoni et al. 1996). Vidal and colleagues
also showed that an intact nrampl gene is not necessary to mount cellular responses
against BCG, for granuloma formation, to contain bacterial dissemination or to
trigger M(j) differentiation into cells capable of killing ingested mycobacteria,
supporting the view that nrampl does not appear to play a major role in elimination
of intracellular parasites by activated M(j)s but prevents their proliferation.
1.8.3 Nramp Family Members
Sequence analysis of nrampl has identified a number of genes and proteins which
have been collectively classified as members of the nramp family. These have been
found in many phylogenically distinct organisms suggesting the fundamental
importance of these proteins throughout evolution. Before murine nrampl (1.8.4-
1.8.6) and human NRAMP1 (1.8.8) are discussed in detail a selection of other
members of their family will be considered. Studying and elucidating the function of
these homologues has enhanced our understanding of the nrampl proteins.
1.8.3.1 Other Mammalian Nramp Genes
In 1995 a murine gene named nramp2 was reported which mapped to chromosome
15 and had been isolated by cross hybridisation of nrampl complementary DNA
(cDNA) clones. The predicted structure of the nramp2 protein is very similar to that
of nrampl, with the proteins having 63% identical (78% similar) residues and the
genes being 86% identical (Gruenheid et al. 1995). A second human NRAMP gene
{NRAMP2) was identified in 1995, which mapped to 12ql3. The full length
NRAMP2 cDNA was published in 1997, the coding region of which was 64%
identical to human NRAMP1 (Kishi and Tabuchi 1997). Two splice variants of the
gene have been identified with the shorter (NRAMP2 non IRE) differing at the 3'
end, lacking a classical iron-responsive element (IRE) and substituting twenty five
novel amino acids for the C-terminal eighteen amino acids of the NRAMP2 IRE form
(Lee et al. 1998). The human NRAMP2 promoter region contains two CCAAT
boxes, three potential Spl binding sites, a potential IRE and five potential metal
response elements but no TATA box.
Electrophysiological studies in Xenopus oocytes demonstrated that nramp2 functions
as a pH dependent divalent cation transporter (reviewed in Atkinson and Barton
1998; reviewed in Hackman et al. 1998). The high level of sequence conservation
between the nrampl and nramp2 proteins reinforced the predicted role of this family
of proteins as multispanning transport proteins. A view substantiated by Fleming and
colleagues when they identified nramp2, using linkage analysis, genetic mapping and
candidate gene approaches, to be the gene responsible for microcytic anaemia (mk)
in mice (Fleming et al. 1997; reviewed in Vulpe and Gitschier 1997). These mice
show defects in intestinal iron absorption and erythroid iron utilisation. Analysis of
nramp2 sequence identified a g>a transition at a CpG dinucleotide in strains of mk
mice from two independent origins, resulting in a glycine (G) to arginine (R)
substitution. This mutation, like the nrampl G>D mutation, is situated in TM 4, two
helical turns away from the equivalent position of the nrampl mutation. Again, a
charged residue replaces a flexible glycine residue with extremely detrimental
consequences for affected mice. This same mutation has also been identified in the
nramp2 gene of the Belgrade rat (b) which has an autosomal, recessively inherited,
microcytic, hypochromic anaemia associated with abnormal reticulocyte iron uptake
and gastrointestinal iron absorption. These rats represent an animal model for
deficiency in intestinal iron uptake (Fleming et al. 1998). This rat homologue was
initially identified as a divalent cation transporter with a broad substrate range
including Fe2+, Zn2+, Mn2+, Co2+, Cd2+, Cu2+, Ni2+ and Pb2+ and was named DCT
(divalent cation transporter) 1 (Gunshin et al. 1997). It is interesting to note, when
hypothesising the specificity of nrampl from studies of its homologues, and potential
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for a shared or similar function of nrampl and nramp2 that nrampl's affinity for Fe2+
was much lower than that ofDCT1 and nramp2 transfection ofRAW264.7 cells was
unable to overcome the nrampl susceptible phenotype (Govoni el al. 1999). DCT1
maps to a region of rat chromosome 7 exhibiting syntenic homology to the distal
portion of mouse chromosome 15, where murine nramp2 maps. Both rat and murine
genes generate alternatively spliced mRNAs which encode 561 or 568 amino acid
proteins. DCTl's amino acid sequence is 73% identical to human NRAMP1 and
92% identical to human NRAMP2. It is expressed in a wide range of tissues, with
particularly high levels in the intestine at the sites responsible for intestinal
absorption ofmost divalent cations, in the S3 proximal tube segments and collecting
ducts of the kidney, in the cortex of the thymus and neurones in the brain. Nramp2 is
an integral membrane protein which is extensively modified by N-linked
glycosylation which contributes more than 40% of its molecular mass (Gruenheid et
al. 1999). The protein has been localised to the plasma membrane and recycling
endosomes which contrasts to the lysosome location of nrampl (discussed in 1.8.6)
(Gruenheid et al. 1997). Nramp2 co-localises with Tf and may be responsible for
transporting Fe2+ into the cytoplasm after acidification of the Tf-positive endosome.
Both release of iron from Tf and iron transport by nramp2 require conditions of low
pH. DCT1 mRNA levels appear to be regulated by iron, with diet induced iron
deficiency resulting in dramatically enhanced expression. This may be due to
stabilisation of the mRNA as the message has a stem-loop-structure in the 3'
untranslated region similar to the iron regulatory element-binding protein site which
mediates stability of the TfR mRNA during iron deficiency (reviewed in Fleet 1998).
It has been suggested that DCT1 may be responsible for non-receptor mediated iron
uptake in the intestine. Though Tf receptor (TfR) mediated endocytosis of iron is
likely to partake in iron uptake, the level of apo-transferrin in the intestinal lumen is
insufficient to account for the total dietary iron absorption, necessitating another
uptake mechanism. It is likely that the phenotypic abnormalities exhibited by the mk
and b animals result from the cumulative effect of metabolic disorders of divalent
cations such as Mn2+, Zn2+ or Co2+ in addition to those mediated by iron.
Complementation studies in yeast, where nramp2 was capable of complementing the
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smfl/smf2 mutant (discussed in 1.8.3.5), suggest nramp2 encodes a protein which is
capable of transporting Mn2+ in yeast and that residues Q384 and G394 in nramp2
were necessary for this complementation (Pinner et al. 1997; reviewed in Govoni
and Gros 1998).
In the human NRAMP2 gene five polymorphic sites and a single nucleotide mutation
have been identified but no observed linkage disequilibrium of haemochromatosis
patients with either mutant or normal HFE genes and a particular haplotype has been
found (Lee et al. 1998), though this does not eliminate NRAMP2 as a potential
contributor to human iron transport pathologies. Zoller et al. propose decreased
amounts of low molecular weight iron in duodenal crypt cells of hereditary
haemochromotosis patients, due to the HFE mutation, may activate the IRE binding
affinities of iron regulatory protein (IRP)-l and IRP-2 resulting in increased TfR and
NRAMP2 mRNA levels. Increased NRAMP2 expression at the apical site of the
duodenal mucosa would then promote uptake of iron leading to iron overload of the
duodenal cells (Zoller et al. 1999).
The most striking difference between nrampl and nramp2 is the ubiquitous
expression of the latter compared to the highly specific M(j> and granulocyte
restricted pattern seen for nrampl. Isotype specific antibodies raised against murine
nrampl and nramp2 have shown M(j)s to co-express both nramp proteins (Gruenheid
et al. 1999). In addition nramp2 does not contain the putative SH3 binding domain of
nrampl. Two nramp genes have been identified in mice, rats and humans; three have
been found in swine and birds; a putative third gene in mice has been mapped to
chromosome 17; and nramp genes have been cloned from sheep and apes (Bussmann
et al. 1998; Roger et al. 1998).
1.8.3.2 Malvolio
Shakespeare's Malvolio in "Twelfth Night" lives on in namesake in a group of
Drosophila mutants who, likewise, "last'd with distemper'd appetite'" (Rodrigues et
al. 1995). These mvl mutants showed a reduced preference for sugars and increased
acceptance of low salt concentrations. The mutants' abnormal taste behaviour could
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be suppressed by Mn and Fe supplementation and the mvl mutation appears to
affect a signal transduction pathway underlying taste perception rather than a
requirement for correct development of the nervous system components involved in
taste perception (Orgad et al. 1998). The amino acid sequence of the protein
responsible for the abnormal taste behaviour is 64%/65% identical and 78%/79%
similar to the mouse nrampl/human NRAMP1 sequences. Mvl is expressed in fully
differentiated neurones in the CNS, and neurones in the PNS and M(j)s throughout
development. Its function is not known but Supek et al suggest it may be involved in
Mn2+ transport on the basis of preliminary experiments in which Mn2+ ions reversed
the taste behaviour phenotype (Supek et al. 1997).
1.8.3.3 Fish
Recent reports have identified nrampl (OmNramp alpha) and nramp2 (OmNramp
beta) homologues, in rainbow trout (a teleost) and smelt. The latter are diploid
relatives of the ancestral tetraploid teleost supporting the hypothesis that OmNramp
alpha and OmNramp beta are independent loci which were present before
chromosomal duplication of salmonids, and the trout loci do not represent a recent
duplication (Dorschner and Philips 1999).
1.8.3.4 crnA
crnA mutants of A. nidulans were discovered which retained wild type growth on
nitrate as a sole source of nitrogen but showed reduced nitrate uptake (Unkles et al.
1991). The crnA gene, which encodes a nitrate transporter, was identified via these
mutants and when nrampl was subsequently isolated the striking sequence
conservation attracted much interest and speculation of a similar function for the
nrampl protein, a view which has now fallen out of favour.
1.8.3.5 SMF
SMF1 and SMF2 were identified as S. cerevisiae genes capable of suppressing the
mifl mutant, which has a defective processing enhancing protein (PEP) of
mitochondria (West et al. 1992). A mutation in the CDC1 gene was also found
which prevented growth of the yeast in the presence of ethylene glycol-bis ((3-
aminoethyl ether)-N,N,N',N'-tetraacetic acid (EGTA) and the mutant could be
suppressed by overexpression of the SMFJ gene. SMF1 appears to be involved in
high affinity Mn2+ and/or Zn2+ uptake and is located in the plasma membrane (Supek
et al. 1996). SMF2 has been identified as a possible low affinity Mn2+ transporter
(Supek et al. 1997) and a third yeast gene of this family has also been identified. As
well as these substrates the SMF1 and SMF2 proteins participate in transport of Cu2+,
Co2+and Cd2+ (reviewed in Liu and Culotta 1999a).
The amino acid sequence of SMF1 is 30%, and SMF2 29%, identical to human and
mouse nrampl proteins with between 53% and 58% overall similarity. The greatest
sequence conservation is over the conserved transport motif (Blackwell et al. 1995).
These findings introduce the possibility that nrampl may function as a Mn2+ and/or
Zn2+ transporter. A gene has been identified which negatively regulates the SMF1
and SMF2 metal transport systems called BSD2. The gene product is situated in the
ER and was postulated to retain the metal ion transporter proteins in the ER
preventing their over accumulation in the plasma membrane and resulting over
accumulation of metal ions (reviewed in Orgad et al. 1998). Recent reports have
elucidated the control of SMF1 and SMF2, mediated by the BSD2 gene product, to
include regulation via manganese and to a lesser extent iron as well. Under normal
situations the bulk of the SMF protein is targeted to the vacuole for degradation,
however, in BSD2 mutants the transporter remains within the secretory pathway and
fails to arrive at the vacuole. Physiological concentrations of manganese induces the
degradation of SMF2 in a bsd2-dependent manner while under conditions of metal
starvation the protein fails to arrive at the vacuole, accumulating at the cell surface in
a bsd2 independent way (Liu and Culotta 1999a). A functional metal transporter is a
prerequisite for movement to the plasma membrane and sequences in the conserved
transport motif and TM4 domains are needed for SMF1 to respond to metal
starvation (Liu and Culotta 1999b). A similar system regulated by the cellular metal
ion concentration is likely to exist controlling the mammalian homologues and it has
been speculated that the haemochromatosis HFE gene may produce an analogous
protein to the bsd2 protein (reviewed in Orgad et al. 1998). SMF1 and SMF2 do not
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share the SH3 binding domain structure suggesting that this domain may be a recent
addition to the nrampl molecule related to its M<J)/granulocyte restricted function.
1.8.3.6 OsNramp
Using the predicted amino acid sequences of the mammalian nrampl proteins a
database search identified several expressed sequence tags (EST) with significant
homology to nrampl (Belouchi et al. 1995). Two of these originated from O. sativa
(rice) and led to identification of a gene named OsNrampl which encodes a protein
with 60% overall homology to nrampl. As for the other nramp family members the
highest degree of sequence conservation is in the regions of predicted functional
importance, the conserved transport motifs, twelve predicted TM domains (including
the charged residues) and N-linked glycosylation sites, though the SH3 binding
domain in nrampl is not conserved. OsNrampl is expressed primarily in roots and
only at very low levels in leaves/stems. Based on hybridisation studies two further
members of the family, OsNramp2 and OsNramp3, have also been identified and
several homologues are believed to exist in other plant species including corn, wheat
and possibly potatoes, tomatoes, cabbage and field beans (Belouchi et al. 1997).
OsNramp2 is primarily expressed in leaves and OsNramp3 in roots and leaves and
the proteins are 69% and 60% similar to nrampl, respectively. Divalent cations such
A | ^ | ^ | 0-4-
as Mg , Mn , Co and Zn" are essential cofactors for many metabolic enzymes
and the OsNramp proteins may be plant transporters of such ions. The three
members may transport similar metal ions in different plant tissues with the
differences in the proteins reflecting differences in their regulation or their ability to
function in a specific cellular environment. It has also been suggested that these
nramp homologues may be implicated in the ethylene response pathway based on
identification of an Arabidopsis thaliana (A. thaliana) homologue which
complemented A. thaliana mutants defective in the ethylene respiratory pathway.
1.8.3.7 Caenorhabditis elegans
Genomic sequencing of C. elegans has revealed two tandem genes encoding peptides
85% identical and 66-70% identical to mammalian nramp, though their function is
unknown (reviewed in Cellier et al. 1996).
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1.8.3.8 Mycobacteria
An nramp family member has been found in M. leprae which shares 37% identity
with its mammalian counterpart and it has been suggested the two proteins may
compete for a common substrate vital for the intracellular survival of the bacteria
(reviewed in Cellier et al. 1996). Additional nramp related sequences have also been
identified in the genomes ofM. tuberculosis, M. avium and M. smegmatis as well as
some gram negative and gram positive bacteria (reviewed in Govoni and Gros 1998;
reviewed in Skamene et al. 1998).
Gene Source Amino acid identity with
nrampl
Function
NRAMP1 Human 88% DCT
nramp2 Mouse 78% DCT (Fe2+)
DCT1 Rat 63% DCT (Fe2+)
Mvll Drosophila 70% DCT (Mn2+)
crnA A. nidulans nitrate transporter
SMF1/SMF2/
SMF3








Table 1.1 Table showing the amino acid identity of a selection of nrampl family
members with the nrampl sequence. Where known the proposed protein function is
given; DCT divalent cation transporter with the cation of highest affinity given in
brackets. Reference sources are as in the text of 1.8.3.
1.8.4 Nrampl Regulation
Murine nrampl is constitutively expressed in M<|)s but the level is dramatically
enhanced by IFNy, LPS and GM-CSF suggesting it has a function in both resting and
activated M<j>s (Atkinson et al. 1997; Brown et al. 1995). Treatment with
corticosterone increases M. avium growth in susceptible but not resistant mice and
suppressed in vitro nrampl mRNA expression in susceptible M(j>s, suggesting a role
of hormones in the gene's regulation (Brown et al. 1995). Nrampl has been shown to
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be expressed in granulocytes at very high levels and in vivo or in vitro maturation of
monocytes to M<j)s upregulates its expression (Govoni et al. 1997).
Upstream of the two predicted transcription initiation sites in the murine nrampl
gene no TATA or CAAT sequences associated with RNA polymerase II transcription
have been found, but a potential initiator (Inr) element exists. The region contains a
GC rich region, two putative AP-2 sites, one AP-1 site, one AP-3 site, a PU-1 binding
site, two NF-IL6 sites, five IFNy response elements (y-IRE), an interferon-stimulated
response element, (ISRE), an IFNy activating sequence (GAS) element, an interferon
binding protein-1 (IBP-1) binding site, two NF-IL6 binding sequences and a Spl
binding site. The latter has been shown to augment transcription of the IL-8 and Ha¬
ras genes during M(j) activation (Blackwell et al. 1995; Govoni et al. 1995). The
presence of these elements is consistent with a M(j> expression profile regulated by
LPS and/or IFNy. Govoni and colleagues have shown murine nrampl expression can
be strongly upregulated by LPS in RAW264.7 cells in a dose and time dependent
fashion, which requires active protein synthesis. Pre-treatment with IFNy prior to
LPS administration increased nrampl induction, showing a synergistic effect of these
stimuli, though IFNy treatment alone did not have a strong modulatory effect on
nrampl mRNA expression. In vivo experiments using intraperitoneal injection of
LPS or thioglycollate also induced nrampl mRNA expression in splenic Mcjis
(Govoni et al. 1997).
1.8.5 Nramp Function and Phenotypic Effects
The role of NO in controlling intra-Mcj) infections and its regulation by nrampl is
unclear. From the sequence similarity of nrampl and crnA, the A. nidulan's nitrate
transporter (1.8.3.4), a similar function was proposed, whereby nrampl mediated
transportation of nitrate or nitrite into the phagosome/phagolysosome might augment
NO production in the acidic environment, with potential anti-pathogen activity.
Blackwell et al. have reported a requirement for NO in the anti-leishmania response
(Blackwell et al. 1991), though Brown and colleagues have ruled out a role for NO
as an effector molecule in Reg-mediated resistance based on in vitro M. avium
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infections (Brown et al. 1995). Though NG-monomethyl-L-arginine (NMMA)
inhibited the antimycobacterial response in M((>s from both resistant and susceptible
mice, corticosterone suppressed NO production in resistant IVtys but did not affect M.
avium growth.
Doherty and Sher (Doherty and Sher 1997) have reported that the mechanism of
control of M. avium appears distinct from that triggered by other intracellular
infections such as M. tuberculosis and T. gondii, being nrampl independent. The
mycobacteria appear to escape the innate phase of the response and TNFa and NO
induction do not seem to be necessary for control of the infection but may actually
contribute to the pathology. The NO resistance has been ascribed to the unusual
nature of the mycobacterium's cell wall. Thus, the phenotypic effect of the nrampl
genotype does not seem to be generalised over all members of a species reflecting a
highly specific defence mechanism and pathogen interaction which may account for
the above discrepancies. Indeed the complex interaction of the genotype of both host
and pathogen has been highlighted by a study of susceptible and resistant mice which
were infected with S. dublin, which contains a virulence plasmid, and the isogenic
plasmid-cured strain LD842. Both strains of mice were resistant to the LD842
bacteria but when mice with the nrampl mutation were made neutropenic they
succumbed to the infection. Mice of both strains, however, were susceptible to the
virulent 5. dublin. The authors of this study suggest that Salmonella have adapted to
grow inside M<j>s, sheltered from neutrophils with neutrophils being the primary host
defence against non typhoid Salmonella carrying virulence plasmids
(Vassiloyanakopoulos et al. 1998).
Nrampl mutations have been reported to have a dramatic effect on the growth rate of
L. donovani, M. bovis, M. intracellulare, M. lepraemurium, S. typhimurium, Brucella
abortus, T. gondii as well as M. avium (in contrast to the findings of Doherty and
Sher mentioned above (Doherty and Sher 1997)) in RE organs but the growth of
other intracellular parasites such as L. monocytogenes, L. pneumophila,
Pseudomonas aeruginosa, S. aureus and Bacillus subtilis does not appear to be under
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nrampl control (reviewed in Gruenheid et al. 1997; reviewed in Govoni and Gros
1998). The impact of nrampl on M. avium growth is controversial.
Resistant and susceptible congenic strains of mice infected with an attenuated
vaccine strain Rv6 of Salmonella abortusovis showed marked differences in their
specific antibody response (Gautier et al. 1998). These responses, particularly IgM
and IgG3 titres, were significantly higher in susceptible mice and may reflect the
higher bacterial load and longer persistence of the bacteria in these mice which
would provide a stronger stimulation for the humoral response. In contrast, in
resistant mice the alternative defence mechanism involving IFNy and TNFa
synthesis and intracellular killing of pathogens by M<j>s is likely to predominate.
Despite IgM and IgG3 being good activators of the complement cascade no
difference in the complement response to infection was seen.
The in vitro effects of LPS/IFNy mediated M()) priming or activation influenced by
nrampl include regulation of the C-X-C neutrophil chemoattractant KC, IL-ip,
iNOS, MHC Class II, 5' nucleotidase, AcM-1, TNFa, NO, L-arginine flux,
respiratory burst and tumouricidal activity. The gene clearly has many pleiotropic
effects and it is hard to reconcile its proposed functions as a
phagosomal/phagolysosomal nitrate transporter, based on homology with crnA
(1.8.3.4), with this multitude. From the sequence similarity of nrampl with the
SMF1 and SMF2 proteins (1.8.3.5) and the mistaken view initially that SMF1 and
SMF2 resided in the mitochondrial membrane it was proposed nrampl may play a
role in mitochondrial function. Mitochondrial derived ROIs and NF-kB activation
are involved in the apoptotic and gene inductive effects of TNFa which some have
suggested nrampl may regulate (Barton et al. 1995). An increase in respiratory burst,
nitrite release and L-arginine transport has been observed in susceptible M(j>s
transfected with the resistant nrampl allele, and the respiratory burst in response to
BCG infection in resistant mice and their splenic adherent cells is superior to that of
their susceptible counterparts (Denis et al. 1988). Nrampl has been proposed to
modulate mitochondrial activity and ROI generation via the electron transport
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system which can lead to NF-kB activation (Barton et al. 1995). It has been
suggested that the respiratory burst, influenced by NRAMP1, may be a more
prominent effector mechanism of human M(j>s, in which NO does not appear to play
a major antimicrobial role, than in murine M<j>s.
It has also been speculated that collaboration between nrampl and the IFNy receptor
may occur to achieve efficient signal transduction. This could be mediated through
the SH3 binding domain of the nrampl protein, and/or an integrin-mediated tyrosine
kinase signal transduction pathway (Formica et al. 1994).
Olivier et al. have shown differences in PKC activity between resistant and
susceptible M(j) cell lines which is consistent with the involvement of PKC in the
biochemical pathways inducing several McJ) functions e.g. phagocytosis, MHC Class
II expression and c-fos mRNA accumulation. These differences may account, in part,
for the pleiotropic effects which have been ascribed to nrampl (Olivier et al. 1998).
The ability of Mtjis from resistant mice to exhibit increased Class II expression over
their susceptible counterparts has been widely accepted to correspond to effective
and defective antigen presentation to T lymphocytes in the resistant and susceptible
mice, respectively, and to contribute to the latter's inability to curtail infection.
Sirova and colleagues question this assumption and suggest that in vivo the activity
of other APCs mask the effect of the nrampl allele on antigen presentation. For
instance, DCs from resistant and susceptible mice possess equivalent antigen
presentation capacity. They found no association with the nrampl allele and in vivo
antibody responses to exogenous antigens despite the splenic adherent cells from
resistant mice inducing higher levels of antigen-specific-T cell-proliferation (Sirova
et al. 1997). However, Lang et al. have shown M<|) clones transfected with wild type
nrampl demonstrate enhanced LPS-dependent antigen processing and IFNy-induced
MHC Class II expression compared to the mutant allele-bearing parent cell line or
clones transfected with the mutant allele (Lang et al. 1997). The influence of nrampl
on antigen processing was only seen with a recombinant leishmania activator of cell
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kinases (LACK-A1) antigen and not with chicken egg ovalbumin, human chorionic
gonadotrophin or bacteriophage lambda cl protein, suggesting the processing effect
was specific to particular amino acid sequences in the LACK-A1 antigen. None of
the antigens used by Sirova and colleagues (Sirova et al. 1997) were derived from
bacteria or parasites associated with the nrampl phenotype and this processing
specificity may help explain their findings. It is of significant importance, in the light
of the development of human vaccination strategies, to note that nrampl wild type
and mutant strains of mice showed differential responses to vaccination with
attenuated S. typhimurium mutants carrying recombinant tetanus toxoid and
leishmanial gp63. The wild type strains developed a Thl protective response when
subsequently challenged with L. major while the mutant mice showed signs of bias
towards a Th2 response and exacerbated disease (Soo et al. 1998).
Measurements of the acidity of susceptible and resistant Mijis' phagosomes infected
with live M. tuberculosis (Hackam et al. 1998) or S. typhimurium (Govoni et al.
1999) have shown that the phagosomes of wild type or nrampl transfected cell lines
are significantly more acidic than those from susceptible mice. This may have a
direct bacteriostatic effect, activate microbicidal enzymes, favour the protonation of
nitrite to nitrous acid leading to RNIs or promote the dismutation of 02~ to H202, all
of which may contribute to restricting the replication of intracellular pathogens.
In a carbon tetrachloride (CC14) model of liver inflammation and fibrosis nrampl
null mice showed significantly higher fibrosis scores compared with their wild type
counterparts (Thompson et al. 1998). KCs are thought to play a pivotal role in this
system and the activity of nrampl in these cells may be an important determinant in
the resulting tissue damage. It is an interesting possibility that human NRAMP1
genotype or expression levels may contribute in determining the severity and extent
of fibrosis and cirrhosis in human hepatic diseases.
Using two-dimensional gel electrophoresis coupled with multivariate analysis of
cellular proteins prepared from murine B10R (resistant), BIOS (susceptible) and
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BIOR-Rb (resistant transfected with nramp-xiboxyvao) cell lines Kovarova et al. have
identified four proteins which were differentially expressed in the cell lines with
resistant or susceptible phenotypes (Kovarova et al. 1998). Two of these were
unidentified but the authors have identified the third as manganese dependent
superoxide dismutase (Mn-SOD) and a candidate for the fourth as bcl-2. These
proteins were more abundant in the resistant cell extracts. This group has also shown
expression of these proteins to be differentially regulated by IFNy or LPS stimulation
in mice with the wild type or mutated nrampl gene and mice with the normal (lpsn)
or defective (lpsd) allele of the Ips gene. The Ips locus affects the natural resistance
of mice to a number of pathogenic organisms, including Francisella tularensis, and
its product is believed to be involved in LPS recognition and/or LPS signalling. In
mice with mutated nrampl neither IFNy nor LPS reconstituted the low levels ofMn-
SOD or the bcl-2 candidate. However, in the lpsd mice Mn-SOD levels were fully
restored with either IFNy or LPS stimulation and the levels of the bcl-2 candidate
were partially restored (Kovarova et al. 1997). Mn-SOD expression is regulated by
ROIs and thiol modulation and it is possible nrampl may be involved in modulating
the intracellular redox balance, membrane potential, osmomolarity or contributing to
the induction of complementary anti-oxidant protective systems, such as Mn-SOD.
The authors speculate that resistant phagocytes may be better suited to coping with
oxidative stress, which may be reflected in attenuation of the apoptotic pathway and
their survival, enabling them to act as APCs (Kovarova et al. 1998). Bcl-2 regulates
the apoptotic pathway which is intricately related to the cell's redox state and may
account for the elevated bcl-2 expression observed. However, this theory is not
supported by the findings of Rojas et al. who have used resistant and susceptible M(j)
cell lines to show the resistant M(|)s were more sensitive to undergo apoptosis when
infected with M. tuberculosis H37Rv or stimulated with purified protein derivative
(PPD) or IFNy than the susceptible Mt)>s (Rojas et al. 1997). The observed increased
apoptosis of the resistant M(()s is dependent on the production of NO, which is
generated at higher levels in the resistant cells, but is independent of ROIs (Rojas et
al. 1998). These workers also found NO, but not ROIs, played a role in the
antimycobacterial activity of murine M<j)s. Further studies suggest there may be at
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least two pathways capable of inducing M(j) apoptosis in M. tuberculosis infected
cells, activation of caspase 1 and the production of NO, which seem to be parallel
but independent events (Rojas et al. 1999). It seems that the nrampl background
controls the production of TNFa and IL-10 and it is the relative amounts of these
which determine the balance between apoptosis and M(j) survival in the infected cells
with TNFa inducing apoptosis, NO production, caspase 1 activation, p53 expression
and down regulation of bcl-2 while IL-10 had opposing effects.
Ectopic expression of nrampl in COS-1 cells has been shown to modulate cellular
iron levels following loading with low molecular iron chelates such that reduced
cellular iron loads were observed in the transfectants (Atkinson and Barton 1998).
Based on this observation it has been proposed that nrampl may play a role in a
salvage pathway of iron recycling. The role of nrampl in iron transport has also been
investigated using a murine in vivo iron-loading system followed by infection with
M. avium (Gomes and Appelberg 1998). These experiments showed a dose
dependent effect on M. avium growth, with increased iron levels increasing
proliferation of the pathogen and decreasing the difference in mycobacterial growth
between resistant and susceptible mice. A number of studies (Barrera et al. 1997;
Brown et al. 1997) have shown that differences in resistance to mycobacterial
growth mediated by nrampl correlates with mRNA stability of IFNy-induced genes
and corticosterone treatment increased the decay ofmRNA in M<j)s from susceptible
mice. These findings led them to contemplate a role of nrampl in controlling iron
transport thereby regulating levels of intracellular iron and mRNA stabilisation
because iron is known to modulate mRNA stability.
Dissecting the physiological function and effects of nrampl is an ongoing project.
Comparison of the different in vivo responses of susceptible and resistant mice to
infection is a complex exercise. It is difficult to determine which phenotypic
differences observed are a direct effect of functional nrampl protein and which are
secondary or downstream events (despite being nrampl dependent) and not the
direct result of nrampl activity/function. In vitro systems, though less physiological,
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can simplify matters to some extent but the problems still remain. Differences
observed may be a consequence of an overall increased activation state of resistant
M(j)s rather than a specific nrampl function, which should be taken into account
when considering the information known.
1.8.6 Cellular Location and Characteristics of Nrampl
As for nrampl protein function, opinions regarding its cellular location are varied
and sometimes contradictory. A major stumbling point has been the development of
specific antisera against the protein, which remain few and far between, with some
doubt as to absolute specificity. Speculative suggestions have been made for a
mitochondrial membrane location and a role in transportation of substrates
regulating the redox state of the organelles. Other suggestions include localisation to
the nuclear envelope where it may regulate translocation of DNA binding proteins
(Blackwell 1996) or a plasma membrane localisation and role in signal transduction
leading to M<|) activation (Barton 1994; Kishi and Nobumoto 1995).
Gruenheid et al. generated rabbit anti-mouse nrampl polyclonal antisera against a
glutathione S-transferase (GST)-nrampl fusion protein which they used to report
localisation of nrampl to late endosomes/lysosomes in resting M(j)s (Gruenheid et al.
1997). Upon phagocytosis they found the sera was reactive with the phagosome
membrane and remained so during its maturation to phagolysosome. They showed
no evidence for a nuclear or plasma membrane location. The authors suggest that
nrampl is targeted to the membrane of maturing phagosomes where it either directly
or indirectly modifies the intraphagosomal environment, affecting replication of
intracellular parasites. They hypothesise transportation of a cytocidal or cytostsatic
agent into the phagososme or elimination of a factor vital for parasite proliferation
via the nrampl protein. Based on this idea they have tried to explain the species-
specific effect of nrampl on a number of pathogens, all of which have their own
defence mechanisms to protect them against their host. For instance L. donovani
synthesises SOD which neutralises reactive oxygen species and M. tuberculosis
blocks acidification of the phagosome by preventing fusion of the phagosome to
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vATPase positive vesicles. 5. typhimurium containing phagosomes acquire lysosomal
glycoproteins and lysosomal acid phosphatase but not mannose-6-phosphate
receptors (a marker for late endosomes), have decreased cathepsin D levels, show
decreased fusion with late endocytic compartments and delayed and attenuated
acidification. However, the three organisms transit through and remain associated
with the phagosome which acquires Lampl at some stage. Lampl and nrampl co-
localise and it is this mutual accumulation of defence molecule and pathogen which
may be of critical importance. In contrast, the entry of L. pneumophilia into M<])s
involves a unique 'coiled phagosome' which does not acidify or become Lampl
positive and L. monocytogenes secretes listeriolysin leading to its escape from the
phagosome. Gruinheid et al. suggest that this escape may occur before a significant
amount of nrampl protein is delivered to the L. monocytogenes containing
phagosomes as escape occurs within twenty minutes (Govoni and Gros 1998)
explaining the indifference of these pathogens to their host's nrampl genotype.
Schmidt and Ernst report the generation of rabbit antisera to human NRAMP1 using
N and C termini oligopeptides. Using the antisera and NRAMP1 transfected COS-1
cells a distinctive intracellular vesicular pattern of immunoreactivity was observed
and a subpopulation of the positive staining organelles appeared to fuse with
endosomes. However, human monocyte-derived Mtjis showed a less obviously
vesicular staining pattern with the sera and the authors conclude neither these cells
nor the COS-1 transfectants showed distribution of NRAMP1 in early endosomes,
lysosomes or mitochondria (Schmidt and Ernst 1996).
Polyclonal rabbit sera has been raised against a C terminal peptide of the human
NRAMP1 sequence (CHFLYGLLEEDQKGETSG) coupled to keyhole limpet
haemocyanin (KLH) via the NH2 terminal cysteine which is not present in the
NRAMP1 sequence (Kishi et al. 1996a). This sera was reactive against a 60kDa
protein in human PBLs, HL-60 (promyelocytic leukaemia cell line), U937
(histiocytic lymphoma cell line), ARH-77 (multiple myeloma cell line), CCRF-CEM
(T cell leukaemia cell line), K562 (myelogenous leukaemia cell line), Raji (B-
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lymphoblstoid cell line) and MOLT-4 (T-lymphoblastoid cell line) cells. These
findings contrast with the M<))/granulocyte specific expression profile reported by
others (Cellier et al. 1997) and could reflect the immortalisation/transformation or
different stage of differentiation of the cultured T and B cell lines, or a lack of
specificity of the antisera. The NRAMP1 open reading frame is predicted to encode a
550 amino acid protein with a molecular weight of 59880, consistent with the weight
of the protein the polyclonal sera reacts against. This protein would, therefore,
represent a post-translationally unmodified NRAMP1 protein, despite the
observation of a number of putative phosphorylation and glycosylation sites and
evidence that the murine homologue is heavily glycosylated with a molecular weight
in the range of 90-100kDa (Vidal et al. 1996). Kishi et al. also identified a 120kDa
reactive product which they suggest may represent dimerisation of the protein, an
interaction maintained under the reducing conditions of the experimental procedure
(Kishi and Nobumoto 1995). It is surprising, based on the increased level of
NRAMP1 mRNA expression after LPS and/or IFNy stimulation and the phenotypic
effects of these stimuli believed to be mediated through, or in part by, NRAMP1 that
no detectable increase in expression of the 60kDa immunoreactant was observed
using this sera when PBLs were stimulated with LPS and/or IFNy (Kishi and
Nobumoto 1995), further querying the specificity of this antisera.
The same sera was used to immunocytochemically localise the reactive material to
the plasma membrane of the U937 cell line (Kishi et al. 1996a). Electron microscopy
of the stained U937 cells confirmed reactivity with the plasma membrane but not
other cellular organelles and the authors concluded the human NRAMP1 molecule
resides on the plasma membrane in contrast to the findings outlined above.
The NH2-terminal region of NRAMP1 shares structural homology with the proline,
serine and threonine rich microtubule-associated protein (MAP)-4 which led Kishi et
al. to speculate a possible cytoskeletal-NRAMP 1 interaction. Using an NRAMP1-
GST fusion protein and affinity purification a- and p-tubulin were found to associate
with the NH2-terminal cytoplasmic domain of NRAMP1 (Kishi et al. 1996a). This
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finding and the plasma membrane localisation led the authors to suggest that
NRAMP1 may act as a membrane-anchor and bind microtubules, promoting
microtubule-mediated vesicle transport, important in phagocytosis of
microorganisms and/or sorting of internalised vesicles. Based on competition studies
for microtuble-binding activity the group subsequently reported that NRAMP1 might
be a new microtubule-associated protein with unique characteristics, forming a new
category ofMAPs (Tokuraku et al. 1998).
Nrampl has been shown to behave as an integral membrane protein, resistant to urea
extraction, as predicted from its sequence. It is phosphorylated and heavily
glycosylated with up to 40% of its mass resulting from post translational addition of
complex carbohydrate side chains (Vidal et al. 1996).
1.8.7 Metal Homeostasis
When studying living, biological systems, it is tempting to neglect how crucial
inorganic chemistry is to organic life. The homeostasis of mineral nutrients within a
cell and the various cellular compartments is maintained by a fine balance of
transport across plasma and organelle membranes, metabolic effects and chelating
agents. Metal ions are generally maintained at low concentrations in the cytoplasm,
which vary depending on the cell's metabolic state, while the organelles often serve
as storage compartments.
Metal ions, particularly of the transition series are vital for the function of countless
cellular enzymes and overall well being. Everyone is aware of the debilitating effects
of iron deficiency and anaemia. Iron imbalances also account for a variety of other
conditions including haemochromatosis, while defects in copper storage in the liver
is the cause of Wilson's disease. Zinc is central to the function of zinc finger
transcription factors and equally important is the toxic effect of high levels of many
metals, including aluminium, which affects the brain.
Maintenance of cellular iron homeostasis is a prerequisite for growth and
proliferation of cells. However, it is also of central importance in regulating immune
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functions, playing a role in lymphocyte proliferation and cell mediated immune
responses involving M(j>s. Increased free, non-ferritin-bound, intracellular iron
concentrations diminish the effectivity of IFNy towards monocytes via reduced MHC
Class II expression, neopterin formation, TNFa production and cytotoxicity towards
intracellular pathogens. A regulatory feedback exists between iron and NO within
the cell. Iron reduces iNOS mRNA transcription and NO formation, and NO in turn
influences the regulation of cellular iron metabolism.
Cellular uptake, storage and consumption of iron are regulated post-transcriptionally
by IRP-1 and IRP-2, which interact with IREs within mRNAs such that iron uptake is
promoted during iron deficiency or oxidative stress and iron storage and
consumption is stimulated when the levels of cellular iron is increased.
Immunostimulatory cytokines (e.g. IL-1, IL-2, IL-6, TNFa and IFNy) influence iron
metabolism via IRE/IRP independent mechanisms. However, IL-4 and IL-13 enhance
expression of molecules involved in iron uptake and storage by M(j)s by regulating
IRP activity. This is mediated by the suppressive effects of the cytokines on NO
formation and by antagonising the IFNy mediated blockage of TfR mRNA
expression. IL-4 nad IL-13 may, therefore, increase iron uptake and storage by M(j>s
which may negatively affect the cells' effector functions and antimicrobial activity
as iron down regulates NO formation and decreases the effectivity of IFNy towards
M(j)s. The IL-4 and IL-13 mediated uptake and storage of iron in M<j>s might also act
as a control mechanism during chronic inflammation by reducing the formation of
toxic hydroxyl radicals via the iron mediated Haber Weiss reaction (discussed in
1.5.2).
The TfR mediated uptake mechanism of iron by mammalian cells has been widely
documented. The pathway involves the adsorption of iron onto Tf, which has two
binding sites for the ions, followed by binding of iron-transferrin (Fe-Tf) to the TfR
on the plasma membrane. The receptor-ligand complex is internalised into
endosomes within which the low pH, generated by vATPase, results in release of
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iron, which is subsequently transported across the endosomal membrane into the
cytoplasm. Though of major significance this is not the sole iron uptake mechanism
by mammalian cells as Tf independent pathways exist, exemplified by the recent
reports and speculations of the function of nrampl and nramp2 (Fleming et al. 1997
and 1998; Gunshin et al. 1997; Atkinson and Barton 1998; Gomes and Appelberg
1998). It is an attractive proposition that nrampl's effects on immune responses and
intracellular pathogens may be, in part, due to regulation of cellular iron levels.
However, our present understanding whether this transport system would be
unidirectional into or out of the phagolysosome, or potentially bi-directional, remains
unresolved (reviewed in Blackwell and Searle 1999). In comparison to iron, our
knowledge of the mechanisms of uptake of metals such as manganese is in its
infancy and the possibility that nrampl may play a role based on the activity of other
nramp family members (1.8) is an exciting area for research.
1.8.8 Human NRAMP1
In 1994 partial (Kishi 1994) and complete (Cellier et al. 1994) cDNA sequences of
NRAMP1, the human homologue ofmurine nrampl, were published.
1.8.8.1 Human NRAMP1 Gene and Protein
The predicted human NRAMP 1 protein sequence shares 88% identity and 93%
similarity to the murine sequence with the extreme NH2- and COOH- terminal ends
showing the least cross species sequence conservation (66% and 74% identity,
respectively). The human protein contains 550 amino acids, two more than the
murine protein. The two predicted N-linked glycosylation sites, the SH3 binding
domain and two of the five PKC phosphorylation sites (those in the NH2 terminal
region of the sequence) found in the murine sequence are conserved. The conserved
transport motif between TM6 and TM7 is highly conserved, incorporating one
conservative substitution, as are eight of the TM domains, which are identical except
for one conservative substitution (Cellier et al. 1994). This remarkable sequence
conservation suggests key structural and/or functional roles of these domains in the
proteins.
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The human N11AMP1 gene spans 16kb and was mapped to human chromosome 2q35
within a syntenic region encompassing the equivalent region of murine chromosome
1, which contains nrampl. As for the murine gene 15 exons have been identified
(Cellier et al. 1994).
Interestingly a splice variant of the human mRNA was identified which contained
74bp of an Alu element belonging to the Sx Alu family mRNA (Cellier et al. 1994).
The Alu element is inserted in the genomic DNA in an inverted orientation relative
to the direction of gene transcription. The alternatively spliced sequence is present at
the position corresponding to intron 4 and was found to be expressed in the U937,
THP-1, KG-1 and HL-60 cell lines at an approximately 1:5 ratio in favour of the
species lacking the Alu sequence. The 74bp insertion introduces a frame shift which
results in the appearance of a stop codon in exon 5. Should such a message be
translated the predicted protein would be truncated prematurely, lacking the majority
of the TM domains and the conserved transport motif, and as such is unlikely to play
a function as a transport protein. It is possible that such a truncated NRAMP1 protein
which would contain the NH2 terminal SH3 binding domain could retain signal
transduction capacity or sequester cellular SH3 domain containing proteins and
hence have a functional role in this respect. However, it is more likely that such a
protein would be targeted for degradation based on evidence that the murine nrampl
gene containing the g>a point mutation does not generate detectable nrampl protein
(Vidal etal. 1996).
Northern blot analysis of the human NRAMP1 mRNA expression pattern showed
tissue specific expression of the gene in PBLs, lung, spleen and liver, with liver
showing the lowest level of expression. Two hybridising species of about 2kb and
4kb were co-expressed. The smaller species may be the result of alternative
polyadenylation sites but this is not certain (Cellier et al. 1994).
The transcription start site of the human gene is 148bp 5' of the ATG initiation
codon and a series of predicted promoter region elements 5' of the transcription start
76
site have been identified. These include thirteen IFNy response elements, three W-
elements, two AP-1 sites, three NF-kB binding sites, two GM-CSF elements, one NF-
IL6 site and several PU-1 binding sites, a number of which create PEA-3 motifs. No
TATA, GC or CCAAT boxes were identified. Thus the murine (1.8.4) and human
promoter regions share many regulatory elements which support the inducible and
myeloid specific expression pattern observed (Blackwell 1995; Kishi et al. 1996b;
Searle and Blackwell 1999).
1.8.8.2 Human NRAMP1 Polymorphisms
Of particular interest in the human NRAMP1 promoter region is a polymorphic
microsatellite repeat region located from -317bp to -274bp 5' of the transcription
start site. The alleles at this site have been inconsistently reported. Blackwell et al.
report four alleles but they have allocated different sequences to allele 4 following
their initial publication. The sequence of these alleles are shown below (* Blackwell.
1996; Shaw et al. 1996 and 1997: $ Blackwell et al. 1995: # Searle and Blackwell
1999):
Liu et al. identified three alleles at this site, which they allocated alleles 1, 2 and 3
with 2bp increments of increasing size and allele 1 having the sequence













The frequencies of the alleles were determined by the two groups in a number of
ethnic populations and in all cases the allele present at highest frequency contained
(gt)9 at the 3' position of the repeat region.
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This promoter region polymorphic microsatellite repeat is of great interest because it
is a putative Z-DNA forming dinucleotide repeat. DNA in the Z-conformation can
interact with a distinct class of eukaryotic DNA binding proteins which may
negatively or positively regulate gene transcription. Gene reporter studies using the
polymorphic promoter regions of the human NRAMP1 gene provide evidence that
this is a functional polymorphism. Blackwell's allele 3 has been reported to drive the
highest levels of expression and as such an individual's genotype at this locus could
affect the levels of NRAMP1 expressed and M(j) function and activity (Blackwell
1995; Bellamy and Hill 1998). The microsatellite repeat is flanked by other promoter
region response elements and there is, therefore, scope for both a direct effect on
transcription through the interaction of transcription factors with the Z-DNA as well
as the potential to influence the juxtaposition of other response elements. Compared
with other microsatellite repeat polymorphisms the number of alleles identified is
small which may suggest that the generation of further polymorphic variants of this
repeat is intolerable in evolutionary terms.
Using a variety of methods to search for mutations in the human NRAMP1 gene,
including single-strand conformation analysis, Southern analysis and direct
sequencing, Liu and colleagues identified nine polymorphic sites/mutations by
analysing native Canadian kindred and Hong Kong families (Liu et al. 1995). Of
these, four sites were in coding sequence: two were silent substitutions in exons 3
and 8 and the other two an A>V conservative substitution (A318V) in exon 9 within
the region between TM5 and TM6 and a D>N substitution (D543N) in exon 15
within the cytoplasmic COOH terminal which could be functional. The remaining
variants were in non coding sequence: a g>a in intron 5 and intron 13, a g>c in intron
4, a 4bp deletion downstream of the last codon in intron 15 and the previously
discussed microsatellite repeat. At the latter site three alleles were identified with
2bp increments of increasing size for alleles 1 to 3 and allele 3 was assigned the
sequence (gt)7ac(gt)5ac(gt)9. The discrepancy between the size of Liu's and
Blackwell's first (gt) repeat of this polymorphic site (Blackwell et al 1995) is likely
to be due to difficulties in sequencing repetitive DNA. A further polymorphic 4bp
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(CAAA) insertion/deletion at the poly A tail of an Alu element of the Alu J family
situated in the 3' untranslated region of the gene has been identified but the
physiological effect or function of these polymorphisms, except the 5' promoter
region microsatellite repeat, has not been reported or fully understood (Buu et al.
1995).
There is no evidence to date for existence of an analogous mutation in the human
NRAMP1 gene to that found in the susceptible strains of mice. Such a mutation
would be expected to have a profound functional effect on the role of the protein.
The only potentially detrimental polymorphism identified to date in the human gene,
an amino acid triplet repeat in exon 2 encoding the putative SH3 binding domain,
occurs at a frequency of less than 0.001 (Blackwell and Searle 1999).
1.8.8.3 Human NRAMP1 Expression
Northern analysis of PBMCs and their fractionation into the granulocyte and non
granulocyte containing fractions identified granulocytes to be the source of the
highest levels of NRAMP1 expression (Cellier et al. 1997). Alveolar M(j>s and
adherent monocytes both expressed NRAMP1. The level of NRAMP1 expressed by
adherent monocytes was lower than that of the alveolar M(j)s but could be increased
to those of the latter by long term culture. The HL-60 cell line showed induction of
NRAMP1 expression when it was differentiated towards either the monocytic or
granulocytic pathway and it appears that expression of NRAMP1 increases during
maturation ofmononuclear phagocytes. The high level of expression by granulocytes
is of interest in the context of the importance of granulocytes in control of virulent S.
dublin infection in wild type mice (Vassiloyanakopoulos et al. 1998). However, this
expression pattern is in contrast to that observed by Yoshida and Kishi using their
rabbit polyclonal anti-human NRAMP1 sera in a flow cytometry study of human
PBLs (Yoshida and Kishi 1997). They report expression of NRAMP1 in 52.9% of
CD14+ monocytes/M<f)S, 22.2% of CD2+ T lymphocytes, 26.6% of CD 19+ B
lymphocytes but only 3.2% of CD16+ neutrophils/granulocytes. The authors suggest
the discrepancy between the widely accepted murine M<j), monocyte/granulocyte
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specific pattern and their observation could be due to a species difference but this
does not account for the inconsistency between their results and those of Cellier et
al. above (Cellier et al. 1997).
1.8.8.4 Infectious Disease and Human NRAMP1
The lack of reliable tools to investigate human NRAMPl protein expression or
function in physiological or disease situations has meant the major avenue, to date,
for human studies has been genetic and polymorphic analysis of the NRAMPl gene.
From knowledge of the phenotypic effect of the murine mutation the human
homologue represented an obvious candidate to have an important effect on the
course of human M. tuberculosis and/or M. leprae infection.
Leprosy is the result of chronic M. leprae infection affecting an estimated 5-6
million people worldwide and susceptibility has a significant genetic component.
Abel and colleagues have studied sixteen Vietnamese and four Chinese multiplex
leprosy families for a number of NRAMPl intragenic haplotypes and extended
haplotypes in the immediate vicinity of NRAMPl (Abel et al. 1998). They found a
significant non random segregation to affected individuals of a small chromosomal
segment carrying NRAMPl. Though it can not be ruled out that another gene in
linkage with NRAMPl might be the cause of the haplotype sharing, the study
suggests that susceptibility to leprosy is a genetically heterogeneous trait with
NRAMPl playing a more pronounced role in certain ethnic populations and more
than one susceptibility locus being involved.
Despite estimates that a third of the world's population is infected with M.
tuberculosis only 10% will develop clinical disease. It is clear that although the
mycobacterium is necessary for development of tuberculosis it is not sufficient and
there is significant evidence that the host genotype is important in determining the
outcome of infection. In situations such as tuberculosis where several genes are
likely to play a role in the aetiology of disease both family-based linkage and
association-based case control studies are required to complement each other when
trying to identify the relevant genes. Association studies are useful to detect genes
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exerting a moderate effect on disease susceptibility, which would be missed by
linkage studies, but can only be used to detect association over short genetic
distances. Such studies often rely on the existence of a candidate gene in the region
of the genome of interest.
Associations between tuberculosis and MHC class II antigens, most frequently HLA
DR2, have been reported, but inconsistently, and are only likely to account for a
relatively small percentage of the total genetic influence. Analysis of a number of
candidate genes including those encoding NRAMP1, TNF, MBP, vitamin D receptor,
IFNy, IL-la, IL-ip, IL-1 receptor antagonist, IL-4, IL-9, IL-10, CR1, ICAM-1, iNOS,
and chemokine receptors is underway to try to determine which, if any, of these
which have the potential to affect the course of tuberculosis, have a genetic
association with disease (reviewed in Bellamy and Hill 1998).
In the context of this thesis studies of a potential genetic association of NRAMP1
with tuberculosis is of interest. In a Gambian case-control study four of six
polymorphic sites within the NRAMP1 gene analysed were found to be strongly
associated with smear positive pulmonary tuberculosis (Bellamy and Hill 1998;
Bellamy et al. 1998). Of the loci analysed the 5' microsatellite repeat region and the
intron 4 g>c transversion were in linkage disequilibrium, as were the exon 15 D543N
and the 4bp deletion downstream of exon 15 polymorphisms, hence these results are
not independent. Individuals who are heterozygous for both the intron 4 g>c
transversion and deletion downstream of exon 15 were significantly over represented
among tuberculosis cases compared to those who do not possess either variant allele
(odds ratio=4.07, confidence interval=1.86-9.12). The allelic association between the
5' promoter region and the 3' region of the gene with disease susceptibility were
independent indicating multiple NRAMP1 polymorphisms influence tuberculosis in
the population studied. Other reports of an association between the promoter region
microsatellite repeat and tuberculosis exist (Bellamy and Hill 1998). With respect to
an NRAMP1 resistant genotype allele 3 homozygotes have been reported to be most
resistant to the development of tuberculosis (Bellamy and Hill 1998). These findings
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are of great interest as they show it is possible to identify host genetic factors leading
to increased risk of disease, but it is not known yet how important these genetic
variants are in different populations and environments or what functional effects the
genetic variants have on the NRAMP1 gene product. The proviso that different genes
contribute to or influence tuberculosis or leprosy susceptibility or outcome in
different races may partially account for the findings of a study of Bolem
tuberculosis multicase families which showed only weak linkage of 2q35, the
NRAMP1 locus, with disease (Blackwell 1998). Liu et al. have failed to find
association between susceptibility to tuberculosis and the nine polymorphic sites
they analysed (Liu et al. 1995). This lack of association may be genuine but may also
be due to the very small number of cases they tested or their choice of cases. It has
been suggested that human NRAMP1 is more likely to be important in the
development of overt disease in contrast to murine nrampl, which determines the
ability to control proliferation of mycobacteria in the early stages of infection.
A presently favoured hypothesis ofNRAMP1 function in relation to innate resistance
to mycobacterium proposes NRAMP1 is located in the membrane of the
mycobacterial phagosome where it transports iron out of the vacuole. Where a non¬
functional NRAMP1 protein exists, bacteria may multiply faster because they have
more iron and other metal ions necessary for growth and proliferation, whereas a
functional NRAMP1 protein effectively starves the pathogen. Metal ions have a
plethora of cellular functions and effects and the pleiotropic effects on M(j) activation
attributed to NRAMP1 may be related to the requirement for metal ions transported
into the cytoplasm from vacuoles. This theory could help explain the iNOS
independent mechanism slowing down bacterial replication observed in mouse
systems prior to M(j> activation. The subsequent killing of the pathogen may also be
due to the effect ofNRAMP1 on M<j) activation.
1.8.8.5 Autoimmune Disease and Human NRAMP1
The murine phenotypic studies related to nrampl genotypic status are based on a
binary outcome - susceptibility/death or resistance/survival - to infection of the
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relevant intracellular pathogens. However, the consequence for a host with less
extreme genotypic variants of the NRAMP1 gene could be hypothesised to have
significant or subtle effects on M<j) function. Enhanced NRAMP1 function or
expression might result in increased resistance to infectious diseases where Mtjis play
an important role in defence. However, such a situation may also be detrimental to
the host, as Blackwell proposes (Blackwell 1996), resulting in hyperactivation and
stimulation of Mcjis and an exaggerated, undesirable immune response, due to
enhanced TNFa, IL-lj3, MHC Class II etc. expression, leading to induction and/or
maintenance of chronic inflammatory or autoimmune disease. This idea has
prompted a number of studies to investigate a possible association of human
NRAMP1 genotypes with human autoimmune/chronic inflammatory diseases in
which M(|)s are believed to play a detrimental role and/or mycobacterial/bacterial
agents are suspected to be important in the aetiology of the disease.
RA is an autoimmune disease for which there is evidence of bacterial/mycobacterial
aetiology, either as a trigger for autoimmunity or as an agent perpetuating disease. A
study of multicase RA affected families supports NRAMP1 as a candidate for disease
susceptibility. The families were typed for the 5' promoter region microsatellite
repeat in NRAMP1 and four close marker genes and the data analysed by a method
based on maximal likelihood of identity-by-descent in affected sib pairs and
transmission disequilibrium testing. The likelihood ratio chi-squared test statistic
was 4.66 and maximum logarithm of the odds (LOD) score was 1.01 for NRAMP1.
There was a significant bias towards transmission of allele 3 in affected offspring.
This allele drives most efficient NRAMP1 expression and this polymorphism may be
one of, or the, disease associated genetic factor in these RA families (Shaw et al.
1996 and 1997). An association between allele 3 and juvenile RA sufferers and
diabetic patients with a first or second degree relative with RA has also been
identified (reviewed in Blackwell and Searle 1999).
Crohn's disease and ulceritive colitis come under the umbrella of inflammatory
bowel disease (IBD) and genetic factors are believed to contribute to the
83
pathogenesis of these diseases. Evidence exists suggesting mycobacteria/bacteria
may contribute to the initiation or maintenance of Crohn's disease and a number of
studies have investigated whether NRAMP1 may play a role in IBD. IBD appears to
be complex, displaying genetic heterogeneity, multilocus inheritance and/or
multifactorial inheritance.
Using two DNA markers (D2S434 and D2S1323) in the vicinity of NRAMP1 on
chromosome 2q35 Crohn's disease and ulceritive colitis sufferers have been
genotyped and the allelic, genotypic and haplotypic distributions compared to those
of normal controls (Hofmeister et at. 1997). The authors of the study suggest two
individual haplotypes were present at a significantly different frequency in patients
with Crohn's disease compared to the control group (p=0.023 and p=0.001).
However, further analysis of larger numbers of patients will be necessary to
determine if there is a difference between the Crohn's disease and ulceritive colitis
frequencies. This study is contentious due to the large number of possible haplotypes
generated from the two DNA markers and hence the "chance" finding of an
association. Closer analysis of the NRAMP1 gene itself will be necessary before
definitive evidence for a genuine association of the gene with IBD can be accepted.
Neibergs et al have claimed in a separate report that NRAMP1 is a major
susceptibility locus for ulceritive colitis based on analysis of the same two DNA
markers mentioned above (Neibergs et al. 1997). However, analysis of 60 Crohn's
disease patients, 52 ulcerative colitis patients, 11 PSC patients and 238 normal
controls for the exon 8 c (allele l)>t (allele 2) transition failed to find an association
with this polymorphic site and IBD, but identified an increased frequency of allele 2
in the small group of PSC patients genotyped; 18.2% for PSC versus 5.5% for
controls compared to Liu et aVs frequencies of 2% for Caucasians (n=120) and 15%
for Asians (n=40) (Liu et al. 1995; Stokkers et al. 1997).
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1.9 AIMS OF THIS PROJECT
Based on the themes I have discussed the aims of this project were to 1)
immunostain PBC and normal liver biopsy sections for markers of apoptosis; 2a)
genotype PBC sufferers for the 5' polymorphic microsatellite repeat in the NRAMP1
gene; 2b) investigate NRAMP1 expression in the liver; 2c) investigate the effect of in
vitro overexpression ofNRAMP1, as expanded on below:
1) To investigate liver biopsy sections of early and late stage PBC and normal
control tissue for the phenotype of the BECs with respect to indicators
suggesting the capacity for, or activation of, execution of the apoptotic pathway.
I wished to determine if there is evidence of abnormal protein expression in the
PBC BECs of a variety of factors known to be important in regulating the
apoptotic pathway, namely bcl-2, bax, bcl-x, p53 and Fas/CD95. Members of the
bcl-2 family have been shown to interact with each other forming homo- and
hetero-dimers and p53 transcriptionally regulates Fas/CD95 and bax (Miyashita
et al. 1994; Selvakumaran et al. 1994; reviewed in Wyllie 1994; Owen-Schaub
et al. 1995). It is possible that the BECs in PBC patients show altered
susceptibility to apoptosis, which might be exhibited by expression of such
factors. I also wished to determine the proliferative status of the BECs using the
MIB-1 antibody against Ki-67 (Gerdes et al. 1991) to see whether the cells were
capable of proliferation because a lack of this regenerative capacity could be a
potential contributing factor resulting in the net loss of biliary structures in the
liver of PBC sufferers.
2a) Despite extensive research the aetiology of PBC remains unclear but I was
interested in investigating the reported familial association and genetic
predisposition of the disease with respect to the NRAMP1 gene. Though most
effort has been directed towards unravelling the acquired and T cell immune
responses of PBC patients, little work has been done to determine the early
initiating influences culminating in these responses. In the light of the apparent
participation of M(|)s in the pathology of PBC, I was particularly interested in
85
investigating whether characteristics of these cells may be contributing to
disease susceptibility in PBC sufferers. By understanding early host factors and
events which may be central in initiation of these responses, such as the activity
of M(j)S, and identifying those at risk of PBC the ultimate aim of disease
prevention becomes tangible. To this end I wished to analyse the 5' polymorphic
promoter region microsatellite repeat in the human NRAMP1 gene in PBC
patients to determine if there is evidence that this gene may play a similar role in
influencing susceptibility to PBC as has been postulated in RA patients, causing
a hyperstimulated M<|> population to exist. Normal controls, alcoholic liver
disease (ALD) and hepatitis C patients were chosen as control populations with
which to compare the allele frequencies of the PBC population. The ALD
population represent a form of chemically induced cirrhosis while the hepatitis
C group represent cirrhosis induced by a virus with tropism for M())S. At present
there is no evidence that NRAMP1 genotype affects the course of viral infections
or any reason to suppose it is influential in the pathogenesis ofALD.
2b) I also wished to investigate the expression pattern of the NRAMP1 gene and
protein in the liver of PBC patients compared with control tissue to determine if
there is evidence of abnormal expression in the disease tissue which might be
influential in generation of the characteristic granulomas in PBC patients and
the chronic immune response. Such responses require an ongoing stimulus,
which could take the form of a hyperactivated M<() perpetuating and maintaining
the response.
2c) Based on the proposal that hyperactivation of M<j)s mediated by overexpression
of NRAMP1 could be an important factor determining human pathology, I
wished to construct a mammalian expression vector containing human NRAMP1
cDNA which would result in overexpression of the gene when transfected into
human M(()s. After developing an assay to determine expression of the
transfected gene, differences in phenotypic effects of overexpression of
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NRAMP1, a gene central to M<J> function, could be analysed in successful
transfectants in the hope of gaining an insight into the function of the NRAMP1
protein.
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2 MATERIALS AND METHODS
All chemical reagents were purchased from Sigma, Poole UK, unless otherwise
stated. Phosphate buffered saline (PBS) used throughout this project for procedures
except tissue culture was purchased from Oxoid, Basingstoke UK. PBS for tissue
culture use was purchased from Life Technologies, Paisley UK.
Nunc sterile plasticware (Life Technologies, Paisley UK) was used for tissue culture
work, unless otherwise stated. Sterile technique and equipment was used for all
tissue culture work which was carried out in a BI02+ Class II microbiological safety
cabinet (Envair, Lancashire UK) and cells cultured in a Gallenkamp C02 incubator
(Fisher Scientific, Loughborough UK) at 37°C, 5% C02. Where necessary solutions
were filter sterilised using a 0.2pm syringe filter (Sartorious, Surrey UK).
1.5 millilitre (ml) tubes were purchased from Life Sciences International, Hampshire
UK and thin walled 0.75ml tubes used for polymerase chain reactions (PCR) were
purchased from Advanced Biotechnologies, Epsom UK. RNase free 1.5ml tubes for
RNA work were purchased from Anachem, Luton UK.
A Life Technologies Model No 3000 (Life Technologies, Paisley UK) power supply,
a Bio-Rad Power Pac 3000 (Bio-Rad, Hemel Hempstead UK) or a MPSU-125/200
power supply (Anachem, Luton UK) were used throughout this project.
Microcentrifugation was carried out using a Micro Centaur, centrifugation was
carried out using a Coolspin 2 or Mistral 2000R centrifuge and 96 well plates were
centrifuged in a Centaur 2 bench top centrifuge (all MSE, Sussex UK).
2.1 SELECTION OF PATIENT AND CONTROL MATERIAL
2.1.1 Paraffin Embedded Liver Tissue for Immunohistochemistry and
DNA Extraction
The diagnosis of PBC was made after full clinical, serological and histological
assessment with the help of a trained pathologist. Fifteen cases showed
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predominantly histological features seen in Stage I or II (14 female, 1 male) and 14
showed Stage III or IV (13 female, 1 male) according to the proposed model of
disease progression reported by Scheuer (Scheuer 1987). Fifteen control liver
samples were obtained from patients during routine lymphoma staging, psoriasis
patients prior to commencing methotrexate therapy, or laparotomy during resection
of colon cancer (6 female, 9 male). All liver tissue in the control group was reported
as histologically normal and there was normal liver biochemical and synthetic
function. Clinical details of the PBC cases are shown in Table 2.1.
Bilirubin Alanine amino¬ Alkaline Albumin
transferase phosphatase
Nonnal range 5-17pM <3 5U/l <130U/1 40-50g/l
Histological
early disease 11 69.5 200 41.5
(Stage I, II) [5-60] [27-194] [104-8911 [29-44]
Histological
late disease 56.5 87 402.5 32
(Stage III, IV) [13-2561 [20-9451 [115-13681 [22-431
Table 2.1 Clinical data assessing liver function of PBC patients at the time of liver
biopsy compared with the normal range. The median and [range] values of bilirubin,
alanine aminotransferase, alkaline phosphatase and albumin of PBC patients whose
biopsy tissue was used for immunohistochemistry are shown. pM: micromolar, U/l:
units per litre, g/1: grammes per litre.
2.1.2 Human Material for NRAMP1 Polymorphism Study
The diagnosis of PBC, hepatitis C and ALD was based on clinical and serological
parameters and on histological assessment of routine liver biopsies. Normal controls
were obtained from the Blood Transfusion Service and have been previously
described (Cantlay et al. 1994). Standard ethylenediaminetetra acetic acid (EDTA)-
blood samples were obtained from 78 normal controls, 76 ALD, 46 PBC and 39
hepatitis C cases. Paraffin embedded liver material, fixed in 10% buffered formalin,
from explanted liver taken at the time of orthotopic liver transplantation (described




Immunohistochemistry procedures were carried out using a humidified chamber, the
semi-automated Sequenza wet chamber (Shandon, Basingstoke UK) or a DAKO
Techmate™ 500 automated immunocytochemistry stainer (DAKO, Cambridge UK).
The Sequenza system utilises plastic clips which hold the slides in a rack in a
position allowing lOOpl of liquid to be held by capillary action between the slide and
clip in an even film. Addition of more fluid to the reservoir at the top of the clip
displaces the fluid held against the section allowing standardisation of volumes and
incubation times. The DAKO Techmate™ 500 automated immunocytochemistry
stainer utilises a robotic arm to move slide holders from location to location during
the staining procedure, increasing throughput, improving accuracy and enhancing
reproducibility. A state-of-the art capillary process is used to ensure reagents are
gently drawn up over the tissue sections. The Techmate™ 500 stainer is linked to
computer software.
3pm sections of tissue, fixed in 10% buffered formalin and processed to paraffin
were cut using a Reichert-Jung Biocut 2030 microtome (Zeiss, Welwyn Garden City,
UK) onto poly-L-lysine (PLL) coated Twin Micro Slides (Blue Star, Warley UK) or,
for automated staining, onto DAKO ChemMate Capillary Gap Microscope Slides
(75mm) (DAKO, Cambridge UK). Sections were dewaxed in xylene (Genta Medical,
York UK) and rehydrated through descending alcohols (absolute to 74% to 64%)
(Genta Medical, York UK) to water.
When the chromogen 3,3-diaminobenzide (DAB) was used for visualisation, with the
humidified chamber or Sequenza, endogenous peroxidase was blocked in 1% w/v
H202 in dH20 for 15 minutes then washed in running tap water prior to antigen
retrieval as described below (2.2.1).
2.2.1 Antigen Retrieval
All antibodies or antisera for which the conditions for immunohistochemistry had
not been previously optimised were initially tested over a range of concentrations on
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paraffin embedded tonsil and/or liver tissue sections which received either no pre-
treatment, had been pre-treated with trypsin or had received microwave antigen
retrieval in citrate buffer to determine the most suitable working conditions. It was
subsequently reported that microwave pre-treatment in EDTA proved a highly
effective form of antigen retrieval (Pileri et at. 1997) and this procedure was used for
a subset of antibodies towards the end of the project. Antigen retrieval procedures
are required for certain antigens due to the paraffin embedding process causing
crosslinking, which may mask certain epitopes. Antigen retrieval was performed as
follows:
1. Trypsin digestion: Sections were incubated at 37°C for 17 minutes in 0.1%
trypsin (ICN Biomedicals Inc., Basingstoke UK), 0.1% calcium chloride pH7.8
then washed in running tap water.
2. Microwave in citrate buffer: Sections were microwaved for 10 minutes at
1000W in 1.05 grammes (g) citric acid/500ml H20 pH6.0, allowed to cool until
tepid then washed in running tap water.
3. Microwave in EDTA: Sections were microwaved for 5-10 minutes at 650W in
0.01M EDTA pH8.0, and cooled under running tap water.
The optimal antigen retrieval procedure for the antibodies used, the working
concentrations and the antibody suppliers are shown in Table 2.2.
2.2.2 Procedure for use with the Humidified Chambers or Sequenza
The following procedures apply to staining procedures using humidified chambers or
the Sequenza. When the Sequenza was used the sections were clipped into the racks
after antigen retrieval and all fluids were added into the reservoir at the top of the
clip. When the humidified chamber was used fluids were gently pipetted to cover the
tissue sections and removed by gently tapping the long edge of the slides on
absorbent paper towel. Washes were carried out in Coppling jars.
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Sections were washed with Tris buffered saline pH7.6 (TBS) and incubated in
blocking serum of the species in which the secondary antibody was raised to reduce
non specific binding i.e. either 20% normal rabbit serum (NRS) (SAPU, Lanarkshire
UK) or nonnal swine serum (NSS) (Harlan Sera-Lab, Loughborough UK) prepared
in TBS. Sections were then incubated in the appropriate dilution of primary
antibody, prepared in the blocking serum, for an hour at room temperature. Sections
were washed three times for 5 minutes in TBS then incubated in biotinylated
secondary antibody (rabbit anti-mouse (RAM-BIO) (DAKO, Cambridge UK) at
1/400 for monoclonal primary antibodies) or swine anti-rabbit (SAR-BIO) (DAKO,
Cambridge UK) at 1/500 for rabbit polyclonal primary antisera) diluted in blocking
serum, for 30 minutes at room temperature. The sections were washed, as previously,
before incubation for 30 minutes in horse radish peroxidase conjugated avidin-biotin
complex (ABComplex-HRP) (DAKO, Cambridge UK) (for DAB chromogen)
(Appendix B) or alkaline phosphatase conjugated avidin biotin complex
(ABComplex-AP) (DAKO, Cambridge UK) (for Fast Red or Vector Red
visualisation) (Appendix B) then washed again before visualisation with either
DAB (2.2.2.1), Fast Red (2.2.2.2) or Vector Red (2.2.2.3).
2.2.2.1 DAB Visualisation
Sections incubated in HRP conjugated secondary antibodies were visualised with
DAB as chromogen. DAB at a final concentration of 0.5 milligramme (mg)/ml
(prepared by adding 4.8ml Tris-HCl buffer pH7.6 and 0.1ml of freshly prepared 1%
H202 to 0.1ml of 25mg/ml DAB) was added to the sections and left for 3-5 minutes
for a brown colour change to occur. The sections were washed thoroughly in TBS
then water, removed from the Sequenza racks and clips where necessary,
counterstained in haematoxylin (Shandon, Basingstoke UK) for about 20 seconds,
washed in tap water and 'blued up' in Scott's Tap water substitute (Appendix B)
for about 20 seconds. The sections were dehydrated through ascending alcohols
(64% to 74% to absolute) (Genta Medical, York UK) then xylene (Genta Medical,
York UK) and mounted in pertex (Cellpath, Hemel Hempstead UK).
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2.2.2.2 Fast Red Visualisation
Sections incubated in AP conjugated secondary antibodies were visualised with Fast
Red as chromogen. All reagents were weighed or measured out ready for rapid
preparation. 4mg naphthol AS MX phosphate was dissolved in 0.4ml N,N
dimethylformamide in a glass beaker. 19.6ml alkaline phosphatase (AP) buffer
(Appendix B) was added with 20pl 1M levamisole, to block endogenous AP.
Immediately prior to use 20mg Fast Red TR was added and dissolved and the
mixture was run through filter paper in a conical funnel. 500jul was added to each
slide in the Sequenza racks and incubated in the dark for about 30 minutes until a
pink colour had developed. The sections were washed thoroughly in tap water,
counterstained and 'blued up', as for DAB visualised sections (2.2.2.1), then
mounted in Aquamount Improved (Merck, Leicester UK).
2.2.2.3 Vector Red Visualisation
Sections incubated in AP conjugated secondary antibodies were visualised with
Vector Red as chromogen. Vector Red (Vector Laboratories, Peterborough UK) was
prepared according to the manufacturer's instructions. Two drops of Reagent 1 was
added to 5ml of 100 millimolar (mM) Tris-HCl pH8.2 and mixed well. Two drops of
Reagent 2 was added, mixed well, followed by two drops of Reagent 3 and mixed
well. The tissue sections were incubated with the substrate at room temperature for
20-30 minutes until suitable staining had developed. The sections were then washed,
counterstained and mounted as described above for the DAB visualised sections
(2.2.2.1).
2.2.3 Procedure for use with the DAKO Techmate™ 500 Automated
Immunocytochemistry Stainer
Sections, pre-treated where necessary as described above (2.2.1), were washed in
PBS/0.1% polyoxyethylene-sorbitan monolaurate (Tween 20) prior to loading onto a
DAKO Techmate™ 500 automated immunocytochemistry stainer (DAKO,
Cambridge UK) according to manufacturer's instructions. Initial runs were carried
out using the manufacturer's recommended programme with subsequent runs
detecting CD68 expression using an altered protocol incorporating an additional
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water wash before staining the sections in haematoxylin. The detection system was
based on streptavidin/biotin complexes and horseradish peroxidase with
3'3'diaminobenzidine as chromogen and was suitable for use with primary
monoclonal antibodies and polyclonal sera. Negative controls omitting the primary
antibody were included. After completion of the immunohistochemistry and
haemotoxylin staining sections were washed in running tap water and taken through
ascending alcohols (64% to 74% to absolute) (Genta Medical, York UK) to xylene
(Genta Medical, York UK) prior to mounting using a Bayer Tissue-Tek automated
cover slip mounter (Bayer, Newbury UK).
Antigen Clone Supplier Pre-treatment Dilution Protocol










MW Citrate 1/50 Automated
Fas/CD95 UB2 Coulter, Luton
UK
MW Citrate 1/200 Automated
Ki-67 MIB-1 Coulter, Luton
UK









MW EDTA 1/300 Automated
Table 2.2 Details of antibodies used for immunohistochemistry. The antibodies'
antigen, the antibody clones and suppliers, the antigen retrieval method and optimal
dilution and the immunohistochemistry procedure used during this study are shown.
The antigen retrieval procedures are described in 2.2.1; Trypsin: trypsin digestion;
MW citrate: microwave in citrate buffer; MW EDTA: microwave in EDTA. The
automated and Sequenza protocols are described in 2.2.3 and 2.2.2 respectively.
2.2.4 Cytospin Preparation and Immunostaining
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2.2.4.1 Preparation ofCytospins
1 x 106 viable cells, determined by trypan blue exclusion (2.18.2), were centrifuged
at 1000 revolutions per minute (rpm) for 10 minutes and the supernatant discarded.
The cell pellet was resuspended in lml PBS containing 10% fetal calf serum (FCS)
and 1 OOjliI (1 x 105 cells) of the cell suspension was pipetted into the funnel of
prepared cytospin chambers, assembled as described by the manufacturer, which had
been placed in a Cytospin 2 (Shandon, Basingstoke UK). The chambers were spun at
300rpm for 3 minutes and carefully dismantled to avoid scraping the cells adhered to
the glass slide with the filter paper separating the slide from the plastic chamber. The
cytospins were air dried and fixed for 3 minutes in 4% paraformaldehyde prepared in
PBS then washed twice in ethanol (Genta Medical, York UK).
2.2.4.2 Immunostaining Cytospins
The prepared cytospins were immunostained using the Sequenza wet chamber as
described in 2.2.2 using DAB visualisation (2.2.2.1) with the following alteration to
the previously described protocol. The cytospins were blocked in TBS containing 1%
bovine serum albumin (BSA) for 20 minutes then incubated in the test rabbit sera
diluted 1/125, 1/250 and 1/500 for 30 minutes. Negative control sections were
incubated in 1% BSA in TBS. After washing in TBS the cytospins were incubated
for 30 minutes in (SAR-HRP) (DAKO, Cambridge UK) diluted 1/125 in 1% BSA in
TBS, washed in TBS then visualised with DAB chromogen as described in 2.2.2.1,
2.3 GENERATION OF ANTI-PEPTIDE SERA
2.3.1 NRAMP1 Peptide Synthesis
The human and murine NRAMP1 protein sequences (Cellier et al. 1994) were
analysed to identify regions of sequence heterogeneity and structural moieties most
suitable for use as synthetic peptides against which an anti-human NRAMP1
antibody response might be raised. The extremely high degree of sequence
conservation between the two species and the intracellular location of regions of the
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molecule severely limited the possible peptides of appropriate length for
immunisation protocols. Two possible candidate peptides were identified, one at the
amino (N) terminus, amino acids 41-58, and the other at the carboxy (C) terminus,
amino acids 532-546 (Cellier et al. 1994). Of these, the C terminal peptide was
chosen because antibodies successfully raised against this epitope of the whole
NRAMP1 protein should only detect full length protein molecules, whereas the N
terminal peptide had the potential to elicit antibodies capable of detecting truncated
NRAMP1 protein molecules, resulting from the +alu mRNA splice variant
(discussed in 1.8.8.1), should these be translated.
The chosen peptide sequence is shown below with the murine sequence variations
denoted underneath where present.
HHHFLYGLLEEDQKGETSG
K PNEGVQGS
20mg of the peptide was synthesised by the Department of Chemistry, University of
Edinburgh, in collaboration with Professor Robert Rammage, using an Applied
Biosynthesis 430A automated peptide synthesiser. The peptide was stored at 4°C as
lyophilised protein. For immunisations of peptide without adjuvant the peptide was
dissolved in PBS to give a concentration of lOOpg/ml.
2.3.2 Preparation of Peptide for Immunisation using Imject Alum as
Adjuvant
Lyophilised peptide was dissolved in PBS to give a concentration of 200pg/ml. An
equal volume of Imject Alum (Pierce and Warriner, Chester UK) was added
dropwise to the peptide solution, inverting to mix between additions, to give a final
peptide concentration of lOOpg/ml. Prior to immunisation the emulsion was rotated
on a SR2 roller mixer (Stuart Scientific, Staffordshire UK) to ensure it was
completely mixed and at room temperature.
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2.3.3 Preparation of Peptide for Immunisation using Nitrocellulose as
Adjuvant
50pg of peptide solution at lmg/ml prepared in PBS was pipetted onto a small piece
of Hybond-C nitrocellulose (Amersham Phannacia Biotech, Little Chalfont UK) of
about 5mm x 6mm. The nitrocellulose was dried at 37°C then placed in a glass bijou.
DMSO was added dropwise until the nitrocellulose completely dissolved, then PBS
was added dropwise until a fine suspension was obtained.
2.3.4 Enrichment of Dendritic Cells By Plastic Adherence and Pulsing
the Cells with Peptide
A standard protocol (Coligan et al. 1995) for the enrichment of DCs from splenic
cells followed by pulsing these cells with peptide prior to immunising mice of the
same MHC haplotype as the isolated DCs was followed making minor adjustments
to the protocol where necessary. All collagenase H solutions were prepared in
Glasgow minimum essential medium (GMEM) (Appendix B), filter sterilised
before use and kept on ice. The supplemented RPMI-1640 medium was as described
in Appendix B with additional mercaptoethanol at 50pM. Where RPMI-1640 is
described in the protocol the medium had no supplements added.
Collagenase Digestion of Spleen
Four female BALB/c mice which had been immunised as described in 5.2.9.1, but
had failed to generate a detectable anti-NRAMPl peptide response, were killed and
the spleens removed to GMEM (Appendix B). About 5ml of filter sterilised
0.25mg/ml collagenase H was added to a sterile 100mm tissue culture grade Petri
dish. The spleens were held with forceps over a second 100mm tissue culture grade
Petri dish. Using a 5ml syringe (Becton Dickinson UK Ltd., Oxford UK) with a
23'AG needle (Becton Dickinson UK Ltd., Oxford UK) 1ml of the collagenase was
injected in lOOpl aliquots into each spleen, starting at the narrowest end of the
spleen and pushing the needle further into the spleen by a few millimetres between
injections, until the needle emerged at the other end of the spleen. The spleens were
torn open using the needle and transferred to the Petri dish containing the 0.25mg/ml
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collagenase H. The cell suspension in the second Petri dish over which the injections
were carried out was collected into a 50ml centrifuge tube (Sterelin, Staffordshire
UK) and placed on ice. The dish was rinsed with about 1.5ml of 0.25mg/ml
collagenase H, adding the washings to the centrifuge tube. A further 1.5ml of
0.25mg/ml collagenase H was added to this dish and the spleens transferred one by
one, using two forceps to tease them into small fragments. After all the spleens had
been fragmented the contents of the dish were pipetted vigorously with a 5ml sterile
plastic Pasteur pipette. The resulting cell suspension was transferred to the 50ml
centrifuge tube on ice, leaving any large fragments in the Petri dish. The dish was
rinsed with 0.25mg/ml of collagenase H and the fine suspension collected and added
to the centrifuge tube.
5ml of lmg/ml collagenase H was added to the spleen fragments, pipetting several
times, and the fragments were incubated at 37°C, 5% C02 for 1 hour. The spleen
fragments were pipetted vigorously and transferred to a sterile tea strainer over a
sterile 100mm tissue culture grade Petri dish. The fragments were rinsed with a few
millilitres of 0.25mg/ml collagenase H and mashed with the plunger from a sterile
5ml syringe (Becton Dickinson UK Ltd., Oxford UK) until any trace of red colour
was removed. The sieve was rinsed with a few millilitres of 0.25mg/ml collagenase
H and the contents of the sieve discarded. The fine suspension was pipetted
vigorously and transferred to the 50ml centrifuge tube. The dish was rinsed with
0.25mg/ml collagenase H and the washing transferred to the centrifuge tube.
Preparation of Low Density Splenocytes
The collagenase H digested splenocytes were centrifuged at 280g (acceleration due
to gravity) for 10 minutes at 4°C and the supernatant carefully removed with a
pipette to avoid disturbing the pellet. The pellet was resuspended in 4ml of dense
BSA (Appendix B), transferred to a 15ml conical tube and carefully overlayed with
lml of RPMI-1640 at 4°C. The column was centrifuged at 5500g for 15 minutes at
4°C, with the brakes turned off. The cells at the interface, all the RPMI-1640
medium and about lml BSA solution from the top of the BSA layer were transferred
98
to a clean 50ml centrifuge tube. The tube was filled with RPMI-1640, mixed by
gentle inversion then centrifuged at 280g for 10 minutes at 4°C. The supernatant was
removed with a pipette and the cell pellet resuspended in RPMI-1640 and placed on
ice. The cells were counted for viability, by trypan blue exclusion (2.18.2), which
should be approximately 107 low density splenocytes per spleen.
Dendritic Cell Enrichment by Plastic Adherence and Pulsing with Peptide
5ml of low density splenocytes at about 107 cells/ml were plated on a 60mm sterile
tissue culture grade Petri dish and incubated at 37°C, 5% C02 for 114 hours. The cell
density should not be greater than 4x107 cells/dish as this reduces adherence and
yield. After incubation the non adherent cells were removed with a pipette and the
dish washed gently several times with RPMI-1640 medium, which had been pre-
warmed to 37°C. A further 4ml of 37°C RPMI-1640 medium was added to the dish,
which was incubated at 37°C, 5% C02 for 30 minutes. The dish was washed as
described above and viewed by phase contrast under an inverted microscope to
determine the proportion of dark, stellate DCs relative to bright, flattened M<j>s and
round lymphocytes and monocytes. The half hour incubations and washes were
continued until the dark, stellate DCs predominated. 4ml of filter sterilised
supplemented RPMI-1640 containing lOOpg/ml NRAMP1 peptide (2.3.1) was
added to the washed dish and the dish cultured at 37°C, 5% C02 overnight. The
surface of the dish was washed with supplemented RPMI-1640 medium and the
eluted cells transferred to a universal tube (Rosslabs, Cheshire UK). The dish was
rinsed with about 2ml of supplemented RPMI-1640 and the washings transferred to
the universal which was centrifuged at 280g for 5 minutes at 4°C. The supernatant
was discarded and the cells resuspended in 1ml of PBS. The viable cells were
counted by trypan blue exclusion (2.18.2), Each spleen is expected to yield 0.5 x 106
- 1 x 106 cells based on DCs comprising about 80% of the cell population.
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2.3.5 Coupling NRAMP1 Peptide to Keyhole Limpet Haemocyanin
using Dimethyl Suberimidate
A standard protocol (Van Regenmortal et al. 1988) was followed and the Perkin-
Elmer web site (Perkin Elmer web site) consulted to determine the appropriate
amount of keyhole limpet haemocyanin (KLH) to use. The bisimido ester dimethyl
suberimidate (DMS) was used as a coupling agent and the protocol followed gives an
estimated 40-70% coupling efficiency.
A forty-fold excess of NRAMP1 peptide (2.3.1) over KLH and a 3 DMS:1 peptide
molar ratio was required. The commercially available lyophilised KLH contained
about 20% of actual KLH, hence, for 2.5mg of KLH (0.5 nanomoles) 12.5mg of the
lyophilised powder was used. This was dissolved in 2.5ml of 0.2M triethanolamine-
HCl pH8.5 and about 44jul of lmg/ml peptide in PBS was added. Immediately prior
to use 16.4pg of DMS was dissolved in 400pl of ice cold triethanolamine-HCl
pH8.5. The DMS solution was quickly transferred, within 30 seconds, to the
KLH/peptide and the mixture incubated at 22°C for 3 hours. The reaction solution
was loaded into a 0.5-3ml Slide-a-Lyzer cassette (Pierce and Warriner, Chester UK)
and dialysed against PBS at 4°C, stirring the PBS gently on a SMI magnetic stirrer
(Stuart Scientific, Staffordshire UK). The PBS was changed three times over 48
hours.
Approximately 3ml of liquid was removed from the cassette, filter sterilised and
stored in aliquots at -20°C. Assuming 55% efficiency the solution would contain
approximately 0.46pg/p.l of coupled protein. The NRAMP1 peptide coupled to KLH
is referred to as NRAMP1/KLH conjugate in future text.
2.3.6 Preparation of Peptide in Complete Freund's Adjuvant
0.7ml of NRAMP1 peptide (2.3.1) at lmg/ml in PBS was added to a glass syringe
attached to a 3-way valve with the third valve closed. 0.7ml of Complete Freund's
Adjuvant (CFA) was added to the glass syringe and the mixture sucked into a second
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glass syringe attached to the valve. The CFA and peptide were mixed well by
pushing between the two syringes until an emulsion formed.
2.3.7 Preparation of Peptide in Incomplete Freund's Adjuvant
The procedure described above for CFA (2.3.6) was followed substituting
incomplete Freund's adjuvant (IFA) for CFA.
2.3.8 Immunisations
All animals were kept in conventional animal housing conditions and fed ad libitum.
For each immunisation procedure animals within groups of two Dutch rabbits or
between three and five BALB/c or C57/Black (C57B1) mice were treated in parallel.
Prior to immunisation test bleeds from the ear of the rabbits were collected, allowed
to clot overnight at 4°C and repeatedly microcentrifuged, transferring the supernatant
to clean 1.5ml tubes until no trace of red blood cells could be seen. The serum was
stored in aliquots at -20°C. Rabbits were injected sub cutaneously (s.c.) at four
separate sites and test bleeds taken and serum collected as described above at
suitable time points. For all steps in the protocols for immunising the mice injections
were intra peritoneal (i.p.) except for intra venous (i.v.) injection in the tail of the
peptide-pulsed enriched DCs (2.3.4). Test bleeds were obtained and pooled from the
immunised mice for the separate immunisation protocols except those receiving
CFA/IFA-peptide where each animal's response was assayed individually. The serum
was collected as above for the rabbit test bleeds. The immunisation protocols
followed are described in 5.2.9,
2.3.9 Fas Ligand Peptide and Anti-Fas Ligand Peptide Polyclonal Sera
A Fas ligand peptide had been synthesised by the Department of Chemistry,
University of Edinburgh, in collaboration with Ian Heslop and Professor Robert
Rammage, using an Applied Biosynthesis 430A automated peptide synthesiser. This
peptide had been used as an immunogen to raise an anti-Fas ligand Ab response in




2.3.10 Sepharose-Protein A Purification of Rabbit Sera
The rabbit sera to be IgG purified were incubated in an equal volume of heat treated
normal human serum (NHS) (Appendix B) at 4°C overnight or at room temperature
for 1 hour to precipitate rabbit anti-human complexes. These complexes were
pelleted by microcentrifugation for 10 minutes and the supernatant aspirated off and
transferred to a clean tube. A column was prepared by adding Sepharose-protein A
beads (Pharmacia Biotech AB, Uppsala Sweden) to a liquid chromatography 0.7 x
10cm column and running 0.2M phosphate buffer pH7.3 (Appendix B) through the
column several times, ensuring the beads were compacted to about a third of the way
up the column. The first serum supernatant sample was run through the column
followed by 40-50ml of 0.2M phosphate buffer pH7.3, to remove unbound protein.
The column was eluted with 0.1M glycine pH2.5 and one 0.5ml fraction followed by
ten 1ml fractions were collected into tubes containing one drop of 0.2M Tris pH10.4.
Between purification of subsequent sera supernatants the column was re-equilibrated
with 20-30ml of phosphate buffer pH7.3, having ensured the final fractions collected
during the glycine elution step were free of protein, as described below, and the
phosphate buffer elute was between pH7.2 and pH7.5. Between use the column was
stored containing phosphate buffer pH7.3 with 0.02% sodium azide.
5jal samples of the ten 1ml collected fractions were dotted, in order of collection, on
to a 2 x 5 grid marked on Hybond-C nitrocellulose (Amersham Pharmacia Biotech,
Little Chalfont UK). The samples were allowed to dry completely and stained in
Coomasie blue staining mixture (Appendix B) for 5 seconds and excess colour
removed in destain mixture (Appendix B). The filters were dried and protein
appeared as a blue stained central spot. The fractions with the most protein were
pooled and pH adjusted, if necessary, to between pH6.5 and pH7.5. The protein
concentration of the IgG purified sera was estimated by measuring the optical density
(OD) at a wavelength (k) of 280 nanometres (nm) (OD2go), using a Philips PU8620
UV/VIS/NIR spectrophotometer (Philip Harris Scientific, Coatbridge UK), and




5 x 106 cells were washed twice in ice cold PBS and pelleted by microcentrifgation
at 650rpm at 4°C. 333pl of protein lysis buffer (Appendix B) was added to the cell
pellet, mixed and left on ice for 45 minutes, vortexing intermittently. The cell lysate
was microcentrifuged as above for 15 minutes and supernatant transferred to a clean
1.5ml tube.
2.4.2 Lowry Assay to Determine Protein Concentration
Reactions for standards and samples were performed in triplicate. 200pl of BSA
standards (200pg/ml, 120jag/ml, 100p.g/ml, 80p.g/ml, 50pg/ml and 20pg/ml prepared
in 0.1M NaOH) and 5pl test sample with 195pl 0.1M NaOH were added to 5ml test
tubes. 1ml alkaline carbonate working solution (Appendix B) was added to each
tube and vortexed, allowed to stand for 10 minutes at room temperature then lOOjal
Folin-coicalteau reagent (Appendix B) added to each tube and left for 30 minutes.
200p.l of each sample was transferred to an enzyme linked immunosorbant assay
(ELISA) plate (Corning, Newbury UK) and the absorbance at 595nm read on a
Dynatech MR5000 plate reader (Dynatech, Guernsey, Channel Islands). Using the
Biolinx software (Dynatech, Guernsey, Channel Islands) a standard curve and
estimation of the protein concentration of the test samples was obtained
2.4.3 Electrophoresis and Electrophoretic Transfer of Protein Samples
Proteins were analysed by sodium dodecyl sulphate polyacrylamide gel
electrophoresis (SDS-PAGE) according to the method of Laemmli (Laemmli 1970).
A 12% separating (Appendix B) with 4.5% stacking (Appendix B) sodium
dodecyl sulphate (SDS) polyacrylamide gel, prepared, cast and run using a Bio-Rad
Protean II xi Cell system (Bio-Rad, Hemel Hempstead UK) according to the
manufacturer's instructions, was found appropriate for resolving proteins in the
molecular weight range of the Fas ligand protein (approximately 40kDa) (Takahashi
et al. 1994). 50p.g of protein lysate (2.4.1-2.4.2) in an equal volume of sample
buffer (Appendix B) was boiled for 5 minutes then loaded in the wells of the cast
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gel and pre-stained Multimark Multi-colored Standard (Novex, Frankfurt Germany)
were electrophoresed in parallel with the protein lysates for reference. The gels were
run in lx running buffer (Appendix B) at a constant current of 50mA per gel until
the samples had traversed the stacking gel, then continued at 30mA per gel until the
4kDa molecular marker was approaching the bottom of the gel.
The electrophoresis apparatus was disassembled and the plates separated. The
stacking gel was removed using a scalpel blade and a corner of the gel marked
uniquely for future orientation. A Trans-Blot Electrophoretic Transfer Cell (Bio-Rad,
Hemel Hempstead UK) was assembled as described by the manufacturer. The
electrophoretic transfer was carried out in transfer buffer (Appendix B), to a level
lcm below the electrodes of the transfer tank, at 250mA overnight. The transfer
apparatus was dismantled and the plastic holder containing the gel and Hybond-C
nitrocellulose (Amersham Phannacia Biotech, Little Chalfont UK) submerged and
opened in TBS Tween (TBST) (Appendix B). Excess nitrocellulose around the gel
was cut away with a scalpel blade and the nitrocellulose cut into sections containing
lanes of appropriate protein samples to be immunoblotted with the sera of choice.
The reference molecular weight standards lanes were cut off and retained for
analysis after the immunoblotting (2.4.4). The gel was removed from the
nitrocellulose and the sections clearly marked for future reference and orientation.
2.4.4 Western Blotting and Dot Blots
All incubations and washes were carried out on a Platform Shaker STR6 (Stuart
Scientific, Staffordshire UK) at room temperature unless stated otherwise and
antisera dilutions were prepared in TBST (Appendix B). The nitrocellulose strips
for the Western blots to test for an anti-Fas ligand peptide antibody response in the
Fas ligand peptide immunised rabbits were obtained as described above (2.4.3). Dot
blots were used to test sera obtained from mice and rabbits immunised with the
NRAMP1 peptide (2.3.1-2.3.8). These were prepared by spotting 10pl containing
lpg of the test or control substance on a strip or triangle of nitrocellulose and the
dots allowed to dry at room temperature. The substances were NRAMP1 peptide (the
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NRAMP1 peptide in PBS) (2.3.1), NRAMP1/KLH conjugate (the NRAMP1 peptide
conjugated to KLH) (2.3.5), KLH (KLH in PBS), BALB/c IgG, BSA and NRS. When
only one species of sera was being tested the positive controls for the detection
method for the other species were omitted (i.e. positive control when testing rabbit
sera: NRS, positive control when testing mouse sera: BALB/c IgG).
The nitrocellulose sections were washed in TBST, blocked in blocking solution
(Appendix B) for 1 hour, or overnight at 4°C, then washed 3x5 minutes in TBST.
The sections were incubated for Vi-VA hours in heat sealed clear plastic "bags"
containing 10ml of the appropriate antisera or, for the triangle dot blots, in 2mls of
sera in small plastic weighing boats. Sera dilutions are shown in Table 2.3 and
negative controls were incubated in TBST. The sections were washed as above and
incubated in the appropriate secondary antisera at 1/1000 for 30 minutes i.e. SAR-
BIO (DAKO, Cambridge UK) for testing rabbit sera or RAM-BIO (DAKO,
Cambridge UK) for testing mouse sera. The sections were washed as above,
incubated in a 1/30 dilution of prepared ABComplex-AP (DAKO, Cambridge UK)
for 30 minutes then washed as above. The sections were incubated in nitro blue
tetrazolium/5-bromo-4-chloro-3-indoyl phosphate (NBT/BCIP) chromogen substrate
(Appendix B) in the dark for 5-20 minutes until the blue colour reaction had
developed and bands or dots were visible. The sections were washed twice for 1
minute and twice for 5 minutes in dH20 and the nitrocellulose allowed to dry. The
Western blots were aligned against the molecular weight standard strips and the size
of immunopositive bands estimated. Anti-CD3 sera was used as a positive control for
the Western blotting to check the PBMCs had been stimulated successfully with
concanavalin A (2.18.4), For the Western blots additional positive controls were
included in the form of dot blots of the Fas ligand peptide and pre-immune rabbit




Polyclonal anti-CD3 (DAKO, Cambridge UK) 1/500
Pre-immune rabbit serum (for Fas ligand response test) lOpg/ml
Fas ligand peptide immunised rabbit sera lOpg/ml
Pre-immune rabbit serum (for NRAMP1 peptide response test) 1/100
NRAMP1 peptide immunised rabbit sera 1/100
NMS 1/100
NRAMP1 peptide immunised mouse sera 1/100
Table 2.3 Dilutions of sera used for Western blotting to test for a rabbit anti-Fas
ligand antibody response, and for dot blots to test for an anti-NRAMPl peptide
antibody response. Immunisation strategies and derivation of sera are described in
2.3 and 5.2.9.5.
2.5 ENZYME-LINKED IMMUNOSORBENT ASSAY AND
CYTOSPINS
2.5.1 To Test Sera for Fas Ligand Peptide Specific Antibody Response
Each test sera dilution and negative control solution was tested in triplicate and the
mean absorbance of the three readings calculated. Half the wells of a 96 well ELISA
plate were coated with lOOpl of Fas ligand peptide solution at ljag/ml in 0.05M
carbonate/bicarbonate buffer pH9.6 and incubated at 4°C overnight. The wells were
washed three times with PBS/0.05% Tween 20 (PBST) and lOOpl of 1% BSA in
PBS was added to each well as blocking agent and incubated at room temperature
for 2/4-3 hours. The wells were washed as above and lOOp.1 of the appropriate
antisera dilutions (Figure 3.5) or 1% BSA in PBS added to the appropriate wells
such that three peptide coated wells and three uncoated wells received each test
dilution and BSA control. The plates were incubated at room temperature for 114
hours and washed as above. lOOpl of SAR-HRP (DAKO, Cambridge UK), diluted
1/1000 in 1% BSA in PBS was added to each well and incubated at room
temperature for 114 hours, then washed as above. lOOpl of TMB
(tetramethylbenzadine) chromogen substrate (Appendix B) was added to each well
and left at room temperature for 5-10 minutes, watching for the optimal colour
change, at which point the reaction was stopped by the addition of 50pl 3 nolar (N)
HC1 (Fisher Scientific, Loughborough UK) and the absorbance at 450nm was read on
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a Dynatech MR5000 (Dynatech, Guernsey, Channel Islands) plate reader. A graph of
anti-sera concentration versus OD450 was plotted to compare the specificity of the
sera samples tested for the peptide.
2.5.2 To Test Sera for Human NRAMP1 Peptide Specific Antibody
Response
A similar protocol to that described in 2.5.1 to test sera for a Fas ligand peptide
response was followed with the following alterations. Each combination of sera
dilution and NRAMP1 peptide concentration coating the plate was performed in
duplicate. NMS at the same concentrations as the test sera were used as controls. The
plate was coated with peptide at concentrations of Opg/ml, 0.5pg/ml, l.Opg/ml,
2.0pg/ml, 4.0pg/ml and 8.0pg/ml and incubated at 37°C for 1% hours or at 4°C
overnight. The sera were tested at dilutions of 1/50, 1/150, 1/450 and 1/1350 and
mouse Ig detected using HRP conjugated rabbit anti-mouse Ig (RAM-HRP) (DAKO,
Cambridge UK) at 1/750 dilution. O-phenylenediamine (OPD) chromogen substrate
(Appendix B) was used to detect a positive reaction, stopping the reaction after
about 5 minutes with 25pi of 3N HC1 and the OD490 read.
2.6 DNA EXTRACTIONS
Extracted genomic DNA was stored at 4°C for short term storage or -20°C for long
term storage. Extracted plasmid DNA was stored at -20°C.
2.6.1 DNA Isolation from Blood
DNA extraction was carried out in a BioMAT-1 Class I microbiological safety
cabinet (Medical Air Technology, Manchester UK). lOOp.1 EDTA-blood in 800pl
Tris-EDTA (TE) (Appendix B) was vortexed and microcentrifuged at 13,000rpm
for 25 seconds. The supernatant was removed and the cell pellet was washed in 50pl
TE, vortexed and microcentrifuged as above and washes repeated until the pellet was
creamy white and free from visible red blood cells. 200pl lysis buffer/proteinase K
(50mM KC1, lOmM Tris, 2.5mM MgCl2, 10% gelatin, 0.45% NEMO, 0.45% Tween
20, 200pg/ml proteinase K) was added and the samples were incubated at 50°C for
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20 minutes. Proteinase K was inactivated by boiling for 20 minutes after addition of
lOOju.1 distilled H20.
2.6.2 DNA Isolation from Paraffin Embedded Tissue
For all the protocols used the following procedures were carried out to avoid
contamination from other DNA sources:
Gloves were worn throughout the procedure.
Excess paraffin was removed from the blocks.
Prior to cutting sections the microtome cutting area was cleaned with alcohol
and any debris from previous cutting removed.
For each block, and after trimming the block to get a full face, a clean part of
the blade was used.
After cutting, the rolled section was transferred from the blade to a sterile
1,5ml tube using a sterile toothpick.
The number and thickness of sections cut depended on the protocol being followed
and the size of the block being used. The majority of blocks used were large wedge
biopsies of approximately 2cm by 1cm and the quantities for these are given. For
smaller blocks the number of sections cut was increased appropriately. For selection
of cases see (2.1.1).
1) DNA was extracted according to the method of Hubbard and Anderson (Hubbard
and Anderson 1993). 15pm sections were boiled for 8 minutes in lOOpl lysis
buffer (50mM Tris pH 8.4, ImM EDTA, 0.5% Tween 20) then microcentrifuged
briefly to pellet the tissue. Extracted DNA was stored at -20°C. When the DNA
solution was being pipetted for PCR analysis (2.9) care was taken to avoid
transfer of paraffin, which formed an upper phase in the tube. Where necessary
this was removed prior to pipetting.
2) 15pm sections were deparaffinised in 600pl xylene (Genta Medical, York UK) at
room temperature for 5 minutes and microcentrifuged at 13000rpm for 10
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minutes. The supernatant was discarded and the xylene wash was repeated. 600pl
absolute ethanol (Hayman Ltd., Witham UK) was added to each tube, incubated at
room temperature for 5 minutes then microcentrifuged at 13000rpm for 10
minutes. The supernatant was discarded and the ethanol wash repeated. The tubes
were drained on paper towel and air dried for 10 minutes. 200pl lysis buffer
(50mM KC1, lOmM Tris, 2.5mM MgCl2, O.lmg/ml gelatin, 0.45% NP40, 0.45%
Tween 20, pH 8.3) containing 200pg/ml proteinase K was added, pipetting gently
to mix, and incubated at 50°C for 2 hours, vortexing after 1 hour. The samples
were microcentrifuged briefly to pellet the contents of the tubes, boiled for 20
minutes to inactivate proteinase K, then microcentrifuged briefly as before and
cooled on ice.
3) DNA was extracted using the Nucleon HT DNA extraction kit (Scotlab,
Coatbridge UK) following the protocol for "DNA extraction from Paraffin
Sections". 20-30|um sections were covered in xylene (Genta Medical, York UK)
and incubated at 37°C for 20 minutes, microcentrifuged at 5000rpm for 5 minutes
and the xylene removed. The sections were recovered in xylene, incubated at
room temperature for 2 minutes, microcentrifuged at 13000rpm for 5 minutes and
the xylene removed. The sections were rehydrated through 100%, 75%, 50% and
25% ethanol (Hayman Ltd., Witham UK) and finally water, incubating for 3
minutes in each alcohol dilution, microcentrifuging at 13000rpm and removing
supernatant between the rehydration steps. After pouring off the water. 350pl
Reagent B (400mM Tris-HCl, 60mM EDTA, 150mM NaCl, 1% SDS, pH 8.0) and
18pl proteinase K solution (lOmg/ml) were added and the tubes incubated at 55°C
overnight. The tissue was deproteinised by addition of lOOpl sodium percholate
and mixed by inverting at least seven times. DNA was extracted by the addition of
600pl chloroform, mixing as above, and 150pl Nucleon resin suspension. Without
remixing the phases the tubes were microcentrifuged at 2000rpm for 1 minute and
the upper brown phase transferred to a fresh tube. The DNA was precipitated in 2
volumes of cold absolute ethanol at -20°C for 114 hours. Precipitated DNA was
pelleted by microcentrifugation at 13000rpm for 15 minutes, the supernatant was
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removed, 1ml cold 70% ethanol added to pellet, inverting several times, and the
tube recentrifuged as before. After removal of the ethanol the DNA was air dried
for about 10 minutes. 25pl sterile dH20 was added and the DNA redissolved on a
rotary mixer (Stuart Scientific, Staffordshire UK) for several hours.
4) DNA was extracted using the Gentra Systems, Inc. Puregene DNA Isolation Kit
(Flowgen, Lichfield UK) following the protocol for "DNA Isolation from Tissue
in Paraffin". Reagents were supplied with the kit unless indicated otherwise. 5-
lOmg of paraffin embedded tissue sections were deparaffinised in 300pl xylene
(Genta Medical, York UK) at room temperature, inverting constantly. The tissue
was pelleted by microcentrifugation at 9000rpm for 2 minutes and xylene
discarded. The xylene wash was repeated twice. 300pl of 100% ethanol (Hayman
Ltd., Witham UK) was added and incubated at room temperature for 5 minutes,
inverting constantly, then microcentrifuged at 9000rpm for 2 minutes and ethanol
discarded. The ethanol wash was repeated once. 300pl Cell Lysis Solution was
added, pipetting several times to homogenise the tissue. 3pl proteinase K
(lOmg/ml) was added to the lysates and the tubes inverted 25 times prior to
incubation at 55°C for 1 hour, inverting the tubes periodically. The tubes were
cooled to room temperature and 1.5pl of RNase A Solution (4mg/ml) was added
to the lysate, mixed by inversion 25 times and incubated at 37°C for 40 minutes
then allowed to cool to room temperature. The protein was precipitated by
addition of lOOjul Protein Precipitation Solution, vortexed for 20 seconds then
microcentrifuged at 9000rpm for 3 minutes to pellet the protein. The supernatant
was poured off into clean 1.5ml tubes and 300pl isopropanol (Fisher Scientific,
Loughborough UK) was added to precipitate the DNA, inverting 50 times,
followed by microcentrifugation at 900rpm for 1 minute. The supernatant was
discarded and the tubes drained on paper towel. 300pl of 70% ethanol was added
to the DNA pellets, inverting to wash the DNA, then microcentrifuged at
9000rpm for 2 minutes. The ethanol was poured off, the tubes were drained on
paper towel and allowed to air dry for 15 minutes. The DNA was rehydrated in
lOjul DNA Hydration Solution at room temperature overnight.
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5) DNA was extracted using the Cleanmix DNA extraction kit (Vh-Bio Ltd.,
Newcastle-upon Tyne UK) following the protocol for "DNA extraction from
paraffin embedded tissues" and "Protocol B". Reagents were supplied with the kit
unless indicated otherwise. 20pm sections were deparaffmised by incubation at
65°C for 10 minutes in lml octane (Sigma, Poole UK). After microcentrifugation
at 13000rpm for 5 minutes the supernatant was discarded and the pellets washed
with lml absolute ethanol (Hayman Ltd., Witham UK) and microcentrifuged as
before. The ethanol wash was repeated and lOOpl proteinase K digestion buffer
(150mM Tris pH 7.5, 50mM EDTA, 1% Triton X100) and 20pl proteinase K
(lOmg/ml) were added to the pellets. The tubes were incubated at 50°C for 24
hours. 450pl Cleanmix Binding Solution and 50pl Cleanmix-High Capacity
Purification Resin (shaken before addition) were added to each tube and mixed by
inversion. The mixture was transferred to 2ml tubes containing a Cleanmix Filter
and microcentrifuged at 13000rpm for 30 seconds. The resin with bound DNA
should remain on the filter. The filtrate was discarded and 500pl Washing
Solution (containing 50% ethanol (Hayman Ltd., Witham UK) was added to the
filter, microcentrifuged at 13000rpm for 30 seconds and the filtrate discarded.
The wash was repeated using 500pl of 80% ethanol and the filter transferred to a
clean tube. DNA was eluted from the filter with 30pl of sterile water pre-warmed
to 65°C, allowing the DNA to resuspend for 1 minute before microcentrifuging
for 30 seconds.
2.6.3 DNA Isolation from Cells
105 viable cells (2.18.2) were pelleted in universal tubes (Rosslabs, Cheshire UK) at
lOOOrpm for 10 minutes and nearly all the supernatant discarded. The cell pellet was
resuspended in residual supernatant and transferred to a 1.5ml tube,
microcentrifuged at 6000rpm for 6 minutes and the supernatant aspirated off. 250pl
lysis buffer (50mM KC1, lOmM Tris, 2.5mM MgCl2, O.lmg/ml gelatin, 0.45% NP40,
0.45% Tween 20, pH 8.3) and 5pl proteinase K (lOmg/ml) were added, pipetting to
mix, and incubated at 50°C for 1 hour. Proteinase K was inactivated by boiling for
15 minutes and the samples were cooled on ice.
2.6.4 DNA Isolation from Bacterial Cultures
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2.6.4.1 "Quick Mini Preps"
The following protocol was used to extract DNA from mini cultures (2.16.1) to
detennine if cloning and bacterial transfection had been successful by subsequent
digestion of DNA with restriction enzymes and analysis of the products. Plasmid
DNA from clones with the desired restriction enzyme digestion profile was
subsequently isolated for sequencing (2.15.2) using QIAprep Spin Plasmid Kit
(2.6.4.2).
1.5ml of turbid mini culture (2.16.1) was poured into a 1.5ml tube and
microcentrifuged at 13000rpm for 1 minute. The culture medium was aspirated off
and the pellet resuspended in 200pl TEN buffer (O.OlmM Tris-HCl pH 8.0, ImM
EDTA, O.lmM NaCl). 200pl phenol:chloroform:isoamyl alcohol (25:24:1) was
added, the samples were shaken quickly and microcentrifuged at 13000rpm for 5
minutes. The aqueous phase was transferred to a clean 1.5ml tube and 400p.l of 95%
ethanol (Hayman Ltd., Witham UK)/5% 3M NaOAc pH5.0 was added, mixed and
microcentrifuged for 10 minutes. The supernatant was removed and the pellet
washed in 70% ethanol. The pellet was air dried at 37°C and resuspended in 50pl
sterile water. 7pi of extracted DNA was used per restriction enzyme digest (2.10),
including lpl of RNase A (lOmg/ml), as this protocol does not separate RNA from
DNA.
2.6.4.2 QIAprep Spin Plasmid Kit (Mini Preps)
Plasmid DNA for manual sequencing of cloned DNA fragments (2.15.2) was
isolated using the QIAprep Spin Plasmid Kit (QIAGEN Ltd., Crawley UK) following
the "Standard Protocol" as described below. The purification procedure is based on
extraction of plasmid DNA from cleared bacterial alkaline SDS lysates, under high
salt binding conditions, binding ofDNA to a silica-gel membrane, ethanol with high
salt washing and elution of DNA. All buffers used were supplied with the kit and
their composition is given below where known.
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1.5ml of turbid overnight mini culture (2.16.1) was poured into a 1.5ml tube and
microcentrifuged at 5000rpm for 5 minutes, the supernatant was discarded and a
further 1.5ml culture added and pelleted as before. The bacterial pellet was
resuspended in 250pl of Buffer PI (50mM Tris-HCl pH8.0, lOmM EDTA, 100p.g/ml
RNase A) and 250pl of Buffer P2 (200mM NaOH, 1% SDS) was added mixing by
gentle inversion. The mixture was incubated at room temperature for no more than 5
minutes to prevent denaturation of plasmid DNA. Chromosomal DNA and protein
was precipitated by addition of 350pl of chilled Buffer N3 (1.32M potassium acetate
pH4.8), mixing immediately by gentle inversion of the tube. Following 10 minutes of
microcentrifugation at 13000rpm the supernatant was transferred to a QIAprep spin
column and placed in a 2ml collection tube. The column was microcentrifuged for
about 1 minute at 13000rpm and the flow-through discarded. DNA in the column
was washed by the addition of 0.75ml of Buffer PE (200mM NaCl, 20mM Tris-HCl,
5mM EDTA diluted with 95% ethanol (Hayman Ltd., Witham UK) to a final ethanol
concentration of 55%) to the column, microcentrifuged for 1 minute, the flow-
through discarded and microcentrifuged again as before, to remove residual wash
buffer. The column was transferred to a clean 1.5ml tube and the DNA eluted with
50pl of water or TE (Appendix B), incubating for 1 minute at room temperature
before microcentrifuging at 13000rpm for 1 minute.
2.6.4.3 Plasmid Maxi Kit (Maxi Preps)
The Plasmid Maxi Kit (QIAGEN Ltd., Crawley UK) was used to prepare DNA of
quality and quantity suitable for ligation (2.14) and transfection (2.17). It is based
on a modified alkaline lysis procedure, followed by binding of plasmid DNA to
QIAGEN anion-exchange resin under low salt and pH conditions. RNA, protein and
low molecular weight impurities are removed by a medium salt wash, plasmid DNA
is eluted in a high salt buffer followed by concentration and desalting by isopropanol
precipitation. All buffers used were supplied with the kit and their composition is
given below where known.
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Turbid overnight maxi culture (2.16.1) was poured into 250ml polypropylene
centrifuge bottles (Sorvall, Stevenage UK) and centrifuged at 5000rpm for 15
minutes at 4°C in a Centrikon H-401B centrifuge (Kontron Instruments, UK) using a
Sorvall GSA rotor (Sorvall, Stevenage UK) and the supernatant discarded. The
bacterial cell pellet was resuspended in 10ml of Buffer PI (resuspension buffer)
(100pg/ml RNase, 50mM Tris-HCl, lOmM EDTA pH8.0). 10ml of Buffer P2 (lysis
buffer) (200mM NaOH, 1% SDS) was added and the bottles rolled gently to mix and
incubated at room temperature for 5 minutes. 10ml of chilled Buffer P3
(neutralization buffer) (3.0M KOAc pH5.5) was added, the bottles were rolled to mix
and incubated on ice for 20 minutes, then centrifuged at ll,500rpm using a Sorvall
SS34 rotor (Sorvall, Stevenage UK) for 30 minutes at 4°C and the supernatant was
transferred to 50ml centrifuge tubes. A QIAGEN-tip 500 was equilibrated with 10ml
Buffer QBT (equilibration buffer) (750mM NaCl, 50mM MOPS pH 7.0, 15%
ethanol, 0.15% Triton X-100) and the eluted sample applied to the QIAGEN-tip. The
sample was allowed to flow through by gravity and the tip was washed twice with
30ml of Buffer QC (wash buffer) (1.0M NaCl, 50mM MOPS pH7.0, 15% ethanol).
The DNA was eluted with 15ml Buffer QF (elution buffer) (1.25M NaCl, 50mM
Tris-HCl pH8.5, 15% ethanol) and collected in a 25ml DuPont Instruments Corex
tube (Sorvall, Stevenage UK). 10.5ml (0.7 volumes) of room temperature
isopropanol (Fisher Scientific, Loughborough UK) was added to precipitate the DNA
and the tube centrifuged at l,500rpm for 30 minutes at 4°C. The supernatant was
discarded and the DNA washed with 5ml of chilled 70% ethanol (Hayman Ltd.,
Witham UK), air dried and resuspended in 500pl TE.
2.6.5 DNA Isolation from Agarose Gels
The QIAEX II Gel Extraction Kit (QIAGEN Ltd., Crawley UK) was used to extract
and purify DNA fragments based on solubilisation of agarose and selective,
quantitative adsorption of nucleic acids to the QIAEX II silica-gel particles in the
presence of high salt. Elution of the DNA is accomplished with a low salt solution.
The buffers used were supplied with the kit.
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Under UV visualisation using a Herolab UVT-28 MP transilluminator (Scotlab,
Coatbridge UK) the appropriate DNA band was excised from agarose gel (2.11.1)
using a clean scalpel blade and excess agarose removed. The gel slice was weighed
in a colourless 1.5ml tube and 3pl of Buffer QX1 for each mg of gel was added. The
QIAEX II was resuspended by vortexing for 30 seconds and the appropriate amount
added to the tube (10pl for ^2pg DNA, 30°C for 2-lOpg DNA). The tube was
incubated at 50°C for 10 minutes to solubilise the agarose and bind the DNA, mixing
by vortexing every 2 minutes to keep the QIAEX II in suspension and ensuring the
mixture remained yellow. The sample was microcentrifuged for 30 seconds and the
supernatant removed with a pipette. The pellet was washed with 500pl Buffer QX1
to remove residual agarose contamination, resuspending by vortexing then
microcentrifuged and the supernatant removed as before. The pellet was then washed
twice with 500pl Buffer PE, to remove residual salt contamination, and the pellet air
dried for 10-15 minutes until it became white. The DNA was eluted by the addition
of 20-40pl dH20 or lOmM Tris-ElCl pH8.5 and incubated at room temperature for 5
minutes. The tube was microcentrifuged for 30 seconds and the supernatant
containing the DNA was pipetted into a clean tube.
2.7 RNA EXTRACTION AND REVERSE TRANSCRIPTION
2.7.1 RNA Extraction
Total RNA was extracted from cells or frozen tissue using Total RNA Isolation
Reagent (Advanced Biotechnologies, Epsom Surrey UK). The method is based on a
14M solution of guanidine salts and urea, which act as a denaturing agent, in
conjunction with phenol and detergents, which are very effective for isolation of
total RNA. Chloroform extraction of RNA is followed by isopropanol precipitation
from the aqueous phase. The labile nature of RNA required all plastic wear,
solutions and filter pipette tips to be RNase free and gloves to be worn throughout all
procedures involving RNA. All water was pre-treated with 0.1% diethyl
pyrocarbonate (DEPC treated dH20) (Appendix B) overnight in a fume hood
(Morgan and Grundy Ltd., Uxbridge, UK) then autoclaved. Following
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homogenization of 1) cells or 2) tissue the same protocol 3) was followed, as
described below.
1) Homogenization of cells
107 viable cells were centrifuged in a universal tube (Rosslabs, Cheshire UK) at
lOOOrpm for 10 minutes and nearly all the supernatant discarded. The cell pellet
was resuspended in the residual supernatant and transferred to an RNase free
1.5ml tube. The cells were not washed prior to RNA extraction as this increases
the possibility of mRNA degradation. The cells were lysed by addition of 1ml
RNA Reagent, pipetting well to ensure complete homogenization.
2) Homogenization of Frozen Tissue
Tissue destined for RNA extraction was frozen as soon as possible after excision
from its source and stored at -70°C. A piece of tissue was cut using a scalpel
blade and transferred to an RNase free 1.5ml tube. The weight of tissue was
calculated by "weighing by difference". 1ml of RNA Reagent per 10-100mg
tissue was added to the tissue and homogenized using a plastic hand homogenizer.
3) The homogenate was kept on ice for 5 minutes to ensure complete dissociation of
nucleoprotein complexes. 0.2ml of chloroform per ml of RNA Reagent used was
added and the sample shaken vigorously for 15 seconds. After a 5 minute
incubation on ice the sample was microcentrifuged at 13000rpm for 15 minutes at
4°C. The upper aqueous phase containing the total RNA was transferred to an
RNase free 1.5ml tube leaving the lower organic phase and interface containing
the protein and DNA. An equal volume of isopropanol was added to the aqueous
phase, mixed by inversion and the RNA allowed to precipitate on ice for about 1
hour. The sample was microcentrifuged at 13000rpm for 10 minutes at 4°C, the
supernatant removed and the RNA pellet washed twice with 75% ethanol
(Hayman Ltd., Witham UK), vortexing and microcentrifuging the sample at
6500rpm for 5 minutes at 4°C between washes. The pellet was air dried for about
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10 minutes and resuspended in 50-1 OOjal DEPC treated dH20. The RNA
concentration was estimated (2.7.2) and the RNA solution stored at -70°C.
2.7.2 Estimation of RNA Concentration
lpl ofRNA solution (2.7.1) was added to 599pl of DEPC treated dH20 (Appendix
B) (2.7), previously used as a reference blank, in a quartz cuvette and the absorbance
at 260nm (A260) read using a Genequant II RNA/DNA Calculator (Phannacia
Biotech, Cambridge UK). The concentration of RNA was obtained using the
Genequant II RNA/DNA calculator, which uses the following equation:
A260 x 40 = pg/ml RNA
An indication of the RNA integrity was obtained from the A260/A280 ratio where pure
RNA has a value of 2.0.
Between samples the cuvette was thoroughly rinsed three times with dH20 and three
times with DEPC dH20.
2.7.3 DNase Treatment of Total RNA
Where PCR primers were not able to distinguish between cDNA and possible carry-
through-plasmid DNA during the RNA extraction procedure RNA was treated with
DNase prior to reverse transcription (2.7.4). lpg of total RNA, lpl
Deoxyribonuclease I, Amplification Grade (Life Technologies, Paisley UK) and
0.909pl 10 x DNasel reaction buffer (200mM Tris-HCl pH8.4, 20mM MgCl2,
500mM KC1), made up to a final volume of 9.09pl with DEPC treated dH20
(Appendix B), was incubated at room temperature for 15 minutes. 0.91 pi 25M
EDTA was added and incubated at 65°C for 10 minutes to inactivate the DNase.




First strand complementary DNA (cDNA) was synthesised from total RNA using
RNase H-Moloney Murine Leukaemia Virus reverse transcriptase (RT). Reagents
were supplied by Life Technologies, Paisley UK, unless stated otherwise. 1 jug of
DNase treated total RNA (2.7.3) or lpg of total RNA (2.7.1), when DNase pre-
treatment was not required, was heated at 70°C for 10 minutes with lpl oligo(dT)18
universal primer (500pg/ml) (Advanced Biotechnologies, Epsom UK) in a final
volume of 11 pi, to allow oligo(dT) primers and mRNA polyA tails to anneal. The
mixture was chilled quickly on ice and microcentrifuged briefly. After addition of
4pl of First Strand Buffer (250mM Tris-HCl pH 8.3, 375mM KC1, 15 mM MgCL),
2pl of 0.1M dithiothreitol (DTT) and 2pl of 20mM DNA polymerisation mix
(Advanced Biotechnologies, Epsom UK), the mixture was incubated at 42°C for 2
minutes and 1 ju.1 Superscript II was added, mixing gently by pipetting. cDNA was
synthesised at 42°C for 50 minutes and the reaction inactivated by heating at 70°C
for 15 minutes using a Hybaid Omni Gene thermal heating block (Elybaid,
Teddington UK). cDNA was stored at -20°C.
2.8 DESIGN OF PCR PRIMERS AND PCR REACTIONS
All primers were synthesised by Cruachem Ltd., Glasgow UK and were received in a
lyophilised state. Primers were rehydrated in sterile dFLO to give stock solutions of
250pM which were diluted to 25p.M working solutions. Lyophilised primers were
stored at 4°C and primer solutions were stored at -20°C.
DNA sequence information was obtained from Genbank and the relevant papers as
referenced. Primers were designed by determining which region of DNA sequence
was required to be amplified and by analysing the intron/exon structure of the genes
to ensure cDNA specificity where required. The candidate primer sequences were
designed to have an equivalent GC:AT ratio, to show no obvious signs for potential
primer-primer interaction and to have equivalent melting temperatures (Tm) of
approximately 60°C. This was based on an approximate calculation, summing the
primer-template base interactions where every A-T interaction is equivalent to 2°C
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and every C-G interaction is equivalent to 4°C. All primers were checked against
sequences entered in the Genbank and EMBL databases using BLAST to check for
potential cross-reactivity of the primers with other published sequences. When
establishing the optimal reaction conditions for the PCRs, an extension time was
tried based on allowing approximately 1 minute for a 1 kilobase (kb) PCR product,
and annealing temperatures were tested at the approximate Tm calculated as
described above and about 5°C lower than the Tm information provided by the
primer synthesisers. Reactions were subsequently altered appropriately and MgCl2
concentrations altered if required. The PCRs designed for this project are described
below.
2.8.1 NRAMPpol
The NRAMPFpol and NRAMPRpol primers were designed to span the 5' promoter
region polymorphic microsatellite repeat region of the NRAMP1 genomic DNA. A
product was required which would generate fragments small enough for a 2bp size
difference to be clearly resolved after digestion with restriction enzymes hence, the
sequence of the product required suitable restriction enzyme sites to be present
which gave products of unique size for all the known alleles. The following primers
met these requirements and the sequence of the 194bp amplified product for allele 3
is given in Figure 2.1 showing the Rsal and Mnll recognition sites used for
restriction fragment length polymorphism (RFLP) analysis described in 2.11.2,
NRAMPFpol GGACATGAAGACTCGCATTAGG
(59-70bp Genbank Accession number X82016)
NRAMPRpol TTAGCTCTGATTTCAGATGCTTCC













Figure 2.1 Sequence of the promoter region of the human NRAMP1 gene
(Accession number X82016, 59-240bp) amplified by PCR to genotype the
polymorphic microsatellite region shown in bold. The Rsal and Mnll restriction
enzyme sites used to digest the amplified DNA are shown. The enzymes recognise
the following sites and cut at the position shown by the vertical slash, n represents
any base.
Mnll | (n)6gagg Rsal gt | ac
I (n)7ctcc ca|tg
The sequence for allele 3 is used in this figure. Sequences over the polymorphic
region of the other alleles identified in this study and those previously published are
shown in Table 4.1,





72°C 15 seconds) x 35
(94°C 30 seconds
65°C 30 seconds
72°C 10 minutes) x 1
2.8.2 GAPDH
The glyceraldehyde-3-phosphate dehydrogenase (GAPDH) primers were designed to
amplify a product specific to the cDNA sequence of GAPDH for use as a control
housekeeping gene against which the relative level of expression of the NRAMP1
and neomycin resistance ([neo) genes could be determined by a semi-quantitative
analysis method. The primers were designed to have a Tm compatible with the
NRAMPalu primers (2.8.3), so both PCRs could be carried out in a single tube if
desired. They were designed to generate a product of approximately the same size as
the NRAMPalu product, ensuring the time for amplification of the two products
would be comparable and they would run to about the same point when
electrophoresed in agarose gel, yet be distinguishable, to enable analysis of the
intensity of the bands (2.11.1) to be carried out over a similar region of the gel with
a homogeneous background. Primer GAPDHF spans sequence in exons 3 and 4 and
primer GAPDHR spans sequence in exons 6 and 7 (Ercolani et al. 1988). The
primers generate a product of 339bp.
GAPDHF GACCTCAACTACATGGTTTAC
(190-210bp human GAPDH gene exon sequence Ercolani et al. 1988)
GAPDHR AGGAGGCATTGCTGATGATC
(529-5 lObp human GAPDH gene exon sequence Ercolani et al. 1988)
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The extension time for the reaction varied depending on whether a semi-quantitative
analysis was being carried out for the U937 and Mono Mac 6 (MM6) transfectancts
(2.20.1) comparing NRAMPalu (2.8.3), NRpCI (2.8.4), neoFl (2.8.5) and neoFexp
PCR (2.8.6) product yields, in which case 1 minute was necessary due to the larger
products of the latter reactions. When the expression in PBC and control liver and
the initial analysis of the cell line expression profiles was being determined a 30
second extension time was sufficient. The cycle number for the reaction also varied
between 26 and 41 for comparison of the liver expression levels and when the
exponential phase of the reaction was being determined. For these variable cycle
PCRs the tubes were removed from the Hybaid Omni Gene thermal heating block
(Hybaid, Teddington UK) at intervals of a constant number of cycles. For semi¬
quantitative gene expression analysis of large sample numbers of transfected cells
and clones (2.20.1) 35 cycles were carried out which lay within the exponential
phase of the reaction. The PCR conditions for GAPDH primers were:
94°C 2Vi minutes
(94°C 30 seconds or 1 minute
60°C 30 seconds or 1 minute
72°C 15 seconds) x as described above
For semi-quantitative analysis no final extension cycle was performed. However, for
reactions to determine if a cDNA had been successfully prepared a final extension
cycle was added at the end of the reaction as follows:
(94°C 30 seconds
60°C 30 seconds
72°C 10 minutes) x 1
2.8.3 NRAMPalu
The NRAMPalu primers were designed to be cDNA specific and compatible with
the GAPDH primers (2.8.2). They were designed to detect both splice variants of the
gene reported, one of which includes the Alu sequence after the end of exon 4 in the
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message encoding the whole protein (Cellier et al. 1994), discussed in 1.8.8. The
product including the Alu repeat sequence is denoted +alu throughout the text and
the product encoding the whole protein -alu and they have the sizes 323bp and
249bp, respectively. NRAMPFalu spans sequence in exons 3 and 4 and NRAMPRalu
spans sequence in exons 5 and 6 (Cellier et al. 1994).
NRAMPFalu GCGGGATTCAAACTTCTCTG
(437-456bp Genbank Accession number D50402)
NRAMPRalu GAGTGGGATTCGTCCAGCT
(685-667bp Genbank Accession number D50402)
The reaction conditions and variations for the NRAMPalu PCR are as follows and
described for the GAPDH PCR (2.8.2), except the variable cycle PCRs were carried
out between 32 and 47 cycles for comparison of two liver cDNAs during any one
analysis or 41 cycles, which lay within the exponential phase of the reaction, when
multiple samples were being analysed semi-quantitatively.
94°C 2Vi minutes
(94°C 30 seconds or 1 minute
60°C 30 seconds or 1 minute
72°C 15 seconds) x as described above
These primers were also used to confirm the pCIneo/NRAMP 1 plasmid (5.2.4)
sequence was present in genomic DNA extracted from cells transfected with the
plasmid (2.20.1) as the cloned NRAMP1 sequence corresponds to the cDNA





72°C 1 minute) x 35
(94°C 30 seconds
60°C 2 minutes
72°C 10 minutes) x 1
2.8.4 NRpCI
The NRpCI PCR was designed to discriminate between NRAMP1 sequence
expressed from the pCIneo/NRAMPl plasmid sequence (described in 5.2.4) and the
endogenous gene in cells transfected with the pCIneo/NRAMP 1 plasmid (2.20.1).
The PCR used the NRAMPRalu primer described previously (2.8.3) and a forward
primer specific for plasmid sequence 5' to the start of the cloned NRAMP1
sequence, which was expressed at the RNA level but was 5' to the translation
initiation site. This primer was named pCIneoF and the PCR, and predicted product
of 706bp generated by these primers, called NRpCI.
pCIneoF AGAATTCACGCGTGGTACCT
(1095-1114bp Promega pCIneo plasmid (pCI-neo Mammalian Expression Vector)
sequence data (Promega, Southampton UK))
As described for the GAPDH primers (2.8.2) variable cycles were carried out to
determine where the exponential phase of the reaction lay and semi-quantitative
gene expression analysis was carried out on products generated after 41 cycles,




72°C 1 minute) x 41
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These primers were also used as double confirmation of the presence of the
NRAMP1 plasmid sequence in genomic DNA from pCIneo/NRAMPl plasmid
transfected cells, in conjunction with the NRAMPalu primers as described in 2.8.3,




72°C 1 minute) x 35
(94°C 30 seconds
60°C 2 minutes
72°C 10 minutes) x 1
2.8.5 neoF1
Primers specific for the pCIneo plasmid were designed to confirm the pCIneo
plasmid sequence was present in genomic DNA from control cells transfected with
the pCIneo plasmid and in cells transfected with the pCIneo/NRAMPl plasmid
(2.20.1). The primers spanned part of the neo gene, generated a product of 729bp
and were called neoFl and neoR. The neoFl primer sequence was 5' of the
transcription initiation site and the neoR primer sequence was within the neo coding
sequence. These primers were used to analyse genomic DNA and to confirm cDNA
prepared from transfected cells did not contain carry-through plasmid DNA (despite
DNase treatment (2.7.3)) which would be detected if the cDNAs were positive for
the neoFl PCR.
neoFl AGCAACCAGGTGTGGAAAGT
(2162-2181bp Promega pCIneo plasmid sequence data (Promega, Southampton UK))
neoR TGTTTCGCTTGGTGGTCGAA
(2880-2861 bp Promega pCIneo plasmid sequence data (Promega, Southampton UK))
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The reaction conditions for analysing the genomic DNA are as for the NRAMPalu




72°C 1 minute) x 35
(94°C 30 seconds
60°C 2 minutes
72°C 10 minutes) x 1
The reaction conditions for analysing the cDNA samples are as for the NRAMPalu




72°C 1 minute) x 41
2.8.6 neoFexp
The neoFexp PCR was designed to detect expression of the neo gene in G418
sulphate ((Geneticin) referred to throughout this thesis as G418), resistant transfected
cells. It used the neoR primer described in 2.8.5 and a forward primer called
neoFexp specific for transcribed sequence in the neo gene 5' to the neoR primer
sequence. The primers generated a 361 bp product and were also used as
confirmation for plasmid presence in control pCIneo plasmid and pCIneo/NRAMPl
plasmid transfected cells (2.20.1),
neoFexp TATTCGGCTATGACTGGGCA
(2520-2539bp Promega pCIneo plasmid sequence data (Promega, Southampton UK)
126





72°C 1 minute) x 41




72°C 1 minute) x 35
(94°C 30 seconds
60°C 2 minutes
72°C 10 minutes) x 1
2.8.7 Fas Ligand
Fas ligand primers were available which had been designed by Dr Graham Cotton,
but the reaction conditions had not been determined. The primers were called FasLl
and FasL2 and lay within exons 1 and 4 of the Fas ligand gene, respectively
(Takahashi et al. 1994). They generated a 319bp product.
FasLl TACAGAAGGAGCTGGCAGAA
(405-424bp Genbank Accession number U624627)
FasL2 ATGTAGACCTTGTGGCTCAG
(723-704bp Genbank Accession number U624627)





72°C 30 seconds) x 39
(94°C 30 seconds
55°C 1 minute
72°C 10 minutes) x 1
2.9 POLYMERASE CHAIN REACTION
All necessary precautions were taken to avoid contamination of reactions and stock
reagents with PCR products or other sources ofDNA. Gloves were worn at all times
and water and 0.75ml and 1.5ml tubes were autoclaved prior to use. A set of Gilson
pipettes used with filter pipette tips (Anachem, Luton UK) were kept exclusively for
RNA and PCR work, prior to addition of template DNA to aliquots of PCR
mastermixes. The mastermixes were prepared in a Gelair Flow BSB4A hood (ICN,
Buckinghamshire UK) and template DNA added in a Pathfinder hood (Pathfinder,
Hampshire UK) in an area spatially isolated from the area where PCR products were
handled.
All reactions were carried out in a final volume of 50pl in 0.75ml thin walled tubes
(Advanced Biotechnologies, Epsom UK). The following standard reaction conditions
were found appropriate: lx PCR buffer minus MgCl2, 1.5mM MgCl2, 2.5U Taq
DNA polymerase enzyme (all from Life Technologies, Paisley UK), 0.2mM of each
deoxynucleotide triphosphate (dNTP) (dATP, dCTP, dGTP, dTTP) (DNA
Polymerisation Mix from Advanced Biotechnologies, Epsom UK), 0.5p.M of each
primer (2.8), autoclaved distilled water as appropriate and lp.1 cDNA (2.7.4) or 10p.l
genomic DNA (2.6). All reactions were overlayed with two drops of paraffin oil
(Fisher Scientific, Loughborough UK) prior to placing on a Hybaid Omni Gene
thermal heating block (Hybaid, Teddington UK).
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2.10 RESTRICTION ENZYME DIGESTION
All restriction enzyme digestions were carried out according to the manufacturers'
instructions with the volume of enzyme never exceeding 1/10th of the final reaction
volume. A typical reaction for digestion of PCR products would have a 30pl total
volume digesting 10-15pl PCR product (2.9) with 2.5U Mnll or 5U Rsal, lx
reaction buffer and lx BSA, where required, overnight at 37°C. Digestions ofmini or
maxi prep DNA typically used 10U of enzyme to digest between 2pl and 7pl of
DNA (2.6.4 and 2.6.5) in a 10-20pl reaction volume for between 2 and 16 hours, at
the appropriate temperature. All enzymes were purchased from Boehringer
Mannheim, Lowes UK; Promega, Southampton UK; Life Technologies, Paisley UK;
or New England Biolabs, Hitchen UK.
2.11 ELECTROPHORESIS AND DETECTION OF DNA
2.11.1 Horizontal Gel Electrophoresis
Agarose gel electrophoresis was carried out to confinn the size of PCR (2.9) or
restriction enzyme digestion products (2.10), to characterise plasmid DNA (2.6.4)
or purify restriction fragments (2.6.5). Standard agarose gels of between 0.8% and
2% were prepared in lx Tris-borate EDTA (TBE) buffer (Appendix B) by melting
the agarose for a couple of minutes in a 1000W microwave (Sambrook et al. 1989).
The gels were allowed to cool until hand hot when lpl ethidium bromide (EtBr)
(lOmg/ml) per 100ml gel was added and mixed well. The gels were cast on a level
surface in the casting trays with appropriate combs, allowed to set and either used
within a few hours or stored overnight at 4°C wrapped in cling film (Merck,
Lutterworth, UK). Gels were submerged in lx TBE buffer and DNA samples, in 1/3
volume agarose loading dye (Appendix B) (typically 15pl final volume), were
loaded in the wells. 1 jug of lkb DNA ladder (Life Technologies, Paisley UK),
prepared for loading as for DNA samples, was run alongside the DNA and used to
estimate the size of the DNA molecules being analysed. The DNA was
electrophoresed towards the positive terminus using a current of 30-60mA in an
Anachem Origo horizontal electrophoresis tank (Anachem, Luton UK). After the
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DNA had been resolved the gels were visualised using a Herolab UVT-28 MP
transilluminator and photographs taken as a record or images stored on disk using
the Herolab Enhanced Analysis System (EASY) (Scotlab, Coatbridge UK).
2.11.2 Polyacrylamide Gel Electrophoresis and Silver Staining
Standard safety precautions were taken when handling unpolymerised acrylamide
and bind silane with procedures being carried out in a safety fume hood (Morgan and
Grundy Ltd., Uxbridge, UK). 6% denaturing polyacrylamide gels (Appendix B)
were prepared using sequencing plates and a 32 square well tooth comb. Both plates
were thoroughly cleaned with dH20 and 70% ethanol (Genta Medical, York UK).
The large glass plate was treated with FMC Gel Slick (Flowgen, Lichfield UK) and
the small glass plate with 20pl bind silane (y-methacryloxypropyltrimethoxysilane)
in 5ml Ultrapure UV treated dH20 from a Milli-UlO and Milli-Qplus 185 system
(Millipore, Watford UK) (Milli-Q dH20) pHed to 3.5, so the gel would remain
adhered to the small plate during the silver staining procedure. Excess bind silane
was rinsed off by washing twice with 70% ethanol and excess Gel Slick removed
with dH20. Set gels were stored overnight at room temperature, well wrapped in
damp paper towels and cling film (Merck, Lutterworth UK). The gel was warmed by
pre-running for an hour at 60 Watts in 0.5x TBE buffer (Appendix B). 6p.l of
digested NRAMPpol PCR product (2.10) and 3pl of 3x acrylamide gel loading
solution (Appendix B) were heat denatured, placed on ice then loaded into the pre-
warmed gel and electrophoresed at 60 Watts. Hinfl (Life Technologies, Paisley UK)
and Marker VIII (Boehringer Mannheim, Lewes UK) molecular weight markers were
run in parallel as reference to estimate the size of digested fragments. The resolved
fragments were visualised by silver staining the gel adhered to the small glass plate
after separating the large plate from the gel.
Milli-Q dH20 was used throughout the staining procedure. The gel, adhered to the
plate, was incubated for 10 minutes in 10% ethanol (Hayman Ltd., Witham UK), for
10 minutes in 1% nitric acid (Fisher Scientific, Loughborough UK), for 5 minutes in
Milli-Q dH20, for 20 minutes in silver nitrate (2.04g/litre), rinsed briefly in Milli-Q
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dH20, rinsed briefly in 600ml developer (160g sodium carbonate decahydrate, 1ml
formaldehyde in 2 litres), the remaining developer was added and left for about 15
minutes until bands were visible then stopped in 0.1M citric acid and washed in
Milli-Q dH20. The silver stained gels were photographed on a light box, then the
adhered gel scraped off and the plates washed thoroughly.
2.12 ESTIMATION OF DNA CONCENTRATION AND PURITY
The concentration ofDNA samples were estimated by 1) spectrophotometry or 2) an
ethidium bromide fluorescent quantitation method (Sambrook et al. 1989).
1) The OD of 1/100 dilutions of DNA solutions was measured at A,=260nm using a
Genequant II RNA/DNA Calculator (Pharmacia Biotech, Cambridge UK):
50|ug/ml of double stranded DNA having an A260 of 1 and the A260 to A280 ratio
giving a measure of the DNA purity.
2) Equal volumes of a range of serially diluted lkb DNA ladder (Life Technologies,
Paisley UK) and the sample being analysed were spotted on 1% agarose gel
containing 5pg/ml EtBr cast in Petri dishes. After allowing the samples to absorb
into the agarose the plate was exposed on a Herolab UVT-28 MP transilluminator
(Scotlab, Coatbridge UK) and the DNA concentration of the sample estimated by
comparison with the fluorescent intensity of the standards.
2.13 DEPHOSPHORYLATION OF THE ENDS OF LINEAR DNA
MOLECULES
When a ligation reaction (2.14) is set up in the presence of a vector which has
compatible or blunt ends background non-recombinant reactions can occur. This
occurrence can be considerably reduced by 5' dephosphorylation of the vector
fragment, increasing the likelihood of desired recombinant molecules being present
in the colonies screened after transformation into E. coli. Gel-purified DNA (2.6.5)
was dephosphorylated using 1 unit of shrimp alkaline phosphatase (SAP)
(Amersham Pharmacia Biotech, Little Chalfont UK) in a reaction containing lx the
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appropriate buffer in a typical final volume of 30-35pl. The reaction was incubated
at 37°C for one hour and the SAP inactivated by heating at 65°C for 15 minutes.
2.14 T/A CLONING OF PCR PRODUCTS AND DNA LIGATION
REACTIONS
Gel-purified PCR products (2.6.5) were cloned by ligation into the pCR2.1 vector
using the TA Cloning System Version 2.0 Kit (Invitrogen BV, Leek The
Netherlands) according to instructions. The linearised pCR2.1 vector has a single 3'
deoxythymidine residue which allows efficient ligation of PCR inserts, due to the
non-template-dependent addition of a single deoxyadenosine to the 3' end of PCR
products by Taq polymerase. Ligation reactions were carried out according to the
manufacturer's instructions overnight at 15°C and typically contained 4pl gel-
purified PCR product (2.6.5), 1-4 units T4 DNA ligase (Promega, Southampton UK),
lx ligation buffer (Appendix B), 2pl pCR2.1 (25ng/pl) in a total volume of 1 Ojal.
Control reactions omitting the vector were also carried out. Competent cells were
transformed with the ligation products as described in 2.17.
2.15 DNA SEQUENCING
2.15.1 Direct Sequencing of PCR Products
The Sequenase PCR Product Sequencing Kit (Amersham Pharmacia Biotech, Little
Chalfont UK) was used according to the recommended protocol. Reagents were
supplied with the kit, unless indicated otherwise, and their composition is given in
Appendix B
lOpl of PCR product (2.9), 2pl of Exonuclease I and 2pl of SAP were mixed and
incubated at 37°C for 15 minutes to remove residual single stranded PCR primers,
any extraneous single-stranded DNA and any remaining dNTPs. The Exonuclease I
and SAP were inactivated by heating at 80°C for 15 minutes. 0.5 picomoles (pmol)
of treated PCR product DNA (estimated using EtBr plate comparison of standards as
described in 2.12) and 5pmol ofPCR primer (2.8.1), in a total volume of 10pl, were
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denatured for 2-3 minutes at 100°C, cooled on ice for 5 minutes, microcentrifuged
briefly then placed back on ice. For some reactions lpl ofDMSO was added with the
primers. 2pl of Sequenase Reaction Buffer, lp.1 of 0.1M DTT, 2pl of Labelling Mix
(diluted 1:4 in dH20), 0.5pl of a°SdATP (5pCi) (ICN Biomedicals Inc.,
Basingstoke UK) and 2pl of Sequenase DNA Polymerase were added to the ice-cold
annealed DNA mixture, mixed and incubated at room temperature for 5 minutes. For
some reactions lp.1 ofMn buffer was added at this point. 3.5pl of the above labelling
reaction was added to 2.5pl of the four Termination Mixes (ddG, ddA, ddT and ddC)
which had been aliquoted in four separate tubes and pre-warmed to 37°C for 1
minute. The reactions were mixed and incubation at 37°C continued for 5-6 minutes
then stopped by the addition of lpl Stop Solution.
The reactions were heat denatured, loaded into wells created by a shark's tooth comb
at the top of a pre-warmed 6% glycerol tolerant polyacrylamide gel (Appendix B)
or 6% formamide glycerol tolerant polyacrylamide gel (Appendix B) and
electrophoresed at 75 Watts in lx glycerol tolerant gel buffer (Appendix B) for YA-
2 hours according to standard protocols using an S2 sequencing apparatus (Life
Technologies, Paisley UK). Prior to pouring the gel the small glass sequencing plate
was treated with FMC Gel Slick (Flowgen, Lichfield UK) and this plate was removed
after the gel had been run. The gel was fixed twice for 5 minutes in 5-10% acetic
acid (Fisher Scientific, Loughborough UK)/15-20% methanol (Merck, Lutterworth
UK), transferred to 3MM paper, covered in cling film (Merck, Lutterworth UK) and
dried in vacuo for 2 hours at 80°C, using a model 583 gel dryer and vacuum pump
(Bio-Rad, Hemel Hempstead UK). The cling film was removed and the gel exposed
to Kodak Biomax MR film in an autoradiography cassette at -70°C for 18-48 hours.
The film was processed in a Hyperprocessor (Amersham Pharmacia Biotech, Little
Chalfont UK).
2.15.2 Sequencing Cloned PCR Products
The T7 Sequenase Version 2.0 DNA Sequencing Kit (Amersham Pharmacia Biotech,
Little Chalfont UK) was used with an amended protocol as described below.
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Reagents were supplied with the kit, unless indicated otherwise, and their
composition is given in Appendix B.
9jul of isolated TA cloned template DNA (2.14) and lpl of -40 M13 primer were
heated at 100°C for 4 minutes and snap frozen on dry ice. 2\i\ of 0.1M DTT1, 2pl T7
Sequenase Reaction Buffer, 0.7pl Labelling Mix (diluted 1:4), 1,5jul of a35SdATP
(5p.Ci) (ICN Biomedicals Inc., Basingstoke UK) and 2.5jal of T7 Sequenase (diluted
1:4 in dH20) was added to the thawed template/primer mixture, mixed and incubated
at 15-20°C for 4 minutes. After a further 30 seconds 4pl of above mixture was added
to 2jul of ddA Tennination Mix and at subsequent 30 second intervals an additional
4pl of the above mixture was added to 2jul of ddC, ddG and ddT Termination Mixes.
After a further 30 seconds and at subsequent 30 second intervals 4pl of Stop Solution
was added sequentially to the ddA, ddC, ddG and ddT reactions.
The reactions were heat denatured, loaded into wells created by a shark's tooth comb
at the top of a 6% denaturing polyacrylamide gel (Appendix B), and
electrophoresed in lx TBE buffer according to standard protocols at 65 Watts using
an S2 sequencing apparatus (Life Technologies, Paisley UK). Prior to pouring the gel
the small glass sequencing plate was treated with FMC Gel Slick (Flowgen, Lichfield
UK) and this plate was removed after the gel had been run. The gel was fixed in 20%
acetic acid (Fisher Scientific, Loughborough UK)/5% methanol (Merck, Lutterworth
UK) for 20 minutes, transferred to 3MM paper, covered in cling film (Merck,
Lutterworth UK) and dried in vacuo for 2 hours at 80°C, using a model 583 gel dryer
and vacuum pump (Bio-Rad, Hemel Flempstead UK). The cling film was removed
and the gel exposed to Kodak Biomax MR film in an autoradiography cassette for
18-48 hours at -70°C. The film was processed in a Hyperprocessor (Amersham
Pharmacia Biotech, Little Chalfont UK).
2.16 BACTERIAL CULTURES AND STORAGE
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2.16.1 Mini and Maxi Cultures
Bacteria were cultured to grow single clones, to make cells competent for
transformation (2.17) or for plasmid DNA isolation (2.6.4) from transfected cells.
All bacteria were grown in Luria-Bertani broth (L-broth) (Appendix B) culture
medium. lOOpg/ml ampicillin was added for cultures of bacteria transfected with a
plasmid containing an ampicillin resistance gene (.AmpR). Single colonies were
picked from an L-Broth/agar plate (2.16.2) with a sterile pipette tip and dropped into
Falcon 2059 tubes (Becton Dickinson UK Ltd., Oxford UK) containing 5ml L-broth
(mini cultures) or 1 litre conical flasks containing 100ml L-broth (maxi cultures).
Bacteria were cultured overnight for no longer than 16 hours at 37°C in a Sanyo
orbital incubator (Fisher Scientific, Loughborough UK) at 220rpm.
2.16.2 L-Broth/Agar Plates
20g agar was added to 1 litre L-broth prior to autoclaving (Appendix B). When the
medium had cooled to about 40°C antibiotics or chromogens were added when
required for selection of transfected bacteria, mixed well and about 25ml poured into
sterile 100mm Petri dishes. Bacteria were plated by spreading evenly over the plate
with a sterile spreader.
2.16.3 Storage
Mini cultures (2.16.1) and L-broth/agar culture plates (2.16.2) were kept at 4°C for
short term storage. For long term storage bacteria were stored at -80°C in 25%
glycerol (Fisher Scientific, Loughborough UK).
2.17 TRANSFORMATION OF BACTERIA
Either 1) XL2 Blue E. Coli (Stratagene, Amsterdam The Netherlands) were
transformed with plasmid DNA using the calcium chloride heat shock treatment as
described by Cohen et al. (Cohen et al. 1972) or 2) XL1 Blue competent cells
(Stratagene, Amsterdam The Netherlands) were transformed following heat shock.
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1) l-2mls of an overnight mini culture (2.16.1) was inoculated into 100ml L-broth
(Appendix B) and cultured at 37°C in an orbital incubator (Fisher Scientific,
Loughborough UK) at 220rpm until in the log phase of growth when an OD550 of
0.4-0.6 was reached. The culture was transferred to universal tubes (Rosslabs,
Cheshire UK), placed on ice for 5 minutes then centrifuged at 3,000rpm for 10
minutes. The cell pellet was resuspended in ice-cold 0.1M MgCl2 and centrifuged
as above. The supernatant was discarded and the cell pellet resuspended in 0.5ml
ice-cold 0.1M CaCl2 then left on ice for 2 hours to become competent. lOOpl of
competent cells and 5pl of PCR product cloned into pCR2.1 (2.14), l-10ng
plasmid DNA or no DNA were mixed and left on ice for 30 minutes, heat shocked
at 42°C for 2 minutes then placed on ice for 15 minutes, before plating out onto
L-amp plates (Appendix B, 2.16.2). Colonies containing plasmid DNA with an
intact Amp1 gene were selected. To select for clones lacking an intact P-D-
galactosidase (lacZ) gene 80pg/ml 5-bromo-4-chloro-3-indolyl galactopyranoside
(X-gal) (Promega, Southampton UK) was included in the L-amp plates. White or
light blue colonies indicated the presence of recombinant plasmids containing
cloned PCR product or disruption of the lacZ a-peptide reading frame by some
other mechanism.
2) Commercially available competent XL1 Blue cells (Stratagene, Amsterdam The
Netherlands) were defrosted on ice and mixed with 1-1 Ong of plasmid DNA. The
reaction was incubated on ice for 20 minutes then the cells were heat shocked at
42°C for 40 seconds and placed on ice for 2 minutes. 200pl room temperature
SOC medium (Appendix B) was added and the cells incubated at 37°C for 1
hour in a Sanyo orbital incubator (Fisher Scientific, Loughborough UK) at
220rpm. The cells were plated onto L-amp plates (Appendix B) and incubated at
37°C for approximately 15 hours to select for ampicillin resistant colonies
containing an intact plasmid AmpK gene.
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2.18 CELL CULTURE
2.18.1 Standard Culture Conditions
Cell lines and isolated cells were cultured in supplemented RPMI-1640 medium
(Appendix B), unless stated otherwise, in 25cm2 (small), 80cm2 (medium) or
175cm (large) tissue culture grade flasks or 6, 24 or 96 well tissue culture plates at
37°C, 5% C02 in a Gallenkamp C02 incubator (Fisher Scientific, Loughborough
UK). Cells were maintained at a density between 105 and 106 cells/ml and
supplemented with fresh medium every 3-4 days, or as required by monitoring the
bicarbonate colour indicator in the medium, yellowing indicating supplementation
was necessary. Transfected cells were cultured in medium as described in 20.2.3,
2.18.2 Cell Viability Counts: Trypan Blue Exclusion
To estimate the concentration of viable cells or total cell numbers in cultures lOpl of
a well mixed sample of cultured cells and 10pl of 0.4% trypan blue solution were
mixed and left at room temperature for a couple of minutes. The cell suspension was
transferred to a Neubauer haemocytometer, viewed using an Olympus inverted
phase-contrast light microscope and the number of blue (dead) and colourless (live)
cells counted within the 4 x 4 square grid. These cell counts were used to estimate
the concentration according to the following calculation:
cell count x 2 (dilution factor) x lxlO4 (haemocytometer chamber factor) = cells/ml
2.18.3 Isolation of Adherent Peripheral Blood Mononuclear Cells
Adherent peripheral blood mononuclear cells (aPBMC) were isolated from single
donor Buffy Coats obtained from the National Scottish Blood Transfusion Service.
All donor blood samples were checked for exclusion ofHIV, hepatitis B, hepatitis C
and syphilis infection by the Transfusion Service prior to collection.
The Buffy Coat was diluted 1:1 with sterile PBS and 25ml of the dilution was
carefully layered onto 15ml Lymphoprep (Nycomed Pharma AS, Oslo Norway) in a
sterile 50ml centrifuge tube (Becton Dickinson UK Ltd., Oxford UK) and
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centrifuged at 2000rpm for 30 minutes with the centrifuge brake switched off. The
interface layer of cells was transferred to clean centrifuge tubes, made up to 50ml
with PBS and centrifuged at 1700rpm for 15 minutes to wash the cells. The
supernatant was removed from the tubes and the cell pellets pooled and resuspended
in Iscoves medium supplemented with lOOU/ml penicillin, lOOpg/ml streptomycin
and 2mM L-glutamine (all Life Technologies, Paisley UK) up to a volume of 50ml.
Prior to centrifuging the cells at 1200rpm for 10-15 minutes a sample was removed
and the cells counted using a Neubauer haemocytometer as described previously but
omitting the trypan blue dilution (2.18.2). The total number of cells was calculated
and the cell pellet resuspended in Iscoves, supplemented as previously, to give
approximately 5 x 106 cells/ml. The cells were plated out in tissue culture plates as
required using 1ml per well of a 24 well plate and 2ml per well of a 6 well plate. The
plated cells were incubated at 37°C, 5% C02 for VA-VA hours after which time the
non adherent cells were aspirated off. The medium was replaced with Iscoves
medium supplemented with lOOU/ml penicillin, 100pg/ml streptomycin, 2mM L-
glutamine and 5% heat treated NHS (Appendix B). The cells were cultured
overnight at 37°C, 5% C02 and the medium aspirated off and replaced with PBS
while the removed medium was centrifuged at lOOOrpm for 10 minutes. The PBS
was removed and replaced with the conditioned medium, without the pelleted non
adherent cells, and the cells cultured as previously for 3-7 days until required.
2.18.4 Isolation of Peripheral Blood Mononuclear Cells and Stimulation
with Concanavalin A
50ml of blood was collected by venous puncture from a healthy volunteer and added
to 500pl of heparin, mixed well, placed on ice and diluted with an equal volume of
ice cold sterile PBS. 10ml aliquots of the dilution were carefully overlayed onto
10ml of Lymphoprep (Nycomed Pharma AS, Oslo Norway) in universal tubes
(Rosslabs, Cheshire UK) and centrifuged at 18000rpm for 15 minutes at 8°C. The
interface cells were transferred to clean universal tubes, washed with excess PBS and
centrifuged at lOOOrpm for 10 minutes at 8°C. The cell pellets were resuspended and
pooled in 3-4ml of PBS. A 1/20 dilution of the cell suspension was made in crystal
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violet (Appendix B) and the cells with deep violet-black stained nuclei in the 4 x 4
grid of a Neubauer haemocytometer counted, from which an estimate of the cell
concentration was calculated as follows:
cell count x 20 (dilution factor) x lxlO4 (haemocytometer chamber factor) = cells/ml
The cells were cultured at a density of lxlO6 cells/ml in standard supplemented
RPMI 1640 culture medium, as described in 2.18.1, or the same medium containing
lpg/ml concanavalin A. After 72 hours the cells were pelleted by centrifugation at
lOOOrpm for 10 minutes and the cell viability estimated (2.18.2). 5 x 106 cell
aliquots were taken for protein extraction (2.4.1) and 2 x 106 cell aliquots were
taken for RNA extraction (2.7.1).
2.19 TRANSFECTION OF aPBMCs
A number of methods, described below, were used in an attempt to transfect
aPBMCs with a (3-gal plasmid (pSV-P-galactosidase Control Vector: Promega,
Southampton UK) containing the lacZ gene encoding P-D-galactosidase. Having
determined a successful procedure it was intended to use this to transfect aPBMCs
with the pCIneo/NRAMP 1 plasmid described in 5.2.4, The aPBMCs were isolated
and plated out (2.18.3) approximately 4 days before transfection.
2.19.1 Lipofectin Reagent
Lipofectin Reagent (Life Technologies, Paisley UK) is a 1:1 (w/w) liposome
formulation of the cationic lipid N-[l-(2-3-dioleyloxy)propyl]-n,n,n-
trimethylammonium chloride (DOTMA) and the neutral lipid dioleoyl
phosphotidylethanolamine (DOPE) in membrane filtered water which interacts
spontaneously with DNA to form a lipid-DNA complex. The complex fuses with
tissue culture cells resulting in uptake and expression of the DNA.
Unless otherwise stated the medium used during transfection and for all dilutions
was Iscoves medium (Life Technologies, Paisley UK) containing 2mM L-glutamine
(no antibiotics or serum). A range of DNA:Lipofectin Reagent ratios were tested for
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transfection of aPBMCs plated in 6 well plates (2.18.3). DNA was diluted to give
concentrations of 0.5jj.g/100|ul, 0.75p.g/100]u.l, 1 .Ojug/1 OOjal and 1.5p.g/100p.l.
Lipofectin Reagent was diluted appropriately to give final concentrations of 4qg/ml,
5pg/ml, 6pg/ml, 7pg/ml, 9pg/ml and 11 jug/ml when added to the cells after
subsequent dilution. The DNA and Lipofectin Reagent dilutions were incubated at
room temperature for 45 minutes then lOOpl DNA and lOOp.1 Lipofectin Reagent of
each dilution mixed gently to give 24 DNA/Lipofectin Reagent combinations. The
DNA/Lipofectin Reagent mixtures were incubated at room temperature for about 15
minutes and then 200pl of each mixture added to 800pl Iscoves medium, mixing
gently by pipetting. The plated cells were washed with Iscoves medium and the
diluted DNA/Lipofectin mixtures added to the washed cells which were incubated at
37°C, 5% C02 for 6 hours. The DNA/Lipofectin mixtures were removed, being
retained for further analysis on some occasions, and replaced with 2ml Iscoves
medium supplemented with lOOU/ml penicillin, lOOpg/ml streptomycin, 2mM L-
glutamine and 5% heat treated NHS (Appendix B) and incubated at 37°C, 5% C02
for 64 hours before assaying for P-gal expression (2.20.2.1),
2.19.2 Lipofectamine Reagent
Lipofectamine Reagent (Life Technologies, Paisley UK) is a 3:1 (w/w) liposome
formulation of the polycationic lipid 2,3-dioleyloxy-N-
[2(sperminecarboxamido)ethyl]-N,N-dimethyl-l-propanaminium trifluoroacetate
(DOSPA) and DOPE in membrane filtered water.
Unless otherwise stated the medium used during transfection and for all dilutions
was Iscoves medium (Life Technologies, Paisley UK) containing 2mM L-glutamine
(no antibiotics or serum). A range of DNA:Lipofectamine Reagent ratios were tested
for transfection of aPBMCs plated in 24 well plates (2.18.3). DNA was diluted to
give concentrations of l.Oju.g/lOOp.1 and 1.5jng/100jnl. Lipofectamine Reagent was
diluted appropriately to give final concentrations of 8pg/300p.l, 10pg/300pl,
12jug/300jul, 14pig/300jul, 18jug/300ptl and 22pg/300|al when added to the cells after
subsequent dilution. lOOpl DNA and lOOp.1 Lipofectamine Reagent of each dilution
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was mixed gently to give 12 DNA/Lipofectamine Reagent combinations and
incubated at room temperature for 45 minutes to allow DNA-liposome complexes to
form. lOOpl of Iscoves medium was added and mixed gently and the diluted complex
solution added to the plated cells, which had been washed with Iscoves medium. The
plates were incubated at 37°C, 5% C02 for 6 hours at which point the transfection
medium was removed, retained for analysis, and replaced with 1ml Iscoves medium
supplemented with lOOU/ml penicillin, 100p.g/ml streptomycin, 2mM L-glutamine
and 5% heat treated NHS (Appendix B) and the plates incubated at 37°C, 5% C02
for 48 hours before assaying for p-gal expression (2.20.2.1).
2.19.3 DOSPER Liposomal Transfection Reagent
DOSPER Liposomal Transfection Reagent (Boehringer Mannheim, Lowes UK) is a
polycationic liposomal reagent consisting of a spennine head group and fatty acid
tails, l,3-di-oleoyloxy-2-(6-carboxy-spermyl)-propylamide. The positively charged
spermine head group binds negatively charged DNA molecules forming polycationic
complexes which are non-specifically adsorbed to the overall negatively charged
surface of cells which take the DNA up.
aPBMCs plated in 24 well plates were used for transfection (2.18.3). DNA and
DOSPER were diluted in HEPES-buffered saline (HBS) (20mM HEPES (Life
Technologies, Paisley UK), 150mM NaCl pH7.4). All Iscoves medium used was
supplemented with lOOU/ml penicillin, 100p.g/ml streptomycin, 2mM L-glutamine
and 5% heat treated NHS (Appendix B). DNA was diluted appropriately to give
0.5pg, l.Opg, 1.5pg or 3.0pg per transfection. DOSPER was diluted appropriately to
give 3pg, 4.5jug, 6pg, 9pg, 12pg or 15pg per transfection. 50pl of each DNA
dilution and 50pl of each DOSPER dilution were mixed gently to give 24
DNA/DOSPER combinations which were incubated at room temperature for 15
minutes. Shortly before transfection the culture medium in the wells was replaced
with 0.5ml fresh supplemented Iscoves medium. 60pl of the DNA/DOSPER
complexes were added dropwise to the appropriate wells, rocking the plate gently to
mix. The plates were incubated at 37°C, 5% C02 for 6 hours at which point an
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additional 0.5ml supplemented Iscoves medium was added to each well and the
plates incubated, as before, for a further 26 hours. The medium was removed from
the wells and retained for analysis replacing it with 0.5ml supplemented Iscoves
medium. The plates were incubated as before and assayed for p-gal activity 48 hours
after the start of transfection (2.20.2.1),
2.19.4 SuperFect Transfection Reagent
SuperFect Transfection Reagent (QIAGEN Ltd., Crawley UK) is a polycation of
defined shape and diameter. It possesses a spherical architecture, with branches
radiating from a central core, terminating at charged amino groups. SuperFect
assembles DNA into compact structures with a net positive charge allowing them to
bind to negatively charged receptors (e.g. sialylated glycoproteins) on the surface of
eukaryotic cells. Inside the cell SuperFect Reagent buffers the lysosome after fusion
with endosomes leading to pH inhibition of lysosomal nucleases ensuring stability of
the complexes and transport of intact DNA to the nucleus.
aPBMCs plated in 24 well plates were used for transfection (2.18.3). DNA dilutions
were prepared in Iscoves medium containing 2mM L-glutamine (both Life
Technologies, Paisley UK) (no antibiotics or serum). DNA was diluted appropriately
to give 0.5|ag, 1.0|ag, 1.5p,g or 2.5pg per transfection. To 60pl of each DNA dilution
9pg, 15jag, 21pg, 27pg, 36pg or 45p.g SuperFect Reagent was added to give 24
DNA/SuperFect combinations, mixing gently by pipetting. The mixtures were
incubated for 10-20 minutes at room temperature to allow complex formation. The
culture medium was removed from the wells of the aPBMCs, which were washed in
pre-warmed PBS. 350jal of supplemented Iscoves medium containing lOOU/ml
penicillin, lOOjug/ml streptomycin, 2mM L-glutamine and 5% heat treated NHS
(Appendix B) was added to each DNA/SuperFect combination, mixed gently by
pipetting and added to the washed wells. The plates were incubated at 37°C, 5% C02
for 2-3 hours at which point the medium was removed and replaced with 1ml
supplemented Iscoves medium (containing the antibiotics and serum), after the wells
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had been washed with pre-warmed PBS. The plates were incubated at 37°C, 5% C02
and assayed for P-gal activity 45 hours after the start of transfection (2.20.2.1).
2.19.5 Diethylaminoethyl (DEAE)-Dextran
aPBMCs plated in 24 well plates were used for transfection (2.18.3). The cells were
cultured overnight prior to transfection in supplemented Iscoves medium (with
lOOU/ml penicillin, 100p.g/ml streptomycin, 2mM L-glutamine (all Life
Technologies, Paisley UK)) containing 20%, 5% or 2% heat treated NHS
(Appendix B). The wells pre-incubated in 20% serum were either transfected in
medium containing 5% heat treated NHS, 2% heat treated NHS or in serum free
medium. The wells pre-incubated in 5% serum were transfected only in medium
containing 5% heat treated NHS and the wells pre-incubated in 2% serum were
transfected only in medium containing 2% heat treated NHS. DEAE-dextran
(Amersham Pharmacia Biotech, Little Chalfont UK) was used at a final
concentration of 250pg/ml in 50mM Tris pH7.4. DNA was used at concentrations of
2pg, 5pg, 8pg, 10pg, 15pg and 20pg per transfection. The wells were washed twice
with pre-warmed Hanks' balanced salt solution (HBSS) (Life Technologies, Paisley
UK) and 500jal of the appropriate combination of DEAE-dextran/Tris, DNA, serum
and supplemented Iscoves medium was added to the wells. The plates were
incubated at 37°C, 5% C02 for 4 hours at which point the transfection medium was
removed from wells which were to receive DMSO osmotic shock or glycerol shock.
To the wells for DMSO shock, 1ml HBSS with 10% DMSO was added for 2
minutes, removed and the wells washed twice with cold HBSS. The wells for
glycerol shock were washed with PBS and 1.5ml 15% glycerol in HBS added and
removed after 30 seconds. The wells were then washed twice with HBSS. The
transfection medium was removed from the remaining wells, which were washed
twice with cold HBSS, and all wells received 1ml supplemented Iscoves medium
containing either 2% or 5% heat treated NHS. The plates were incubated as before
for 50 hours then assayed for |3-gal activity (2.20.2.1).
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2.20 ELECTROPORATION OF CELL LINES AND REPORTER GENE
ASSAYS
2.20.1 Electroporation of U937 and MM6 Cell Lines
5 x 106 MM6 or U937 cells were pelleted at lOOOrpm and resuspended in 0.25ml
RPMI-1640 with 20% FCS (both Life Technologies, Paisley UK) (no antibiotics or
L-glutamine), transferred to a 0.4cm electrode Bio-Rad Gene Pulser Cuvette (Bio-
Rad, Hemel Hempstead UK) and placed on ice for 10 minutes. lOpg of plasmid
DNA was added, mixed gently and the cells were electroporated, using a Bio-Rad
Gene Pulser with Capacitance Extender (250mV, 960pF) (Bio-Rad, Hemel
Hempstead UK). Time constants varied between 48 and 55 milliseconds. The cells
were placed on ice for 10 minutes after electroporation then made up to 12ml with
supplemented RPMI-1640 medium (Appendix B) and plated in 6 well plates. The
cells were cultured at 37°C, 5% C02 for about 24 hours, at which point 1ml medium
was removed from each well and replaced with medium containing G418 (Life
Technologies, Paisley UK) to give an appropriate final concentration to select stable
transfectants on the basis of expression of the plasmid neo gene (2.20.3).
2.20.2 Detection of p-D-Galactosidase Expression
The P-D-galactosidase gene (lacZ) was used as a reporter gene to determine whether
cells transfected with a P-gal plasmid (pSV-P-galactosidase Control Vector:
Promega, Southampton UK) containing the lacZ gene successfully expressed the
gene and protein. Expression can be assayed by the activity of the lacZ gene product,
P-D-galactosidase (P-gal). Two protocols were followed to detennine the efficiency
of various transfection methods of aPBMCs and cell lines (2.19-2.20.1), The first
(2.20.2.1 ) uses cleavage of X-gal by p-gal to liberate an intensely blue halogenated
indoxyl derivative, which can be visually identified in transformed cells by
examination under light microscopy. The second (2.20.2.2) involves liberation of a
bright green fluorescent product, which can be detected by flow cytometry. The
fluorogenic substrate in this DetectaGene Green lacZ Gene Expression Kit
(Cambridge Bioscience, Cambridge UK) is 5-chloromethylfluorescein di-P-D-
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galacto-pyranoside (CMFDG) which reacts with intracellular glutathione through a
glutathione S-transferase-mediated reaction. In lacZ positive cells the CMFDG-
glutathione adduct is converted to a bright green fluorescent product which, being a
peptide, does not readily cross cellular membranes hence the fluorescent product is
well retained in the cell.
2.20.2.1 X-gal Cleavage by p-gal
This method was used to detect expression of p-gal in transfected aPBMCs in 6 well
or 24 well plates (2.19). The volumes stated here refer to 24 well plates and were
increased appropriately for the 6 well plates. The plates were centrifuged briefly at
lOOOrpm after incubation for the appropriate period following transfection. The
wells were washed with PBS and the cells fixed for 5 minutes in 0.05%
glutaraldehyde (TAAB Laboratories Equipment Ltd, Aldermaston UK) prepared in
PBS. The wells were washed once quickly with PBS then washed in PBS for 10
minutes. 250pl ofX-gal stain (Appendix B) was added to the washed wells and the
plates were incubated in a sealed humidified container at 37°C for approximately 24
hours. The plates were viewed under an inverted phase contrast light microscope for
visible signs of blue cells, replacing the X-gal stain with PBS when the incubation
period in the stain was deemed sufficient.
2.20.2.2 CMFDG
Reagents were provided in the DetectaGene Green lacZ Gene Expression Kit
(Cambridge Bioscience, Cambridge UK), unless indicated otherwise, and their
composition is given in Appendix B. This method was used to detect expression of
P-gal in cell lines which grow in suspension. After an appropriate incubation period
following transfection by electroporation (2.20.1) the cells were counted by trypan
blue exclusion (2.18.2) and a cell suspension containing 2.5 x 105 live cells was
pelleted at lOOOrpm. The pellet was resuspended in 100pl of pre-wanned
supplemented RPMI-1640 medium (Appendix B) containing lOmM HEPES (Life
Technologies, Paisley UK) and 50pM DetectaGene Green Substrate Reagent. The
cells were plated in wells of a 96 well plate and incubated at 37°C, 5% C02 for 40
minutes then transferred to 200pl of ice cold PBS. 6jul of propidium iodide was
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added and the cell suspension diluted in PBS as appropriate for immediate analysis
by flow cytometry. A Coulter EPICS XL Flow cytometer (Coulter, Bedfordshire UK)
with an air cooled, software controlled, 15mW argon ion laser operating at 488nm
was set up and calibrated to detect fluorescein, propidium iodide and forward scatter
according to standard procedures. To compensate for the background
autofluorescence of the cells the voltage of the flow cytometer was adjusted
appropriately.
2.20.3 Selection of G418 Resistant Transfectants
G418 sulphate (G418) is an amino glycoside antibiotic that induces cytotoxicity by
blocking translation. Neomycin phosphotransferase, encoded by the neo gene,
inactivates G418 through phosphorylation blocking the antibiotic's toxic effects. The
lethal concentration of G418 (Life Technologies, Paisley UK) for the U937 and
MM6 cell lines was determined by generating a "G418 death curve" for the two cell
lines. The percentage of viable cells for each concentration of G418 which the cells
were cultured in was monitored and recorded graphically over a 2-3 week period to
determine the lethal dose of G418 for the cell lines. This was repeated for a second
batch of G418 because the specific activity of preparations is known to vary. The
concentrations of G418 to kill 100% of the cells were 300mg/ml for U937 cells for
the first batch of G418 and 500mg/ml for U937 and 400mg/ml for MM6 cells for the
second batch of G418. The cytotoxic effect of the G418 was apparent by day 13 of
culture in the antibiotic. Cells were selected for the presence and expression of the
neo gene in the appropriate G418 concentration for several weeks after control plates
of cells, which had been electroporated in the absence of DNA (2.20.1) or not
electroporated, showed 100% cell death. The transfected cells were subsequently
maintained at half the selection concentration of G418 to ensure the plasmid DNA
was retained in the transfectants.
2.20.4 Single Cell Cloning by Limiting Dilution
The concentration of viable cells in the population from which single clones were
being derived was determined from an average of at least two cell viability counts by
trypan blue exclusion (2.18.2). The cells were gently drawn up and down the bore of
a 19G needle (Becton Dickinson UK Ltd., Oxford UK), to ensure a suspension of
single cells existed. Cells were sequentially diluted to give no more than 485 cells in
97ml of supplemented RPMI-1640 medium (Appendix B) containing G418 (Life
Technologies, Paisley UK) at the appropriate concentration (2.20.3), 200pl aliquots
of the diluted cell suspension were plated into the wells of five 96 well plates which
should, theoretically, result in one cell per well.
2.21 ANALYSIS OF CELLULAR METAL CONTENT
In peripheral blood 1 pig/litre ofMn can be detected using inductively coupled plasma
mass spectophotometry (ICPMS). The normal white blood cell count is
approximately 1010/litre (Department of Haematology 1997). An estimation of the
number of cultured cells necessary to enable accurate analysis of the metal content
6 7
is, therefore, of the order of 10 -10 cells.
2.21.1 Cell Culture and Pelleting Cells for Analysis of Cellular Metal
Content
Cells were typically cultured at an initial concentration of 3 x 103 cells/ml in large
flasks for 2-3 days prior to checking for their viability (2.18.2) before pelleting as
follows. All cells analysed in parallel were cultured in the same batch of
supplemented RPMI-1640 medium (Appendix B) with the exception of
comparison of transfectants and parent cell lines. Transfectants had G418 (Life
Technologies, Paisley UK) at 150pg/ml added to the medium which the parent cell
line received. Samples of the medium used to culture the cells were taken for
analysis when the cultures were set up to ensure the media had uniform
concentrations of the metals analysed.
The cell suspensions were transferred to sterile universal tubes (Rosslabs, Cheshire
UK), pelleted at lOOOrpm for 10 minutes and the pellets washed in PBS. The washed
pellets were centrifuged as before and the pellets resuspended in PBS, pooling the
pellets into a single universal tube for each sample. The cell suspensions were
counted for viability (2.18.2) and the total cell number calculated. The cell pellets
were carefully transferred to 1.5ml tubes, ensuring maximum transfer, and
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microcentrifuged at 2000rpm for 5 minutes and the supernatant carefully aspirated
off.
The cell pellets were frozen at -20°C to rupture the cell walls and a known volume of
Milli-Q dH20 added to the ruptured cells. The lysed cells were pipetted to ensure the
cells were completely fragmented and then microcentrifuged at 13000rpm for 10
minutes. The supernatants were transferred to fresh tubes and the cell extracts were
analysed by ICPMS (2.21.2),
2.21.2 Inductively Coupled Plasma Mass Spectophotometry Analysis
Determination ofMn, Cu, Zn and Fe concentrations were carried out simultaneously
by ICPMS using a VG Elemental Plasmaquad 3 (VG Elemental, Winsford UK) at the
Department of Chemistry, University of Edinburgh in collaboration with Dr Marina
Patriarca and Professor Peter Sadler. Samples of the cell extracts (2.21.1) were
diluted 1 in 10 with a solution containing 0.2% HN03 and lOpg/litre rhodium as
internal standards. Calibration was obtained for each experiment using aqueous
standard solutions prepared from appropriate dilution of a certified multi element
standard solution for ICP analysis (10580 ICP Multi Element Standard VI, Lot No.
70240283, Merck, Leicester UK). All intensities were corrected for drift using the
internal standard. Calibration curves and concentrations of the samples were
calculated using the Plasmavision instrument software (VG Elemental, Winsford
UK). The analysis of a certified reference material (SRM 2670 'Toxic Metals in
Urine', National Institute of Standards and Technology, Gaithersburg, Maryland,
USA) containing 0.13 ± 0.02mg/litre of Cu with an indicative value of 0.03mg/litre
for Mn yielded average values of 0.141 ± 0.007mg/litre (4.6%) for Cu, 0.031 ±
O.OOlmg/litre (3.6%) for Mn, 1.61 ± 0.047mg/litre (2.9%) for Zn and 0.874 ±
0.041mg/litre (4.7%) for Fe (mean ± standard deviation (relative standard deviation))
when analysed with batches of cell samples on six different occasions. Information
on the content ofFe and Zn in this material was not available. Precision was assessed
by replicate analysis of the same cell extracts.
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3 IMMUNOHISTOCHEMISTRY OF PBC LIVER SECTIONS
FOR MARKERS OF APOPTOSIS, PROLIFERATION AND
THE PRESENCE OF MACROPHAGES
3.1 Introduction
There is no doubt that PBC sufferers have a marked paucity of BECs, a situation that
increases as disease progresses. However, the manner in which these cells are lost is
uncertain. It is possible, and evidence exists suggesting, the cells may die by
apoptosis (Nakanuma et al. 1983; Kuroki et al. 1996; Koga et al. 1997.). However,
the transient nature of this cellular phenomenon makes histological observation of
apoptotic BECs in sections from small liver biopsies a challenging task. Such
sections from PBC patients contain ever decreasing numbers of the cells of interest
and as execution of the apoptotic pathway itself may take only a couple of hours
(Howie et al. 1994) the likelihood of catching the "process in action" in a liver
section of area 3-4mm~ is optimistic.
Rather than try to identify apoptotic cells morphologically the following study
attempted to examine, immunohistochemically, the cellular expression pattern of
proteins which participate in regulating the apoptotic pathway. In this way an
indication of the potential for these cells to undergo apoptosis, and whether they
possess a different profile from normal BECs, might be determined. The aim was to
determine if the PBC BECs express the pro-apoptotic bax, bcl-x (reviewed in Adams
and Cory 1998) and p53 (reviewed in Evan and Littlewood 1998) proteins and the
anti-apoptotic bcl-2 protein (reviewed in Adams and Cory 1998). I was also
interested in identifying whether these cells express the Fas/CD95 antigen, whose
presence and ligation provides a possible stimulus to initiate apoptotic death
(Ashkenazi and Dixit 1998) and to identify which cells may be expressing the Fas
ligand antigen and, as such, potential initiators of cell death. As any net loss of tissue
may have a component due to a lack of cell proliferation and tissue regeneration, I
also examined the proliferative status of the BECs by analysing the expression
profile of the Ki-67 antigen, a marker of cell proliferation (Gerdes et al. 1991).
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In addition to determining the expression pattern of the above proteins, I was
interested in observing the well documented presence of M<j)s in PBC liver and the
extent of granuloma formation in sections from early and late stage biopsies, on the
basis that the presence and activity of these cells may be significantly important in
the initiation and/or maintenance of PBC. The PG-M1 monoclonal antibody was
chosen to identify Mtjis. PG-M1 detects the CD68 antigen which belongs to a family
of highly glycosylated lysosomal/plasma membrane shuttling proteins known as the
LAMP1 group. The antibody does not react with granulocytes or their precursors,
which are also known to express CD68.
For all the antigens except Fas ligand commercially available antisera were available
for the study. For Fas ligand, antisera which had been raised against a synthetic Fas
ligand peptide was available which required characterisation to determine its
reactivity against the peptide and Fas ligand protein.
3.2 Results
3.2.1 Immunohistochemical Analysis of Bax, Bcl-x, Bcl-2, CD95/Fas
and Ki-67 Expression in Liver Sections
3.2.1.1 Analysis of Results
The intensity of immunostaining for bcl-2, bax, bcl-x and Fas/CD95 was
homogeneous with little variation between cells within a single duct or between
ducts. For this reason biopsies were scored as follows; strong (that is, clearly visible
granular stain at low power examination (x400)); moderate (definite but weak
immunopositivity visible at low power but needing confirmation by high power
microscopic examination (x200)); weak/negative (equivocal staining, not
consistently greater than in negative control section where primary antibody was
omitted). When Ki-67 or p53 were present they produced clear, discrete, nuclear
staining. Cases were scored positive if the nucleus of one or more BEC was stained
and negative if no positive cells were seen. Thereafter, an estimate was made of the
proportion of individual biliary epithelial cells stained. Bile ducts were classified as
150
small (<75mm) or large (>75mm) by measurement using the Highly Optimised
Microscope Environment (HOME) semi-automated computer system (Carl Zeiss,
Welvyn Garden City UK).
PG-M1 positive cells were clearly visible as intensely stained cells.
3.2.1.2 Normal Liver: Bax, Bcl-x, Bcl-2, CD95/Fas and Ki-67 Expression
Bax (Figure 3.1a) and bcl-x (Figure 3.2b) were expressed uniformly in both
hepatocytes and bile ducts but were not detected in Kupffer cells or endothelial cells.
Moderate bax expression was seen in bile ducts <75mm in 11/15 sections (Table
3.1) and moderate bcl-x expression in 8/15 sections (Table 3.2). Only 3/15 cases
expressed detectable bcl-2 in biliary epithelium. Bcl-2 was not detected in
hepatocytes. Eight of fifteen cases showed moderate staining of biliary epithelium
with the anti-Fas/CD95 antibody. In all cases hepatocytes were positive with the anti-
Fas/CD95 antibody, the staining pattern being granular as previously reported in
paraffin embedded tissue (Mochizuki et al. 1996). p53 was not detected and BECs
did not express Ki-67. A lack of immunohistochemical reactivity of the anti-Fas
ligand peptide sera prevented determination of the expression pattern of Fas ligand
(see 3.2.2.3),
bax (<75jj.m) bax (>75ptn)
strong moderate weak/
negative
n strong moderate weak/
negative
n
Normal 0 11 4 15 0 10 2 12
Early 14 1 0 15 12 0 0 12
Late 6 4 4 14 8 3 3 14
Table 3.1 Results of bax immunocytochemistry in bile ducts <75mm and >75mm of
histologically normal and early and late stage PBC liver biopsy material. The figures
are the number of sections with detectable strong, moderate and weak/negative
expression scored as described in 3.2.1.1, Expression when detected was
homogeneous and uniform, n: total number of sections.
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bcl-x (<75pm) bcl-x (>75pm)
strong moderate weak/ n strong moderate weak/ n
negative negative
Normal 0 8 7 15 0 8 4 12
Early 14 0 1 15 11 0 1 12
Late 13 1 0 14 13 1 0 14
Table 3.2 Results of bcl-x immunocytochemistry in bile ducts <75mm and >75mm
of histologically normal and early and late stage PBC liver biopsy material. The
figures are the number of sections with detectable strong, moderate and
weak/negative expression scored as described in 3.2.1.1. Expression when detected
was homogeneous and uniform, n: total number of sections.
3.2.1.3 PBC Liver: Bax, Bcl-x, Bcl-2, CD95/Fas and Ki-67 Expression
Residual bile ducts showed strong staining of bax (Table 3.1, Figure 3.1c) and
bcl-x (Table 3.2, Figure 3.2a) which appeared more intense than in normal liver.
Bax and bcl-x were expressed strongly in "metaplastic" biliary ductules (Figure
3.1c and Figure 3.2a). Lymphocytes showed intense expression of bcl-2 (Figure
3.3). Bcl-2 expression seen in surviving BECs was weak and inconsistent, similar to
normal liver (3.2.1.2), No change in Fas/CD95 staining was noted compared with
the nonnal sections (3.2.1.2). p53 expression was not detected. In PBC cases up to
8% of BECs in large ducts and in residual small ducts expressed Ki-67 (Figure 3.4).
The number of positive nuclei seen was greatest in ducts >75mm in sections showing
histological early stage PBC. Areas of ductal "metaplasia" remained Ki-67 negative.
A lack of immunohistochemical reactivity of the anti-Fas ligand peptide sera
prevented determination of the expression pattern of Fas ligand (see 3.3.2.3),
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Figure 3.1 Immunohistochemical detection of expression of bax in a) normal bile
ducts (and hepatocytes ( ); b) PBC stage I liver showing strong
expression in bile ducts and upregulation of bax in hepatocytes m); c)
PBC stage II liver showing upregulation of bax in "metaplastic ductules" (— and
hepatocytes(). Original magnification x200. Immunohistochemistry protocols
are described in 2.2.
Figure 3.2 Immunohistochemical detection of expression of bcl-x in a) PBC stage
IV liver hepatocytes ( ) and "metaplastic ductules" ( ) which show
upregulation compared with b) histologically normal liver showing only mild
steatosis; hepatocytes ( ) and bile duct (r). c) Negative control omitting
primary antibody on histologically normal liver section, bile duct (^» ). Original
magnification x200. Immunohistochemistry protocols are described in 2.2
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Figure 3.3 Immunohistochemical detection of expression of bcl-2 in infiltrating
lymphocytes in PBC stage IV liver showing strong expression in lymphocytes.
Original magnification x200. Immunohistochemistry protocols are described in 2.2.
Figure 3.4 Immunohistochemical detection of expression of Ki-67 in a proliferating
biliary epithelial cell ( and infiltrating cells (— in PBC stage I liver. Original
magnification x200. Immunohistochemistry protocols are described in 2.2.
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3.2.2 Characterisation of Rabbit Polyclonal Anti-Fas Ligand Peptide
Serum
No commercial anti-Fas ligand antisera were available while this study was in
progress which would ideally have been used to investigate the Fas ligand expression
pattern in conjunction with the monoclonal anti-Fas antibodies. Flowever, rabbit sera
from two animals immunised with a Fas ligand peptide, synthesised by Ian Heslop at
the Department of Chemistry, were available (2.3.9). The reactivity and specificity
of the sera were not known, requiring their characterisation before any potential use.
3.2.2.1 ELISA
Using an ELISA to test the pre-immune sera and sera from the immunised rabbits
before and after IgG purification with protein A, reactivity against the peptide
immunogen was detected in the immunised sera from both animals which was not
seen in the pre-immune sera (Figure 3.5).
3.2.2.2 RT-PCR and Western Blotting
RNA and protein extracted from PBMCs which had been stimulated with
concanavalin A (2.18.4), known to upregulate Fas ligand expression, showed
detectable upregulation of Fas ligand expression at the gene and protein level
assayed by RT-PCR and Western blotting, respectively. The upregulation of Fas
ligand mRNA expression confirmed successful stimulation of the cells (Figure
3.6a). Western blotting using a mixture of equal protein concentrations of the IgG
purified immunised rabbit sera showed obvious upregulation of an immunoreactive
product of approximately 40kDa, consistent with the estimated size of the Fas ligand
protein (Figure 3.6b) (Takahashi et a/. 1994). This was not observed in the blot
using the pre-immune rabbit sera suggesting an anti-Fas ligand antibody response
had been raised successfully in the immunised rabbits (Figure 3.6b). The positive
control blots showed upregulation of CD3 after stimulation with concanavalin A and
negative control blots, omitting the primary sera, showed lack of specific
immunoreactivity (Figure 3.6b). Control dot blots for the chromogen detection
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Figure 3.5 showing reactivity of a) unpurified rabbit sera and b) sepharose A
purified rabbit sera against a Fas ligand peptide assayed by ELISA, as described in
2.5.1, 1 and 2 refer to two rabbits immunised with the Fas ligand peptide and PI to
the sera from the rabbits prior to immunisation. FasL and Nil denote the ELISAs
where the plate was coated with the Fas ligand peptide or control blocking agent,
respectively. The error bars show the standard deviation from triplicate results.
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method were positive and dot blots of the Fas ligand peptide showed a positive
reaction with the immunised sera but not with the pre-immune serum.
3.2.2.3 Immunohistochemistry
When the pre-immune serum and sera from the rabbits immunised with the Fas
ligand peptide were used for immunohistochemistry on paraffin embedded tonsil
sections, using the standard ABC-FIRP-DAB detection method and humidified
chambers (2.2), no specific staining pattern was seen with the immunised sera. This
lack of specificity was present on all sections regardless of the antigen retrieval pre-
treatment they had received (i.e. microwave in citrate buffer, trypsin digestion or no
pre-treatment) but the sections which had been microwaved in citrate buffer showed
the strongest staining. Both the pre-immune and immunised sera showed high levels
of non-specific background staining. To try to overcome this problem the sera were
incubated overnight at 4°C with NHS, to complex rabbit anti-human epitope
responses contributing to the background staining, and the complexes removed after
centrifugation. The sera were subsequently IgG purified by running them through a
sepharose-protein A column. The IgG purified sera was tested on tonsil sections as
before using a sheep fragment antigen binding (F(ab')2) anti-rabbit Ig secondary
antisera (diluted 1/1000) to reduce the background staining. No specific staining was
seen with any of the pre-treatments of the tonsil sections at any of the sera
concentrations tested. This suggests the immunised sera does not recognise an
epitope present in the native protein, or the epitope was not successfully unmasked
after paraffin embedding by the antigen retrieval methods tried or the epitope is
sterically inaccessible due to the membrane location of the Fas ligand protein. The
anti-Fas ligand sera were, therefore, unsuitable for immunohistochemical analysis of
Fas ligand expression in the PBC cases analysed for markers of apoptosis and
proliferation (3.2.1).
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Figure 3.6 showing upregulation of Fas ligand a) mRNA by RT-PCR and b)
protein by Western blotting (Immunised blot) in PBMCs after stimulation with
concanavalin A (+ ConA lanes) compared to unstimulated PBMCs (- ConA lanes).
In a) the arrow points to the 319bp Fas ligand product. Molecular weight marker,
with sizes shown in bp, was run in the right hand lane adjacent to the negative
control lane. In b) positive control blot (aCD3 blot) incubated in anti-CD3
polyclonal rabbit sera shows upregulation of CD3 protein expression in ConA treated
cells indicated by the arrow. The pre-immune rabbit sera (Pre-immune blot) and
negative control (No primary blot) blots do not show the specific reactivity (arrow)
with ConA stimulated PBMCs seen with the Fas ligand peptide immunised rabbit
sera (Immunised blot). Molecular weight marker is shown to the right of each blot
with the kDa sizes shown at the far right. RT-PCR and Western Blotting are
described in 2.7, 2.8.7, 2.9 and 2.4.4,
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3.2.3 PG-M1 Immunohistochemistry
All liver biopsy sections showed discrete positive staining of cells distributed
throughout the parenchyma. These cells had a spindly, elongated appearance and
their parenchymal location suggests they may be resident KCs (Figure 3.7). The
number of these cells was noticeably increased in the PBC sections compared with
the normal sections. As disease progressed and fibrosis became apparent these
positive cells concentrated in the areas of remaining non-fibrotic tissue. In addition
to cells situated in the parenchyma, positive cells were also seen in the leucocyte
infiltrates of the disease sections. These had a different morphology being rounder
and bearing more resemblance to blood monocytes (Figure 3.7b and c). The most
significant observation in the PBC sections was the areas where many positive cells
were congregated together, forming regions of extensive positivity (Figure 3.7b).
These regions were obvious granulomas and their development from the initial
formation to extensive immune foci could be seen in the different sections analysed.
In some sections the granulomas appeared focused around or in close proximity to
damaged bile ducts, but they were also seen in the parenchyma. From the two-
dimensional view of the sections the latter did not appear to be in close proximity to
bile ducts. Granulomas were seen in sections representing all histological stages of
PBC progression.
3.3 Discussion
The results of this immunohistochemistry study (Graham et al. 1998) show that bile
ducts constitutively express pro-apoptotic proteins, particularly bax, and the
apoptotic regulator bcl-x. In contrast the anti-apoptotic protein bcl-2 is barely
expressed and thus appears to play little part in regulating apoptosis in BECs in the
cases studied. In addition to exhibiting a phenotype permissive for apoptosis, there is
evidence that BECs retain the ability to proliferate based on the positive Ki-67
staining seen in PBC liver sections. This supports the observation of Nakanuma and
Harada who showed increased proliferative activity of epithelial cells in affected
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Figure 3.7 Immunohistochemical staining (described in 2.2) with the PG-M1
monoclonal antibody to stain CD68 positive cells in a) normal liver and b) and c)
PBC stage II liver sections. In a) Kupffer cells, stained brown with DAB, can be seen
in the parenchyma (-—*-) and an undamaged bile duct is marked —'). In b) pink
(Fast Red) stained granulomas are visible around damaged bile ducts (-^O within a
region of extensive leukocyte infiltration. In c) two bile ducts showing signs of
damage (-^-) are visible surrounded by inflammatory cells including pink (Fast Red)
stained CD68 positive cells. Original magnification a) x400, b) xlOO and c) x200.
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Charlotte et al. have reported that normal bile ductules and small bile duct
epithelium, but not large bile duct epithelium or hepatocytes, show weak expression
of bcl-2 as detected immunohistochemically (Charlotte et al. 1994). However,
Kuroki et al. found no bcl-2 expression in biliary epithelium of normal or PBC livers
(Kuroki et al. 1996). The weak/equivocal bcl-2 staining pattern I observed in both
histologically normal and PBC sections appears consistent with these previous
reports with bcl-2 likely to be expressed at levels bordering on the undetectable by
immunohistochemistry. Other studies have shown more prominent bcl-2 staining in
ductules at the borders of cirrhotic nodules relative to normal liver (Koukoulis et al.
1995). However, I did not notice a similar consistent pattern in the cases examined.
This suggests a potential "life-saving" mechanism for BECs in the presence of a pro-
cirrhotic environment may be lacking in PBC liver and contributing to the
destruction of these cells. The absence of bcl-2 expression I observed in hepatocytes
is consistent with previous observations (Charlotte et al. 1994; Krajewski et al.
1994). Parenchymal damage in PBC is generally accepted as being, primarily, the
result of secondary responses in the liver with the resulting fibrosis and cirrhosis
apparent in the later stages of disease. On the basis of this immunohistochemistry
study bcl-2 does not appear to be exerting protection against hepatocyte cell death.
The intense bcl-2 staining of infiltrating lymphocytes and those around bile ducts
under destruction is consistent with previous reports (Deguchi et al. 1998). Though I
did not seek to identify whether these bcl-2 positive cells were CD4+ or CD8+ T
lymphocytes these authors report the same distribution of bcl-2 positive and CD4
positive cells in the PBC biopsies they immunostained and propose CD4/bcl-2
double positive cells have a pathological role in PBC. Autoreactive T lymphocytes
expressing bcl-2 may escape apoptosis leaving them free to accentuate tissue
destruction and cause autoimmune disease.
I observed weak expression of Fas/CD95 in bile ducts in normal and PBC liver
sections which supports the findings of Kuroki et al. (Kuroki et al. 1996) and, as
previously reported, I am able to confirm its presence in hepatocytes (Hiramatsu et
al. 1994; Galle et al. 1995; Okazaki et al. 1995; Mochizuki et al. 1996; Harada et al.
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1997b; reviewed in Faubion and Gores 1999). It is worth noting that my findings and
those of others (Kuroki et al. 1996) differ from those of Harada and colleagues who
failed to identify Fas/CD95 expression in BECs of the normal liver sections used in
their study. They did, however, observe various intensities of cytoplasmic staining of
the antigen in bile ducts of PBC, chronic hepatitis and extrahepatic biliary
obstruction sections with the PBC cases showing the strongest staining (Harada et al.
1997b). The discrepancies between my findings and these results may reflect the
different antisera used in the two studies or the nature of the normal control tissue
used. Though biopsy reports state a tissue may appear histologically normal with
respect to malignant growth it is possible that the tissue exhibits other pathological
phenomena which may or may not be apparent from microscopic examination. In at
least one of the normal cases used in my study a degree of infiltration of
inflammatory cells was observed which suggests this biopsy was obtained from liver
undergoing some reaction not expected of ideal control tissue. Finding a source of
true "normal" control liver material for these studies is always a problematic issue.
As previously mentioned the monoclonal Ab I used against Fas/CD95 did not detect
increased levels of the antigen in the PBC livers. TNFa and IFNy expression in PBC
liver has been reported (Tovey et al. 1991, Martinez et al. 1995, Shindo et al. 1996),
which might suggest an accompanying elevation in Fas expression. However, many
of the experiments which have shown increased Fas expression induced by TNFa
and IFNy were in vitro studies using high doses of cytokine (Maciejewski et al. 1995;
Panayiotidis et al. 1995). In contrast, PBC is a chronic disease and levels of these
cytokines present in the liver have not been quantified. In addition most reports for
cytokine expression patterns in liver of PBC patients rely on mRNA analysis, the
results of which can not always be transposed to the protein expression pattern. It is
possible that any changes in Fas expression which may be induced by the presence of
these cytokines are not of sufficient magnitude for detection by
immunohistochemistry with the antisera I used. Alternatively, these pleiotropic
cytokines may be exerting other effects on the disease state in PBC independent of
Fas.
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1 had hoped to study the expression pattern of Fas ligand in conjunction with that of
Fas/CD95. However, at the time of this study no commercially available antiserum
against Fas ligand was available and I found the rabbit sera raised in our laboratory
against a synthetic Fas ligand peptide was unreactive on paraffin embedded tissue.
As all the material used for this study was archival paraffin embedded tissue and I
had access to only two frozen PBC liver biopsies, attempts to determine whether the
antisera was reactive with frozen sections were not pursued. The lack of reactivity of
the antisera for immunohistochemical use was unfortunate, particularly in the light
of its reactivity against the denatured protein, which I identified by Western blotting
using protein from concanavalin A stimulated PBMCs. The fact that increased Fas
ligand expression was detected by RT-PCR as well as Western blotting in the
concanavalin A treated PBMCs, and the reactive band on the Western blot which
showed this increase was of the appropriate size for Fas ligand (Takahashi et al.
1994), strongly suggests the sera was reactive against denatured Fas ligand protein.
The use of synthetic peptides as an immunogen to raise specific antisera can be
highly successful. However, there are a number of problems that may be
encountered. The peptides used need to contain both a T cell and B cell epitope to
induce an effective antibody response. As linear peptides represent a tiny fraction of
the whole amino acid sequence of the native protein, potential secondary structure,
which this region of the molecule may naturally adopt, is unlikely to form. As a T
cell epitope this is not an issue but recognition of the native protein by Abs may
require retention of this structure. In the case of the anti-Fas ligand sera it may be
that the amino acids of the synthetic peptide adopt a particular structure in the native
protein which Abs raised against the peptide fail to recognise. It is also possible that
the Abs raised against the peptide recognise part of the molecule that is sterically
hindered and inaccessible when the protein is expressed at the cell surface.
Expression of Fas ligand has subsequently been detected by others using
immunohistochemistry. It was reported to be expressed occasionally by infiltrating
mononuclear cells within the portal tracts, and at a significantly higher level in PBC
liver around injured bile ducts. The expression in the PBC liver was greater than in
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normal, chronic hepatitis and extrahepatic biliary obstruction liver (Harada et al.
1997b). This study also identified expression of perforin and granzyme B in
infiltrating mononuclear cells and BECs. Granzyme B was expressed at a higher
level in PBC liver than the control livers while perforin expression was higher in the
three groups of liver disease compared with the normal tissue. These findings may
support the reports of apoptosis of biliary epithelial cells in PBC (Bernuau et al.
1981; Nakanuma et al. 1983; Harada et al. 1997b; Koga et al. 1997) and be
associated with the presence of cytotoxic CD8+ T cells (Si et al. 1984; Krams et al.
1990; Hashimoto et al. 1993). Analysis of Fas ligand expressing cells in PBC has
shown CD4+, CD8+ and CD3- cells to express the antigen, but only the former two
cell types were closely localised around the bile ducts (Koga et al. 1998). These
authors suggest both CD4+ and CD8+ T cells may be involved in inducing apoptosis
of BECs. However, my findings of the low level of Fas/CD95 expression in PBC
BECs suggest a Fas/CD95-mediated mechanism is unlikely. Such mechanisms have
been invoked in a number of inflammatory diseases of the liver, especially viral
hepatitis (Hiramatsu et al. 1994; Galle et al. 1995; Okazaki et al. 1995; Mochizuki et
al. 1996) and ligation of constitutively expressed Fas/CD95 on hepatocytes by
antibodies results in rapid hepatocyte apoptosis (Trauth et al. 1989; Yonehara et al.
1989; Ogasawara et al. 1993). CD8+ T cells are able to induce apoptosis in target
cells via Fas independent mechanisms, such as perforin or cytokine mediated cell
death (reviewed in Griffiths 1995; reviewed in Kagi et al. 1996), and a
perforin/granzye B mediated induction of cell death remains a possibility,
particularly in the light of the perforin and granzyme B expression in PBC liver
mentioned above (Harada et al. 1997b).
Both bax and bcl-x proteins appeared to be upregulated in biliary epithelium in the
PBC cases I studied. These results are based on staining intensities for the two
antigens observed by eye under light microscopy and such conclusions must be
considered with caution. Immunohistochemistry is not an ideal technique for
quantitating levels of expression of antigens because of possible inter-section
variations throughout the course of the procedure. The DAKO Techmate™ 500
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automated immunocytochemistry stainer was used for this study to enable large
numbers of sections to be stained in a single run with all the sections being incubated
for the same time under the same conditions throughout the protocol. Using bench
top staining techniques there is an increased chance of introducing inter-section
variability when staining large numbers of sections at one time. In addition to
potential variations during the staining procedure, the fixation process the biopsy
material undergoes may introduce variation out with the control of the
immunostainer. Bearing in mind these potential problems the staining intensity
observed in the majority of disease sections examined was stronger when compared
with the control sections, suggesting an increased level of protein expression which
may be indicative of an increased potential to undergo bax-mediated apoptosis. The
expression of bax is induced by p53 (Miyashita et al. 1994; Selvakumaran et al.
1994) and the protein heterodimerises with bcl-2, inhibiting the anti-apoptotic effect
of bcl-2 (Oltvai et al. 1993). I did not see upregulation of p53 suggesting p53-
independent induction of bax and bcl-x may be occurring, as has been reported by
others (Hung and Chuang 1996). The bcl-x gene codes for two splice variants, full
length bcl-X! protein and a smaller bcl-xs (Boise et al. 1993). Bcl-X! protects cells
from apoptosis and bcl-xs blocks the protective effect of bcl-2 and bcl-X], acting as an
"anti-anti-apoptosis" protein. It is the relative ratio of homo- and hetero-dimeric
forms of these interactive proteins which affects the apoptotic pathway. At the time
of this study no antibody specific for the short or long form of bcl-x was
commercially available so the polyclonal serum I used does not discriminate
between bcl-xi and bcl-xs. Because of this I am unable to draw any conclusions as to
their relative ratios and role in regulating cell death in PBC BECs. One could
hypothesise a pro-apoptotic agonistic effect accentuating the elevated bax expression
or, alternatively, an antagonistic effect.
My findings of bax and bcl-x expression in BECs of normal and PBC liver are
supported by Dr Matthias Dollinger who carried out a similar immunohistochemistry
study phenotyping liver biopsy sections from cases of acute and chronic rejection
following orthotopic liver transplantation. He identified particularly strong
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expression in BECs during acute rejection and, in biopsies with identifiable bile
ducts, during chronic rejection (personal communication).
It is of significant interest to note that at least a proportion of BECs in the PBC liver
sections were capable of proliferation. Though the level of proliferating cells may
appear relatively low (less than 8% of cells in any duct) it is feasible that, as for the
analogous situation where a low level of apoptosis over a long period of time results
in a significant, accumulative net loss of tissue, a low level of proliferation may be
capable of regenerating a significant amount of tissue. However, one must also
consider the differential time length of the two processes with apoptosis proceeding
in a fraction of the time taken to complete the cell cycle (Alberts et al. 1989;
Yonehara et al. 1989; Howie et al. 1994). Ki-67 positive BECs were more prevalent
in the sections showing histological early stage disease, which may reflect a state
throughout the liver because studies analysing the proliferative status of hepatocytes
in PBC have shown increased proliferation of these cells, which was particularly
apparent in the early stages of disease (Rudi et al. 1995). There is mounting evidence
that intrahepatic bile ducts develop from primitive hepatocytes around branches of
the portal vein. A ring of primitive hepatocytes closest to the portal vein branches
transforms into bile duct type cells, followed by a second layer forming a double-
walled cylinder with a slit like lumen, called the ductal plate. The ductal plate is
gradually remodelled, forming a system of anastomising bile ducts. The pattern of
expression of a subset of cytokeratins (CK) appears to be specific for this
developmental process (Van Eyken et al. 1988). Hepatocytes and BECs both express
CK8 and CK18, but as the primitive hepatocytes differentiate into BECs they begin
to express CK19 followed by CK7. In the adult, liver hepatocytes appear to retain the
capacity to acquire these latter "bile duct type" CKs, transforming into bile duct type
cells. This has been observed in cases of chronic choleostasis, hepatocellular
carcinomas and a case of focal nodular hyperplasia. It is interesting to consider
whether the ductular hyperplasia seen in PBC liver sections is an attempt to
regenerate the lost BECs via a process analogous to the initial development of the
liver during ontogeny. If this is indeed taking place then a better understanding of the
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developmental processes resulting in bile duct formation might enable appropriate
intervention to enhance this process and regenerate functional bile ducts. However,
such a proposition requires elucidation and prevention of the processes causing
destruction of BECs to prevent new or regenerated cells succumbing to the same
fate.
These results have not, nor did they attempt to, elucidate the actual mechanism by
which BECs are destroyed during the course of PBC. We still remain at a loss in
understanding how the initial destruction takes place. There is the possibly over
pessimistic view that even once we have grasped this knowledge the chronicity of
this disease will hamper successful intervention. Patients frequently do not present at
clinics until they experience symptoms due to significant and extensive tissue
damage, by which time secondary responses probably predominate and prevention of
the initial destructive mechanism is likely to be of little therapeutic benefit. In one of
the animal models, using a murine graft-versus-host reaction to attempt to induce
PBC-like hepatic lesions, administration of monoclonal antibody against LFA-1, but
not ICAM-1, was found to inhibit the lesions (Kimura et al. 1996). However, the Abs
had to be administered prior to cell transfer for this effect to be seen necessitating
foresight of the impending tissue destruction, which in the case of PBC is presently
unavailable. Does this suggest we should be putting more resources into identifying
those most likely to succumb to disease for potential therapies to be successful? If
we are able to identify genetic factors that appear to predispose an individual to
PBC, when should preventative intervention of the future be initiated? At present
there is a relatively wide age range over which patients present but the actual time of
disease initiation may be even more variable. PBC is likely to be the result of a
multitude of genetic and environmental factors, which will make accurate
identification of those unfortunate to suffer the disease a daunting process.
As expected cells ofM((>/monocyte lineage expressing the CD68 antigen were seen in
all liver sections stained with PG-M1. KCs represent 30% of the non-parenchymal
sinusoidal cells in the liver (reviewed in te Velde 1994) and were obviously visible
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in tissue sections distributed throughout the parenchyma, bearing an elongated,
spindly morphology. As there is no antibody which specifically recognises KCs it is
not possible to say definitively whether these cells I observed are KCs, though their
morphology and situation is strongly suggestive of this. It is interesting to note that
the density of these cells was increased in the PBC liver sections. Whether this
represents an influx of blood monocytes developing in situ into KCs or proliferation
of existing KCs is not known. It is also not known whether these cells are
contributing directly to the pathogenesis of PBC or merely represent a visible marker
of a generally pro-inflammatory, immuno-stimulating environment within the
diseased liver. More of these cells were seen in sections showing histological late
stage disease suggesting their accumulation may be a secondary effect. If they are
involved in BEC destruction one would expect them to be focused around the
damaged ducts, however, such PG-M1 positive cells were generally rounder and
larger with increased cytoplasmic staining. This morphology is suggestive of
activated and stimulated M(j>s. Many reports have highlighted the presence of
extensive epithelioid granulomas in PBC liver (Nakanuma and Ohta 1983; Takezawa
and Yamada 1984; Yunoue et al. 1984; Nakanuma et al. 1997) and this study has
confirmed their presence in both early and late stage tissue, but not normal liver.
Though it has been suggested that granulomas are particularly apparent in early stage
disease, I also saw extensive granulomas in late stage disease. One problem with
allocating a stage to a particular section is the continuity of this disease. In any
section, particularly from larger wedge biopsies, from which late stage sections were
frequently derived, there may be tissue destruction representative of several stages of
the disease. One duct may be undergoing what histologically appears to represent
early stage destruction while other ducts may be completely destroyed. Thus, in such
a section allocated histologically late stage, features of early stage disease are also
likely to be present. Analysing a single section from a needle biopsy also only gives a
two-dimensional view of a tiny section of a vast organ. Though granulomas were
often centred around bile ducts, both those apparently intact as well as those
undergoing destruction, I frequently observed granulomas in the parenchyma, as
others have (Yunoue et al. 1984). A three-dimensional image might actually show
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these latter granulomas to be focusing around ducts out of the plane of the section.
Serial sections would need to be analysed to determine whether this may be the case,
but the scarcity of PBC liver biopsy material thwarts such extensive studies.
Granulomas are often seen in diseases such as tuberculosis, leprosy and sarcoidosis
where M(j>s centre around indigestible or poorly degradable, persistent substances. It
is interesting to speculate whether such material is present in PBC liver stimulating
the granulomatous response and what the origin of such material might be. As
mentioned in 1.1.4 a variety of infectious agents (M. gordonae, enterobacteriacae,
Salmonella and E. coli) have been advocated to play a role in the aetiology of PBC.
Such agents could act as a persistent trigger for an immune response and, if they
infected primarily BECs, could explain the focused attack on the ducts. It is also
possible that the BECs concentrate some granuloma-inducing material because the
cells act as a passage for excretion into the bile ducts and the liver, being a major
organ for detoxification, would be a prime site for extraction of such material from
the circulation. This localised concentration of such a trigger may explain the initial
focused destruction.
Though the actual function of the M<J) in PBC has not been addressed this analysis of
the presence and distribution of PG-M1 positive cells of M(j>/monocyte lineage
supports a role of these cells in the pathogenesis of PBC. Their large numbers, the
focused, localised situation of positive cells with increased cytoplasm and extensive
epithelioid granulomas suggests they are playing a greater role than merely the result
of secondary stimulation accompanying inflammation of the liver.
3.4 Conclusion
To conclude I have shown the presence of proteins involved in executing apoptosis
in BECs in PBC consistent with previous reports of apoptosis of these cells
(Nakanuma et al. 1983; Kuroki et al. 1996; Harada et al. 1997b; Koga et al. 1997). It
is still not known what causes this apoptosis but I have also shown at least a subset
of BECs is capable of regeneration. It may be that a change in the balance between
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apoptosis and regeneration of biliary epithelial cells during the course of disease
contributes to the ultimate loss of bile ducts in PBC. However, because of the
prolonged time course of this chronic disease and the secondary effects and immune
response resulting from bile duct loss intervention of apoptosis is unlikely to be a
therapeutic target in the treatment of PBC. I have also confirmed the reports of
others showing cells of M(|)/monocyte lineage contribute to the immune response in
PBC. Their presence is increased in diseased liver sections and significant, extensive
granulomas exist in tissue of all histological stages.
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4 GENOTYPIC ANALYSIS OF THE 5' POLYMORPHIC
MICROSATELLITE REGION IN HUMAN NRAMP1 IN
PATIENTS WITH LIVER DISEASE AND EXAMINATION OF
NRAMP1 EXPRESSION
4.1 INTRODUCTION
4.1.1 Analysis of the 5' Promoter Microsatellite Polymorphic Region in
the Human NRAMP1 Gene.
The identification of nrampl as a pivotal factor in determining murine susceptibility
to a variety of intracellular pathogens was a revelation (Vidal et al. 1995a and
1995b). By understanding the mode of action of the gene it was hoped light would be
cast upon natural resistance mechanisms against such pathogens, not only in mice
but also in the human race where affliction with diseases such as TB and leprosy
remain an ever increasing clinical problem. As yet a human equivalent of the murine
G>D mutation at residue 169 of the murine protein has not been identified but the
human gene has been shown to have at least ten polymorphic sites (Blackwell et al.
1995; Buu et al. 1995; Liu et al. 1995). To date the most interesting of these sites,
situated in the 5' untranslated promoter region of the gene, has been associated with
susceptibility to RA (Shaw et al. 1996 and 1997), TB (Bellamy and Hill 1998;
Bellamy et al. 1998) and leprosy (Bellamy and Hill 1998). This polymorphic site was
reported to have four alleles differing by the number of gt dinucleotide repeats at a
putative Z-DNA forming microsatellite repeat. The identified alleles affect NRAMP1
mRNA expression with allele 3 driving the highest level of expression (Searle and
Blackwell 1999). Genotypic-phenotypic analysis has shown an association of this
allele with RA (Shaw et al. 1996 and 1997) and it has been proposed that under
situations where NRAMP1 is overexpressed hyperstimulated M(j>s could initiate and
perpetuate tissue damage, chronic pathology and autoimmune disease. Conversely,
in situations where insufficient NRAMP1 is expressed understimulated M<J>s may fail
to overcome and contain pathogens, such as M. tuberculosis or M. leprae, resulting
in increased susceptibility to disease or an inability to fight these infections: an
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hypothesis which appears to hold credibility with the reported association between
allele 2 and susceptibility to TB (Bellamy and Hill 1998; Bellamy et al. 1998).
Reporter gene studies have shown allele 3 drives up to ten fold higher levels of
expression than alleles 1,2 or 4. After exogenous stimulation with IFNy, reporter
gene expression increased for all the constructs. However, after addition of LPS, as a
second exogenous signal, a further two fold enhancement of expression was seen
with allele 3, expression driven by alleles 1 and 4 remained unchanged and there was
a significant decrease in allele 2 driven expression (Searle and Blackwell 1999).
It is the possible association of autoimmune disease and the polymorphic
microsatellite repeat region that interested me with respect to susceptibility to PBC.
As for RA (reviewed in Kingsley and Panayi 1997) mycobacterial or bacterial
infection has been proposed as a contributory factor in initiation of PBC. In both
diseases M<|)s appear to play an important role, being particularly obvious
histologically in granulomas in PBC liver. In both RA and PBC high levels of AAbs
are present, though it has yet to be proved whether these are pathogenic. For
instance, rheumatoid factor, an Ab directed against the Fc portion of Ig, is found in
the majority ofRA patients, though it is not specific for RA and is often undetectable
in early disease. I wished to genotype PBC patients by RFLP analysis for the 5'
microsatellite repeat polymorphism to identify if these patients resemble RA patients
in showing a similar increased frequency of allele 3, which may be indicative of M<j>
induced pathology mediated in part via the NRAMP1 gene. As control populations
hepatitis C sufferers were chosen to represent individuals with cirrhosis resulting
from infection with a M(|)-tropic virus, individuals with alcoholic liver disease (ALD)
to represent a chemical induced form of cirrhosis and normal non-cirrhotic blood
donors. There is no evidence that NRAMP1 affects the outcome of viral infections
and none of the control populations were expected to be associated with a particular
NRAMP1 genotype.
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4.1.2 Analysis of NRAMP1 Expression by Semi-Quantitative RT-PCR
The focus of this project centres around the genotypic and phenotypic effect of
NRAMP1, in particular with respect to PBC and disease. It was, therefore, natural to
investigate the expression of NRAMP1 in PBC patients at the site of tissue damage,
namely the liver. Working on the principle that NRAMP1 overexpression might be a
contributory factor in the pathogenesis of such diseases through its effect on Mcj)
activation and function, I wished to analyse the expression profile of the gene in liver
biopsy material from PBC patients compared to control tissue. I was interested to
determine whether NRAMP1 was expressed and if a difference in the relative
expression levels of the two splice variants of the NPAMP1 mRNA (Cellier et at.
1994) existed in the disease sufferers. The significance of the two identified splice
variants of NRAMP1 is not known but their differential expression represents a
possible mode of regulating the amount of functional NRAMP1 protein synthesised.
The +alu variant introduces a premature stop codon, which would be expected to
result in either a truncated protein or degradation of the partial protein. The analysis
was approached by extracting RNA from frozen liver material and developing a
semi-quantitative RT-PCR assay to determine the ratio of the two mRNA species
expressed using the intensity of the resolved PCR products measured under UV
radiation with the Herolab EASY store software. The primers NRAMPFalu and
NRAMPRalu (2.8.3) were cDNA specific and generated products of different sizes
depending on whether the Alu insert was present in the template cDNA. The
expression levels of the splice variants were compared to those of the housekeeping
gene GAPDH, which acted as an internal control. Normal tonsil material was also




4.2.1 Genotypic Analysis of the 5' Polymorphic Microsatellite Region in
Human NRAMP1
4.2.1.1 Development of Genotyping Strategy
Using the primers NRAMPFpol and NRAMPRpol the optimal annealing temperature
and cycle number of 65°C and 35, respectively, were determined to give a specific
product of approximately 194bp at a point during the exponential phase of the PCR
reaction (Figure 4.1). It was important that a point during the exponential phase of
the reaction was chosen if PCR products were to be analysed on a non-denaturing gel
to exclude heteroduplex formation of single stranded DNA sequences of the different
alleles in heterozygotic cases. Attempts to resolve the PCR products in 4.5%
MetaPhor agarose gel (Flowgen, Lichfield UK) and subsequent staining with EtBr
failed to discriminate between the 2bp size differences in PCR products of
approximately 194bp, despite manufacturer's claims. This had been anticipated,
hence, the Rsal and Mnll digestion strategy, discussed in 2.8.1, had been designed
and was used for all subsequent analyses. Recommended instructions using a rapid
horizontal 5% MetaPhor agarose gel procedure to resolve the digested PCR products
were followed, but proved problematic due to overheating of the gel (despite running
it at 4°C) and the inconvenience of handling the high concentration gel mixture.
Lower MetaPhor agarose concentrations were unable to resolve the fragments with





Figure 4.1 NRAMPpol PCR products amplified from genomic DNA of patients
with liver disease, prior to restriction enzyme digestion for RFLP analysis to
genotype the polymorphic microsatellite repeat region in the promoter of the
NRAMP1 gene. Molecular weight marker, with sizes shown in bp, was run in the left
hand lane.
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As polyacrylamide gels have better resolution capacity than agarose and its
equivalents, MDE gels (Flowgen, Lichfield UK) and 6% and 12% denaturing
polyacrylamide gels were tried, with subsequent silver staining of the digested PCR
products. Silver staining has a much higher sensitivity as a DNA stain than
intercalation of EtBr and UV visualisation. The 6% denaturing polyacrylamide gels
gave clear, distinct bands enabling accurate genotyping and were used to genotype
all the DNA samples analysed. By using a denaturing gel any possible problem of
heteroduplexes arising during late stages of the PCR reaction were eliminated and a
double band was observed for each of the denatured fragments.
4.2.1.2 Identification of Novel Polymorphisms
The system of allele identification was designed to identify individual alleles on the
basis of differential mobility by gel electrophoresis according to the length of the
digested fragments (Figures 4.2a and 4.2b). As predicted I found the band patterns
expected for the previously published alleles 1, 2 and 3 whose sequence is shown in
Table 4.1, but have not identified a pattern representing any of the sequences
published as allele 4 in any of the 246 cases I analysed. The sequence of the
microsatellite repeat region of allele 2 and allele 3 were initially confirmed by
sequencing undigested PCR products. PCR products from individuals homozygous
for allele 3 (according to the RFLP analysis results) gave a clear, distinct sequence
with nine (gt) repeats for the terminal repeat (Figure 4.3). At the time of
sequencing the PCR products no individuals homozygous for allele 2 had been
identified by RFLP analysis so PCR products from an allele 2/allele 3 heterozygote
were sequenced. As expected clear, distinct sequence was obtained until the ninth
(gt) repeat of the terminal repeat, after which point the sequences of allele 2 and
allele 3 became superimposed. Though this technique proved capable of generating
sequence data over the microsatellite repeat region for the two alleles it was
insufficient for obtaining sequence data across the whole length of the PCR products,
despite exhaustive attempts altering the protocol by adding DMSO and/or
manganese, substituting 7-deaza-dNTPs for the dNTPs, altering the primer
concentrations and including formamide in the sequencing gel. Therefore, the alleles
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were subsequently sequenced completely after cloning the PCR products in the
pCR2.1 vector (Figure 4.4).
In addition to the expected alleles described above, I found two unexpected banding
patterns showing variation in size of the Rsal and Mnll bands, predicted to be of
constant size 84bp and 77bp respectively. These were investigated further and named
allele 5 and allele 6, respectively. Identification of these allele patterns were
consistent when analysis was repeated several times from DNA extracted at different
times from the same blood sample, from separate blood samples from the same
individual, and from DNA extracted from blood and paraffin embedded material
from the same individual. Alleles 5 and 6 were only seen in the heterozygous state.
The banding patterns corresponding to alleles 2, 3, 5 and 6 are shown in Figures
4.2c and 4.2d.
Allele Sequence






Allele 5 t(gt)4ac(gt)5ac(gt) 10ggcaga(g)6
Allele 6 t(gt)5ac(gt)5ac(gt)4at(gt)4ggcaga(g)7
Table 4.1 Summary of alleles of human NRAMP1 5' promoter polymorphic site
showing the sequence of the alleles identified in previous studies (alleles 1-4) (*
Blackwell 1996; Shaw et al. 1996 and 1997: $ Blackwell et al. 1995: n Searle and
Blackwell 1999) and in this study (alleles 1, 2, 3, 5 and 6).
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Figure 4.2 showing the type of RFLP gel for a) Rsal and b) Mnll restriction
enzyme digestion of NRAMPpol PCR products amplified from genomic DNA from
patients with liver disease (1-15) from which genotypes were deduced. Patients 3
and 7 show the allele 5 banding pattern. Precise identification of allele 5 and allele 6
can be seen in close up in c) depicting the Rsal digestion products for alleles 2, 3
and 5 and d) depicting the Mnll digestion products for alleles 2, 3 and 6. Molecular
weight marker with sizes in bp is shown in the left hand lane in a) and the right hand
lane in b).
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4.2.1.3 Characterisation of Allele 5
In cases showing the banding pattern associated with allele 5 the Mnll digestion
repeatedly resulted in a variable fragment consistent with allele 2
(t(gt)5ac(gt)5ac(gt)iog) but a product 2bp less than the predicted 84bp "constant"
fragment (Figure 4.2c). This predicted a 2bp deletion in the region of the amplified
sequence 5' to the first Rsal site and, based on the Mnll digestion results, 3' to the
first Mnll site (Figure 4.5). This region includes the initial (gt)5 of the
microsatellite region. The Mnll digestion gave a fragment encompassing this region
predictive of allele 3 (t(gt)5ac(gt)5ac(gt)9g), 2bp less than allele 2 (not shown). To
confirm this hypothesis and identify the site of the predicted deletion I cloned
undigested PCR products from DNA known to contain allele 5, genotyped the cloned
DNA and sequenced the insert of clones giving a pattern representing allele 5. This
showed allele 5 to have the sequence t(gt)4ac(gt)5ac(gt)i0g, with a gt deletion in the
first (gt)5 dinucleotide repeat identified in the other alleles (Figure 4.6).
4.2.1.4 Characterisation of Allele 6
In the case showing the banding pattern associated with allele 6 the Rsal digestion
gave a product of size intermediate to that predicted for alleles 2 and 3 (not shown).
The Mnll digestion produced a variable fragment predictive of allele 3 and a product
estimated to be lbp larger than the "constant" 77bp fragment (Figure 4.2d). These
findings were consistent with a lbp insertion 3' to the secondMnll site downstream
of the polymorphic microsatellite repeat region (Figure 4.5). To confirm this
hypothesis and identify the site of the predicted insertion I cloned undigested PCR
products from DNA known to contain allele 6, genotyped the cloned DNA and
sequenced clones giving a pattern representing allele 6. This showed insertion of an
extra dGTP in a hexanucleotide g repeat seven base pairs 3' of the final gt of the
polymorphic site. In addition sequencing of this allele showed the final polymorphic





Figure 4.3 Sequence of allele 3 of the polymorphic microsatellite region in the
NRAMP1 promoter, sequenced from NRAMPpol PCR products (as described in
2.8.1 and 2.15.1). A: adenine, C: cytosine, G/g: guanine, T/t: thymine.
G A T C
allele 2
Figure 4.4 Sequence of allele 2 of the polymorphic microsatellite region in the
NRAMP1 promoter, sequenced from cloned NRAMPpol PCR products (as described













Figure 4.5 Sequence of part of the promoter region of the human NRAMP1 gene
(Accession number X82016, 59-240bp) amplified by PCR using NRAMPpol primers
to genotype the polymorphic microsatellite region, shown in bold. The Rsal and
Mnll restriction enzyme sites used to digest the amplified DNA are shown. The
enzymes recognise the following sites and cut at the position shown by the vertical
slash; n represents any base.
Mnll | (n)6gagg Rsal gt I ac
I(n)7ctcc ca|tg
The sequence for allele 3 is used in this figure. Sequences over the polymorphic
region of the other alleles identified in this study and those previously published are
shown in Table 4.1.
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4.2.1.5 Frequency of Alleles Identified in the Groups Studied.
The sequence of the five alleles I detected (alleles 1, 2, 3, 5 & 6) and allele 4
reported by Blackwell et al., as three different sequences, are shown in Table 4.1.
Table 4.2 shows the frequency of alleles in the normal group I analysed and those
reported in previous studies. The frequencies of the five alleles identified in the four
groups I genotyped: normal controls, PBC, ALD and hepatitis C patients are shown
in Table 4.3. In the PBC population genotyped allele 5 was significantly more
common, though still rare, than in the other groups studied (p<0.024 compared with
normal controls; p<0.012 compared with ALD or hepatitis C; Fisher Exact Test).
Allele
1 2 3 4 5 6
Present
study n=78
<0.01 0.27 0.70 0.00 0.02 0.00
^Brazilian
n=72
0.02 0.33 0.64 <0.01 0.00 0.00
#Caucasian
n=120
0.02 0.25 0.73 0.00 0.00 0.00
#Asian
n=40
0.05 0.10 0.85 0.00 0.00 0.00
Table 4.2 Frequencies of alleles at the 5' NRAMP1 microsatellite repeat
polymorphic site identified in the normal control group in this study (Present study)
compared to the frequencies of alleles in normal Brazilian, Caucasian and Asian
control groups published previously (* Blackwell et al. 1995: # Liu et al. 1995). The
sequences of the six alleles are given in Table 4.1.
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C T A G
allele 5
Figure 4.6 Sequence of allele 5 of the polymorphic microsatellite region in the
NR.4MP1 promoter, sequenced from cloned NRAMPpol PGR products (as described
in 2.8.1 and 2.15.2). C: cytosine, T/t: thymine. A: adenine, G/g: guanine.
GATC GATC
allele 6 allele 2
Figure 4.7 Sequence of allele 6 and allele 2 of the polymorphic microsatellite
region in the NRAMP1 promoter, sequenced from cloned NRAMPpol PCR products





























































Ap<0.024 compared to normal control.
Table 4.3 Numbers and frequencies, in brackets, of the alleles at the 5' NRAMP1
microsatellite repeat polymorphic site identified in the four groups, Normal controls,
alcoholic liver disease (ALD), primary biliary cirrhosis (PBC) and Hepatitis C,
analysed in this study. The sequences of the alleles are given in Table 4.1.
Statistical analysis of frequencies was carried out using the Fisher Exact Test.
4.2.2 Analysis of NRAMP1 Expression by Semi-Quantitative RT-PCR
4.2.2.1 Developing Semi-Quantitative RT-PCR Assay
The housekeeping gene encoding the GAPDH protein was chosen as a standard
control against which expression ofNRAMP1 could be compared. Only a ratio of the
two NRAMP1 splice variants relative to each other and to GAPDH was sought, not
absolute amounts of message of the three species. Titrations of RNA, cDNA and
2 j
Mg in the reactions determined the optimal conditions to be a fixed amount of 1 pg
RNA as template for the RT reaction and a fixed amount of 1 pi template cDNA and
2_j_ ,1.5mM Mg in the PCR. Comparison of the intensity of the different species was
made over the exponential phase of the reactions, determined by comparing the
intensity of the products, resolved by 2% agarose gel electrophoresis, at different
cycle numbers using the Herolab EASY store software. Figure 4.8 shows a typical
graphical representation showing the exponential phase for amplification of
GAPDH. The +alu (containing the Alu sequence insert) and -alu (encoding the full
length message) products, generated using the NRAMPalu primers, were amplified
at equal efficiency over the cycle numbers analysed (Figure 4.9), which is





Figure 4.8 Log intensity values for GAPDH RT-PCR products removed after
variable numbers of cycles during the PCR reaction to determine where the
exponential phase of the reaction occurs. The RNA was extracted from normal and
PBC liver tissue; the patient numbers correspond to those used in Figures 4.12 and
4.13.
Figure 4.9 Log intensity values for two normal liver samples of the +alu (open
diamonds) and -alu (closed squares) RT-PCR products removed after variable
numbers of cycles during the PCR reaction to determine where the exponential phase
of the reaction occurs and confirm the two splice variant products are amplified with
equal efficiency. The NRAMPalu primers used are described in 2.8.3.
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designed with each primer spanning an intron-exon boundary all products resulted
from amplification ofmature spliced message. The primers were designed to work at
the same annealing temperature and extension time so all three species could
theoretically be amplified in one reaction to reduce pipetting errors. However, after
checking for cross-primer interference by adding primers specific for genomic DNA
(NRAMPFpol and NRAMPRpol described in 2.8.1) to PCRs for amplification of
GAPDH cDNA there was an obvious decrease in the yield of the GAPDH product
when the second pair of primers was present. This interference, solely due to the
presence of the second set of primers which were not generating any PCR product,
suggested results obtained from a PCR containing both the GAPDH and NRAMPalu
primers would be unrepresentative of the real message status of the samples. Hence,
all analyses were carried out with separate reaction tubes for the GAPDH and
NRAMPalu PCRs using the same PCR thermal heating block to eliminate inter¬
block temperature variations.
4.2.3 mRNA Expression in Human Tissue
GAPDH mRNA expression was detected by RT-PCR in all the human tissues tested
(Figure 4.10) which acted as a positive control for successful RNA extraction and
cDNA synthesis. In normal tonsil expression of the +alu splice variant was seldom
detected by RT-PCR and on the one occasion when it was found it was at a low level
(Figure 4.11).
Both -alu and +alu splice variants were consistently detected by RT-PCR in normal
(Figure 4.11) and PBC liver material. However, due to the scarcity of frozen PBC
and normal liver material only limited analysis and comparison of the expression
pattern of NRAMP1 in these samples could be carried out. Figure 4.12 shows the
ratios of the intensities of the -alu/+alu message and the -alu and +alu product
intensities relative to the GAPDH product intensities for the analyses carried out
with three PBC and two normal liver samples. When cDNAs prepared from the three
PBC livers and two normal livers were compared two of the patients had a higher
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Figure 4.10 GAPDH RT-PCR products showing expression of GAPDH mRNA in
normal liver (lanes 1-3 and 5-7) and normal tonsil (lanes 4 and 8). Lane 9 shows the
negative control reaction and a molecular weight marker, with sizes shown in bp,






Figure 4.11 NRAMPalu RT-PCR products showing expression of NRAMP1 mRNA
in normal liver (lanes 1-3) and normal tonsil (lane 4). The higher molecular weight
band represents the +alu product and the lower molecular weight band represents the
-alu product. Lane 5 shows the negative control reaction and a molecular weight
marker, with sizes shown in bp, was run in the left hand lane. For details of
NRAMPalu primers see 2.8.3,
ratio of the intensity of the -alu:+slu message compared to the control liver analysed
in parallel. In the third paired analysis the reverse was found with the normal liver
having a higher -alu:+alu message ratio (Figures 4.12 and 4.13). As such, no
conclusion could be drawn as to the relative levels of expression of the two splice
variants of the NRAMP1 mRNA in the disease liver samples compared to the normal
liver samples. In the two samples where the PBC liver showed a higher -alu:+alu
message ratio over the normal liver samples the same normal liver material was
being used as the control. In all liver samples analysed more -alu message was


















Figure 4.13 Bar chart showing the ratio of PBC liver -alu/+alu RT-PCR products
relative to normal liver -alu/+alu RT-PCR products for tissue from two PBC and two
normal cases. The NRAMPalu primers and RT-PCR design are described in 2.8.3.
Attempts to determine relative levels of expression of the NRAMP1 splice variants in
liver tissue from hepatitis C sufferers were unsuccessful. These samples were chosen
to represent a cirrhosis disease mediated by a viral infection for comparison with the
PBC cases. In none of the six cDNAs used as template DNA was +alu message
detected. In two of the cases a barely detectable -alu species was identified. Re-
amplification of PCR products from the initial amplification rounds still failed to
generate detectable NRAMP1 message in the majority of the samples, only
increasing the level of product of the -alu species in cases where a very low level of
product had been detectable after the first PCR amplification round. GAPDH
message was successfully amplified from all cDNAs from the hepatitis C cases.
4.3 DISCUSSION
This study identified two novel alleles (Graham et al. in press) at the previously
identified polymorphic microsatellite repeat sequence in the promoter of the human
NRAMP1 gene (Blackwell et al. 1995). One of these, allele 5, is significantly more
frequent, but still uncommon, in the PBC population studied (8/53) compared to the
PBC1/Normal1 PBC2/Normal1 PBC3/Normal2
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normal controls (3/78) (p<0.024), ALD (2/76) (p<0.012) or hepatitis C patients
(0/39) (p<0.012) (Fisher Exact Test). The repetitive nature of the sequence analysed
required a stringent, sensitive and reproducible detection method, due to the
possibility of slippage or infidelity of the Taq polymerase enzyme during PCR
amplification. The method I adopted gave consistent results when DNA was
extracted from the same blood sample at different times, when DNA was extracted
from blood taken from the same individual at different times and when DNA was
extracted from blood and paraffin embedded material from the same individual.
A number of alleles at this site have previously been reported by sizing this
polymorphic region as a single fragment (Blackwell et al. 1995; Liu et al. 1995).
However, my strategy used restriction enzyme digests designed to size both the
whole polymorphic site as a single fragment (Mnll), and the size of fragments
containing the 5' dinucleotide and 3' dinucleotide repeats of the region as distinct
entities (Rsal) (Figure 4.5). It was the combined results of these digests which
allowed detection of allele 5 and allele 6 and confirmation of the previously reported
alleles 1, 2 and 3 (reviewed in Blackwell 1996; Shaw et al. 1996 and 1997).
Allele 5, has a gt deletion in the first, normally (gt)5, repeat region of the
microsatellite repeat of allele 2.1 am confident that this is a genuine allele and not an
artefact or the result of infidelity of the Taq polymerase enzyme used. The allele was
identified consistently and repeatedly when samples were reanalysed. Allele 5 was
only found in the heterozygous state with no bias to inheritance with allele 2 or 3. I
do not know what effect, if any, this allele has on the levels of NRAMP1 expression
but it is feasible that its position within this Z-DNA forming sequence may influence
expression, as the previously described alleles have been reported to do (Searle and
Blackwell 1999). When NRAMP1 expression levels have been compared for the
previously reported alleles 1, 2, 3 and 4, allele 3 was shown to drive the highest
levels of expression of a reporter gene under unstimulated conditions. Stimulation
with IFNy and LPS differentially affected expression from the alleles with allele 1
showing a significant increase on addition of IFNy and a further increase when LPS
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was added. Allele 2 responded to IFNy stimulation by increasing reporter gene
expression, however, subsequent LPS addition resulted in decreased expression. The
other two alleles were unresponsive to LPS addition but showed increased
expression in response to IFNy (Searle and Blackwell 1999). Reporter gene
expression studies, similar to those described, would be required to investigate the
effect of allele 5 on mRNA expression compared to the other identified alleles, but
in the light of the above report it is highly likely that this allele will have a functional
effect on expression. Whether this has a significant impact physiologically,
particularly in the subset of PBC patients carrying allele 5, to influence the course of
disease or infection remains an area for further research. None of the individuals
who carried allele 5 were homozygotes and, therefore, for the allele to have a
significant phenotypic effect one would expect it would need to act in a dominant
fashion. However, the overall levels of expression will reflect the message
potentially derived from both alleles, so an individual carrying one allele which
drives either a very high or a very low level of expression, or an allele which
responds optimally or is unresponsive to immune stimulants, could display a
phenotypic effect despite carrying a second "normal" allele which lacks such
extreme characteristics. It is possible that the increased frequency of allele 5 in the
PBC population reflects inheritance of another susceptibility locus or functional
NRAMP1 polymorphism, in partial linkage disequilibrium with allele 5, which
contributes to initiation or maintenance of the disease.
It is important to note that had I been relying solely on results from a single analysis
of the size of the microsatellite repeat as a whole, then allele 5 would have been
mistaken for allele 3, the allele which is at highest frequency in all previously
published reports, as both alleles are the same length. Previous reports have been
sizing the whole microsatellite repeat region within PCR fragments of 108-122bp
(Blackwell et al. 1995) or 286-290bp (Liu et al. 1995; Abel et al. 1998) and
individuals actually carrying allele 5 may have been mistakenly identified as allele 3
bearers. As allele 5 is at a much lower frequency than allele 3, sequencing random
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cases genotyped to have an allele the size of allele 3 in these studies would be
unlikely to include a case with allele 5, hence, these might go undetected.
I failed to find evidence for any of the alleles 4 previously published in the 246 cases
I genotyped. However, allele 4 was only found at a frequency of <0.01 when 72
Brazilians were genotyped for this polymorphic site (Blackwell et al. 1995).
Publication of the sequence allele 4 represents has been inconsistent with three
sequences published to date (Blackwell et al. 1995; reviewed in Blackwell 1996;
Shaw et al. 1996 and 1997; Searle and Blackwell 1999). In the most recent
publication the authors say the initial sequence published (Blackwell et al. 1995) was
an error but publish a third sequence in this paper (Searle and Blackwell 1999). It is
presently not known whether this is the genuine sequence or a further error.
Allele 6 is unlikely to be present in the general population at a significant level and it
was only found in one ALD patient. This individual had altered sequence in both the
final dinucleotide repeat and in a single nucleotide repeat region, in close vicinity to
the microsatellite repeat under investigation, which may reflect the instability of
such repetitive DNA sequence. As my procedure for allele designation is reliant on
differences in the size of digested fragments of DNA it can not be ruled out that
other individuals may have interrupted repeats or altered sequence at sites other than
the Mnll or Rsal restriction enzyme recognition sites, which could only be
determined by sequencing every individual for both alleles.
It is perhaps surprising that greater variation at this polymorphic site has not been
reported by others or identified in this study. Such dinucleotide repeats are inherently
unstable and subject to expansion or retraction during DNA replication. It appears
that this stability also extends to sequence further upstream of the site I analysed
because a study of the region from -3434 to -594, upstream of the transcription start
site at position zero, has identified eleven Alu element-related sequences and one
Mer family element (Roger et al. 1998). Over 500,000 Alu repeated sequences exist
interspersed throughout the haploid genome with an average spacing of 4kb. The 11
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Alu elements in this 3kb region flanking NRAMP1 is, therefore, unusual particularly
with the additional presence of a relatively rare Ivlet" element. This high density of
different DNA repeats and recombination hot spots would lead one to believe the
region would be a focus of genomic instability, genetic recombination and/or
sequence variability. However, this does not appear to be the case and the region has
been well conserved since the divergence of humans and great apes. The oldest Alu
elements of the five Alu subfamilies present in the region, Alu J. is estimated to have
transposed 80 million years ago, providing ample opportunity for variation. It is also
interesting to point out that Alu insertions are not restricted to the flanking region of
A TT) A A SD 7 ~ WD\TA *- „^A A .T, A O O A
ivrwiivir i as me: inrvi\.rv. bjpiiC/'C vaiiant, ucnuw anu in i.u.u. i? reruns nufii
alternative splicing of an Alu sequence element.
A familial predisposition to PBC has been reported (Bach and Schaffner 1994) and,
as discussed in 1.1.4, studies to investigate association between PBC and
polymorphisms at a number of genetic loci, including HLA (Emilia et ctl. 1979;
Santrach et al. 1990: Fueeer et al. 1991: Morlinn et al. 1992: Underhill et al. 1992
and 1995; Gregory et al. 1993; Seki et al. 1993; Onishi et al. 1994; Zhang et al.
1994a; Mella et al. 1995), TNFa (Fugger et al. 1989; Spengler et al. 1990; Messer et
al. 1991; Gordon et al. 1996; Watt et al. 1997), TAP1 and 2 (Gregory et al. 1994),
GSTM1 (Davies et aL 1993) and interleukin-10 (Zanpala et al 1998) have been
carried out. However, to date only weak associations with C4B2 (Briggs et al. 1987)
and TNFa have been reported and HLA Class II associations remain controversial.
The idea that overexpression of NRAA/fPl, due to inheritance of allele 3, in
combination with additional genetic, infectious and environmental factors is an
attractive proposition in the initiation of chronic pathology or autoimmune disease
such as RA. However, T did not find a similar association in the PBC population I
studied: in fact the frequency of allele 3 was lowest in the PBC group of the 4 groups
tested, the decreased incidence being accounted for in the increased frequency of
allele 5. Susceptibility to PBC, and the other diseases which NRAMP1
polymorphisms have been reported to associate with (Shaw et at. 1996 and 1997;
Hofmeister et ctl. 1997; Neibergs et ctl. 1997; Abel et ctl. 1998; Bellamy et al. 1998),
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are complex diseases and likely to result from a combination of interacting factors,
which may include NRAMP1 genotype. The low, but significantly increased
frequency of allele 5 I have found in PBC patients, compared to control groups, may
affect the activity or function of these individuals' macrophages. However, its
presence in only 15% of the cases I studied suggests it is unlikely to play a
significant role in the aetiology ofPBC.
Using RT-PCR analysis to characterise the expression profile of the NRAMP1 gene
in human tissue I have successfully shown expression of the -alu mRNA splice
variant in normal tonsil, but little or no expression of the +alu variant. The tonsil
RNA was extracted from pieces of stored frozen material, but it is not known if these
originated from one or more than one individual. If they were from a single donor
then the repeated lack of detection of the +alu message may be of little significance.
If, however, the results are representative of a larger number of paediatric tonsillitis
sufferers, the lack of +alu message may reflect the state of activation of M(()s
partaking in the inflammatory immune response present in this peripheral lymphoid
organ. As the tonsil material available was derived from sufferers with severe
tonsillitis one would expect influx into the tissue of a large number of activated M<j)s.
It is interesting to consider what the expression status ofNRAMP1 in an uninflamed,
resting tonsil might be and whether the relative levels of the splice variants may
alter, suggesting a potential regulatory role of the +alu species.
My RT-PCR results, analysing a limited supply of normal and PBC liver, confirmed
previous reports ofNRAMP1 expression in this tissue (Cellier et al. 1994). The aim
of analysing the relative levels of expression of the +alu and -alu splice variants and
their comparison with GAPDH expression was hampered by the lack of frozen liver
tissue for RNA extraction. Therefore, comparative results of only three paired
analyses are available and two of these include the same normal liver sample. As
such it is not possible to conclude whether the expression pattern varies in the
disease liver, though the presence of large numbers of M<j>s in a histologically
activated state in PBC liver biopsy material suggests this is a likely possibility. Had
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further liver samples been available one would have hoped to determine if these
preliminary results represent natural widespread variations between liver expression
profiles or an isolated occurrence in one of the two normal liver samples analysed,
with the disease and normal livers showing genuine differences.
It was unfortunate that results were unavailable to compare the third, hepatitis C,
population's NRAMP1 expression profile with the PBC and normal cases. It is not
known whether the lack of NRAMP1 RT-PCR products detected in these cases is
indicative of expression of the relevant mRNAs below a threshold for detection by
the procedure adopted or a genuine lack of expression in the liver of these hepatitis
C patients. I am in no doubt of the quality of the RNA the cDNA was derived from
as it was kindly provided by an experienced and professional colleague, Mrs Frances
Rae, who had utilised a similar practice and technique to myself when undertaking
the extraction.
Semi-quantitative RT-PCR analyses have been frequently criticised and it is
important to take into account the potential pitfalls and limitations of this technique.
The exponential amplification nature of PCR means small errors can be greatly
amplified. Throughout the experiments great care was taken to standardise the
procedure and tissue samples were taken through the whole analysis study in
parallel. Though potential inter-tube variations can not be eliminated by this
approach, external variations between separate experiments, such as ambient
temperature, stock reagents etc., can be excluded. When extracting the RNA the
appropriate weight of tissue to RNA Reagent ratio was used, and the sample weights
were kept as similar as possible. After the RNA had been extracted its concentration
was estimated by spectrophotometry and cDNA synthesised from 1 jag of total RNA
in a fixed volume so the cDNA reflected the messages present in this fixed amount
of RNA. The PCRs used lpl of the cDNA solution and all reactions and pipetting
were performed as scrupulously as possible to avoid incorporating inter-tube
variations. When semi-quantitatively comparing PCR products it is essential that the
species in question are amplified equivalently and this was confirmed by analysing
194
the intensity of the product band, after agarose gel electrophoresis, of samples
removed from the PCR thennal heating block after successive cycles of the reaction.
A point during the exponential phase of the amplification reaction must be used for
analysis before the reaction plateaus off due to exhaustion of the enzyme or reagents
in the tube. My analyses consistently found the range of the exponential phase to be
over the same cycle numbers and they also showed the +alu and -alu species were
amplified at the same rate, enabling a genuine comparison to be made between the
initial levels of the mRNAs. By comparing the levels ofGAPDH products I was able
to confirm the starting levels of RNA were equivalent in the samples supporting the
fidelity of the technique. When analysing the PCR products great care was taken to
load the agarose gels with an equal volume of the amplified DNA. The intensity
reading of the bands varies depending on the integration at which the detector is set,
the thickness of the agarose gel and the amount of EtBr incorporated in the gel.
Therefore, samples to be compared were always loaded as close to each other on the
gel as possible, which reduced variation in the background reading of the gel against
which the bands' intensities were measured. I designed the PCR primers so that they
would amplify products of approximately similar sizes but which were still easily
resolvable. This was because the intensity of the detected product band is
proportional to the amount of EtBr incorporated by the DNA, which is dependent on
the size of the DNA fragment, and I did not want large variations in the intensity of
the bands to reflect excessive variations in product size. Such variations might have
introduced problems when comparing the band intensities if different integration
settings were required to avoid saturation of the detector with very bright bands and
to allow detection of weaker bands. These principles proved effective in generating
consistent patterns in the relative levels of expression of the products of interest.
Efowever, it is important to stress that only relative levels were being sought and I
would not advocate this approach for absolute quantitative analysis.
4.4 CONCLUSION
NRAMP1 expression has been successfully detected by RT-PCR in the liver of
normal and PBC patients. A scarcity of frozen PBC and normal liver material has
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meant attempts to determine the relative levels of expression of the +alu and -alu
mRNA splice variants in these populations remain inconclusive, though all cases
expressed higher levels of the -alu message encoding the full length protein. In the
tonsil material analysed the +alu message was seldom detected though the -alu
message was present. A study to genotype cirrhotic and normal individuals for the
functional 5' promoter region microsatellite polymorphism has identified two novel
alleles (allele 5 and allele 6) at this site and confirmed the existence of three
previously published alleles (allele 1, allele 2 and allele 3). Allele 5 was found at a
significantly higher frequency in the PBC population studied; though it was still
uncommon. Whether its presence in 15% of the PBC population has a functional
effect in this sub group remains unresolved and the effect of this allele on regulating
NRAMP1 expression warrants further investigation.
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5 GENERATION OF A MAMMALIAN EXPRESSION VECTOR
CONTAINING NRAMP1 cDNA FOR TRANSFECTION
STUDIES AND DETECTION OF NRAMP1
OVEREXPRESSION
5.1 INTRODUCTION
Evidence is mounting to support the theory that the level of NRAMP1 expression,
and polymorphic variants regulating its expression, play a significant role in
determining the susceptibility of individuals to autoimmune or infectious disease
(reviewed in Blackwell and Searle 1999). Certain infectious diseases such as
tuberculosis and leprosy appear to be influenced by NRAMP1 genotype with
increased susceptibility being associated with allele 2 at the 5' promoter
polymorphic microsatellite repeat region. Reporter gene studies have identified this
allele to respond to IFNy stimulation by increasing transcription of NRAMPJ, but
subsequent LPS stimulation resulted in decreased expression (Searle and Blackwell
1999). Such a scenario can be envisaged to have a major impact on the ability of
M(j>s to control infection and it is, therefore, not surprising that allele 2 adversely
influences the outcome of an individual faced with microbial pathogens. Conversely,
allele 3 has been identified as driving the highest levels of NRAMP1 expression
under non-stimulatory conditions and when stimulated with IFNy or IFNy and LPS.
High levels of NRAMP1 expression are likely to partake in Mcj) activation enabling
them to deal effectively with pathogens. However, should this activation state
continue once an infection has been eliminated, or under situations where stimulated
M(j)s are not required, self-tissue destruction and an uncurtailed immune response is a
probable outcome. It is this idea of overexpression of NRAMP1 contributing to
autoimmune disease initiation and/or maintenance in which I was particularly
interested. I wished to investigate what effect such expression has on cells of M(j)
origin and determine whether physiological functions or effects of NRAMP1
overexpression could be identified which would increase the likelihood of
autoimmunity.
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To this end, I aimed to construct a plasmid containing the human NRAMP1 cDNA
which would result in high levels of NRAMP1 expression when transfected into
human cells. I wished to use cells of M<j) origin for my transfection studies because I
believed that the effect ofNRAMP1 might be inextricably linked to M(j) function as a
whole and their defence mechanisms. The broad spectrum of effects of the gene on
M(j)s which have been reported (reviewed in Blackwell 1996) are suggestive of a
necessity for an intact biological system which centred on the inherent characteristics
of the M(|). The most physiological system was sought, which appeared to be
transient transfection of human aPBMCs isolated from Buffy Coats. These cells are
derived from blood monocytes but develop the characteristics of M())s as they are
cultured in vitro. After transient transfection of the cells I wished to assay the
physiological effect of overexpression of the gene after verifying NRAMP1 was
being overexpressed at the RNA level, by RT-PCR analysis, and at the protein level,
using antisera raised against an NRAMP1 peptide.
The aim, therefore, was to construct a mammalian expression vector containing the
intact NRAMP1 cDNA and transfect aPBMCs with the plasmid. It is a generally
accepted fact that such cells are inherently difficult to transfect so it was necessary to
seek a transfection method resulting in successful expression of transfected genes.
To try to find such a technique a plasmid containing the easily assayed reporter gene
encoding (3-D-galactosidase (lacZ) was used; successful expression of which
indicated a transfection procedure that might be appropriate for use with the plasmid
containing the NRAMP1 cDNA.
To assay for the presence and expression of the plasmid containing the NRAMP1
cDNA I aimed to design suitable PCR and RT-PCR protocols and to generate
NRAMP1 specific antisera, as no commercially available antisera exist.
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5.2 RESULTS
5.2.1 Information known about the NRAMP1 cDNAs used for
Construction of pClneo/NRAMPI Plasmid
Three cloned NRAMP1 cDNAs were the kind gift of Fumio Kishi. These cDNAs had
been named phNRAMPl (D38171), 5'NRAMP8 (D50402) and 5'NRAMP37
(D50402) and the following information was available.
5.2.1.1 phNRAMPl (D38171)
phNRAMPl (D38171) was cloned in the pUC12 vector and contained 2245bp of
NRAMP1 cDNA sequence, which was provided by Kishi with the cDNA (Appendix
C). Analysis of this cloned NRAMP1 sequence compared with the cDNA sequence
published by Cellier and colleagues (Cellier et al. 1994) showed phNRAMPl lacked
5' sequence data. This missing sequence data included an ATG initiation codon
encoding the first methionine residue resulting in the translated cDNA sequence of
phNRAMPl lacking 52 N terminal amino acid residues. Compared with the full
length sequence (Cellier et al. 1994) phNRAMPl lacked 230bp of 5' sequence.
5.2.1.2 5'NRAMP8 (D50402)
This was the cDNA clone that had been requested from Kishi after analysing the
Genbank entries ofNRAMP1 cDNA sequences registered by his group. D50402 was
entered as the 'human mRNA for NRAMP' and was 2573bp long. However, the
"5'NRAMP8" name of the plasmid I received suggested this may not be the case and
the cloned sequence might not be the full 2573bp entered in Genbank. Additional
diagrammatic information accompanying the three cDNA clones showed the 5'-
RACE strategy used by Kishi to identify the extreme 5' end ofNRAMP1 cDNA and
indicated 5'NRAMP8 and 5'NRAMP37 represented a relatively short length of
sequence with 5'NRAMP8 extending further into the 5' promoter region of
NRAMP1 than 5'NRAMP37. This was consistent with the Genbank D50402 entry
which contained an extra 89bp at the 5' end of the sequence over that of the D50403
entry. However, no information accompanied 5'NRAMP8 about the vector or the
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plasmid size, except for the diagram depicting the insert as much smaller than, and
spanning, the 5' end of the phNRAMPl insert.
5.2.1.3 5'NRAMP37 (D50403)
The D50403 Genbank entry was registered as 2484bp of 'human mRNA for
NRAMP'. However, the information accompanying the 5'NRAMP37 clone showed
it to represent 718bp of sequence cloned in the vector pCRII (Appendix C). As
mentioned in 5.2.1.2, the accompanying diagram of the 5'-RACE strategy was
consistent with an insert much smaller than that of the phNRAMPl plasmid and
more concordant with a size of 718bp. This suggested that the cloned sequence
included 5' sequence of phNRAMPl and additional sequence 5' to this, which was
present in the Genbank D50403 entry. A similar situation was likely to exist for the
5'NRAMP8 plasmid (5.2.1.2),
This fragmented and partially circumspective information about the three cDNAs
clones required their analysis by restriction enzyme digestion to try to determine
which components of the NRAMP1 cDNA sequences entered in the Genbank
database by Kishi they represented, and the orientation of the DNA inserts in the
plasmids. To obtain sufficient plasmid DNA for this analysis XL1 Blue cells were
transformed with the three plasmids (2.17) and maxi preps carried out (2.6.4.3).
5.2.2 Characterisation of NRAMP1 cDNAs
The insert sequence of phNRAMPl and 5'NRAMP37 provided, the Genbank
sequences D38171, D50402 and D50403 and the sequence for the vectors pUC12
and pCRII were used with the Vector NTI software (Infonnax Inc., Maryland USA)
package to identify suitable restriction enzymes to characterise the cDNA clones.
In order to design the restriction enzyme digestions to characterise the plasmids,
initial postulations had to be made on the possible cloning strategies which had been
adopted by Kishi. Therefore, I started by assuming that the cDNA inserts had been
cloned using the vectors' EcoRl sites in the polylinkers, as this is common practice,
particularly when TA cloning methods are used. As no information was available
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regarding the vector which 5'NRAMP8 had been cloned into it was hypothesised
that either pCRII or pUC12 had been used, and most likely pCRII, because of the
similarity of 5'NRAMP8 in name and diagrammatic representation to 5'NRAMP37.
5.2.2.1 phNRAMPI
Two double digests of phNRAMPI were carried out:
Nhel and Xbal: Nhel was expected to cut once in the NRAMP1 insert after base 273
of the accompanying phNRAMPI sequence (Appendix C). Xbal was expected to
cut once in the pUC12 polylinker at position 255 of the vector sequence. As
expected two fragments were obtained from the plasmid. The small fragment was
estimated to be in the region of 300bp consistent with an expected size of about
297bp. It was not possible to accurately determine the size of the large fragment due
to its high molecular weight. Based on sequence information of the pUC12 vector
being 2680bp and the insert being 2245bp this fragment should have been of the
order of 4.6kb.
Nhel and Hindlll. Nhel was expected to cut once in the NRAMP1 insert and Hindlll
was expected to cut once in the vector polylinker at position 276 and also 16 lbp
downstream of the Nhel site in the NRAMP1 insert. Three fragments were released,
as expected. The largest fragment was slightly smaller than the equivalent fragment
generated from the Nhel and Xbal digestion. The smallest fragment was estimated to
be smaller than the 220bp molecular weight standard and the third fragment smaller
than the 364bp molecular weight standard. These latter two fragments were
predicted to be 16lbp and 318bp, respectively.
These results showed the insert had been cloned in a reverse orientation as the Nhel
site was proximal to the Xbal site and, in conjunction with available sequence data,







Figure 5.1 Diagram showing the sizes in bp of fragments of the phNRAMPl
plasmid determined from restriction enzyme digestion and known sequence data.
The Hindlll, Nhel and Xhal sites are shown and the NRAMP1 cDNA insert, with its
5' and 3' ends denoted, is shaded.
5.2.2.2 5'NRAMP8
A double digest with Nhel and Xhal, and single digests with EcoRI and Nsil were
carried out:
Nhel and Xhal
Two fragments were generated when 5'NRAMP8 was digested with Nhel and Xbal.
The smaller fragment ran between the 5117bp and 1018bp molecular weight
standards and was estimated to be approximately 600-700bp. The larger fragment
could not be sized accurately but was smaller than the high molecular weight
fragments generated from the digestions of phNRAMPl, described above.
EcoRI
Two fragments were detected when 5'NRAMP8 was digested with EcoRI. No EcoRI
sites are present in the published NRAMP1 sequence so the sites had to be present
within the vector sequence. pCRII is used as a TA cloning vehicle. When inserted in
this way the cloned DNA is flanked on both sides by EcoRI sites with 15bp of vector
DNA in addition to the cloned DNA between the two sites. It was highly probable
that this was the situation for 5'NRAMP8. Alternatively, the insert could have been
cloned directly using the EcoRI sites in the polylinker, in which case the 1 lbp of
intervening vector sequence would be absent from the plasmid. The smaller of the
two released fragments ran with a slightly higher molecular weight than the smaller
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fragment generated from the Nhel and Xbal digestion and was estimated to be 700-
800bp. The larger fragment ran with a slightly lower molecular weight than the
larger fragment from the Nhel and Xbal digestion.
Taken in conjunction with the likely situation that 5'NRAMP8 consisted of the 5'
region of the D50402 Genbank entry and the results of the 5'NRAMP37 digests
(5.2.2.3), I was able to conclude that the cloned sequence had 5' NRAMP1 sequence
of phNRAMPl which extended at least as far as the Nhel site. The whole insert was
slightly larger than 712bp (the expected size of the equivalent region of the
5'NRAMP37 insert) and the similar size of the smaller fragments released from the
two digests of 5'NRAMP8 implied the insert had been cloned in the reverse
orientation because the Nhel site was distal to the Xbal site.
However, these results did not determine which vector 5'NRAMP8 was cloned in as
pCRII and pUC12, the likely candidates, both have an EcoRI cloning site and neither
has an Nhel site. There was also the possibility that another common vector, pCR2.1,
may have been used to clone 5'NRAMP8 and 5'NRAMP37 because the hand
written-pencilled vector name on the sequence accompanying the latter was rather
indistinct and ambiguous. As pCRII and pCR2.1 can be distinguished by digestion
with Nsil this digestion was carried out to resolve the issue. pCRII has two Nsil sites
flanking the TA cloning site in the vector whereas pCR2.1 only has one site. No Nsil
site exists in the NRAMP1 sequence or pUC12.
Nsil
When 5'NRAMP8 and 5'NRAMP37 were digested with Nsil two fragments were
released from each plasmid, providing evidence that pCRII was the plasmid in which
both cDNAs had been cloned.
A diagrammatic representation of the structure of 5'NRAMP8 is shown in Figure
5.2
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Figure 5.2 Diagram showing the approximate size of the NRAMP1 cDNA insert in
the 5'NRAMP8 plasmid and the position of the EcoRl, Nhel and Xbal restriction
sites. The NRAMP1 cDNA insert, with its 5' and 3' ends denoted, is shaded.
5.2.2.3 5'NRAMP37
As described above for 5'NRAMP8 (5.2.2.2) a double digest with Nhel and Xbal,
and single digests with EcoRl and Nsil were carried out:
Nhel and Xbal
Two fragments were generated when 5'NRAMP8 was digested with Nhel and Xbal.
The smaller fragment ran between the 5117bp and 1018bp molecular weight
standards with a lower molecular weight than the equivalent 5'NRAMP8 fragment
(5.2.2.2) and was estimated to be approximately 600bp. This was consistent with a
calculated size of 615bp, based on the sequence data available. The larger fragment
could not be sized accurately but was expected to be 4015bp. It was of a similar size
to the larger fragment generated from the Nhel and Xbal digestion of 5'NRAMP8
giving an indication of the size of the latter.
EcoRI
Two fragments were detected when 5'NRAMP37 was digested with EcoRl. As
discussed in 5.2.2.2 no EcoRl sites are present in the published NRAMP1 sequence,
hence, the sites had to be present in the vector. The expected size of the fragments
generated from the EcoRl digestion were based on the assumption that a TA cloning
strategy had been employed, as discussed previously (5.2.2.2). The smaller of the
two released fragments ran with a slightly higher molecular weight than the smaller
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fragment generated from the Nhel and Xbal digestion and was estimated to be
between 700bp and 800bp, consistent with a calculated size of 712bp. The larger
fragment ran with a slightly lower molecular weight than the larger fragment from
the Nhel and Xbal digestion. It appeared very similar to the equivalent 5'NRAMP8
fragment and was calculated to be 3918bp.
As for 5'NRAMP8 the similar size of the smaller fragments released from the Nhel
and Xbal double digest and EcoRl single digest showed the insert had been cloned in
the reverse orientation, as the Nhel site was distal to the Xbal site.
As discussed above, when 5'NRAMP37 was digested with Nsil two fragments were
released confirming pCRII was the plasmid used to clone the cDNA (5.2.2.2).
A diagrammatic representation of the structure of 5'NRAMP37 is shown in Figure
Figure 5.3 Diagram showing the sizes in bp of fragments of the 5'NRAMP37
plasmid determined from restriction enzyme digestion and known sequence data.
The EcoRI, Nhel and Xbal sites are shown and the NRAMP1 cDNA insert, with its 5'






5.2.3 Construction of the Whole NRAMP1 cDNA in pUC12
The phNRAMPl plasmid was chosen as the vector in which the entire NRAMP1
cDNA would be constructed with the majority of the cDNA being derived from this
plasmid. 5'NRAMP8 was chosen as the source of 5' sequence to complete the cDNA
because the restriction enzyme characterisation supported this cDNA to have more
5' NRAMP1 sequence than 5'NRAMP37. It is desirable to have the maximum
upstream regulatory elements of genes when attempting to express them in
transfected cells.
To construct the whole cDNA, phNRAMPl and 5'NRAMP8 were digested with
Nhel and Xbal. The smaller 5'NRAMP8 fragment of approximately 700bp contained
the 273bp of sequence excised from phNRAMPl 5' to the Nhel site, present in both
plasmids, plus the additional NRAMP1 sequence lacking in phNRAMPl. This
fragment was ligated into the larger fragment generated from digestion of
phNRAMPl of approximately 4900bp (4902bp) as depicted in Figure 5.4. After
transforming competent XL1 Blue cells with the ligated plasmid DNA, colonies were
analysed for correct orientation and insertion of the DNA fragment and two were
found to be suitable. Nhel and Xbal are isoschizomers though religation ofNhel and
Xbal digested DNA ends can not be redigested with the enzymes enabling
appropriately ligated plasmids to be identified. Clones 1 and 10 released the
appropriate 5'NRAMP8 derived fragment of approximately 700bp and phNRAMPl
derived fragment of approximately 4900bp when digested with Nhel and Xbal.
5.2.4 Cloning NRAMP1 cDNA in pClneo
The pCI-neo mammalian expression vector (Promega, Southampton UK), referred to
as pClneo plasmid, was chosen as a suitable vehicle for overexpression studies in
mammalian cells. The vector carries the human cytomegalovirus (CMV) immediate-
early enhancer/promoter region, to promote constitutive expression of cloned DNA
inserts in mammalian cells, and the neomycin phosphotransferase (neo) gene from
Tn5, under control of the SV40 enhancer and early promoter region, enabling






Figure 5.4 Diagram showing how the whole NRAMP1 cDNA sequence was
constructed in the pUC12 vector. ^ shows the section of phNRAMPl which was
discarded. The Nhel and Xbal sites used are shown. The NRAMP1 sequence was
subsequently cloned into the pCIneo mammalian expression vector as described in
5.2.4,
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The NRAMP1 cDNA sequence in pUC12 was excised using Mscl and Xbal. Xbal
cuts in the vector polylinker proximal to the 5' end of the cDNA insert. The Mscl
site was present at the 3' end of the phNRAMPl sequence 629bp downstream of the
termination codon: thus, all the coding sequence was present in the excised
fragment.
An attempt was made to identify the NRAMP1 polyadenylation signal so that it could
be included in the excised DNA. However, no single site was found with several
possible regions of consensus. As the pCIneo vector contains the SV40 late
polyadenylation signal downstream of the multiple cloning site it was not imperative
for the cloned DNA to have its own polyadenylation site, though it may further
enhance the stability ofRNA transcribed from the plasmid.
The pCI-neo plasmid was digested with Xbal and Smal to linearise it prior to
insertion of the NRAMP1 cDNA. The Xbal site was proximal to the CMV
immediate-early enhancer/promoter and the Smal site was proximal to the SV40 late
polyadenylation signal. Ligation of the Xbal generated end of the plasmid with that
of the cDNA sequence and ligation of the blunt Smal generated end of the plasmid
with the blunt Mscl generated end of the cDNA resulted in the correct orientation of
the insert in the vector. Successful ligations were confirmed by digesting plasmid
DNA from XL1 Blue transformed colonies singly with Kpnl and Nhel. Seven clones
were isolated which generated fragments of the appropriate size, approximately
3.4kb and 4.5kb, when digested with Kpnl. This showed the plasmids contained a
cDNA insert of the expected size. Two of these seven clones were taken for further
analysis and by digesting them with Nhel they were shown to contain the insert in the
correct orientation. The Nhel digestion was expected to generate fragments of 774bp
and 7187bp. The successfully cloned whole NRAMP1 cDNA in the pCIneo plasmid
was named pCIneo/NRAMPl and is referred to in this way throughout the text.
5.2.5 Transfection of Adherent Peripheral Blood Mononuclear Cells
Having constructed the pCIneo/NRAMPl plasmid (5.2.4) a suitable method for
transfecting primary aPBMCs was sought. As described in (5.2.5.2) a variety of
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protocols were attempted using lacZ, encoding (3-D-galactosidase (P-gal), as a
reporter gene.
5.2.5.1 Isolation of Adherent Peripheral Blood Mononuclear Cells (aPBMC)
Adherent peripheral blood mononuclear cells (aPBMC) were successfully isolated
from Buffy Coats and cultured in vitro. The cells had the characteristics and
morphology ofM(j)s and survived in culture for approximately 7-10 days.
5.2.5.2 Transfection with p-D-Galactosidase Plasmid
Several attempts were made to transfect the aPBMCs with a plasmid containing the
P-D-galactosidase (P-gal) encoding gene (Promega, Southampton UK) to determine
if an efficient transfection procedure could be established and adopted for use with
the pCIneo/NRAMPl plasmid. aPBMCs were chosen because 1 wished to study the
effect of overexpression of the NRAMP1 gene in cells which have the phenotype and
capacity to exhibit the characteristics and effects which NRAMP1 overexpression
may result in, and which may be required for the full effect of the gene's activity to
be realised. Expression of the lacZ gene was chosen as a reporter gene for successful
transfection and expression because it is easily assayed using X-gal substrate and
detection of a blue colour in P-gal expressing cells (2.20.2.1).
Lipofectin Reagent
When aPMMCs were treated with twenty four combinations of concentrations of
Lipofectin (4pg, 5p.g, 6pg, 7p.g, 9p.g and llpg) and P-gal plasmid (0.5pg, 0.75p.g,
l.Opg and 1.5pg) and stained for expression of P-gal only a very faint blue colour
was seen in a minority of the cells. The observed faint blue colour was equivocal and
may not have been genuine staining but was more apparent in the wells transfected
with the higher DNA concentrations. There was a dramatic reduction in the number
of adherent cells remaining in the wells of the tissue culture plates after the
transfection and staining procedure. When this transfection and staining for P-gal
expression procedure was repeated negligible blue staining was observed again but
the obvious reduction in confluency of the cells was seen, which had reduced to
about one eighth of that at the start of the transfection.
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Lipofectin/Lipofectamine Reagent Comparison
When aPBMCs were transfected with Lipofectin Reagent, as just described, or
Lipofectamine Reagent (8pg 12pg, 14pg, 18pg and 22pg) with 1.0 or 1.5pg of P-gal
plasmid no blue stained cells were observed in the Lipofectin Reagent transfected
cells. During the washing stages after the transfection and during the staining
procedure any de-adhered cells were collected to determine if these cells had been
successfully transfected. None of the de-adhered cells showed a blue colour after
staining for p-gal expression. After transfection with Lipofectamine Reagent the cell
confluency and morphology was similar to that at the start of the experiment. No
bright blue cells were visible after staining for P-gal expression though the wells
containing cells transfected with 12pg/ml and 14pg/ml Lipofectamine Reagent
contained a low level of very pale blue cells, visible when the objective lens control
of the microscope was racked up and down. It is not known if this represented
genuine weak expression of P-gal or was an artefact.
DOSPER Liposomal Transfection Reagent
When aPMMCs were treated with twenty four combinations of DOSPER (3pg,
4.5pg, 6pg, 9pg, 12pg and 15pg) and P-gal plasmid (0.5pg, 0.75pg, l.Opg and
1.5pg) and stained for expression of P-gal no blue cells were visible. The majority of
cells remained adherent throughout the procedure and the few cells which had de-
adhered and been collected were also negative for P-gal expression.
SuperFect Transfection Reagent
When aPMMCs were treated with twenty four combinations of SuperFect Reagent
(9pg, 15pg, 21pg, 27pg, 36p.g and 45pg) and P-gal plasmid (0.5, 0.75, 1.0 and
1.5pig) and stained for expression of P-gal no blue cells were seen. The cells had an
unhealthy appearance and looked smaller and "caving in".
Diethylaminoethyl dextran (DEAE Dextran)
It has been reported that higher transfection efficiencies of murine peritoneal M(j)S
were obtained using a diethylaminoethyl dextran (DEAE dextran) approach
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compared with Lipofectin Reagent or calcium-phosphate protocols (Rupprecht and
Coleman 1991) so this method was tried on the human aPBMCs. Cells were
transfected with 5pg, lOpg, 15pg or 20pg P-gal plasmid DNA after pre-incubation in
20% or 5% heat treated NHS, with and without osmotic shock with 10% DMSO or
glycerol shock after transfection. Transfection of the cells pre-incubated in 20%
serum was carried out in the presence or absence of heat treated NHS while cells
incubated in 5% serum were only transfected in 5% serum. In three of the twenty-
four wells representing the different combinations of conditions a few strongly blue
stained cells were seen after assaying for P-gal expression. Of the cells pre-incubated
with 20% NHS, transfected in the presence of 5% NHS with 5pg DNA, without any
shock treatment, at least one strongly and two weakly stained cells were seen. A
weakly stained cell was seen in the well receiving the above treatment but
transfected with lOjag DNA. Several strongly stained cells were seen in the cells
which were pre-treated with 5% NHS and transfected with 20pg of DNA without
DMSO osmotic shock. All the remaining wells showed no sign of successful
transfection.
Though transfection of aPBMCs using DEAE-dextran showed a few cells expressing
P-gal the level of transfection was far too low to be used successfully to study the
effect of NRAMP1 overexpression in these cells. I, therefore, decided to try to
transfect the MM6 and U937 cell lines.
5.2.6 Transient Transfection of the U937 Cell Line
The level of efficiency of transfection using any of the methods attempted (5.2.5.2)
was insufficient for analysing the effect of expression of any gene of interest in
primary cultures of aPBMCs. As an alternative transfection of cell lines of
monocyte/M<j) lineage was attempted. Though less physiological than primary
cultures of aPBMCs the U937 and MM6 cell lines represent cells whose phenotype
of monocyte/M(|) related activities could be compared with their pCIneo/NRAMP 1
transfected counterparts. MM6 is a monocytic cell line which was established from
peripheral blood of a 64 year old male patient with monoblastic leukaemia. The cell
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line exhibits phenotypic and functional features of mature monocytes (Ziegler-
Heitbrock et al. 1988; Cytokines Online Pathfinder Encyclopaedia web site). U937 is
a cell line established from a diffuse histiocytic lymphoma of a 37 year old male
patient and displays many monocytic characteristics (Cytokines Online Pathfinder
Encyclopaedia web site).
Successful transfection by electroporation of U937 cells has been reported (Hewison
et al. 1994; Zhang et al. 1994b; Dobrescu et al. 1995; Rhoades et al. 1995) and a
similar protocol was followed, electroporating the cells with equal quantities of
circular or linearised p-gal plasmid, to determine if the circular DNA was more
resistant to endogenous exonucleases within the cells. Personal communication with
fellow colleagues highlighted the difficulties that may be encountered when
attempting to transfect monocyte/Mcj) cell lines. It is possible that the low efficiency
of such transfections results from the cells' innate degradative activity of
phagocytosed and internalised material. I successfully electroporated U937 cells with
circular P-gal plasmid DNA, assayed by DetectaGene Green CMFDG using a flow
cytometry read out (2.20.2). The events were gated to exclude dead cells on the
basis of forward and side scatter and propidium iodide positivity. A significant shift
in the fluorescein peak (p-gal expressing cells) was observed in cells electroporated
with the circular plasmid (Figure 5.5). 95.5% of the gated viable cell population
showed a positive fluorescein signal with a mean fluorescence signal of 2.4. Of the
cells electroporated with the linearised DNA a much smaller shift in the mean
fluorescence intensity to 0.7 was seen. Compared to the controls, where cells were
electroporated in the absence of DNA (mean fluorescence intensity of 0.6) or were
not electroporated (mean fluorescence intensity of 0.5), the increase in the
fluorescein signal of the cells electroporated with the linearised plasmid was not
significant. Events gated for propidium iodide positivity showed a significant
increase in positive cells in the electroporated samples. Cells electroporated with
circular plasmid, with linearised plasmid and in the absence ofDNA showed 21.5%,
19.7% and 17.2% propidium iodide positive cells, respectively, contrasting with
3.1% for the cells which were not electroporated. These results suggested that the
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efficiency of transfection of cell lines of monocyte/M<)) lineage by electroporation is
dramatically increased when the plasmid DNA is not linearised prior to transfection.
The act of electroporation induces a significant amount of cell death regardless of
the presence or absence ofDNA.
SINGLE PARAMETER
Log fluorescence
Figure 5.5 showing the shift in the fluorescence intensity for events, gated to
exclude propidium iodide positivity, for cells electroporated with circular (green) or
linearised (red) (3-gal plasmid DNA, cells electroporated in the absence of DNA
(blue) and cells not electroporated (grey), assayed by DetectaGene Green CMFDG
and flow cytometry as described in 2.20.1 and 2.20.2.2,
5.2.7 Stable Transfection of MM6 and U937 Cell Lines with the
pClneo/NRAMPI Plasmid and Generation of Clones
5.2.7.1 Stable Transfection of MM6 and U937 Cell Lines with the
pClneo/NRAMPI Plasmid
All transfections of the MM6 and U937 cell lines were carried out using circular
plasmid DNA based on results of the transient transfection with the J3-gal plasmid
(5.2.6). Each cell line was electroporated with the pClneo/NRAMPI plasmid and
the control pCIneo vector lacking the NRAMP1 cDNA. Due to the lack of success in
generating specific anti-NRAMPl sera (5.2.9) successful transfection was
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determined by analysing genomic DNA by PCR for the presence of the plasmid
DNA in question and expression of the plasmid sequence was analysed by semi-
quantative RT-PCR. Single cell clones of stable transfectants were sought to give a
homogeneous population of long lasting cells that could be used for functional
studies.
5.2.7.2 Generation of Clones of MM6 and U937 Transfectants by Limiting
Dilution




where m is the average number of cells per well and x is the occupancy number of a
well (Wardlaw 1992).
Ideally, if time had allowed, the limiting dilution and clonal selection would have
been repeated at least once more to increase the likelihood of cells selected from a
single well being truly clonal. Cell populations which had been assayed by PCR
(5.2.8.1) and RT-PCR (5.2.8.2) and determined to contain cells successfully
transfected with and expressing the plasmid DNA were used as the source of cells
from which clones were derived. "Clones" were selected from wells which showed
signs of cell proliferation. Wells were carefully selected, avoiding any which showed
evidence of poor cell proliferation or in which the cells' distribution suggested they
may have originated from more than one region within the well. The cells were
chosen from wells which were showing yellowing of the culture medium, indicating
active cellular metabolism, and in which the clonal proliferation appeared to
originate from one region at the outer edge of the well. Of these clones, genomic
analysis for the presence of the plasmid of interest (5.2.8.1) and appropriate gene
expression (5.2.8.2) was carried out.
For the MM6 cells electroporated with the pCIneo/NRAMPl plasmid, five 96 well
plates were prepared for each of five mixed cell populations from five wells of cells
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cultured in a six well plate. Seventeen of these clones were selected, as described
above, and sequentially transferred to 24 well plates, 6 well plates, small and then
medium tissue culture flasks. Clones were discarded which failed to proliferate or
which failed the genomic DNA and RT-PCR analysis for presence and expression of
the plasmid, leaving four clones for analysis of the effect of NRAMP1
overexpression. These clones were identified as D12, B4, B6 and F12 (Appendix
D).
A similar selection process for cloning the MM6 cells electroporated with the control
pCIneo plasmid involved plating five 96 well plates for the limiting dilution for each
of five mixed cell populations from five wells of a six well plate. Twenty-four clones
were selected and transferred to 24 well plates of which cells from nine wells were
cultured on to small flasks and eight on to medium flasks. Six of these clones
showed the presence of the plasmid DNA at the genomic level by PCR and
expression of the neo gene by RT-PCR and were selected as suitable control
transfectants. These clones were identified as M/pB2, M/pB10, M/pC6, M/pF2, M/p
F7, and M/pG3 (Appendix D).
For the U937 cells electroporated with the pCIneo/NRAMPl plasmid five 96 well
plates were prepared by limiting dilution for each of four mixed cell populations
from four wells of cells cultured in a six well plate. Forty-seven clones were
transferred to 24 well plates and cells from twenty-three of these to six well plates.
PCR analysis identified thirteen of these clones to be positive for PCRs showing
presence of the plasmid and five of these were selected as suitable for NRAMP1
overexpression studies on the basis of their gene expression profiles determined by
RT-PCR. These clones were identified as 2, 4, 5, 18 and 27 (Appendix D).
For the U937 control cells, electroporated with the pCIneo plasmid, clones were
selected by limiting dilution from five 96 well plates prepared from a single mixed
cell population. Seventeen clones were transferred to 24 well plates, cells from
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eleven of these wells were transferred to small flasks and PCR analysis showed ten
of them to contain the plasmid sequence. One of these was selected as a control
clone which showed the appropriate gene expression profile and was identified as 39
(Appendix D).
5.2.8 Characterisation of MM6 and U937 Cells Transfected with the
pClneo/NRAMPI and pClneo Plasmids
5.2.8.1 Detection of Plasmid DNA in G418 Resistant Cells
All DNA extracted from transfected cells was positive for the NRAMPpol PCR used
for the NRAMP1 5' promoter region polymorphism analysis described in 2.8.1 and
4.2.1 (Figure 5.6a). This PCR acted as a positive control to show genomic DNA
had been successfully extracted. NRAMPalu PCRs were positive for genomic
template DNA from cells successfully transfected with the pClneo/NRAMPI
plasmid (Figure 5.6b and Figure 5.7b). As these primers were designed for
detection of expression of the mature spliced NRAMP1 mRNA message by RT-PCR
they were suitable for detection of the presence of the pClneo/NRAMPI plasmid
which contained the NRAMP1 cDNA sequence. Successful transfectants also gave a
positive reaction with the NRAMPRalu and pCIneoF primers, referred to as NRpCI
and described in 2.8.4 (Figure 5.7a). The latter primer was designed to
discriminate between expression from the endogenous NRAMP1 gene and the
plasmid sequence, but acted as additional evidence for presence of the
pCIneo/NRAMP 1 plasmid in transfectants and showed the 5' region of the sequence
was intact. In addition to detection of the NRAMP1 cDNA sequence in successful
transfectants the presence of the plasmid neo gene sequence was demonstrated by
two PCRs referred to as neoFl (Figure 5.8a) and neoFexp (Figure 5.8b). All
successful transfectants gave products of the appropriate size for these PCRs. The
design of these primers is detailed in 2.8.5 and 2.8.6
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Figure 5.6 a) NRAMPpol and b) NRAMPalu PCR products amplified from
genomic DNA extracted from the parent cell line (lane 1) and cells transfected with
the pCIneo/NRAMP 1 plasmid (lanes 1-6). Lanes 7 and 8 show positive and negative
control reactions, respectively. Molecular weight marker, with sizes shown in bp,
was run in the left hand lanes. For details of NRAMPpol and NRAMPalu primers











Figure 5.7 a) NRpCI and b) NRAMPalu PCR products amplified from genomic
DNA extracted from cells transfected with the pCIneo/NRAMPl plasmid (lanes 1-
6), the parent cell line (lane 7) and control cells transfected the pCIneo vector (lane
8). Lanes 9 and 10 show positive and negative control reactions, respectively.
Molecular weight marker, with sizes shown in bp, was run in the left hand lanes. For
details of NRpCI and NRAMPalu primers and transfectants see 2.8.4, 2.8.3, 5.2.7
and 5.2.8
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Figure 5.8 a) neoFl and b) neoFexp PCR products amplified from genomic DNA
extracted from cells transfected with the pCIneo/NRAMPl plasmid or pCIneo
vector. Molecular weight maker, with sizes shown in bp, was run in the left hand
lane. For details of neoFl and neoFexp primers and transfectants see 2.8.5, 2.8.6,
5.2.7 and 5.2.8
5.2.8.2 Detection of Expression of Plasmid Derived NRAMP1 Sequence
Analysis of the expression of endogenous and plasmid derived DNA sequences,
assayed by RT-PCR, showed a positive result for the GAPDH PCR for all clones.
This PCR acted as a positive control for successful generation of cDNA. Though all
RNA samples were DNase treated prior to the RT reaction, samples were checked to
ensure no contaminating genomic or plasmid DNA was present in the cDNAs. Any
samples that gave a positive result with the neoFl PCRs, designed to detect
untranscribed plasmid sequence (described in 2.8.5), were repeated and eliminated
where necessary. NRAMPalu, NRpCI and neoFexp PCRs were positive in clones of
successful pCIneo/NRAMPl transfectants and NRAMPalu and neoFexp PCRs were
positive in the vector transfected control clones. Clones successfully transfected with
the pCIneo/NRAMPl plasmid and pCIneo plasmid had the profile shown in Table
5.1
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Table 5.1 The profile of cells successfully transfected with the pCIneo/NRAMPl
plasmid (pCI/NRAMPl transfectant) and pCIneo plasmid (pCIneo transfectant)
for PCR analysis of genomic DNA (gDNA) and RT-PCR analysis of cDNA. Design
of the primers and PCRs (NRAMPpol, GAPDH, NRAMPalu, NRpCI, neoFl and
neoFexp) is described in 2.8. + denotes a positive PCR/RT-PCR result. - denotes a
negative PCR/RT-PCR result.
5.2.8.3 Semi-Quantitative Analysis of NRAMP1 Expression
For semi-quantitative gene expression analysis of the transfected clones by RT-PCR
the samples being analysed were taken through the whole procedure in parallel to
eliminate as many potential inter-sample variations as possible. The GAPDH PCR
was used as a standard housekeeping gene whose level of expression was compared
with that of the PCR product in question by measuring the intensity of the signal of
the PCR products by densitometry. As the products for the complete RT-PCR
analysis from only three or four cDNA samples could be loaded on any one row of
the agarose gels a comparison of every sample's GAPDH level with that of all the
other samples could not be carried out. To obtain some level of inter-sample
GAPDH expression comparison a ratio of the intensities of the GAPDH products for
the samples run on the same row of each gel was calculated. Clones of successful
pCIneo/NRAMPl transfectants showed a variation in the level of plasmid encoded
NRAMP1 and neo expression. When repeated analyses of the clones of interest were
carried out, particular clones consistently showed the highest levels of expression.
An example of a gel from which the intensity of the RT-PCR products of interest
(namely NRAMPalu, NRpCI and neoFexp) relative to GAPDH was determined is
shown in Figure 5.9, with the results depicted graphically in Figure 5.10.
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Figure 5.9 RT-PCR mRNA expression analysis of parent cell line MM6 and
transfected clones. Lanes 1a-1e: pCIneo vector transfected clone; lanes 2a-2e:
parent MM6 cells; lanes 3a-3e: pCIneo/NRAMPl plasmid transfected clone F12;
lanes 4a-4e: pCIneo/NRAMP 1 plasmid transfected clone B4. a: GAPDH, b:
NRAMPalu, C: NRpCI, d: neoFexp, e: neoFl RT-PCR products. Molecular weight
marker, with sizes shown in bp, was run in the right hand lane. For details of PCR
primers and transfected clones see 2.8, 5.2.7 and 5.2.8
The MM6 derived pCIneo/NRAMP 1 plasmid transfected clone named D12
consistently showed the highest level of expression of plasmid encoded NRAMP1
sequence as shown by the high NRpCI to GAPDPI product ratio (Figure 5.10). The
F12, B4 and B6 clones also showed expression but at a lower level. The relative
NRAMPalu product intensity was also increased in these clones when compared
with that of the parent cell line. D12 was the pCIneo/NRAMPl transfected clone of
particular interest during investigation of the possible effects of NRAMPl
overexpression.
Of the U937 transfectants at least fifteen clones were identified which exhibited
plasmid derived NRAMPl expression. Nine of these were considered to show high
levels of expression but unfortunately, for some of these clones, on one out of the
several repeated RT-PCR assays the DNase treated cDNA gave a product with the
neoFl PCR. This suggested carry through plasmid DNA was present in the cDNA. In
these cases it was not possible to determine how much of the NRpCI signal was due
to expression of the plasmid sequence and how much due to plasmid DNA carry
through. These clones require further analysis to determine whether they are
genuinely expressing high levels of pCIneo/NRAMP 1 encoded NRAMPl. At present
at least three clones appear to be doing so, identified as clones 2, 5 and 18 and a
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For both the MM6 and U937 cells transfected with the control pCIneo plasmid many
clones were successfully isolated and analysed as described in 5.2.7.2, As
mentioned previously, the levels of the neo sequence expressed in the
pCIneo/NRAMPl plasmid transfected clones varied and the significance or impact
this heterogeneity may have on the cells is not known. There did not appear to be
consistent high expression of neo accompanying high expression of NRAMP1 in
pCIneo/NRAMP 1 transfectants, but for experiments looking at functional or
phenotypic effects ofNRAMP1 overexpression control pCIneo plasmid transfectants
were chosen which expressed similar levels of neo to the pCIneo/NRAMPl
transfectants being analysed.
5.2.8.4 Morphology of Transfected Cells
Examination of pCIneo/NRAMP 1 transfectants under light microscopy and
monitoring cell proliferation showed no obvious detrimental effect to survival of the
cells. The MM6 parent cell line shows significant polyploidy, anuploidy and often
multinuclear cells that were much larger than mononuclear cells. These
characteristics were also apparent in cultures of the MM6 derived transfectants but
the frequency of massive cells with more than one nucleus appeared greater when
the D12 clone was examined in close detail. It is not known if this was an effect of
the electroporation procedure, the presence and expression of plasmid DNA or the
rate of growth of the cells. It is possible these large multinuclear cells are the result
ofmultiple rounds of proliferation and mitosis and as the cells age mitosis proceeds
with defective cytokinesis. The D12 cells may have been cycling at an increased rate
when analysed.
5.2.8.5 Immunocytochemistry using Sera from Rabbits Immunised with an
NRAMP1 Peptide
Despite evidence at the genomic and cDNA level of the presence and expression of
pCIneo/NRAMPl plasmid encoded sequence, I had no way of showing NRAMP1
overexpression at the protein level in the transfected clones. Though attempts to
show NRAMP1 peptide specificity of sera from rabbits immunised with an
NRAMP1 peptide were unsuccessful (5.2.9), the sera were tested on cytospins
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prepared from MM6 cells, U937 cells, two MM6 and three U937 derived clones
transfected with the pCIneo/NRAMP 1 plasmid and one MM6 and one U937 derived
clone transfected with the control pCIneo plasmid. A membrane-staining pattern was
observed in a subset of cells of the cytospins. However, this pattern was also seen in
cells treated with the pre-immmune rabbit sera and was, therefore, not specific for
NRAMP1. The antigen(s) the sera reacted with is not known but could potentially be
an Fc receptor interaction, with differential expression of these receptors accounting
for only a subset of cells exhibiting the membrane-staining pattern.
5.2.9 Generation and Testing of Serum from Animals Immunised with
an NRAMP1 Peptide
No antiserum to human or murine NRAMP1 was commercially available, so
attempts were made to generate Abs specific for human NRAMP1. Previous
attempts in the laboratory raising Abs against low molecular weight synthetic
peptides had been successful so a similar approach was followed. Each
immunisation procedure adopted will be described and their results presented in
turn, though some were carried out simultaneously or were dependent on material or
results from another procedure. The methods for the peptide preparations are
described in 2.3.1-2.3.7,
5.2.9.1 Immunisation of BALB/c Mice using Imject Alum as Adjuvant
Five female BALB/C mice, over 10 weeks of age, were immunised (2.3.8) as









lOpg peptide i.p. in Imject Alum (2.3.2)
10pg peptide i.p. in PBS (2.3.1)
lOpg peptide i.p. in PBS (2.3.1)
7.5jug peptide i.p. in Imject Alum (2.3.2)
ELISA to test first test bleed (2.5.2)
lOpg peptide i.p. with nitrocellulose (2.3.3)
ELISA to test second test bleed (2.5.2)
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Day 37 ELISA (First bleed test)
There was little evidence of an anti-NRAMPl peptide Ab response in the immunised
mice compared to the NMS control when the sera were tested by ELISA. At 1/50 and
1/150 dilutions of sera from the immunised mice in wells coated with 4.0pg/ml and
8.0pg/ml peptide there was a slight, approximately 1.5 to 2 fold, increase in the
absorbance measured. However, this finding did not extend to the wells coated with
lower peptide concentrations or the more dilute sera samples tested. The absorbance
readings of the wells that had not been coated with peptide were similar to, or in
some instances greater than, those of wells coated with peptide, which showed this
negative control was not working appropriately.
Due to the low or negligible response mounted in the immunised mice, they were
immunised with a peptide/nitrocellulose mixture 38 days after the initial
immunisation, in the hope that the nitrocellulose would act as a more effective
adjuvant.
Day 51 ELISA (Second bleed test)
A similar result to the Day 37 ELISA was obtained with the lowest sera dilutions and
highest peptide coating concentrations giving the highest absorbance readings.
However, these were still only approximately 1.5 to 2 fold greater than the NMS
controls. The wells that had not been coated with peptide still showed absorbencies
of a similar order of magnitude to those coated with peptide. This may have been
due to the carbonate/bicarbonate buffer added at the peptide coating stage, which
was used to dilute the peptide and increase the adherence of the peptide to the plate.
When the mouse sera was subsequently added to the wells, the effect of the
carbonate/bicarbonate buffer might be increasing non-specific adherence of the sera.
Because the wells which were not coated with peptide were proving unsuitable as a
negative control and no positive control anti-NRAMPl sera was available, it was
decided that future sera samples would be tested using dot blots.
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Dot Blots
When the second bleed serum was tested alongside subsequent sera samples, to be
described in 5.2.9.2 and 5.2.9.3, there was no difference in the reactivity of this
serum to any of the test substances on the dot blots when compared to the reactivity
of the NMS (Figure 5.11).
5.2.9.2 Immunisation of BALB/c Mice with NRAMP1 Peptide-Pulsed Dendritic
Cells
As the DC is the most potent and efficient APC I attempted to isolate DCs from the
spleens of the BALB/c mice immunised with NRAMP1 peptide, described in
5.2.9.1. These cells were subsequently pulsed with the peptide in vitro and injected
i.v. (2.3.8) into four female BALB/c mice, over 10 weeks of age. By loading the DCs
with the peptide prior to injection it was hoped they would act as efficient APCs in
vivo, presenting the NRAMP1 peptide to T cells which would initiate an effective
anti-peptide response and provide T cell help for a B cell anti-peptide Ab response.
Day 0 4.35 x 103 peptide-pulsed DCs injected i.v. (2.3.4)
Day 13 lOpg peptide i.p. in Imject Alum (2.3.2)
Day 28 lOpg peptide i.p. in PBS (2.3.1)
Day 60 lOpg peptide i.p. in PBS (2.3.1)
Day 69 Dot blots to test first test bleed (sera at 1:100) (2.4.4)
Day 96 10pgNRAMPl/KLH conjugate in PBS (2.3.5)
Day 107 Dot blots to test second test bleed (sera at 1:100) (2.4.4)
Day 69 Dot Blots (First Bleed Test)
Dot blots were performed using pooled sera from the NRAMP1 peptide-pulsed DC
immunised mice, NMS and omitting mouse sera to test for reactivity against the
NRAMP1 peptide, NRAMP1/KLH conjugate, KLH, BALB/c IgG, BSA and NRS.
No Ab response against the NRAMP1 peptide was seen in the developed dot blots
testing the sera from mice immunised with the NRAMP1 peptide-pulsed DCs or
225
NMS (Figure 5.11). This implied the immunised animals had failed to mount an
appropriate B cell response against the peptide. A weak positive reaction against the
KLH dot and a very weak positive reaction against the NRAMP1/KLH conjugate was
seen with the immunised sera and the NMS which was likely to be due to the
presence of pre-existing Abs cross reactive with epitopes of the KLH molecule
(Figure 5.11). A strong blue dot was seen for the BALB/c IgG positive control dot
for all the mouse sera tested and the negative control incubated without mouse serum
demonstrating the anti-mouse Ig detection method had been carried out successfully
(Figure 5.11). The negative control strip was negative for all the other dots except
for a virtually negligible response against the KLH dot, which may be due to the
presence of pre-existing Abs in the secondary, rabbit anti-mouse sera, cross reactive
with KLH epitopes (Figure 5.11). The NRS dot was negative in all the blots as
expected (Figure 5.11). Interestingly a response was observed against the BSA dot
when the immunised sera were tested which was absent in the control dot blot tested
with NMS (Figure 5.11). This response must have been mounted against residual
FCS, containing BSA, in the DC preparation after the in vitro culture and showed
that these mice were capable of mounting an Ab response.
As all the mice to date had failed to mount an appropriate response against the
NRAMP1 peptide when it was given with Imject Alum or nitrocellulose adjuvant
and boosted in PBS, or when the mice were immunised with DCs which had been
pulsed with the peptide, an attempt was made to conjugate the peptide to KLH. KLH
acts as a carrier protein for peptides and stimulates an immune response against KLH
which can spread to and enhance a response against small, attached peptides which
on their own are non-immunogenic. Peptides are most easily and efficiently
conjugated by terminal cysteine residues but the NRAMP1 peptide did not have such
a residue. Instead the peptide was conjugated to KLH via NH2 amino groups using
DMS (2.3.5). The five BALB/c mice, previously unresponsive to the peptide-pulsed
DCs were immunised with the KLH conjugated peptide in PBS and a second bleed








Figure 5.11 Dot blots to test reactivity of mouse sera. Blots were incubated with 1
sera from mice immunised with the NRAMP1 peptide with Imject Alum and
nitrcellulose as adjuvant, 2 sera from mice immunised with NRAMP1 peptide-
pulsed DCs, 3 sera from mice immunised with the NRAMP1/KLH conjugate, 4
NMS, 5 no primary sera. A diagram showing the position of the dots of test
substances on the strips is shown to the right hand side. KLH: Keyhole limpet
haemocyanin, BALB/c IgG: control IgG from BALB/c mice, BSA: bovine serum
albumin, NRS: normal rabbit sera. Immunisation protocols are described in 5.2.9.1-
5.2.9.3
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Figure 5.12 Dot blots to test reactivity of rabbit sera. Blots were incubated with
pre-immune sera from rabbits 1 5IFF and 2 62FF, sera from rabbits 3 5IFF and 4
62FF after immunisation with NRAMP1 peptide/KLFI conjugate or 5 no primary
sera. A diagram showing the position of dots of test substances on the strips is shown
to the right hand side KLH: Keyhole limpet haemocyanin, BALB/c IgG: control IgG
from BALB/c mice, BSA: bovine serum albumin, NRS: normal rabbit sera. The
immunisation protocol is described in 5.2.9.5,
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Day 107 Dot Blots (Second Bleed Test)
Blots were performed to test the pooled sera from mice immunised with the
NRAMP1 peptide-pulsed DCs followed by the NRAMP1/KLH conjugate, NMS or
omitting mouse sera.
No Ab response against the NRAMP1 peptide was seen in the developed dot blots
testing the sera from any of the groups. The results of the NMS were as for the Day
69 dot blot (Figure 5.11) with the exception that a faint blue colour was seen over
the NRS dot. This was also seen with the sera from mice immunised with the
NRAMP1 peptide-pulsed DCs followed by the NRAMP1/KLH conjugate, and is
likely to be due to the presence of mouse anti-rabbit Abs which became detectable
when the blots were developed for slightly longer than in the previous analysis. The
results of the rest of the blot for the immunised sera were also as for the Day 69 blot
(Figure 5.11), except for an increase in the response against dots containing KLH.
This showed the mice had successfully mounted an Ab response against the KLH
component of the conjugate with which they had been immunised. The results for
the negative control strip incubated without mouse sera were as for the Day 69 dot
blot (Figure 5.11).
5.2.9.3 Immunisation of BALB/c Mice with the NRAMP1 peptide/KLH
Conjugate
The NRAMP1 peptide/KLH conjugate previously discussed (5.2.9.2) was used as an
immunogen with Imject Alum as an adjuvant to immunise five 8 week old, female,
BALB/c mice according to the following protocol.
Day 0 8-9pg NRAMP1/KLH conjugate in Imject Alum i.p.
(2.3.5)
Day 28 10pg NRAMP1/KLH conjugate in Imject Alum i.p.
(2.3.5 and 2.3.1)
Day 40 Dot blots to test first test bleed (sera at 1:100) (2.4.4)
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Day 67 lOpg NRAMP1/KLH conjugate and lOgig peptide in
PBS i.p. (2.3.5 and 2.3.1)
Day 78 Dot blots to test second test bleed (sera at 1:100) (2.4.4)
Day 40 Dot Blots (First Bleed Test)
The pooled sera from the first test bleeds from the mice immunised with the
NRAMP1/KLH conjugate were tested alongside the Day 69 dot blots described in
5.2.9.2, therefore, the NMS and negative control results have been outlined. The
sera from the NRAMP1/KLH conjugate immunised mice failed to show any Ab
response against the NRAMP1 peptide dot but a strong reaction against the KLH and
NRAMP1 peptide/KLH dots was seen (Figure 5.11). This implied a successful Ab
response had been mounted by the mice against the KLH molecule but a response
against the NRAMP1 peptide component of the conjugate could not be detected.
There was no detectable response against the BSA or NRS dots (Figure 5.11). The
positive control BALB/c IgG dot was strongly positive confirming the successful
detection method for the murine Igs (Figure 5.11).
The mice had already received two immunisations with the NRAMP1/KLH
conjugate in Imject Alum so, despite none of the animals showing any adverse
effects of the immunisations, the final immunisation was carried out without the
adjuvant. Because the mice had mounted such a strong response against the KLH
component of the conjugate the final immunisation of this group of mice consisted
of a mixture of the conjugate, to increase the immunogenicity of the peptide, and the
NRAMP1 peptide alone, to increase the relative concentration of the component
against which a response was desired.
Day 78 Dot Blots (Second Bleed Test)
The results of the dot blots to test the second test bleed for the pooled sera from mice
immunised with the NRAMP1/KLH conjugate were similar to those of the first test
bleed for this group ofmice. The only difference was a slight increase in the relative
intensity of the response to the dots with a KLH component compared to the BALB/c
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IgG dot, as might be expected after the booster immunisation. A very weak colour
was seen over the NRS dot implying the presence of anti-rabbit Abs in the mouse
sera tested. This was also seen in the other groups of murine sera tested and was not
a result of the immunisation procedures. No detectable Ab response was seen against
the NRAMP1 peptide or the BSA dot in any of the groups of mice tested. The
negative control blot incubated without mouse sera showed a positive result for the
BALB/c IgG dot, confirming the anti-mouse Ig detection method had been
successful, and a very weak blue colour over the dots with a KLH component,
suggesting the presence of Abs in the secondary rabbit anti-mouse Ig which cross
react with KLH epitopes.
5.2.9.4 Immunisation of BALB/c and C57/BI Mice using Freund's Adjuvant
All previous immunisation strategies and adjuvants had failed to generate a
detectable anti-NRAMPl peptide Ab response so it was decided to try an
immunisation protocol using the more potent Freund's adjuvant. Freund's complete
adjuvant (CFA) and Freund's incomplete adjuvant (IFA) have proved highly
effective in stimulating Ab responses against molecules which are non-immunogenic
when given alone. The amount of peptide given to each mouse was also increased to
determine if this might enhance the response.
All the previous immunisations had been carried out on BALB/c mice because
established techniques exist for raising monoclonal Abs from lymphocytes derived
from these mice. However, BALB/c mice carry the susceptibility allele of the murine
nrampl gene and, hence, may have a genetic trait that affects their capacity to
respond to an NRAMP1 peptide. Therefore, I wished to immunise a group of C3H
mice, which carry the resistance nrampl allele, in parallel with a group of BALB/c
mice, to try to eliminate this as a possible reason preventing the desired response.
However, due to shortages in the animal house C3H mice were unavailable so
C57/B1 mice were used instead. These mice also carry the susceptibility nrampl
allele though they have a different H2 haplotype from the BALB/c mice. Three mice







50jug peptide in CFA (1:1) i.p. (2.3.6)
50pg peptide in IFA (1:1) i.p. (2.3.7)
Dot blots to test first test bleed (sera 1:100) (2.4.4)
50pg peptide in IFA (1:1) i.p. (2.3.7)
Dot blots to test second test bleed (sera 1:100) (2.4.4)
Day 25 Dot Blots (First Bleed Test)
Triangular dot blots were performed with test dots of the NRAMP1 peptide, BSA
and BALB/c IgG. The serum samples from each of the six immunised mice and
NMS were tested separately and a negative control blot, incubated without mouse
serum, was included. On all the blots no detectable Ab response was seen against the
NRAMP1 peptide. The BSA dots were all negative except for a very faint reaction
with the serum from one of the C57/B1 mice. All the dot blots showed a strong
positive blue colour over the BALB/c IgG dot confirming the anti-mouse Ig detection
method had worked successfully.
As no detectable Ab response was detected against the peptide, the mice were
immunised again with the peptide in IFA and a second test bleed taken.
Day 55 Dot Blots (Second Bleed Test)
As for the first bleed dot blots no Ab response was detected on any of the dot blots.
All of the serum samples tested, but not the negative control blot, showed a weak
response to the BSA dot, which may reflect a longer development period in the
NBT/BCIP substrate rather than any increased Ab response in the immunised
animals. This is supported by the NMS blot's BSA dot also being weakly positive,
which was not seen when the same serum sample was used as a control when the
first bleeds were tested. The BALB/c IgG dot was positive on all the dot blots,
confirming the anti-mouse Ig detection method had worked successfully.
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5.2.9.5 Immunisation of Rabbits with the NRAMP1//KLH Conjugate
As attempts to raise NRAMP1 peptide-specific Abs in mice had failed, immunisation
of two rabbits with the NRAMP1/KLH conjugate was tried. The rabbit nrampl gene
or protein sequence was not available so the degree of conservation between the
peptide sequence and the equivalent region of the rabbit protein was not known.
Rabbits have previously been immunised successfully with substances that have been
non-immunogenic in mice and they have the advantage that a larger amount of serum
can be obtained from each animal. However, established methods to raise
monoclonals from rabbits are not available. The rabbits were immunised sub
cutaneously (s.c.) at four sites with the NRAMP1/KLH conjugate in the Imject Alum
adjuvant to increase the immunogenicity of the NRAMP1 component. The rabbits
were identified as 62FF and 5IFF and a pre-immune serum sample was collected
from each animal prior to immunisation as outlined below.
Day 0 lOOpg NRAMP1/KLH conjugate in Imject Alum at 4 sites s.c.
Day 40 Dot Blots (First Bleed Test)
Dot blots for the pre-immune and first bleed sera were performed and a negative
control dot blot, incubated without any rabbit serum, was included. None of the blots
showed any detectable Ab response against the NRAMP1 peptide dot. Both of the
pre-immune serum samples showed a weak response against the KLH dot and an
even weaker response against the NRAMP1/KLH conjugate dot. A similar intensity
of blue colour was seen in the dot blot incubated without any rabbit serum,






lOOpg NRAMP1/KLH conjugate in Imject Alum at 4 sites s.c.
(2.3.5 and 2.3.2)
Dot blots to test first test bleed (sera at 1 TOO) (2.4.4)
lOOpg NRAMP1/KLH conjugate and lOOpg peptide in PBS at
4 sites s.c. (2.3.5 and 2.3.1)
Dot blots to test second test bleed (sera at 1:100) (2.4.4)
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rabbit Ig which were cross reactive with KLH epitopes. The intensity of these
responses was greatly increased in the serum samples from the two immunised
rabbits, which showed a successful response had been mounted by both animals to
the KLH component of the immunogen. A response was also seen against the BSA
dot and a weaker response against the BALB/c IgG dot in the serum from immunised
rabbit 5 IFF. The response of serum from immunised rabbit 62FF against the BALB/c
IgG dot was negligible and against the BSA dot was undetectable. The dot blots for
the pre-immune serum from both animals and the negative control blot were all
negative for the BALB/c IgG and BSA dots. All the dot blots gave a positive reaction
for the NRS dot confirming the anti-rabbit Ig detection method had been successful
(Figure 5.12),
The rabbits' Ab response against the KLH component of the conjugate showed they
were capable of mounting Ab responses. In an attempt to extend this response to the
NRAMP1 component of the conjugate, the animals were immunised with a mixture
of the conjugate and the unconjugated peptide. By increasing the concentration of
the peptide in the innoculum, I hoped the desired response against the peptide might
occur.
Day 78 Dot Blots (Second Bleed Test)
The results for all the dots on all of the blots were as described for the Day 40 dot
blots, described above. Where very weak dots had been seen previously these were
stronger because the blots had been developed for a longer time in the NBT/BCIP
chromogen, but no positive reaction against any of the dots previously negative was
seen.
5.2.9.6 Immunocytochemistry on NRAMP1 Transfected Cell Lines
Sera from the rabbits immunised with the NRAMP1 peptide (5.2.9.5) showed no
evidence of specific anti-NRAMPl reactivity when tested on clones of MM6 and
U937 cells which had been transfected with the pCIneo/NRAMPl plasmid and
shown to express the plasmid NRAMP1 sequence at the RNA level (5.2.7-5.2.8),
233
5.3 DISCUSSION
A mammalian expression vector containing the whole NRAMP1 cDNA
(pCIneo/NRAMPl) was successfully constructed from partial NRAMP1 cDNAs in
the pCIneo plasmid. The initial intention to use this as a vehicle for overexpression
of NRAMP1 in primary cultures of aPBMCs was hampered by the failure to find a
means of efficient transfection of these cells. In order to carry out experiments to
assay a physiological effect of NRAMP1 overexpression a reproducible, efficient
transfection procedure was necessary. The liposome based methods I attempted
(Lipofectin Reagent, Lipofectamine Reagent, DOSPER Liposomal Transfection
Reagent and SuperFect Reagent) have been documented by the respective suppliers
for use with many cell lines from a variety of species. However, the data on
successful transfection of primary cell lines is sparser. Such reported successes have
generally used primary fibroblasts, hepatocytes, endothelial cells or smooth muscle
cells and none of the suppliers were able to confirm success using their product for
transfection of primary aPBMCs. Personal communication with other scientists
attempting similar transfections revealed comparable problems were being
encountered. It is interesting to note that these workers also found the most
promising, though still inefficient, results with DEAE-dextran transfection. For
successful transfection genes must be delivered intracellularly, ultimately to the
nucleus, in functional form and retained and expressed therein. Electron microscopy
studies of cationic liposomes alone or complexed with DNA and/or gold particles
have tracked their transit in cultured cells, including a variety of cell lines and
primary human peripheral blood monocytes, primary rat alveolar type II cells and
primary rat alveolar M<j>s (Friend et al. 1996). The results suggest the DNA-cationic
liposome complexes enter the cell in a manner resembling receptor mediated
endocytosis in clathrin coated pits. The complexes were seen in early endosomes,
late endosomes and lysosomes. Some cells showed evidence of gold particles
dispersed through the cytoplasm and a membrane system resembling the ER
developed in the nucleus of some CV-1 (African green monkey kidney) and U937
cells. The authors suggest the DNA complexes are released from the endosomal
compartment and are transferred through the cytoplasm to the nucleus, though, in
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some instances the cationic lipid may react with the nuclear envelope. I have not
tracked the passage and fate of the liposome-DNA complexes used when trying to
transfect my primary aPBMCs and can not confirm or quantitate successful entry of
DNA into the nucleus. The nature of these cells, which are highly efficient at
degrading foreign internalised material, suggests problems in the delivery of intact
DNA are likely. The reported study was looking at transit of the complexes and did
not determine whether the cells successfully expressed the transfected DNA. It
appears that in primary Mijis there are additional problems getting the cells to express
exogenous DNA. Despite evidence of transfected DNA being present in the nucleus
it is common for the DNA to remain unexpressed (personal communication).
Whether this is the result of an inherent aversion to expression of foreign DNA by
cells designed to eradicate pathogens, such as viral particles, is not known but
emphasises the complexity of the problems to be considered. All my attempts at
transfection were carried out with non-linearised plasmid DNA which I found to be
expressed successfully in comparison to linearised DNA when U937 cells were
electroporated and, hence, the DNA should have been more resistant to exonuclease
digestion.
Primary cultures of murine peritoneal M(j>s have been transfected more successfully
with DEAE-dextran, followed by osmotic shock with DMSO, than by a variety of
other protocols, including calcium-phosphate precipitation or lipofection (Rupprecht
and Coleman 1991). Despite finding a few cells which showed expression of the
reporter gene encoding p-gal when I tried to transfect primary aPBMCs under
various DEAE-dextran conditions, the efficiency was still exceedingly low and of no
use for the studies with which I hoped to continue. As my results also showed greater
transfection success using DEAE-dextran rather than lipofection, as this report
found, it appeared unlikely calcium phosphate precipitation would be any more
successful in my system. The decision was, therefore, taken to try to transfect cell
lines with the pCIneo/NRAMP 1 plasmid, rather than persevere further with primary
cultures. It is possible, however, that I might have had more success with particle
bombardment techniques (Burkholder et a/. 1993) but in the light of the lack of anti-
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NRAMP1 antisera which would be necessary for rapid detection of NRAMP1
overexpression to identify successful pCIneo/NRAMPl transient transfectants, stable
transfection seemed more appropriate.
Both MM6 and U937 cell lines were successfully transfected on the basis of the
presence of plasmid DNA in transfected cells, assayed by PCR, and plasmid encoded
expression, assayed by RT-PCR, of NRAMP1 and neo, or neo alone, in the
pCIneo/NRAMPl and pCIneo plasmid transfected cells, respectively. Despite
exhaustive attempts to raise Abs against NRAMP1 in mice and rabbits, I failed to
detect any sera specific for the peptide that was used as an immunogen, and hence
was unable to confirm translation of the NRAMP1 mRNA. It is well documented that
nrampl family members are highly conserved across species (Cellier et al. 1995) and
this may be the reason for the lack of response encountered in the immunised
animals. Where highly homologous proteins exist, tolerance induction to the
endogenous protein of one species may extend to proteins of another species.
Though the sequence of the peptide used as an immunogen was from the region of
greatest divergence between the murine and human proteins significant conservation
still existed. To raise an Ab response both a T cell and B cell epitope are required
and there may have been a shortfall on this account with the NRAMP1 peptide used.
It is not known whether the alternative peptide sequence I considered as an
immunogen, at the N terminus of NRAMP1, may have proved more successful in
generating anti-NRAMPl Abs. The C terminal peptide was chosen in preference for
two reasons. Firstly, it is not known whether the +alu NRAMP1 splice variant is
translated to protein, but if it is, the resultant protein would not be detected by Abs
raised against the C terminal peptide. In contrast, Abs raised against the N terminal
peptide considered could theoretically react with both truncated and full length
protein and, hence, would be uninformative with respect to the levels of full length
functional NRAMP1 protein known to be functional. Secondly, the generation of
polyclonal rabbit sera has been reported which was against a very similar NRAMP1
peptide, conjugated to KLH (Kishi and Nobumoto 1995; Kishi et al. 1996a).
However, in the light of more recent information about the expression pattern,
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localisation and molecular weight of NRAMP1 and nrampl (Atkinson et al. 1997;
Gruenheid et al. 1997) the specificity of this sera is now in question.
Both strains of mice used for the immunisations with the NRAMP1 peptide, BALB/c
and C57B1, carry the nrampl susceptibility allele. As this allele is a null allele and
nrampl protein is undetectable in these mice, the question of tolerance induction
against nrampl is an interesting consideration. In the absence of nrampl protein one
could hypothesise that these animals should not have specific nrampl tolerance and
would, therefore, be an ideal strain in which to raise such a response. However, it is
also possible that there is a level of translation of the mutant mRNA to protein which
is then subsequently degraded due to potential misfolding and recognition by the
cells' protein degradative machinery. In this case one could envisage a system
flooded with nrampl peptides to which the mice could become tolerant. These
potential peptides might encompass the C terminal peptide I used as an immunogen
and, as such, explain the failure to mount an Ab response. Had mice carrying the
resistance allele been available for immunisation, it would have been interesting to
see if these mice were any more responsive to the peptide, though these strains
would be expected to have unequivocal nrampl tolerance. The BALB/c and C57B1
mice carry different H2 haplotypes, but these differences did not appear to influence
the lack of an Ab response against the NRAMP1 peptide. Whether exhaustive
attempts of immunising mice carrying other H2 haplotypes would have been met
with more success remains unclear, though the general lack of success in all the
animals immunised suggests not. Rabbits have been found to be more responsive to
certain antigens which appear non-immunogenic in mice, though in the case of the
NRAMP1 peptide this was not so. It is relevant to point out that Professor Jenefer
Blackwell, the eminent scientist working in the nrampl field in this country, has also
been unsuccessful in raising antisera against human NRAMP1 despite having
antisera reactive against the murine protein (personal communication).
Analysis of the pCIneo/NRAMPl and pCIneo plasmid transfected cell lines was,
therefore, totally reliant on DNA and mRNA analysis. A methodical procedure was
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exercised to identify G418 resistant mixed cell populations which contained the
relevant plasmid DNA, assayed by PCR. Southern blots were considered as an
alternative assay but were rejected in favour of the PCR strategy for a number of
reasons. The plasmids were transfected in a circular form and as such no control was
had over where the DNA would linearise prior to integration into the genomic DNA.
Choosing a region of the plasmid which would be suitable as a probe for all the
clones was, therefore, a problem in case the chosen fragment spanned the point of
linearisation. The NRAMPalu PCR primers I used were conveniently available,
having been designed to detect RNA expression. They were cDNA specific and
would not cross react with the endogenous NRAMP1 gene sequence. Cross-
hybridisation of a probe with the endogenous gene or other homologous NRAMP1
family members was a potential issue if Southern hybridisation had been performed.
Perfecting the stringency to detect only the plasmid DNA might have been
problematic. As I was dealing with large numbers of clones which I wished to screen
rapidly, whose RNA expression profile also needed extensive analysis, PCR was
considered a relatively quick and straightforward procedure in comparison to
Southern blotting. In addition because I designed a variety of primers I had four
reactions for the pCIneo/NRAMPl transfectants and two reactions for the pCIneo
transfectants to confirm presence of the plasmid DNA and, hence, quadruplicate or
duplicate proof.
From the mixed cell populations showing the appropriate PCR and RT-PCR profiles,
single clones were derived on the basis of limiting dilution. Due to time constraints
this process was carried out once for each of the mixed cell populations selected.
Ideally, limiting dilution of the clones derived from the first round would have been
repeated at least twice more to increase the probability of obtaining a genuine clone.
Taking this into consideration the cell samples I have considered as single clones
may actually be derived from more than one founder cell.
The semi-quantitative RT-PCR assay successfully and consistently identified certain
clones as expressing higher or lower levels of the plasmid DNA. The clone
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expressing the highest level ofNRAMP1 was D12, derived from the MM6 parent cell
line. Inclusion of RT-PCR reactions with primers specific for untranscribed plasmid
DNA enabled me to ensure only cDNA sequence, and not carry through plasmid
DNA which had been incompletely DNase-treated, was amplified. Semi-quantitative
RT-PCR approaches have been criticised as being unreliable and open to the
"quirks" of PCR. I did not find this to be a problem because I was not looking for an
absolute quantitative result, which appears a challenging task using a PCR approach,
but only a measure of the relative amount of message of the genes of interest with
respect to the housekeeping GAPDH gene. By measuring the intensity of the product
bands by UV densitometry a relatively simple and reproducible result could be
obtained. Though the ratios for a single clone analysed repeatedly were not identical
the hierarchy of ratios for the different clones consistently identified the same clones
to be expressing the greatest or least amounts of plasmid message. There are several
stages involved in the analysis from extraction ofRNA from the cell lines through to
the final analysis of the electrophoresed RT-PCR products, and hence multiple
opportunities for incorporating error in the samples. However, it is unlikely that the
same clone would be subjected to the same error during every analysis I undertook,
hence, I believe my results are genuine. As mentioned previously I do lack evidence
of translation of the plasmid NRAMP1 mRNA to protein and I have no information
with respect to the cellular localisation of such protein in the transfectants. In
interpreting any results of experiments investigating the effect of NRAMP1
overexpression it is important to acknowledge this short fall. Increased levels of
plasmid-originating NRAMP1 protein directed to the plasma membrane, for
instance, may well cause a measurable physiological effect. However, if the
endogenous protein is targeted to late endosomes/lysosomes (Gruenheid et al. 1997)
the results may be very misleading. Taking this into consideration the tools were now
available to further investigate the effect of overexpression of plasmid derived
NRAMP1 mRNA in clones derived from the MM6 parent cell line.
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5.4 CONCLUSION
I have successfully constructed a mammalian expression vector (pCIneo/NRAMP1)
for overexpression of the human NRAMP1 gene and have transfected the MM6 and
U937 cell lines with this plasmid and the control pCIneo plasmid. I have shown the
presence of plasmid sequence by PCR in G418 resistant transfectants, which were
cloned by limiting dilution, and plasmid encoded mRNA expression by RT-PCR.
Attempts to raise Abs against NRAMP1 were unsuccessful and I found no evidence
of an anti-NRAMPl peptide Ab response in any of the mice or rabbits which had
been immunised with the NRAMP1 peptide using a variety of adjuvants (Imject
Alum, nitrocellulose, CFA, IFA), as peptide alone, conjugated to KLH or given i.v. in
the form of peptide-pulsed DCs. The lack of antisera specific for NRAMP1 meant I
was unable to identify NRAMP1 protein expression patterns or profiles in the parent
and pCIneo/NRAMP 1 transfected cells. Therefore, all expression data for the
NRAMP1 gene was dependent on analysis ofmRNA expression by semi-quantitative
RT-PCR which identified the clone expressing the highest levels of NRAMP1 to be
D12, a MM6 derived transfectant.
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6 FUNCTION OF NRAMP1
6.1 INTRODUCTION
Since the initial identification and cloning of the murine nrampl gene (Vidal et al.
1993) significant light has been shed on the physiological function of the encoded
protein. The majority of information suggesting the protein acts as a divalent cation
transporter was primarily gleaned indirectly from comparison of the function of
homologous proteins from other species including the Drosophila mvl (Orgad et al.
1998), S. cerevisiae SMFJ and SMF2 (Supek et al. 1996 and 1997), O. sativa
Osnramp (Belouchi et al. 1997) and, more recently, the nramp2 (Fleming et al. 1996
and 1997; Nussberger et al. 1997) gene product homologues. Murine and rat nramp2
proteins encode transporter proteins with a broad substrate range for a number of
divalent cations, though they have highest affinity for Fe2+ ions. Mutations in these
genes are responsible for the mk mouse (Fleming et al. 1997) and Belgrade rat
(Fleming et al. 1998) phenotypes which result from defects in iron uptake and
transport. Nrampl and nramp2 proteins are 63% identical (Gruenheid et al. 1995)
and though it is possible, and has been shown to be the case (Atkinson and Barton
1998 and 1999), that the former may also act as an iron transporter there is sufficient
divergence between the proteins to suggest nrampl could have a higher affinity for
another metal ion. Recent reports have focused on the ability of nrampl to transport
iron (Atkinson and Barton 1998 and 1999), but its affinity for Fe2+ has been shown to
be much lower than that of the rat nramp2 protein (Gunshin et al. 1997) which may
be indicative of a function distinct from that of nramp2.
Comparatively little is known about transport mechanisms of manganese in cells
compared with a variety of other metal ions. The suggestion that the mvl gene
product might play an important role in this process (Supek et al. 1996 and 1997)
prompted me to investigate whether NRAMP1 functions as a manganese transporter
protein. I wished to determine whether the cells which I had transfected with the
pCIneo/NRAMPl plasmid (5.2.7 and 5.2.8), designed to overexpress NRAMP1,
behaved differently, compared to their parent cell line, with respect to their cellular
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content of manganese under standard culture conditions or when cultured in
increased Mn2+ concentrations. I addressed this problem by utilising the highly
sensitive inductively coupled plasma mass spectophotometry (ICPMS) system to
measure the levels of a variety of metal isotopes (Mn53, Cu65, Zn66 and Fe37) in
extracts obtained from lysed cells after in vitro culture.
Initial analysis of cells cultured in parallel under standard culture conditions were
performed to determine if the base levels of the metals of interest differed between
the parent cell line and pCIneo/NRAMPl plasmid transfectants. The MM6 parent
cell line and the D12 transfected cell clone, which had been shown by RT-PCR to
express high levels of the plasmid derived NRAMP1 (5.2.8.3), were then analysed
after culture in standard culture medium or medium containing lpM or 10pM
MnCl2.
6.2 RESULTS
6.2.1 Analysis of Cellular Metal Content
The sensitivity of ICPMS necessitated rigorous care being adopted to ensure all
flasks of cells were cultured under the same conditions with media containing the
same content of the metals of interest. Samples of prepared culture media were
routinely analysed to exclude variations in media components contributing to
potential differences in cellular metal content. These checks showed the metal
content of the various media samples to be equivalent and, hence, not a source of
variation in results between the different cell samples.
Extracts from cells, which had been cultured and treated in parallel, were analysed
and the results obtained displayed graphically for comparison. This method of
illustrating the results showed a general trend between samples, which was
reproducible when extracts were reanalysed, though the absolute concentrations may
have varied between separate analyses. For this reason absolute concentrations are
not being quoted in the text and the graphical results represent one of the sets of
results where the same cell extract sample was analysed more than once.
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6.2.2 Metal Content of Cells Cultured under Standard Culture
Conditions
6.2.2.1 MM6 and U937 Parent Cell Lines
When the MM6 and U937 parent cell lines were cultured under standard conditions
(2.18.1) and their Mn, Cu and Zn cellular content measured, a marked difference
was seen in the levels ofMn and Cu between the two cell lines. The MM6 cells had
a higher cellular content ofMn and Cu (Figures 6.1a and 6.1b) but there was no
marked difference in the Zn levels of the two cell lines (Figure 6.1c).
6.2.2.2 MM6, B6, D12 and F12 Cell Lines
When the MM6 parent cell line was compared with the D12 clone, cultured under
standard conditions (2.18.1), it was noted that the absolute concentrations of the
three metals measured varied between separate samples from the same cell
line/clone which were analysed at the same time. The overall pattern did not show a
conclusive elevated level ofMn, Cu or Zn in extracts from either the MM6 or D12
cells (Figures 6.2a, 6.2c and 6.2e). In some of the analyses the D12 cells appeared
to have a slightly elevated Mn content, but this was not seen consistently (Figure
6.2a).
A similar situation existed for the B6 and F12 clones, with cell extracts from neither
clone showing a marked difference in the levels of the metals analysed (Figures
6.2b, 6.2d and 6.2f). The comparison of Cu levels for these cells is shown for
completion. However, one of these readings for the B6 cells appears to be extraneous
and may be the result of an experimental error or Cu contamination at some point in
the procedure (Figure 6.2d).
The MM6 and D12 cells were cultured and analysed in parallel, as were the B6 and
F12 cells. Though I have found it inappropriate to compare absolute values of the
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a)
Figure 6.1 Comparison of the a) Mn, b) Cu and c) Zn content in extracts from MM6 and
U937 cells cultured under standard conditions. The symbols (open diamonds and solid
squares) represent two separate analyses where samples were analysed in parallel. Extracts
from U937 cells have a lower Mn (a) and Cu (b) content compared to the MM6 cell extracts.
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Figure 6.2 Comparison of the Mn (a and b), Cu (c and d) and Zn (e and f) content
in extracts from MM6 and D12 cells (a, c and e) and B6 and F12 cells (b, d and f)
cultured under standard conditions. The symbols represent separate analyses where
samples were analysed in parallel. There is no significant difference in levels of the
metals in the MM6 parent cell line and the D12, B6 and F12 clones of
pCIneo/NRAMPl transfected cells (described in 5.2.7 and 5.2.8). The ICPMS
analysis method used is described in 2.21.
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metal concentrations between cells cultured and analysed at different times the
values obtained for B6 and F12 cells appear to be of the same order of magnitude as
those for the parent MM6 cell line, suggesting there are no obvious variations
between the parent cell line and any of the transfectants analysed (Figure 6.2).
In conclusion, it appears that under standard culture conditions in resting MM6 and
cells transfected with the pCIneo/NRAMPl plasmid there is no significant difference
between the Mn, Cu or Zn cellular content of the cells analysed. This suggests that if
active NRAMP1 protein is being expressed in the transfectants, under standard
culture conditions no effect on transport of these metals is detectable when measured
by the procedure I adopted. Therefore, I wished to investigate if the transfectants
behaved differently when cultured under conditions of increased Mn concentrations,
which may reflect a physiological function for the protein as a putative Mn
transporter protein.
6.2.3 Metal Content of Cells Cultured in Manganese Chloride
Duplicate flasks of MM6 and D12 cells were cultured under standard culture
conditions (2.18.1) or in medium which had been supplemented with lpM or 10p.M
manganese chloride (MnCl2). Prior to setting up these flasks the potential toxicity of
these increased MnCl2 concentrations was checked by comparing the viability of
cells cultured in a range of MnCl2 concentrations with that of cells cultured in
standard medium. No difference in viability was apparent over the range of MnCl2
concentrations tested and it was assumed that at the levels of MnCl2 to be used for
the subsequent experiment there would be no detrimental effect to the health of the
cells. The results of this single experiment were illustrated graphically and will be
discussed in detail in 6.2.3.1-6.2.3.4, The samples were analysed twice and both
analyses gave a similar pattern, though absolute concentrations varied slightly. The
average values of the duplicate samples for each cell line were used when comparing
the concentration change of the metals, and the percentage change of the metal
content of the cells cultured in the different MnCl2 concentrations.
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6.2.3.1 Copper Content
As for the previous analyses of the MM6 and D12 cells cultured in standard medium
(6.2.2.2) both groups of cells had a similar cellular Cu content when the samples
from cells which had been cultured without additional MnCl2 were compared
(Figure 6.3a). When cultured in IpM MnCl2 both MM6 and D12 cells showed a
similar pattern of a slight, but insignificant, increase in cellular Cu content (Figures
6.3a-c) compared to the standard culture condition values. However, when the cells
were cultured in IOjuM MnCl2 the Cu level in the MM6 cells remained
approximately the same as when they were cultured without or with lpM MnCl2
supplementation, while the level in the D12 cells dropped below that of the cells
cultured without MnCl2 (Figures 6.3b and 6.3c). This could be the result of
• "2 4" ? I
competition of Mn ions at the elevated MnCl2 concentration for Cu sites in a
transporter molecule which is either NRAMP1 itself, or physiologically affected by
transfection of the cells with the pCIneo/NRAMP 1 plasmid. Elevated levels of
NRAMP1 protein in the D12 cells could be transporting both Cu and Mn but the Mn
ions compete at the expense of the Cu ions when the cells are cultured in lOpM
MnCl2. This effect might only be observable when both the NRAMP1 protein and
one or other of the relevant metal ions are present at non-physiological levels, hence,
the MM6 cells remaining unaffected.
It is also possible that the NRAMP1 protein may be responsible, directly or
indirectly, for the export ofCu from the cells.
6.2.3.2 Zinc Content
Comparison of the effects of culturing MM6 and D12 cells in the different MnCl2
concentrations on cellular Zn levels showed a remarkably similar picture to that
described in 6.2.3.1 for the cellular Cu content of the cells. Both groups of cells
showed a slight increase in Zn content when cultured in medium with 1 pM MnCl2
compared to cultures with no added MnCl2 (Figure 6.4a). The average percentage
increase in zinc content of extracts from MM6 and D12 cells from cultures
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:igures 6.3 and 6.4 The effect on Cu (Figure 6.3) and Zn (Figure 6.4) content in MM6 and D12
cells cultured in medium supplemented with OpM, 1pM and 10pM MnCl2. a) shows the metal content
of extracts from triplicate cultures of the two cell lines, b) shows the percentage of the average metal
content of the triplicate samples relative to those of the cells cultured without added MnC^. c) shows
the difference between the average metal content of the triplicate samples and the cultures without
added MnCl2. Extracts from D12 cells cultured with 10|_iM MnCl2 supplementation show a decrease in
Cu and Zn levels compared to the extracts from the cells cultured in the lower MnCl2 concentrations.
This effect is not seen in the equivalent MM6 extracts. The ICPMS analysis method used is described
in 2.21 and the D12 pCIneo/NRAMPl transfected clone is described in 5.2.7 and 5.2.8,
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approximately the same (Figure 6.4b). When samples of the cells cultured in 10p.M
MnCl2 were compared, the Zn level in the MM6 cells was similar to that of the cells
cultured in lpM MnCl2, however, the D12 samples showed a decrease in Zn content
compared to samples from D12 cells cultured without MnCl2 supplementation
(Figures 6.4a-c). This pattern of alteration in cellular Zn content of the cell lines
cultured at the different MnCl2 concentrations could be postulated to be the result of
similar mechanisms as mentioned above for the effect of the culture conditions on
the cellular Cu content of the D12 cells (6.2.3.1).
6.2.3.3 Manganese Content
The level of Mn in the cells cultured without additional MnCl2 was similar to the
results obtained from previous analyses of the two cell lines (6.2.2.2, Figures 6.2a
and 6.5a). The D12 samples had a slightly higher content than the MM6 samples, a
difference that became accentuated when extracts from cells cultured in lpM MnCl2
were compared (Figures 6.5a and 6.5c). Though the difference between the Mn
content of the cells cultured without and with lp.M MnCl2 supplementation was
greater in the D12 cells (Figure 6.5c), the percentage increase in Mn content in the
lpM cultured cells relative to those without added MnCl2 was similar in the MM6
and D12 extracts, with extracts from both cell lines showing an approximate two
fold increase (Figure 6.5b).
There was little further increase in Mn content of the extracts from D12 cells
cultured in lOpM MnCl2 compared to the samples from D12 cells cultured in lpM
MnCl2. This suggested that these cells experienced a maximal physiological effect in
the presence of the lower, lp.M MnCl2 concentration. However, the MM6 cells
cultured in lOpM MnCl2 showed a further increase in cellular Mn content over the
lpM levels. These cells reached approximately the same Mn level which the D12
cells reached when cultured in lpM and lOpM MnCl2 (Figure 6.5a). The
difference in Mn content of the samples from the two cell lines cultured in medium
supplemented with IOjuM MnCl2 compared to the cells cultured without additional




Manganese content in MM6 and D12




























content in MM6 and D12 cells










Percentage manganese in MM6and
D12 cells cultured in MnCI2 relative to




























Figure 6.5c Figure 6.6c
Difference in manganese content of
MM6 and D12 cells cultured in MnCI2









Difference in iron content of MM6
and D12 cells cultured in MnCI2












Figures 6.5 and 6.6 The effect on Mn (Figure 6.5) and Fe (Figure 6.6) content in MM6 and D12
cells cultured in medium supplemented with 0p.M, 1piM and 10pM MnCl2. a) shows the metal content
of extracts from triplicate cultures of the two cell lines, b) shows the percentage of the average metal
content of the triplicate samples relative to those of the cells cultured without added MnCl2. c) shows
the difference between the average metal content of the triplicate samples and the cultures without
added MnCl2. D12 cells show a maximal Mn content when supplemented with 1 pM MnCl2, whereas
MM6 cultures require supplementation with lOpM MnCl2 to reach this level. D12 cells show a higher
Fe content than MM6 cells when supplemented with OpM and 1 pM MnCl2 but this level falls to
approach that of the MM6 cells under supplementation with 1 OpM MnCl2. The ICPMS analysis
method used is described in 2.21 and the D12 pCIneo/NRAMP 1 transfected clone is described in
5.2.7 and 5.2.8
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content was reached by both cell lines, but the D12 cells reached this level when
cultured in a ten fold lower concentration ofMnCl2 than the MM6 cells.
6.2.3.4 Iron Content
When samples from MM6 and D12 cells cultured without MnCl2 supplementation
were analysed for their cellular iron content the D12 samples were found to have a
higher level than the MM6 samples (Figure 6.6a). The isotope of iron chosen to be
S7 S7
measured by ICPMS was Fe . Fe is a rare isotope, present naturally at only 2.19%
of the total iron. As such one must take into account potential problems with the
sensitivity of detection of this ion and the amplification of small errors when low
levels ofFe"7 are being compared. It was not possible to measure the levels of Fei6,
the most abundant Fe isotope and isotope of first choice which is present at 91.66%,
because of the presence of argon oxide generated in the plasma core of the ICPMS,
which has the same molecular weight as Fe56. Taking the potential problems into
consideration, when D12 cells were cultured without or with lpM MnCl2
supplementation the Fe levels in the samples were higher than in the equivalent
MM6 samples (Figure 6.6a). A slight increase in iron content was seen in samples
from the D12 cells cultured with ljuM MnCl2 supplementation compared to those
cultured without additional MnCl2 (Figures 6.6b and 6.6c). An equivalent increase
was not seen in the MM6 samples (Figures 6.6b and 6.6c). Flowever, when
samples from D12 cells cultured in lOpM MnCl2 were analysed there was a dramatic
decrease in Fe content to a level approaching the MM6 samples (Figures 6.6a and
6.6c). Under all MnCl2 culture conditions the iron content of the MM6 cells
remained approximately the same (Figures 6.6a-c). These results suggest that
elevated NRAMP1 expression in the D12 cells affects the intracellular iron content
of these cells, resulting in increased uptake or retention of the metal. When cultured
in elevated levels ofMn this effect is reversed, possibly due to competition ofMn for
Fe sites in the transporter protein.
6.3 DISCUSSION
Results measuring the levels ofMn, Cu and Zn in extracts from the MM6 parent cell
line and pCIneo/NRAMPl plasmid transfected clones, cultured under standard
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conditions, did not show a consistent or significant difference in the content of these
metals in the samples analysed. These results suggest that, provided functional
NRAMP1 protein is being over expressed in the transfectants, there is no observable
effect of high levels of NRAMP1 on the cellular content of Mn, Cu or Zn when
assayed by ICPMS. It was unfortunate that data for the iron content of these cell
extracts was not available, considering the present interest in nramp family members
functioning as iron transporter proteins (Fleming et al. 1997 and 1998; Atkinson and
Barton 1998 and 1999). Measuring iron levels using ICPMS is a difficult task
because it is not possible to measure levels of the most abundant iron isotope (Fe36)
due to the generation of species within the plasma core, i.e. argon oxide, which have
the same molecular mass as this iron isotope. Therefore, less abundant iron isotopes
are the only measurable form of iron, by ICPMS, which means very low levels of the
measurable species are present in normal samples. At the time of analysis of the
samples cultured under standard conditions results for the Fe37 isotope levels were
not available. Had further investigation of the iron levels in the cells been warranted
it might have been possible to supplement the growth medium of the cells with Fe37
in place of the more abundant Fe56 isotope, which would then be assimilated in the
same way as the Fe56 isotope. Alternatively, electron paramagnetic resonance (EPR)
spectroscopy analysis (Farcasanu et al. 1996), chemical assays such as the ferrozine
method (Carter 1971) or radioactive detection methods after incubation with
radioisotopes of iron could have been tried. However, one of the reasons the ICPMS
system was adopted was to determine if the technique was a suitable alternative to
the use of radioisotopes for measuring the cellular content of a variety of metals
using a single detection procedure.
It is interesting to note that a significant difference was seen in the Mn and Cu
content, and to a lesser extent the Zn content, of the cell extracts from the MM6 and
U937 cell lines. It is not known whether the increase in cellular content of these
metals in the MM6 cells is associated with their more mature phenotype and
function of the MM6 cells or a reflection of their size. This observation is, however,
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a useful control showing that the ICPMS system was capable of detecting differences
at the concentrations of cell extracts being analysed.
The results obtained for the MM6 and pCIneo/NRAMPl plasmid transfected clone,
D12, cells cultured under various concentrations of MnCl2 are interesting. Though
they represent a single experiment, albeit analysed more than once, further
investigation to confirm these initial findings could substantiate whether the
differences I have observed are reproducible. The experiment was designed to
determine if increasing the Mn concentration in the culture medium affected the Mn
content of in vitro cultured cells and whether the level of NRAMP1 expression was
influential. My preliminary results suggest that the cells overexpressing NRAMP1
respond to lower levels of increased Mn by accumulating higher levels of the metal.
When cultured with lpM MnCl2 supplementation the D12 cells reached a level of
Mn content which remained largely unaltered when compared to extracts from cells
cultured with 10pM MnCl? supplementation. On the other hand the MM6 cells
showed an increase in cellular Mn content when cultured in lpM MnCl2
supplementation and a further increase when cultured in 10pM MnCl2 supplemented
medium. The MM6 cells only approached the absolute Mn concentration which the
D12 cells had reached in lpM MnCl2 when the MM6 cells were cultured in lOpM
MnCl2. These findings suggest that the NRAMP1 protein may be affecting the Mn
content of the cells, such that a greater concentration of the protein results in more
ready uptake ofMn in the D12 cells, possibly due to the affinity of the protein for the
metal. When lower levels of the protein are present, in the untransfected MM6 cells,
a higher concentration of extracellular Mn appears to be required for the cells to
reach their saturation level of intracellular manganese.
One major problem in interpreting these results is the lack of information regarding
the cellular localisation of any overexpressed NRAMP1 protein in the transfectants.
Recent immunolocalisation studies suggest murine nrampl exists primarily in
lysosomes and it has been challenged whether an effect of alterations in the
extracellular ligand concentration could, therefore, be observed (Gruenheid et al.
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1999). It is possible that my transfectants display mistargeting of the overexpressed
protein such that an increased level of NRAMP1 is expressed at the plasma
membrane. This could be due to the form the gene exists as in the plasmid, or a
failure of the normal cellular regulation ofNRAMP1 localisation when faced with an
excess of the protein. If a parallel can be drawn between the proposed post-
translational control of SMF1 then one could hypothesise that there is insufficient of
a human bsd2 homologue to control all the NRAMP1 protein in the D12 cells (Liu
and Culotta 1999a). In S. cerevisiae the bsd2 protein targets SMF1 to the vacuole for
degradation. When cells are depleted of Mn, SMF1 is targeted to the plasma
membrane in a bsd2 independent fashion and rescued from degradation. Re-
supplementation with Mn results in a bsd2 dependent return to the situation of SMF1
being targeted to the vacuole for degradation. It has been proposed that synthesised
SMF1 bound to the metal ion is recognised by bsd2 and targeted to the vacuole for
degradation. However, apo SMF1, which is not metal bound e.g. under metal
depleted conditions, is not recognised by bsd2 and, hence, traffics to the plasma
membrane. It is conceivable that in the D12 transfectants there is an excess of
NRAMP1 protein to the extent that a bsd2-homologue regulatory protein is in short
supply. Though most reports favour a lysosomal localisation for nrampl it is possible
that under this artificial situation of transfection, NRAMP1 may be expressed at the
plasma membrane.
An alternative proposition exists where NRAMP1 remains located in intracellular
vacuoles and Mn enters the cell by NRAMP1-independent transport systems, for
instance Tf/Tf-receptor mediated endocytosis. The increased uptake of the metal
9-f-
ions by both MM6 and D12 cells would be equivalent in the elevated Mn"
concentrations, and the ions could pass through the vesicular pathway to NRAMP1-
located compartments. Here, in the D12 cells, expressing elevated NRAMP1 levels,
the accumulating Mn2+ ions could be transported out into the cytoplasm increasing
the cytoplasmic Mn concentration. However, in the MM6 cells bearing normal
NRAMP1 levels, or decreased levels due to potential down regulation of the
endogenous protein under elevated Mn conditions, the rate of export of the
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accumulating ions into the cytoplasm may be insufficient, resulting in a percentage
of the ions being recycled to the cell surface and exported into the extracellular
medium.
Mn is an essential trace element and a component of a number of enzyme systems
including mitochondrial Mn-SOD, the astrocyte specific glutamine synthase in the
CNS, concanavalin A, galactosyl transferase, pyruvate carboxylase and chloroplast
photosystem II, to name a few (reviewed in Frausto da Silva and Williams 1991). It
is especially critical during development and is essential for growth and development
of the CNS (Aschner and Aschner 1990). In mammals the majority of research into
Mn uptake has been carried out on cells and cell lines of CNS origin due to the
known toxicity of excess Mn which include "manganese madness", bradykinesia and
a Parkinson-like rigidity (reviewed in Suarez et al. 1995). Though not conclusive, the
neurotoxicity effects appear to be mediated by Mn3+, not Mn2+, and have been
proposed to be at least partly due to effects on mitochondrial function. Mn toxicity
may be mediated through its accumulation in mitochondria and interference with
oxidative phosphorylation, most likely due to binding the FjATPase (Gavin et al.
1992). The mitochondrial electron transport system is one of the few known
significant sources of superoxide, which may initiate the oxidation of Mn2+. An
important factor in the potential toxicity of Mn within mitochondria is the apparent
imbalance of influx and efflux mechanisms, with the latter occurring at an extremely
slow rate. Gavin et al. have also shown Mn2+ to inhibit Na+-dependent Ca2+ efflux
2-b • ■ 2~fand enhance Ca influx, which they propose may increase mitochondrial Ca
sufficiently to create significant oxidative stress and decrease mitochondrial GSH
(Gavin et al. 1990). It has been suggested that Mn may inhibit dopamine production
or storage and/or reduce the number of neurones in the substantia nigra. This has
been hypothesised to be mediated by Mn-dopamine complexes being transported
into neurones via the Na+- and CF-dependent dopamine reuptake carrier (DAT) and
Mn may compete with Na+ for co-transport with dopamine (reviewed in Aposhian et
al. 1999).
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Mn can also act as a mutagenic agent at high concentrations, which is a serious
threat to eukaryotic DNA, but not such a problem for prokaryotes as mutation leads
to variation in the species. It is generally accepted that mitochondria and chloroplasts
are derived from prokaryotic cells, all of which accumulate Mn to a greater degree
than eukaryotic cytoplasm. Eukaryotic cells appear to transport Mn into any
vesicular partition (e.g. lysosomes, chloroplasts, mitochondria, Golgi apparatus,
thylakoids, vacuoles) rather than leave it in the cytoplasm (reviewed in Frausto da
Silva and Williams 1991).
Mn accumulates in many tissues to several times the blood plasma concentration of
0.05-0. lpM. The liver is one of the major sites of Mn accumulation, the majority
being contained in the mitochondria, and it is also the major secretory organ with
bile containing several fold increased Mn concentrations compared to those of
plasma (Galeotti et al. 1995). It is apparent that homeostasis of this metal is critical
for normal physiology and, therefore, transport mechanisms for Mn are of significant
interest.
Manganese can assume eleven different oxidation states but in living tissues is found
in the +2, +3, and +4 oxidation states. Due to its formation of very tight complexes
with other substances the free plasma and tissue concentrations ofmanganese tend to
be very low (reviewed in Aschner 1999). Manganese appears to be taken up by cells
via at least three mechanisms. Transport across the blood brain barrier includes
facilitated diffusion, active transport and Tf dependent transport (reviewed in
Aschner 1999); three apparently saturable uptake systems exist in liver (Aschner and
Gannon 1994; Galeotti et al. 1995); and rabbit erythroid cells possess three saturable
manganese transport systems (Chua et al. 1996). Though Mn enters the brain more
readily when non-protein-bound than when Tf bound (reviewed in Aschner 1999) the
Tf-Fe3+/TfR mediated uptake mechanism can be utilised to take up Mn3+ (Ashner
and Ashner 1990; Suarez et al. 1995). Tf molecules have two binding sites for their
substrate ions and under normal plasma concentrations of iron (0.9-2.8pg/ml) and Tf
(3mg/ml), 30% ofTfmolecules are occupied by Fe3+, leaving 50pmol of unoccupied
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potential Mn binding sites available per litre (Ashner and Ashner 1990). A
bicarbonate-binding site is activated for each bound manganese ion, which requires
carbonic anhydrase. Once internalised via the metal ion-Tf/TfR complex,
acidification in endosomes results in release of the metal ion, which is reduced to
Mn2+, and the TfR recycles to the surface. One of the Mn uptake systems identified
in rabbit erythroid cells involves Mn-Tf uptake and the similarities in the
characteristics of the three identified Mn uptake mechanisms in these cells with
those of Fe suggest both metals may be transported by the same mechanisms (Chua
et al. 1996). It is of interest to note that the Tf-mediated Mn uptake ceases as
reticulocytes mature to erythrocytes, due to loss of TfR expression, highlighting a
maturation state-dependency in Mn uptake. Ontogenic studies in rats also suggest
there is an age-related uptake, retention and distribution ofMn in the brain (reviewed
in Aschner and Gannon 1994; Takeda et al. 1999) and the TfR expression status of
sub classes of brain cells, such as oligodendrocytes, varies with maturity, adding to
the complexity of this system (reviewed in Malecki et al. 1999). The Tf mediated
uptake system has a relatively extensive substrate range and, likewise, it is not
surprising that the divalent transporter proteins of the nramp family may similarly be
capable of transporting, amongst other metal ions, both Fe2+ and Mn2+. It is feasible
that some of the Mn2+ ions used in my culture experiments may have been oxidised
3"h
to Mn ions and Tf mediated uptake ofMn may contribute to the observed results.
However, it is unlikely that oxidation would have been extensive over the course of
the experiment and this mechanism appears unable to explain the difference
observed between the MM6 and D12 cells.
Though the MM6 and D12 cells appeared to respond differently when cultured in the
MnCl2 concentrations I used, it can not be ruled out that this effect was mediated via
one of the other Mn uptake mechanisms which exist in cells, and not that mediated
by NRAMP 1. The existence of several transport systems makes it difficult to
interpret my results, particularly in the light that these systems are likely to be
affected differently in the presence of elevated or decreased concentrations of other
ions. For instance, increased Zn2+ and Cu2+ levels have been shown to increase Mn2+
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accumulation in astyrocytes whereas Ca:+ competitively inhibited Mn2+ uptake by
these cells and mitochondrial Mn2+ uptake (reviewed in Aschner 1999). The ALR1
2~band ALR2 genes of S. cerevisiae encode Mg" transporters but, like similar systems
throughout biology, the transporters are capable of transporting other ions including
Mn2+, Zn2+, Cu2+, Ni2+, Ca2+, Co2+ and La2+ (MacDiarmid and Gardner 1998). The
true physiological implications of this broad spectrum of substrates is not known.
However, it may be that the comparatively high Km values for these secondary
substrates mean they are unlikely to contribute to the accumulation of such cations at
physiologically significant concentrations and this must be acknowledged when
interpreting observations made from systems where substrates or relevant genes are
present at abnormal levels, such as my own. Whether the ability ofMn2+ to substitute
for Ca2+ in the Na+/Ca2+-exchange transport of red blood cells, or for Ca2+ in
receptor-operated channels of hepatocytes (reviewed in Galeotti et al. 1995) occurs
2_|_
physiologically is open to question. In rat brain mitochondria Mn does not
I 7-f-
exchange with Na across the inner membrane in place of Ca" , yet its presence
enhances Ca2+ uptake by these organelles (Gavin et al. 1990). It has also been
proposed that the low affinity Mn uptake system in rabbit reticulocytes and
erythrocytes may be mediated by a Na+/Mg2+ antiport (Chua et al. 1996). The high
• • .... 2~f~ ? l
affinity transport system observed in rabbit reticulocytes is inhibited by Fe , Zn ,
»2+ 2A- • ...Ni and Co as well as NaCl and a number of metabolic inhibitors, while it is
stimulated by valinomycin and SITS (4-acetamido-4'-isothyocyanatostibene-2,2'-
disulphonic acid). These findings suggest changes in transmembrane potential
difference and changes in membrane surface potential may be involved in a transport
system for this range of substrates. Not all transition metal transporter systems and
the relevant metals, however, seem to be inter-dependent and capable of affecting
the expression of the transporters or concentration of metal ions. Though the SMF
proteins may be able to transport iron, their expression was unaltered, and their
deletion had no effect, on S. cerevisiae with a deletion of the surface ferroxidase
(FET3) which is involved in high affinity iron transport (Li and Kaplan 1998). This
serves to illustrate a partial interconnection of this complex homeostatic regulatory
system in which a functional capacity measured under certain conditions may not
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transpose to a similar activity under physiological or different conditions, and only a
subset of those genes or proteins potentially responding or being affected by a
change in the status quo actually being so.
The influence of one particular metal ion on the uptake and physiological effect of
another does not always appear to be explained as simply as competition for a
common transport mechanism. S. cerevisiae displays reduced Mn2+ uptake and can
be protected from Mn2+ toxicity following pre-incubation with Mg2+. The resistant
2"b
Mg -loaded cells did not need to be present in Mg-enriched medium when the high
levels of Mn2+ were added (Blackwell et al. 1997). Al3+ toxicity in S. cerevisiae
appears to be the manifestation of reduced Mg2+ influx, and the resulting
intracellular deficiency of this essential element, rather than a direct effect of
increased intracellular aluminium (MacDiarmid and Gardner 1998). In addition, in
vivo incubation of rat oligodendrocytes with Al-Tf down regulated surface
expression of TfRs, and limited Fe and Mn uptake via the Tf/TfR system (Golub et
al. 1996).
It is often possible to glean some insight into mammalian systems from studying
those of lower organisms. Mn2+ is essential for the glucan-associated adhesion of
some mutans group streptococcal species and for pneumococcal transformation,
necessitating uptake mechanisms for this ion. The Streptococci gordonii scaCBA
operon, which encodes genes also found in S. parasanguis and S. pneumoniae, is
necessary for the activity of a high affinity Mn2+ uptake system (reviewed in
Kolenbrander et al. 1998). This system is inhibited by Zn2+ but not Mg2+, Ca2+, Hg2+,
2"F 21Cu or Fe . The operon encodes an abc transport system, which is of interest in the
light of the presence of the conserved transport motif in a number of bacterial abc
transporter proteins and nramp family members. S. gordonii also contains one or
more lower affinity Mn2+ uptake systems which allow growth under Mn2+-replete
conditions. The lower affinity system was proton motive dependent and not
significantly inhibited by Zn2+. In addition an Adc Zn2+ transporter has been
proposed to be capable of transporting Mn2+. The S. pneumoniae psa locus encodes
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an abc-type Mn permease complex hypothesised to be part of a signalling pathway
indirectly affecting adhesion, lysis, transformation and virulence, though Mn
transport only partially contributes to this signalling (Novak et al. 1998). Thus, even
2+in these organisms Mn transport is a complex multi-system process.
Insight into the regulation of the S. cerevisiae SMF proteins via the bsd2 protein and
Mn levels prompts consideration that a similar system may exist in mammals
regulating nramp protein levels and its cellular localisation (Liu and Carlotta 1999a).
As discussed previously, the finding that physiological Mn2+ concentrations result in
SMF1 targeting for vacuolar degradation introduces the possibility that
overexpressed NRAMP 1 protein in the D12 cells may be destined for a similar fate,
mediated via a mammalian bsd2 homologue. Particularly noteworthy is the
observation that in Mn -starved cells SMF1 was redirected to the cell surface in a
bsd2 independent way, saving SMF1 from degradation. When re-supplemented with
2+Mn' the SMF protein was again targeted for degradation in a bsd2 dependent way. It
is possible, therefore, that a proportion of overexpressed NRAMP 1 protein in my
system escapes the degradation pathway due to a comparative shortage of the
hypothesised bsd2 homologue, and the effects observed in my functional studies do
reflect the presence of increased NRAMP 1 protein levels. This vacuolar-targeting
pathway is consistent with the immunolocalisation studies of the murine nramp 1
protein (Gruenheid et al. 1997) to vacuolar compartments, such as lysosomes, and
may help explain the failure to identify significant levels of the protein at the plasma
membrane.
Gruenheid et al. report unpublished results of a failure to demonstrate nramp 1-
mediated transport of 54Mn or 55Fe in RAW cells transfected and overexpressing
nrampl protein. They suggest this might be due to the non-overlapping distribution
of the nrampl and nramp2 proteins. Despite both proteins being capable of
transporting the ions, the lysosomal localisation of nrampl may preclude its transport
of extracellular ligand, which plasma membrane located nramp2 could perform. The
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authors suggest an observable effect of overexpression of nrampl would require the
presence of its ligand in the phagolysosomal space (Gruenheid et al. 1999).
The main variation I observed in the behaviour of the MM6 and D12 cells with
respect to their Cu and Zn content was seen when the cells were cultured in medium
supplemented with lOpM MnCl2. In extracts from D12 cells the absolute
concentration of both metals decreased below the levels of samples from these cells
cultured without or with lpM MnCl2 supplementation. In contrast, the MM6 cells
behaved in a similar manner when cultured in both lp.M and 10pM MnCl2, deviating
only slightly from the control culture conditions. Assuming the overexpressed
NRAMP1 protein was functional in the D12 cells the slight increase in the cellular
content of the two metals when supplemented with lpM MnCl2 could be the result
of increased uptake via NRAMP1. Alternatively, because the MM6 cells varied in a
similar way, showing an approximately equivalent percentage increase relative to the
control cell samples cultured without additional MnCl2, this observation may be
NRAMP1 independent and the result of other transport mechanisms or experimental
variation. The decrease in Cu and Zn content in the D12 cells cultured under the
highest MnCl2 concentration suggests a competitive effect of Mn at the expense of
transport of these metals. As the decrease was only seen in the D12 cells it is
tempting to speculate that it is a direct or indirect effect ofNRAMP1 overexpression.
It is possible that the physiological effect of NRAMP1 overexpression down
regulates transport systems that would otherwise transport Cu and Zn. If it was the
case that the relative affinities of the three metals in question were such that at 10p.M
MnCl2 Cu and Zn could not compete for uptake by NRAMP1 in the D12 cells, and
Mn was transported at the expense of the other metals, one might expect to see a
decrease in the Cu and Zn concentrations in the MM6 cells as well due to the effect
on transport by the endogenous NRAMP1 protein. This was not seen, suggesting a
more complex interaction of metal ions, transport systems and their regulation may
be operating. It is possible, however, that the effect of elevated levels of NRAMP1
on Cu and Zn transport is only seen at 10pM MnCl2 culture conditions in the D12
cells and the other slight variations seen in the remaining samples are coincidental
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and independent of NRAMP1. The competitive effect of Mn for transport at the
expense of Cu or Zn might only be seen when both the NRAMP1 protein and one of
the relevant metal ions is present at extreme non-physiological levels, hence the
MM6 cells being unaffected. Though there is no evidence as far as 1 am aware it is
also possible that NRAMP1 may be capable of exporting Cu and Zn in a Mn
dependent way.
Taking into consideration the drawbacks in analysing iron concentrations by
S7
measuring the level of the low abundance Fe isotope the results are worthy of
discussion. Under normal culture conditions and supplementation with 1 pM MnCl2,
extracts from D12 cells had a markedly elevated Fe content compared to the
equivalent MM6 samples. This suggests that overexpression of NRAMP1 may be
increasing transport of Fe into the D12 cells; or from the cytoplasm into intracellular
vacuoles; or from intracellular vacuoles into the cytoplasm, depending on the
direction of transport of the metal, to an extent that a continuous uptake of Fe from
the extracellular medium continues to replenish the Fe depleted compartment(s). In
the MM6 cell samples with normal NRAMP1 levels this increase in Fe content is not
seen under any of the culture conditions analysed. However, in the D12 extracts from
cultures supplemented with lOpM MnCl2 the level of Fe in the cells approached that
of the untransfected cells, suggesting that Mn at this high concentration is sufficient
to compete with Fe and inhibit the effect of NRAMP1 overexpression on Fe
transport, which was seen at the lower extracellular Mn concentrations. If this is the
case one would expect the difference in Mn levels of extracts from D12 cells
cultured in lpM and lOpM MnCl2 to be significant. However, this was not seen,
introducing the possibility of another Mn export system operating which prevents
intracellular Mn accumulating above a certain level. This might also explain the
plateau effect of the maximum Mn concentrations observed in both MM6 and D12
cells. One could envisage a continuous import followed by export cycle ofMn, at the
expense of Fe, when the D12 cells were cultured in 10p.M MnCl2 due to Mn
competing for Fe transport.
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These preliminary results suggest NRAMP1 may be partaking in the regulation of
intracellular Fe levels which supports previous studies (Atkinson and Barton 1998
and 1999). However, the physiological effect of this regulation remains unresolved
with a variety of suggestions being propounded (reviewed in Blackwell and Searle
1999). NRAMP1 may be involved in transporting iron out of the endosome/lysosome
following release of the metal from internalised Tf/TfR complexes. This would be in
keeping with the requirement of low pH for iron dissociation and fusion of early
lysosomes with nrampl-positive late endosomes/lysosomes for its transport. Nrampl
has also been postulated to be involved in scavenging Fe from phagocytosed
senescent red blood cells, by transporting it into the cytoplasm from whence it can be
returned to the blood stream. One effect of this efflux of Fe from phagolysosomes
would be to starve pathogenic bacteria of this vital nutrient, which could account for
the phenotypic difference observed in nrampl mutant mice following infection with
certain microorganisms. However, not all observations are consistent with these
ideas and Zwilling et al. have hypothesised that nrampl may be transporting Fe into
phagosomes, where the low pH environment would favour the generation of toxic
free radicals, via the Fenton reaction, to kill invading microorganisms (Zwilling et al.
1999). These workers found that the growth inhibitory effect on M. avium of M(j)s
from resistant mice was stimulated by the addition of iron. Inhibitors of hydroxyl
radical generation prevented this effect and the group suggest 'OH, generated from
2~b
H202 via the Fe catalysed Fenton reaction, was mediating the antimicrobial effect,
with nrampl regulating the Fe2+ transport. In contrast to M<j>s from resistant mice
they found that addition of iron to susceptible M(J)s stimulated the growth of M.
avium. Splenic adherent cells from resistant mice show superior 'OH production on
infection with BCG compared to their susceptible counterparts, which is consistent
with this hypothesis (Denis et al. 1988). IFNy treatment was shown to decrease the
levels of intracellular iron in resistant M<(>s, but not susceptible M(J>s, an effect
speculated to be mediated by NO (Zwilling et al. 1999). NO induces the loss of iron,
in part, by attacking iron-sulphur centres with associated inhibition of cell
metabolism and growth. The increased NO production by resistant M(j>s (Barton et al.
1995) may be responsible for the loss of intracellular iron following IFNy treatment.
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The role of NO in /?raw/?/-mediated growth inhibition of the relevant pathogens
remains controversial (reviewed in Blackwell et al. 1991; Brown et al. 1995) but this
idea suggests an indirect role of the free radicals affecting the cells' iron status, with
potential knock on effects. Further work is obviously required to clarify the situation
regarding the direction of transport of nrampl's substrate(s). The two schools of
thought remain open with Zwilling feeling a scavenger function, removing effete
iron, too passive a role of nrampl. The proponents of this hypothesis challenge
Zwilling's theory, questioning such a unique role of nrampl in enhancing
antimicrobial activity, which poses problems reconciling the pleiotropic effects of
nrampl in regulating many cellular functions. The latter problem may be accounted
for in the regulatory effect of iron on mRNA stability (reviewed in Zwilling et al.
1999).
It is interesting to consider what effect an alteration in localised concentrations of
divalent cations may have on signalling pathways and cell activation. Mn2+ has been
shown to modulate integrin function, altering the ligand binding affinity and
specificity of VLA-3 (Elices et al. 1991), VLA-5 (Gailit and Ruoslahti 1988),
GPIIb/IIIa (Kirchhofer et al. 1990), vitronectin receptor (Conforti et al. 1990), VLA-
4 and VLA-6 (Sonnenberg et al. 1988). It appears to directly alter the conformation
of LFA-1 in a manner that favours LFA-l/ICAM-1 binding, an effect only seen with
Mg2+ when Ca2+ is removed by chelation with EGTA (Dransfield et al. 1992).
ICAM-3 is also dependent on the presence of Mn2+ or Mg2+ for binding to LFA-1
(Woska Jr et al. 1998). This modulatory effect of divalent cations on ligand/receptor
interactions involved in signal transduction may be a wide spread phenomenon
affecting a variety of integrins. It is worth considering whether nrampl partakes in
regulating cell function in this way through its effect on divalent cation transport and
cellular localisation.
Whether Fe2+ and/or Mn2+ is the physiological substrate for nrampl it is likely that
the protein plays a critical regulatory role within phagocytes with respect to the cells'
redox balance. The effect of altering the redox balance could modulate the effect of
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other genes and ultimately affect bacterial killing, as well as altering the function of
enzymes and the environment within which the pathogen resides.
It is clear that further investigation is needed to address the transport of Mn in its
different oxidation states as well as different exposure routes at physiologically
relevant concentrations ofMn in the blood.
6.4 CONCLUSION
Overexpression of NRAMP1 in the MM6 derived pCIneo/NRAMPl transfected
clone, D12, does not appear to affect the cellular content of Mn, Cu or Zn under
standard culture conditions when compared to the parent cell line. However, when
cultured in increased levels of MnCl2, D12 and MM6 cells show differential effects
with respect to their Fe, Mn, Cu and Zn levels. The effect on Cu and Zn levels were
similar with D12 cells showing a decrease in cellular content of these metals when
the cells were cultured in the highest (lOpM) MnCl2 concentration. This decrease
was not seen in the MM6 cells. The Mn levels in both D12 and MM6 cells increased
when cultured in lpM MnCl2, with the D12 cells reaching a maximal plateau level
which did not increase further when the cells were cultured in 10pM MnCl2. In
contrast, the Mn level of MM6 cells cultured in lOpM MnCl2 increased above its
level in lp.M MnCl2 approaching the plateau level observed in the D12 cells cultured
in lpM MnCl2. The Fe levels were greater in D12 cells than in MM6 cells when the
cells were cultured under conditions without and with supplementation of ljuM
MnCl2. When cultured in lOpM MnCl2 the Fe level in D12 cells decreased
significantly, approaching that of the MM6 cells, whose Fe content remained
approximately the same under all MnCl2 culture conditions. These findings suggest
NRAMP1 transfection of the MM6 cell line influences the homeostasis of a number
of divalent cations when the cells are cultured under increased concentrations of
2"bMn . How the protein is controlling and affecting the transport and cellular
localisation of these metals remains an area for further investigation, as does
elucidation ofNRAMPl's physiological substrate(s).
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7 FINAL DISCUSSION
As the project to sequence the human genome races to completion the science world
will be faced with an ever increasing pool of genes influencing health and disease.
Dissecting the extent to which these impact on our daily well being and constitution,
and their complex interaction is likely to be a major challenge. The genes
responsible for many of the genetic diseases caused by mutations in a single gene
have now been identified, but we face the problem of the more common multi-
gene/multi-factorial ailments. It is likely that numerous genes, each carrying a small
weight, contribute in an additive way in combination with particular environmental
and life style factors, culminating in these ailments. NRAMP1 is one such candidate
gene and its influence on M(j> function, in the context of other contributory factors,
could have subtle or significant effects. It is interesting to consider the interaction of
M<j>s and the genes expressed by these cells with the NRAMP1 profile of those with
human primary immunodeficiencies with a M<J> involvement (e.g. CVID, CHS,
WAS); parasitic, viral and bacterial infections; and autoimmune diseases, as
summarised in 1.6. These conditions and their outcome are not accountable to a
simple or single cause and the complex immune system interactions involved result
from additive cellular, genetic, molecular and environmental inter-dependent factors.
The effect of APCs, such as M(j>s, in initiating and skewing these responses can not
be underestimated. Though this project has not shown a strong association of PBC, a
typical example of one such complex disease, with the NRAMP1 polymorphic site
affecting expression levels of the gene which I investigated, an influence of
NRAMP1 can not be ruled out entirely. Further expression studies and more
extensive genetic analysis of this gene and the potential factors regulating expression
and function of the protein, such as bsd2 homologues (Liu and Culotta 1999b), is
warranted in PBC patients. In addition, it is tempting to hypothesise that the novel
allele, allele 5, which I have identified at an increased frequency in the PBC
population I genotyped, may be contributing to pathology in this subset of patients by
influencing expression levels of NRAMP1 and hence, M(j) function. Reporter studies
will shed light on this proposal.
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The nrampl genotype has a significant effect on induction of murine M(j> apoptosis
induced by M. tuberculosis, which is dependent on the production of elevated NO by
resistant M<|)s (Rojas et a/. 1998). It is probable that NRAMP1, likewise, influences
the antimycobacterial/antibacterial activity of human Mijis and their apoptosis.
Whether this extends to induction of apoptosis in non-M<j> cells is an interesting point
to consider. The potential role of mycobacterial and bacterial infection in induction
of autoimmune conditions such as PBC, which is characterised by the presence of
extensive granulomas in the diseased liver, harkens to M<j>s playing a significant role
in the pathogenesis. It is tempting to extend this possibility to include the status of
Mcjis with respect to the pleiotropic effects ofNRAMP1 on the activity of these cells.
This may parallel those of RA sufferers' Mtjis whose NRAMP1 genotype appears
significant in influencing disease susceptibility (Shaw et al. 1996 and 1997).
However, my study does not provide evidence for an analogous increased frequency
of the RA associated NRAMP1 allele 3 at the 5' promoter region polymorphic site,
but it is notable that if allele 5 carriers were present in the RA populations studied,
they may have been inadvertently classified as allele 3 carriers. This suggests
reanalysis of the RA populations should be considered. It is worth contemplating
whether NRAMP1 may influence the severity of PBC after its initiation rather than
actually determining susceptibility to the disease. There are two sides to this coin.
Individuals with an NRAMP1 genotype resulting in hyperstimulated Mijis might face
a worse prognosis due to an accentuated and extended destructive immune response,
as proposed in the case of RA patients (reviewed in Blackwell 1996). On the other
hand, if PBC really is triggered by an as yet unidentified infection, effective control
of this pathogen in the early stages may limit or reduce the extent of the potential
subsequent pathological immune responses of the autoimmune syndrome.
Elucidation of the significance of expression of the two NRAMP1 splice variants I
have shown in PBC and normal liver might shed light on potential post-
transcriptional regulation of NRAMP1 and, hence, the level of functional protein
expressed. Exactly how NRAMP1 exerts its pleiotropic effects on M(j) function and
activity is a fascinating area of research. At first sight a divalent cation transporter
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seems an unlikely candidate for such a regulator. My preliminary studies, using cells
transfected to overexpress NRAMP1 cultured in increased concentrations of MnCl2,
support previous reports that NRAMP1 alters transport of such cations, in particular
iron and manganese. Further investigation and clarification of the direction of
transport and intracellular location of the overexpressed protein need elucidation
before meaningful interpretation of these results can be made.
With respect to the mechanism of BEC destruction in PBC I have identified further
evidence that apoptosis may be the mechanism by which these cells die on the basis
of their expression of the pro-apoptotic bax and bcl-x proteins. The stimulus or
trigger for this fate is still under investigation but a number of potential candidates
exist, including NO which is produced at high levels by M<j>s. Serum NO levels are
increased in PBC patients (Notas et al. 1999) and decrease as disease progresses
(Battista et al. 1997). NO production by DCs from PBC patients has been shown to
be greatly enhanced in in vitro allogeneic MLR when compared with that of chronic
hepatitis sufferers or normal controls, and DCs from PBC patients are defective in
their stimulatory capacity (Yamamoto et al. 1998a and 1998b). It is worth noting that
NO induced apoptosis can be independent of p53 (Messmer and Briine 1995), the
stabilisation of which I failed to observe in the PBC liver sections I immunostained.
A number of observations support a role of free radicals in association with a
decrease in antioxidant levels in the pathogenesis of PBC (Gibbons et al. 1999),
oxidative stress being a significant feature of early stage PBC (Aboutwerat et al.
1999). The NRAMP1 protein acts as a divalent cation transporter and its proposed
substrates, including Fe2+ and Mn2+, have the potential to partake in redox regulation.
It is worth considering whether NRAMP1 is a factor contributing to the oxidative
imbalance in PBC. Though the observations mentioned above do not prove a direct
role of NO and APCs, a potential NO source, in the pathogenesis of PBC they are
suggestive that PBC is the result of more complex abnormalities than mere T
lymphocyte or AAb mediated destruction. These non-antigen-specific components of
the immune system may prove to be of major significance as we glean a greater
understanding of the true events initiating and perpetuating this perplexing disease.
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Another possible initiator of apoptosis of BECs in PBC is TNFa which is widely
recognised for its role in triggering cell death (Cytokines Online Pathfinder
Encyclopaedia web site). TNFa expression by BECs in PBC liver sections has been
reported and the accompanying upregulated expression of TNFaR by these cells
presents potential for an autocrine destruction method (Yasoshima et al. 1998). As
well as exerting receptor-mediated effects TNFa can act indirectly, inducing
mediators such as IL-1 and NO. TNFa can disturb the barrier function of bile ducts,
which may lead to leakage of toxic bile substances and initiation of local
inflammatory processes. It is interesting to note that UDCA, the most widely used
therapy for PBC pre-transplantation, has the effect of decreasing serum TNFa levels
(Angulo et al. 1999) and iNOS mRNA and protein expression (Elattori et al. 1996;
Invernizzi et al. 1997). Thus, decreasing levels of these mediators may be one of the
therapeutic benefits of UDCA, amongst other reported immunomodulatory and cell
membrane effects. The beneficial effect of this drug has also been suggested to
involve decreased apoptosis. Glycoursodeoxycholic acid reduces caspase-3 like
activity; mitochondrial cytochrome c release; and apoptosis in BECs induced to
undergo apoptosis (Que et al. 1999). The drug has also been proposed to exert
beneficial effects by acting as an antioxidant, blocking the peroxidative effect of
hydrophobic bile acids, such as deoxycholic acid, and suppressing KC activation
(Ljubuncic et al. 1996). It remains to be seen whether these observations identify
significant players in pathology specific to PBC and how they could be manipulated
to delay or halt disease progression. I have shown that BECs in PBC patients are
capable of proliferation, which offers some hope that increasing this innate capacity
might be possible, in conjunction with decreasing BEC destruction. The increased
IL-6 production by BECs of PBC patients may be inducing this proliferation in an
autocrine manner (Yasoshima et al. 1998) and directed, controlled IL-6 therapy may
be one future option.
Though this project has centred on the M<j> as playing an important role in the
pathogenesis of PBC, and in investigating the fascinating NRAMP1 gene and
NRAMP1 function it is important to emphasise that multicellular organisms exist as
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holistic entities. M<[)s interact with, influence and are influenced by a host of other
cells, chemicals and mediators and though we would be lost without them, and
medicine has a lot to learn and appreciate about their functions, Sir Ralph
Bloomfield Bonington in Bernard Shaw's The Doctor's Dilemma was possibly
granting them slightly more omnipotence than they merit when he claimed "There is
at bottom only one genuinely scientific treatment for all diseases, and that is to
stimulate the phagocytes" (Shaw 1947).
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9 APPENDIX A
9.1 Diagnosis of the first 227 orthotopic liver transplantation
patients performed at the Scottish Liver Transplantation Unit.
Diagnosis Total
Primary biliary cirrhosis 63
Alcoholic liver disease 33




Hepatic artery thrombosis 9
Chronic rejection 9
Chronic active hepatitis 8
Primary Graft Non Function 8
Hepatitis B 5
Hepatitis C 5
Secondary biliary cirrhosis 3
Unknown cause 2
Budd Chari 2












10.1 Components of Solutions and Reagents
TE





about 55.Og boric acid added until pH8.3, made up to 1 litre with dH20
lOx TBS for Immunohistochemistry
500ml 0.5M Tris pH to 7.6
Make up to 2 litres with dH20
Normal Saline
42.5g NaCl in 5 litres
lx TBS for Immunohistochemistry
100ml lOx TBS for Immunohistochemistry
90ml normal saline
lOx TBS for Western Blotting
60g Tris base
90g NaCl
pH to 7.9, made up to 1 litre with dH20
ABComplex Buffer
0.05M Tris-HCl pH7.6
ABComplex-HRP (DAKO, Cambridge UK)
5ml ABComplex buffer
1 drop of reagent A
1 drop reagent B
Mix well, prepare at least 30 minutes before use
ABComplex-AP (DAKO, Cambridge UK)
5ml ABComplex buffer
1 drop of reagent A
1 drop reagent B










Scott's Tap Water Substitute
2g potassium carbonate
20g magnesium sulphate
made up to 1 litre in dH20
0.2M Phosphate Buffer pH7.3
5.6ml 0.4M sodium di-hydrogen phosphate (NaH2P04-H20)
14.4ml 0.4M di-sodium hydrogen phosphate (Na2HPO4-2H20)
pH to 7.3, make up to 400ml with dH20.
Coomasie Blue Staining Mixture
Dissolve 0.25g Coomasie blue in 10% methanol (Merck, Lutterworth UK)/7% acetic
acid (Fisher Scientific, Loughborough UK) in a final volume of 100ml.
Destain Mixture
10% methanol (Merck, Lutterworth UK)





made up to 100ml with dH20
The following anti-proteases were added to 1ml to give a final concntration of:












pH to 8.8, made up to 500ml with dLLO
lOx Running Buffer
120. lg Tris base
80g glycine
20g SDS
made up to 2 litres with dH20
12% Separating Gel
11.1ml 30% acrylamide (Flowgen, Lichfield UK)
9.25ml separating gel buffer




1.5ml 30% acrylamide (Flowgen,Lichfield UK)
2.5ml stacking gel buffer




10ml stacking gel buffer
2g SDS
5ml 2-mercaptoethanol
10ml glycerol (Fisher Scientific, Loughborough UK)
5mg bromophenol blue
made up to 100ml with dH20
TBST
500pl Tween 20 in 1 litre of lx TBS
Blocking Solution
3g Marvel low fat dried milk
100ml TBST





5ml 1% copper sulphate
5ml 2% sodium potassium tartrate
490ml alkaline carbonate stock solution
Folin-coicalteau reagent
Dilute 1:1 with dH20 before use
Transfer Buffer
35.8g di-sodium hydrogen phosphate
41 dH20
11 methanol (Merck, Lutterworth UK)
Make up fresh before use
NBT/BCIP Chromogen Substrate
66pl NBT stock (50mg NBT in 1ml 70% dimethylformamide)
33pl BCIP stock (50mg BCIP in lml 100% dimethylformamide
990pl AP buffer
TMB Buffer
25.7ml 0.2M di-sodium hydrogen phosphate (Na2HPO4-2H20)








25.7ml 0.2M di-sodium hydrogen phosphate (Na2HPO4-2H20)












16.875ml 40% acrylamide/bis (19:1)
75jul TEMED
750jll1 10% APS




0.05% xylene cyanol FF
GMEM
10ml of lOx stock GMEM (Life Technologies, Paisley UK) was diluted in 90ml
sterile dH20.
3.7ml stock sodium bicarbonate solution was added to buffer the medium.
Filter sterilised before use.
Supplemented RPMI-1640 Medium






All purchased from Life Technologies, Paisley UK
Heat Treated NHS
Normal human serum was obtained from the Scottish National Blood Transfusion
Service and heated for 1 hour at 56°C to inactivate complement components.
Crystal Violet




0.58ml INNaOH (0.574gNaOH in 14.35ml dH20)
1.3ml dH20
2.12g BSA was poured carefully onto the top of the PBS/NaOH/dH20 in a 25ml
beaker which was covered with foil and left overnight to dissolve. The mixture was
swirled gently then centrifuged for 5 minutes at 300g to ensure all the BSA was in
solution.
Filter sterilised before use and stored at 4°C.
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X-Gal Stain
20mM sodium di-hydrogen phosphate (NaH2P04)
80mM di-sodium hydrogen phosphate (Na2HP04)
3mM K3Fe(CN)6
3mM K4Fe(CN)6
lmg/ml X-Gal (Promega, Southampton UK)
1M MgCl2
Prepared in dH20
Filtered prior to use.
DEPC Treated dH20
lml DEPC in 1 litre dH20 left overnight then autoclaved.







lOg Bacto-tryptone (Becton Dickinson UK Ltd., Oxford UK)
5g Bacto-yeast extract (Becton Dickinson UK Ltd., Oxford UK)
pH to 7.5 with 5N NaOH made up to 1 litre with dH20, autoclaved
L-Amp plates
7.5g Bacto agar (Becton Dickinson UK Ltd., Oxford UK)
500ml L-broth
autoclaved and cooled to 50°C, 50pg/ml ampicillin added, poured into Petri dishes
and allowed to set
SOC Medium
20g Bacto-tryptone (Becton Dickinson UK Ltd., Oxford UK)
5g Bacto-yeast extract (Becton Dickinson UK Ltd., Oxford UK)
0.5gNaCl
made up to 1 litre with dH20, autoclaved
prior to use add 10ml 1M MgCl2
10ml 1 M MgS04
10ml 2M glucose solution
Filter sterilise before use
Sequenase PCR Product Sequencing Kit (Amersham Pharmacia Biotech, Little
Chalfont UK) contained:
Exonuclease
lOU/pl in 20mM Tris-HCl pH7.5, 5mM 2-mercaptoethanol, 50% glycerol
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SAP
2U/pl in 25mM Tris-HCl pH 7.6, ImM MgCl2;0.1mMZnCl2;50% glycerol
Sequenase Version 2.0 DNA Polymerase
1.6U/ pi with inorganic pyrophosphatase (2U/ml) in 20mM Tris-HCl pH7.5,
2mM DTT, 0.ImM EDTA, 50% glycerol
Sequenase Reaction Buffer
200mM Tris-HCl pH 7.5
lOOmM MgCl2
250mM NaCl








ddC, ddA and ddT Termination Mixes for dGTP
as above replacing ddGTP with ddCTP, ddATP and ddTTP.












ddC, ddA and ddT Termination Mixes for 7-deaza-dGTP
as above replacing ddGTP with ddCTP, ddATP and ddTTP.












0.05% xylene cyanol FF




made up to 1 litre with dH20
6% Glycerol Tolerant Polyacrylamide Gel
15ml 40% acrylamide/bis (19:1)
42g urea
5ml 20x glycerol tolerant buffer
made up to 100ml with dH20
lml 10% APS and 25pl added to polymerise gel immediately before pouring
6% Formamide Glycerol Tolerant Polyacrylamide Gel
15ml 40% acrylamide/bis (19:1)
42g urea
30ml deionized formamide
5ml 20x glycerol tolerant buffer
made up to 100ml with dH20
lml 10% APS and 80pl added to polymerise gel immediately before pouring
T7 Sequenase version 2.0 DNA sequencing kit (Amersham Pharmacia Biotech,
Little Chalfont UK)
Reagents are as for Sequenase PCR Product Sequencing Kit except:
T7 Sequenase Version 2.0 DNA Polymerase
13U/jul in 20mM KP04 pH7.4, ImM DTT, 0.1 mMEDTA, 50% glycerol
DetectaGene Green lacZ Expression Kit (Cambridge Bioscience, Cambridge UK)
contained:
Detectagene Green Substrate Reagent
lOmM CMFDG in 1:1 (v/v) water/DMSO
Propidium Iodide
150p.M propidium iodide in water
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11 APPENDIX C
11.1 Sequence of phNRAMPI (D38171) plasmid insert.
The Hindlll and Nhel restriction enzymes used to characterise phNRAMPI (5.2.2.1)
cut after base 434 and 273, respectively. Nhel was also used to construct the whole
NRAMP1 cDNA as described in 5.2.4. The MscI restriction enzyme used to clone
the whole NRAMP1 cDNA in the pCIneo plasmid cuts after base 2128.
The enzymes recognise the following sites and cut at the position shown by the









































































































































































































































11.2 Sequence of 5'NRAMP37 (D50403) plasmid insert.
Vector sequence at the 5' and 3' end of the NRAMP1 sequence is shown in bold. The
anchor primer used by Kishi when using the 5'-RACE method to define the extreme
5' end ofNRAMP1 is underlined. The EcoRl restriction enzyme used to characterise
5'NRAMP1 cuts after base 1 and 713. The Nhel restriction enzyme used to
characterise 5'NRAMP1 and construct the whole NRAMP1 cDNA as described in
5.2.2.3 and 5.2.4 cuts after base 571.
The enzymes recognise the following sites and cut at the position shown by the
vertical slash; n represents any base.










































































12.1 Abbreviated names used for MM6 and U937 transfected
clones
For clarity and simplicity when writing this thesis the MM6 and U937 transfected
clones have been identified by abbreviations of the names used during laboratory
work and in my laboratory books. If reference is to be made between this thesis and
my books or stocks of frozen cells the full names of the clones discussed in this
thesis are given below.


















12.1.4 U937 Clones Transfected with the pClneo Plasmid
39 U/p,962F9
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Bile duct cells in primary biliary cirrhosis are
'primed' for apoptosis
Alexandra M. Graham, Matthias M. Dollinger, Sarah E.M. Howie
and David J. Harrison
Objective Primary biliary cirrhosis (PBC) is characterized
by progressive, immune-mediated destruction of bile
ducts « 75 (xm diameter) and secondary changes related
to cholestasis which may involve apoptosis. In this study
we sought to examine the protein expression of genes
involved in apoptosis in biliary epithelium of PBC cases.
Design In order to investigate the susceptibility of biliary
epithelial cells to apoptosis and their ability to proliferate,
we examined the expression of a number of apoptosis
related proteins in early and late stage PBC and
histologically normal liver control tissue using immuno-
histochemistry.
Methods Liver biopsies from 15 early (stages I and II)
and 14 late (stages III and IV) cases of PBC and 15
normal cases were examined immunohistochemically for
expression of p53, CD95/Fas, bax, bcl-x, bcl-2 and the
proliferation marker Ki-67.
Results CD95/Fas, bax and bcl-x were identified in biliary
epithelium in 8/15, 11/15 and 8/15 normal biopsies.
Weak expression of bcl-2 was found, but p53 was not
identified. In cases of PBC surviving bile ducts showed
strong bax and bcl-x expression. Inflammatory infiltrates
were strongly bcl-2 positive. In cases showing a marked
ductular reaction there was increased reactivity for bax
and bcl-x in ductules. No change in CD95/Fas or p53
expression was seen. An increase in Ki-67 positive biliary
epithelial cells was seen in PBC cases, indicating cell
cycle activity.
Conclusions Bile duct epithelium constitutively expresses
several genes involved in the execution of apoptosis but
these cells also retain the ability to proliferate.
Eur J Gastroenterol Hepatol 10:553-557 © 1998 Lippincott-Raven Publishers
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Introduction
Primary biliary cirrhosis (PBC) is a chronic, slowly progres¬
sive cholestatic liver disease characterized by destruction
of bile ducts of < 75 fxm diameter [1]. The destruction is
thought to be the result of apoptosis of biliary epithelial
cells, triggered by autoimmune mechanisms [reviewed in
References 2 and 3]. The aetiology remains unknown
although various factors such as HLA type [4] and micro¬
biological infection have been invoked [5-8]. One of the
major diagnostic criteria for PBC is the presence of high
titres of anti-mitochondrial antibodies in patients' sera,
frequently specific for the E2-subunit of pyruvate dehy¬
drogenase complex (PDC-E2) [reviewed in Reference 9].
However, the precise role of autoantibodies in patho¬
genesis has not been established.
CD8+ T lymphocytes are present in inflammatory infil¬
trates within the livers of PBC patients [10-13]. They are
centred around small bile ducts and may initiate damage
directly through apoptosis induced via CD95/Fas and
CD95L/Fas ligand or perforin mediated cytotoxic mech¬
anisms [14]. Thus, cellular components of the immune
response around the targeted bile ducts may release
cytokines, generating an environment which increases the
neighbouring biliary epithelial cells' sensitivity to apop¬
tosis. Tumour necrosis factor alpha (TNFa) [15], inter¬
feron gamma (IFNy) [16] and transforming growth factor
beta (TGF(3) [17-19] have been shown to cause apop¬
tosis of hepatocytes and mRNA for each has been
detected in human PBC liver [20-22].
The reason why biliary epithelial cells are specifically
targeted in this disease and are vulnerable to death as an
initiating event is unknown, but it does not appear to be
the result of aberrant MHC Class II expression or antigen
t
presentation by these cells as such changes occur late in
the disease [23,24].
To test the hypothesis that in PBC the sensitivity of
biliary epithelial cells to apoptosis is altered we examined
the expression of a number of apoptosis related proteins
in the bile ducts and liver of early and late stage PBC
and normal control tissue. p53, Fas/CD95 and members
of the bcl-2 family have been shown to interact with one
another, for example p53 transcriptionally regulates
Fas/CD95 and bax [25-27], and members of the bcl-2
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family homo- and heterodimerize [reviewed in Reference
28], The proliferative status of biliary epithelial cells was




The diagnosis of PBC was made after full clinical, sero¬
logical and histological assessment. Fifteen cases showed
predominantly histological features seen in stage I or II
(14 women, one man) and 14 showed stage III or IV (13
women, one man) according to the proposed model of
disease progression reported by Scheuer [30]. Fifteen
control liver samples were obtained from patients during
routine lymphoma staging, psoriasis patients prior to
commencing methotrexate therapy, or laparotomy during
resection of colon cancer (six women, nine men). All liver
tissue in the control group was reported as histologically
normal and there was normal liver biochemical and
synthetic function. Clinical details of the PBC cases are
shown in Table 1.
Immunohistochemistry protocols
Liver tissue was fixed in 10% buffered formalin and
processed to paraffin. Sections of 3 |xm thickness were cut
onto Dako ChemMate Capillary Gap Microscope Slides
(75 mm). Sections were dewaxed in xylene and rehydrated
through descending alcohols. Pre-treatment with trypsin
(ICN Biomedicals Inc.) (0.1% trypsin, 0.1% calcium chlo¬
ride (Sigma), pH 7.8 at 37°C for 17 min) was required with
the anti-bcl-x (Autogen Bioclear UK Ltd, dilution 1/100)
and anti-bax (Autogen Bioclear UK Ltd, dilution 1/200)
antibodies. Microwave antigen retrieval (2x5 min at
1000 W; slides immersed in 1.05 g citric acid (BDH
Chemicals Ltd)/500 ml HzO, pH 6.0) was required for the
anti-bcl-2 (Dako UK, dilution 1/50), anti-CD95/Fas
(Immunotech UK, dilution 1/200) and anti-Ki-67
(Immunotech UK, dilution 1/100) antibodies. p53 (Dako
UK) was used at 1/100 dilution. All sections were washed
in running tap water then phosphate buffered saline
(Oxoid)/0.1% Tween 20 (Sigma) prior to loading onto a
Dako Techmate 500 automated immunocytochemistry
stainer according to the manufacturer's instructions using







omitting primary antibody were
Table 1 Clinical data assessing liver function of patients at time
of liver biopsy. Median and (range) values of bilirubin, alanine
aminotransferase, alkaline phosphatase and albumin of PBC
patients at time of biopsy
Alanine amino¬ Alkaline
Stage Bilirubin transferase phosphatase Albumin
Normal range 5-1 7 fxM <35 U/l <130 U/l 40-50 g/l
Histological early disease 11 69.5 200 41.5
(Stage I, II) (5-60) (27-194) (104-891) (29-44)
Histological late disease 56.5 87 402.5 32
(Stage III, IV) (13-256) (20-945) (115-1368) (22-43)
(a) Expression of bax in normal bile ducts (*^) and hepatocytes (if).
(b) PBC stage I liver showing strong expression in bile ducts (■*")
and upregulation of bax in hepatocytes (if), (c) PBC stage II liver
showing upregulation of bax in 'metaplastic ductules' [Jf) and
hepatocytes (if). Original magnification x 20.
Analysis of results
It was noted that the intensity of immunostaining for
bel-2, bax, bcl-x and Fas/CD95 was homogeneous with
little variation between cells within a single duct or
between ducts. For this reason biopsies were scored as
follows by three independent observers: strong (that is.
I
Apoptotic proteins in bile ducts Graham et al. 555
clearly visible granular stain at low power examination
(x 4)); moderate (definite but weak immunopositivity
visible at low power but needing confirmation by high
power microscopic examination (x 25)); or weak/negative
(equivocal staining, not consistently greater than in nega¬
tive control section where primary antibody was omitted).
Where inter-observer discrepancies were observed results
were recorded after discussion of the individual case.
Fig. 2
When Ki-67 or p53 were present they produced clear,
discrete nuclear staining. Cases were scored positive if
one or more nuclei of biliary epithelial cells was stained
and negative if no positive cells were seen. Thereafter an
estimate was made of the proportion of individual biliary
epithelial cells stained.
Bile ducts were classified as small (<75 pm) or large
(>75 pm) by measurement using the HOME (Highly
Optimized Microscope Environment) semi-automated
computer system.
S .r. • .*
• • O I •
*« * . ' r
Expression of bcl-x in (a) PBC stage IV liver hepatocytes (« )
'metaplastic ductules' bile ducts ( f ) showing upregulation,
compared with (b) histologically normal liver showing only mild
steatosis; hepatocytes (V ) and bile ducts ( * ). (c) Negative
control omitting primary antibody on histologically normal liver




bax (Fig. la) and bcl-x (Fig. 2b) were expressed uniformly
in both hepatocytes and bile ducts but were not detected
in Kupffer cells or endothelial cells. Moderate bax expres¬
sion was seen in bile ducts < 75 pm in 11/15 sections
( fable 2) and moderate bcl-x expression in 8/15 sections
(Table 3). Only 3/15 cases expressed detectable bcl-2 in
biliary epithelium, bcl-2 was not detected in hepatocytes.
Eight of fifteen cases showed moderate staining of biliary in Fas/CD95 staining was noted. p53 was not expressed,
epithelium with the anti-Fas/CD95 antibodies. In all cases In PBC cases up to 8% of biliary epithelial cells in large
PBC liver
Residual bile ducts showed strong staining of bax (Table 2,
Fig. lb) and bcl-x (Table 3) which appeared more intense
than in normal liver, bax and bcl-x were expressed strongly
in 'metaplastic' biliary ductules (Figs lc and 2a).
Lymphocytes showed intense expression of bcl-2. bcl-2
expression seen in surviving biliary epithelial cells was
weak and inconsistent, similar to normal liver. No change
hepatocytes were positive, the staining pattern being gran- ducts and in residual small ducts expressed Ki-67 (Fig. 3).
ular as previously reported in paraffin embedded tissue The number of positive nuclei seen was greatest in ducts
[31,32]. p53 was not detected and biliary epithelial cells >75 pm in sections showing early stage PBC. Areas of due-
did not express Ki-67. tal 'metaplasia' remained Ki-67 negative.
Table 2 Results of bax immunocytochemistry in bile ducts < 75 |xm and > 75 |i.m in normal and early and late stage PBC liver biopsy
material. The figures are the number of cases with detectable strong, moderate and weak/negative expression. Expression when
detected was homogeneous and uniform, n, total number of sections
Stage
bax (<75 jxm) bax (>75 fxm)
Strong Moderate Weak/negative n Strong Moderate Weak/negative n
Normal 0 11 4 15 0 10 2 12
Early 14 1 0 15 12 0 0 12
Late 6 4 4 14 8 3 3 14
Table 3 Results of bcl-x immunocytochemistry in in bile ducts <75 p.m and >75 in normal and early and late stage PBC liver
biopsy material. The figures are the number of cases with detectable strong, moderate and weak/negative expression. Expression
when detected was homogeneous and uniform, n, total number of sections
Stage
bcl-x (< 75 jim) bcl-x (>75 ^m)
Strong Moderate Weak/negative n Strong Moderate Weak/negative n
Normal 0 8 7 15 0 8 4 12
Early 14 0 1 15 1 1 0 1 12
Late 13 1 0 14 13 1 0 14
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Fig. 3
Proliferating biliary epithelial cell ( % ) and infiltrating cells ( / )
expressing Ki-67 in PBC stage I liver. Original magnification x 20.
Discussion
We have shown that bile ducts constitutively express pro-
apoptotic proteins, particularly bax, and the apoptotic
regulator bcl-x. In contrast the anti-apoptotic protein
bcl-2 is barely expressed and thus appears to play little
part in regulating apoptosis in biliary epithelial cells in
the cases we have studied. In addition to having a pheno-
type that allows apoptosis there is evidence that biliary
cells retain the ability to proliferate, as shown by the posi¬
tive Ki-67 staining seen in PBC liver. This supports the
observation of Nakanuma and Harada [33] who showed
increased proliferative activity of epithelial cells in
affected ducts. Charlotte et al. [34] have reported that
normal bile ductules and small bile duct epithelium, but
not large bile duct epithelium or hepatocytes, show weak
expression of bcl-2 as detected immunohistochemically.
However, Kuroki et al. [35] found no bcl-2 expression in
biliary epithelium of normal or PBC livers, and other
studies have shown more prominent bcl-2 staining in
ductules at the borders of cirrhotic nodules relative to
normal liver [36]. The absence of bcl-2 expression we
report in hepatocytes is consistent with previous obser¬
vations [34,37]. We have shown weak expression of
Fas/CD95 in bile ducts supporting the findings of Kuroki
et al. [35] and confirm its presence in hepatocytes
[31,38—40]. The antiserum used against Fas/CD95 did not
detect increased levels of Fas in the PBC livers. The pres¬
ence of TNFa and IFN7 in PBC liver [20-22] might
suggest an accompanying elevation in Fas expression.
However, many of the experiments showing increased Fas
expression by TNFa and IFNy are in vitro studies using
high doses of cytokine [41,42]. PBC is a chronic disease
and levels of these cytokines present in the liver have
not been quantified. Any changes that they may induce
in Fas expression might not be sufficient for detection by
immunohistochemistry, or in this disease these pleiotropic
cytokines may be exerting other effects on the disease
state independent of Fas.
Apoptosis of biliary epithelial cells in PBC has been
shown [32,43,44] and this may be associated with the pres¬
ence of cytotoxic CD8+ T cells [10,11,13]. How these cells
may be inducing apoptosis is unknown but a Fas-medi¬
ated mechanism is unlikely in view of the low level of
expression we have seen. Such mechanisms have been
invoked in a number of inflammatory diseases of the liver,
especially viral hepatitis [31,38-40] and ligation of consti¬
tutively expressed Fas/CD95 on hepatocytes by anti¬
bodies results in rapid apoptosis [45-47].
Both bax and bcl-x proteins appeared to be upregulated
in biliary epithelium in PBC cases. The expression of bax
is induced by p53 [25,26] and the protein heterodimer-
izes with bcl-2, inhibiting the anti-apoptotic effect of
bcl-2 [48]. We did not see upregulation of p53, suggesting
p53-independent induction of bax and bcl-x may be
occurring, as has been reported by others [49]. The
bcl-x gene codes for two splice variants, full length bcl-
x, protein and a smaller bcl-xs [50]. bcl-x, protects cells
from apoptosis and bcl-xs blocks the protective effect of
bcl-2 and bcl-x,, acting as an 'anti-anti-apoptosis' protein.
It is the relative ratio of homo- and heterodimeric forms
of these interactive proteins which affects the apoptotic
pathway. The polyclonal serum against bcl-x used does
not discriminate between the long and short forms and
hence we cannot draw any conclusions as to their rela¬
tive ratios and role in regulating cell death in PBC biliary
epithelial cells.
We have shown that the presence of proteins involved in
executing apoptosis in biliary epithelial cells in PBC is
consistent with previous reports of apoptosis of these cells
[32,41,42]. We do not know what causes this apoptosis
but we have also shown these cells are capable of regen¬
eration. It may be that a change in the balance between
apoptosis and regeneration of biliary epithelial cells during
the course of disease contributes to the ultimate loss of
bile ducts in PBC. However, because of the prolonged
time course of this chronic disease and the secondary
effects and immune response resulting from bile duct loss,
intervention of apoptosis is unlikely to be a therapeutic
target in the treatment of PBC.
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